POCKET COMPANION TO ACCOMPANY

DAVIS’S
DRUG GUIDE FOR NURSES
SEVENTH EDITION

JUDITH HOPFER DEGLIN, PharmD
Adjunct Clinical Instructor of Pharmacy Practice
University of Connecticut
School of Pharmacy
Storrs, Connecticut

APRIL HAZARD VALLERAND, PhD, RN
Wayne State University
College of Nursing
Detroit, Michigan

F. A. DAVIS COMPANY • Philadelphia
# CONTENTS

## SECTION I: CLASSIFICATIONS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agents Used During Pregnancy/Lactation*</td>
<td>P–1</td>
</tr>
<tr>
<td>Agents Used in the Management of Impotence*</td>
<td>P–2</td>
</tr>
<tr>
<td>Androgens/Anabolic Steroids*</td>
<td>P–4</td>
</tr>
<tr>
<td>Anesthetics/Anesthetic Adjuncts*</td>
<td>P–6</td>
</tr>
<tr>
<td>Angiotensin-Converting Enzyme (ACE) Inhibitors</td>
<td>P–8</td>
</tr>
<tr>
<td>Anorexiant*s</td>
<td>P–8</td>
</tr>
<tr>
<td>Antianginal Agents</td>
<td>P–9</td>
</tr>
<tr>
<td>Anti-anxiety and Sedative/Hypnotic Agents*</td>
<td>P–11</td>
</tr>
<tr>
<td>Antiarrhythmic Agents</td>
<td>P–13</td>
</tr>
<tr>
<td>Anticholinergic Agents</td>
<td>P–15</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>P–16</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>P–18</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>P–20</td>
</tr>
<tr>
<td>Antidiabetic Agents</td>
<td>P–25</td>
</tr>
<tr>
<td>Antiarrhythmic Agents</td>
<td>P–25</td>
</tr>
<tr>
<td>Antidiarrheal Agents</td>
<td>P–26</td>
</tr>
<tr>
<td>Antidiabetic Agents</td>
<td>P–28</td>
</tr>
<tr>
<td>Antifungal Agents</td>
<td>P–30</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>P–32</td>
</tr>
<tr>
<td>Antihypertensive Agents</td>
<td>P–33</td>
</tr>
<tr>
<td>Anti-infective Agents</td>
<td>P–36</td>
</tr>
<tr>
<td>Antineoplastic Agents</td>
<td>P–38</td>
</tr>
<tr>
<td>Antiparkinson Agents</td>
<td>P–42</td>
</tr>
<tr>
<td>Anti-platelet Agent*s</td>
<td>P–43</td>
</tr>
<tr>
<td>Antipsychotic Agents</td>
<td>P–45</td>
</tr>
<tr>
<td>Antipyretic Agents</td>
<td>P–48</td>
</tr>
<tr>
<td>Antiretroviral Agents</td>
<td>P–49</td>
</tr>
<tr>
<td>Antithyroid Agents</td>
<td>P–51</td>
</tr>
<tr>
<td>Antitubercular Agents</td>
<td>P–52</td>
</tr>
<tr>
<td>Antitussive Agents</td>
<td>P–54</td>
</tr>
<tr>
<td>Anti-ulcer Agents</td>
<td>P–55</td>
</tr>
<tr>
<td>Antiviral Agents</td>
<td>P–58</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>P–60</td>
</tr>
<tr>
<td>Cardiotoxic and Inotropic Agents*</td>
<td>P–62</td>
</tr>
<tr>
<td>Central Nervous System Stimulants*</td>
<td>P–63</td>
</tr>
<tr>
<td>Cholinergic Agents</td>
<td>P–65</td>
</tr>
<tr>
<td>Corticosteroids*</td>
<td>P–67</td>
</tr>
<tr>
<td>Diuretics</td>
<td>P–69</td>
</tr>
<tr>
<td>Estrogens/Progestins/Hormonal Contraceptives*</td>
<td>P–71</td>
</tr>
<tr>
<td>Immunosuppressant Agents*</td>
<td>P–73</td>
</tr>
</tbody>
</table>

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
Laxatives .................................................. P–75
Lipid-Lowering Agents ................................. P–76
Minerals/Electrolytes* ................................ P–78
Non-opioid Analgesics* .............................. P–79
Nonsteroidal Anti-inflammatory Agents* .... P–81
Opioid Analgesics* .................................. P–83
Skeletal Muscle Relaxants ......................... P–85
Thrombolytic Agents* ............................... P–86
Vascular Headache Suppressants ............... P–89
Vitamins ..................................................... P–90

SECTION II: DRUGS NOT REPRESENTED IN DAVIS'S DRUG GUIDE FOR NURSES, 7TH EDITION* ....................................................... P–93
Calcitonin .................................................... P–93
Human: Cibacalcin; Salmon: Calcimar, Miacalcin, Osteocalcin, Salmonine

Fexofenadine ............................................. P–95
Allegra

Methyldopa ................................................ P–96
Aldomet, {Apo-Methyldopa}, {Dopamet}, {Novamedopa}, {Nu-Medopa}

Naproxen (and Naproxen Sodium) .............. P–98

Oxycodone (including both aspirin and acetaminophen forms). .......... P–101
Oxycodone: Endocodone, Oxycontin, OxyFAST, OxyIR, Percodan, Roxicodone, Roxicodone SR, {Supeudol}; Oxycodone/acetaminophen: {Endocet}, {Oxyocet}, Percocet, {Percocet-Demi}, Roxicet, Roxilox, Tylox; Oxycodone/acetaminophen: {Endodan}, {Oxycodan}, Percodan, Percodan-Demi, Roxiprin

Quinine ..................................................... P–103
Rosiglitazone ............................................. P–105
Avandia

COMPREHENSIVE INDEX ............................... P–107

( ) = Available in Canada only.
*Because of space limitations, additional classes or drugs not represented in Davis's Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
**SECTION I**

Classifications

**AGENTS USED DURING PREGNANCY/ LACTATION**

**PHARMACOLOGIC PROFILE**

**General Use:**
Drugs used during labor and delivery include tocolytic and oxytocic agents. Tocolytics suppress uterine muscle activity to prevent preterm labor. Oxytocsics are used to stimulate uterine muscles to induce labor, control postpartum hemorrhage, terminate pregnancy, or to promote milk ejection in lactation.

**General Action and Information:**
Tocolytics include beta-sympathomimetics (ritodrine) and magnesium sulfate. Beta-sympathomimetics relax uterine smooth muscles by binding to beta_2_-receptors. Oxytocsics (prostaglandins, synthetic oxytocin, and methylergonovine) stimulate uterine smooth muscle contractions.

**Contraindications:**
Beta-sympathomimetics are contraindicated in women with a history of cardiac, renal, or hepatic disease and in migraines, hyperthyroidism, asthma, or hypertension. Oxytocin is contraindicated in hypersensitivity and in anticipated nonvaginal delivery. Ergot alkaloids are contraindicated in hypersensitivity, hepatic and renal impairment, hypertension, and cardiovascular disease. Ergots should not be used to induce labor.

**Precautions:**

**Interactions:**
- **Oxytocin**—Severe hypertension if given after vasopressors. Excessive hypotension if used concurrently with cyclopropane anesthesia. **Methylergonovine**—Excessive vasoconstriction may result when used with other vasopressors. **Beta-sympathomimetics (ritodrine)**—Additive adrenergic side effects with other sympathomimetics. Use with MAO inhibitors may result in hypertensive crisis.

**NURSING IMPLICATIONS**

**Assessment**
- Monitor frequency, duration, and force of contractions and uterine resting tone. Opioid analgesics may be administered for uterine pain.
- Monitor temperature, pulse, and blood pressure periodically throughout therapy for cervical ripening or termination of pregnancy.

---

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Potential Nursing Diagnoses

- Knowledge deficit, related to medication regimen (Patient/Family teaching).

Implementation

- Administer RhoGAM into the deltoid muscle within 3 hr and up to 72 hr after delivery, miscarriage, abortion, or transfusion.
- Warm suppositories to room temperature just prior to use. Patient should remain supine for 10 min after vaginal suppository.
- Vaginal inserts are placed transversely in the posterior vaginal fornix immediately after removing from foil package. See monograph for dinoprostone for specific directions pertaining to administration.
- Endocervical gel is applied after determining degree of effacement. Do not administer above the level of the cervical os. Follow manufacturer’s guidelines for administration.
- Wear gloves when handling unwrapped suppository and the gel to prevent absorption through the skin. Should skin contact, occur wash hands immediately.
- Administer intranasal oxytocin nasal spray by squeezing the bottle while the patient is in a sitting position.

Patient/Family Teaching

- Advise patient to administer oxytocin nasal spray 2–3 min prior to planned breast feeding. Patient should notify health care professional if milk drips from non-nursed breast or if uterine cramping occurs.
- Explain the purpose of cervical ripening and abortifacient medications with the need for vaginal exams. Advise patient to inform health care professional if contractions become prolonged.
- Provide emotional support.
- Instruct patient receiving abortifacients to notify health care professional immediately if fever and chills, foul-smelling discharge, lower abdominal pain, or increased bleeding occurs.

Evaluation

Effectiveness of therapy is demonstrated by:
- Complete abortion
- Cervical ripening and induction of labor
- Effective letdown reflex
- Prevention of preterm labor.

Agents Used during Pregnancy/Lactation Included in
Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>Abortion</th>
<th>Oxytocics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carboprost 1172</td>
<td>Methylergonovine 631</td>
</tr>
<tr>
<td>Dinoprostone 297</td>
<td>Oxytocin 740</td>
</tr>
</tbody>
</table>

Miscellaneous

<table>
<thead>
<tr>
<th>Tocolytics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritodrine, 1181</td>
</tr>
</tbody>
</table>

AGENTS USED IN THE MANAGEMENT OF IMPOTENCE*

PHARMACOLOGIC PROFILE

General Use:

Treatment of erectile dysfunction.
General Action and Information:
Sildenafil inhibits enzyme that inactivates cyclic guanosine monophosphate (cGMP). cGMP produces smooth muscle relaxation of the corpus cavernosum, which enhances blood flow and subsequent erection. Alprostadil is a prostaglandin that acts locally to relax trabecular smooth muscle and dilate cavernosal arteries.

Contraindications:
Hypersensitivity. Sildenafil should not be used concurrently with nitrates (nitroglycerin, isosorbide). Alprostadil should not be used concurrently with penile implants or in cases of structural or pathologic abnormalities of the penis.

Precautions:
Sildenafil should be used cautiously in patients with serious underlying cardiovascular disease, those already using antihypertensives or glipizide, and those with anatomic penile deformity. Use with caution in conditions associated with priapism and bleeding disorders or active peptic ulcer disease. Alprostadil should be used cautiously in patients with coagulation abnormalities.

Interactions:
Sildenafil blood levels may be increased by cimetidine, erythromycin, ketoconazole, and itraconazole. Increased risk of serious hypotension when sildenafil is used with nitrates. (Concurrent use is contraindicated.)

NURSING IMPLICATIONS

Assessment
- Determine erectile dysfunction prior to administration. Sildenafil has no effect in the absence of sexual stimulation.
- Exclude disorders of the vascular system and cavernous body damage prior to use of alprostadil, because the drug is ineffective with these disorders.

Potential Nursing Diagnoses
- Sexual dysfunction (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Sildenafil is administered PO. Dose is usually administered 1 hr prior to sexual activity. It may be administered 30 min to 4 hr before sexual activity.
- Alprostadil is injected into the dorsolateral aspect of the proximal third of the penis avoiding visible veins. Rotate injection sites from side to side. Dosage is determined in the prescriber’s office.

Patient/Family Teaching
- Instruct patient taking sildenafil to take the medication 1 hr prior to sexual activity and not more than once a day.
- Advise patient that sildenafil has not been approved for use in women.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
■ Caution patient not to take sildenafil concurrently with nitrates.
■ Instruct patient using alprostadil that it is not to be used more than 3 times per week.
■ Teach patient that priapism (prolonged erection of >60 min) is dangerous, and immediate medical assistance should be sought. Failure to treat priapism may result in permanent irreversible damage.
■ Drugs to treat erectile dysfunction do not protect against transmission of sexually transmitted diseases. Counsel patient that protection against sexually transmitted disease and HIV infection should be considered.

Evaluation

Effectiveness of therapy can be demonstrated by: ■ Male erection sufficient to allow intercourse without evidence of adverse effects.

Agents Used in the Management of Impotence Included in Davis’s Drug Guide for Nurses
alprostadil, 1168 sildenafil, 921

ANDROGENS/ANABOLIC STEROIDS*

PHARMACOLOGIC PROFILE

General Use:
Androgens (testosterone) are used to replace androgen deficiencies in hypogonadism. They are also used in endometriosis and for palliative treatment in metastatic breast cancer. Danazol, also an androgen, is used in the management of endometriosis, fibrocystic breast disease, and hereditary angioedema. Nandrolone (an anabolic steroid) is used to manage anemia associated with chronic renal failure.

General Action and Information:
Testosterone is necessary for the formation of the male sexual organs and for the development of primary and secondary male sex characteristics.

Contraindications:
Contraindicated in pregnancy and lactation; carcinoma of the prostate or male breast and hepatic disease; hypercalcemia; and coronary artery disease.

Precautions:
Use cautiously in elderly men who have an increased risk of prostatic hypertrophy and carcinoma and in patients with a history of liver or cardiac disease.

Interactions:
Increased sensitivity to oral anticoagulants, insulin, NSAIDS, and oral hypoglycemic agents. Use with adrenal corticosteroids may increase occurrence of edema. Danazol may increase cyclosporine levels. Nandrolone increases the risk of hepatotoxic reactions to drugs.
NURSING IMPLICATIONS

Assessment

- Monitor intake and output ratios, weigh patient twice weekly, and assess patient for edema.
- Report significant changes indicative of fluid retention.
- Men: Monitor for precocious puberty in boys (acne, darkening of skin, development of male secondary sex characteristics—increase in penis size, frequent erections, growth of body hair). Bone age determination should be measured every 6 mo to determine rate of bone maturation and effects on epiphyseal closure).
- Monitor for breast enlargement, persistent erections, and increased urge to urinate in men. Monitor for difficulty urinating in elderly men, because prostate enlargement may occur.
- Women: Assess for virilism (deepening of voice, unusual hair growth or loss, clitoral enlargement, acne, menstrual irregularity).
- In women with metastatic breast cancer, monitor for symptoms of hypercalcemia (nausea, vomiting, constipation, lethargy, loss of muscle tone, thirst, polyuria).
- Danazol: Assess for endometrial pain prior to and periodically throughout therapy.
- Nandrolone: Monitor responses for symptoms of anemia.

Potential Nursing Diagnoses

- Sexual dysfunction (Indications, Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- General Info: Range of motion exercises should be done with bedridden patients to prevent mobilization of calcium from the bone.
- Treatment of endometriosis or fibrocystic breast disease with danazol should be started during menstruation or preceded by a pregnancy test.
- IM: Administer deep IM into the gluteal muscle.
- Transdermal: Apply patch to clean, dry, hairless skin.

Patient/Family Teaching

- General Info: Advise the patient to report the following signs and symptoms promptly; in male patients, priapism (sustained and often painful erection) or gynecomastia; in female patients, virilism (which may be reversible if medication is stopped as soon as changes are noticed), hypercalcemia (nausea, vomiting, constipation, and weakness), edema (unexpected weight gain, swelling of the feet), hepatitis (yellowing of the skin or eyes and abdominal pain), or unusual bleeding or bruising.
- Explain rationale for prohibition of use for increasing athletic performance. Testosterone is neither safe nor effective, but this use has the potential risk of serious side effects.
- Advise diabetics to monitor blood for alterations in blood sugar concentrations.
- Emphasize the importance of regular follow-up physical exams, lab tests, and x-rays to monitor progress.
- Advise patient to use a nonhormonal form of contraception during therapy.
- Radiologic bone age determinations should be examined every 6 mo in prepubertal children to determine rate of bone maturation and effects on epiphyseal centers.
- Transdermal: Advise patient to notify health care professional if female sexual partner develops mild virilization.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
Evaluation

Effectiveness of therapy can be demonstrated by: ■ Resolution of the signs of androgen deficiency without side effects. Therapy is usually limited to 3–6 mo, followed by bone growth or maturation determinations. ■ Increase in activity tolerance. ■ Decrease in size and spread of breast malignancy in postmenopausal women. In antineoplastic therapy, response may require 3 mo of therapy; if signs of disease progression appear, therapy should be discontinued. ■ Decrease in symptoms of endometriosis. ■ Increased hemoglobin and red cell volume with decrease in symptoms of anemia.

Androgens/Anabolic Steroids Included in *Davis’s Drug Guide for Nurses*

- Danazol 261
- Nandrolone 687
- Testosterone 966

ANESTHETICS/ANESTHETIC ADJUNCTS*

PHARMACOLOGIC PROFILE

General Use:

Anesthetics (general, local, regional) are used to induce anesthesia during surgery, childbirth, dental or diagnostic procedures, and other treatments. General anesthesia is administered parenterally or by inhalation to produce progressive and reversible stages of CNS depression. Local anesthetics (topical, injectable) produce anesthesia in small, localized areas. Regional anesthetics are used for larger areas (spinal, epidural). Anesthetic adjuncts are given preoperatively, intraoperatively, or postoperatively to aid in the anesthetic process. Anesthetic adjuncts (anti-anxiety and sedative/hypnotic agents, anticholinergic agents, narcotic analgesics, neuromuscular blocking agents) are used to enhance anesthetic agents.

General Action and Information:

Reversibly block transport of ions in neuronal membrane channels and thereby prevent initiation and conduction of normal nerve impulses.

Contraindications:

Hypersensitivity and cross-sensitivity may occur.

Precautions:

Use cautiously in patients with liver disease, cardiac disease, hyperthyroidism, respiratory depression, shock, or heart block. Use with caution in pregnancy or lactation (safety not established).

Interactions:

Additive CNS depression when administered with other CNS depressants. Additive cardiac depression and toxicity when administered with phenytoin, quinidine, procainamide, or propranolol.
NURSING IMPLICATIONS

Assessment

- Assess degree of numbness of affected part.
- Topical applications should have site assessed for open wounds prior to application. Apply only to intact skin.
- When using lidocaine/prilocaine, assess application site for anesthesia following removal of system and prior to procedure.
- In local epidural drugs, assess for systemic toxicity, orthostatic hypotension, and unwanted motor and sensory deficits.
- When using a systemic agent (propofol), assess respiratory status, pulse, blood pressure, and level of consciousness continuously throughout therapy and following administration.

Potential Nursing Diagnoses

- Pain, acute (Indications).
- Physical mobility, impaired (Adverse Reactions).
- Breathing patterns, ineffective (Adverse Reactions).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- **Local Infiltration**: Epinephrine may be added to lidocaine to minimize systemic absorption and prolong local anesthesia.
- **Lidocaine/Prilocaine**: Apply dose in a thick layer at the site of the impending procedure and cover with an occlusive dressing at least 1 hr before the start of the procedure.
- **Epidural Medications**: Dose is titrated to patient response until anesthetic response is achieved.
- **Propofol**: Dose is titrated to patient response. Does not affect pain threshold, and adequate analgesia should always be used as an adjunct to surgical procedures. Shake well before IV administration, and use strict aseptic technique when administering.

Patient/Family Teaching

- **Local Block or Infiltrate**: Instruct patient to notify health care professional if any sensation of pain is felt.
- **Lidocaine/Prilocaine**: Explain the purpose of the cream and occlusive dressing to patient and parents.
- **Epidural Medications**: Instruct patient to notify nurse if signs of systemic toxicity occur.
- **Propofol Use**: Inform patient that this medication will decrease recall of the procedure. Avoid use of alcohol or other CNS depressant agents for 24 hr following administration. Avoid driving or other activities requiring mental alertness for 24 hr after administration.

Evaluation

Effectiveness of therapy can be demonstrated by: **Local Infiltration and Epidural Medication**: Complete blocking of pain sensation. **Lidocaine/Prilocaine**: Anesthesia in the area of application. **Propofol**: Induction maintenance of anesthesia; amnesia.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Anesthetics/Anesthetic Adjuncts Included in *Davis’s Drug Guide for Nurses*

**Anesthetics (epidural)**
- bupivacaine 342
- levobupivacaine 342
- ropivacaine 342

**Anesthetics (general)**
- ketamine 1177
- propofol 844

**Anesthetics (topical, mucosal)**
- lidocaine 577
- lidocaine/prilocaine 579

**ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS**

See Antihypertensive Agents, page C23.

**ACE Inhibitors Included in *Davis’s Drug Guide for Nurses***

- benazepril 63
- captopril 63
- enalapril, enalaprilat 63
- fosinopril 64
- lisinopril 64
- moexipril 64
- perindopril 64
- quinapril 64
- ramipril 64
- trandolapril 64

**ANOREXIANTS***

**PHARMACOLOGIC PROFILE**

**General Use:**
Short-term management of exogenous obesity in conjunction with behavior modification, diet, and exercise.

**General Action and Information:**
Appetite suppression probably due to depression of CNS appetite control center (phentermine, phenylpropanolamine). Act as inhibitors of the reuptake of serotonin, norepinephrine, and dopamine and increase the satiety-producing effects of serotonin (sibutramine).

**Contraindications:**
Safety not established in pregnancy and lactation and in children under age 12.

**Precautions:**
Use cautiously in patients with cardiovascular disease (including hypertension), glaucoma, hyperthyroidism, diabetes mellitus, and prostatic hypertrophy.

**Interactions:**
Additive sympathomimetic effects with other adrenergic agents. Should not be used with MAO inhibitors. May increase the risk of hypertension with reserpine, tricyclic antidepressants, or ganglionic blocking agents.
NURSING IMPLICATIONS

Assessment

- Exclude hypertension and diabetes prior to instituting phentermine.
- Assess patient for weight loss, and adjust concurrent medications (antihypertensive agents, antidiabetic agents, lipid-lowering agents) as needed.
- Monitor nutritional intake periodically throughout therapy.
- Sibutramine: Monitor blood pressure and heart rate regularly during therapy. Increases in blood pressure or heart rate, especially during early therapy, may require decrease in dose or discontinuation of the drug.

Potential Nursing Diagnoses

- Body image disturbance (Indications).
- Nutrition, altered: more than body requirements (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Take once daily without regard to meals.
- Phentermine: Take once daily 30 min prior to breakfast or 10–14 hr before bedtime.

Patient/Family Teaching

- Instruct patient to take medication as directed and not to exceed recommended dose. Some medications may need to be discontinued gradually.
- Sibutramine: Caution patient to avoid using other CNS depressant or excessive amounts of alcohol.
- Advise patient to follow a reduced-calorie diet in conjunction with exercise, as recommended by their health care professional.
- Phentermine and Phenylpropanolamine: Warn patient to avoid large amounts of coffee, tea, or colas containing caffeine.

Evaluation

Effectiveness of therapy can be demonstrated by: ■ Slow, consistent weight loss when combined with reduced-calorie diet.

Anorexiants Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>Drug</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>phentermine</td>
<td>1179</td>
</tr>
<tr>
<td>sibutramine</td>
<td>919</td>
</tr>
<tr>
<td>phenylpropanolamine</td>
<td>788</td>
</tr>
</tbody>
</table>

ANTIANGINAL AGENTS

PHARMACOLOGIC PROFILE

General Use:

Nitrates are used to treat and prevent attacks of angina. Only nitrates (sublingual, lingual spray, or intravenous) may be used in the acute treatment of attacks of angina pectoris. Calcium chan-

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
nel blockers and beta-adrenergic blockers are used prophylactically in long-term management of angina.

General Action and Information:
Several different groups of medications are used in the treatment of angina pectoris. The nitrates (isosorbide dinitrate, isosorbide mononitrate, and nitroglycerin) are available as a lingual spray, sublingual tablets, parenterals, transdermal systems, and sustained-release oral dosage forms. Nitrates dilate coronary arteries and cause systemic vasodilation (decreased preload). Calcium channel blockers dilate coronary arteries (some also slow heart rate). Beta-adrenergic blocking agents decrease myocardial oxygen consumption via a decrease in heart rate. Therapy may be combined if selection is designed to minimize side effects or adverse reactions.

Contraindications:
Hypersensitivity. Avoid use of beta blockers or calcium channel blockers in advanced heart block, cardiogenic shock, or untreated congestive heart failure.

Precautions:
Beta-adrenergic blockers should be used cautiously in patients with diabetes mellitus, pulmonary disease, or hypothyroidism.

Interactions:
Nitrates, calcium channel blockers, and beta-adrenergic blockers may cause hypotension with other antihypertensive agents or acute ingestion of alcohol. Verapamil, diltiazem, and beta-adrenergic blockers may have additive myocardial depressant effects when used with other agents that affect cardiac function. Verapamil has a number of other significant drug-drug interactions.

NURSING IMPLICATIONS

Assessment
- Assess location, duration, intensity, and precipitating factors of patient’s anginal pain.
- Monitor blood pressure and pulse periodically throughout therapy.

Potential Nursing Diagnoses
- Pain (Indications).
- Tissue perfusion, altered (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Available in various dose forms. See specific drugs for information on administration.

Patient/Family Teaching
- Instruct patient on concurrent nitrate therapy and prophylactic antianginal agents to continue taking both medications as ordered and to use SL nitroglycerin as needed for anginal attacks.
Advise patient to contact health care professional immediately if chest pain does not improve; worsens after therapy; is accompanied by diaphoresis or shortness of breath; or if severe, persistent headache occurs.

Caution patient to make position changes slowly to minimize orthostatic hypotension.

Advise patient to avoid concurrent use of alcohol with these medications.

**Evaluation**

*Effectiveness of therapy can be demonstrated by:* ■ Decrease in frequency and severity of anginal attacks ■ Increase in activity tolerance.

**Antianginal Agents Included in *Davis’s Drug Guide for Nurses***

**beta-adrenergic blocking agents**
- atenolol 79
- metoprolol 638
- nadolol 678
- propranolol 849

**calcium channel blockers**
- amlodipine 41
- bepridil 98

**nitrates and nitrites**
- isosorbide dinitrate 539
- isosorbide mononitrate 539
- nitroglycerin 714

---

**ANTI-ANXIETY AND SEDATIVE/HYPNOTIC AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**

Antianxiety agents and sedatives are used to treat anxiety disorders and to provide sedation before procedures. Hypnotics are used to treat insomnia. Selected agents are useful as anticonvulsants (clorazepate, diazepam, phenobarbital), as skeletal muscle relaxants (diazepam), as adjuncts in the treatment of alcohol withdrawal syndrome (chlordiazepoxide, clorazepate, diazepam, oxazepam), and as general anesthetic adjuncts (droperidol) or anesthetics (midazolam, diazepam).

**General Action and Information:**

Cause general CNS depression. May produce tolerance with chronic use and have potential for psychological or physical dependence. These agents have no analgesic properties.

**Contraindications:**

Hypersensitivity. Should not be used in comatose patients or in those with pre-existing CNS depression. Should not be used in patients with uncontrolled severe pain. Avoid use during pregnancy or lactation.

**Precautions:**

Use cautiously in patients with hepatic dysfunction, severe renal impairment, or severe underlying pulmonary disease. Use with caution in patients who may be suicidal or who may have had previous drug addictions. Hypnotic use should be short term. Geriatric patients may be more sensitive to CNS depressant effects (initial dosage reduction may be required).

---

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
Interactions:
Additive CNS depression with alcohol, antihistamines, antidepressants, opioid analgesics, or phenothiazines. Barbiturates induce release of hepatic drug-metabolizing enzymes and can decrease the effectiveness of drugs metabolized by the liver. Should not be used with MAO inhibitors.

NURSING IMPLICATIONS

Assessment
- **General Info:** Monitor blood pressure, pulse, and respiratory status frequently throughout IV administration.
- Prolonged high-dose therapy may lead to psychological or physical dependence. Restrict the amount of drug available to patient, especially if patient is depressed, suicidal, or has a history of addiction.
- **Insomnia:** Assess sleep patterns before and periodically throughout therapy.
- **Anxiety:** Assess degree of anxiety and level of sedation (ataxia, dizziness, slurred speech) before and periodically throughout therapy.
- **Seizures:** Observe and record intensity, duration, and characteristics of seizure activity. Institute seizure precautions.
- **Muscle Spasms:** Assess muscle spasms, associated pain, and limitation of movement before and throughout therapy.
- **Alcohol Withdrawal:** Assess patient experiencing alcohol withdrawal for tremors, agitation, delirium, and hallucinations. Protect patient from injury.

Potential Nursing Diagnoses
- Sleep pattern disturbance (Indications).
- Injury, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Supervise ambulation and transfer of patients following administration of hypnotic doses. Remove cigarettes. Side rails should be raised and call bell within reach at all times. Keep bed in low position.

Patient/Family Teaching
- Discuss the importance of preparing environment for sleep (dark room, quiet, avoidance of nicotine and caffeine). If less effective after a few weeks, consult health care professional; do not increase dose. Gradual withdrawal may be required to prevent reactions following prolonged therapy.
- May cause daytime drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
- Advise patient to avoid the use of alcohol and other CNS depressants concurrently with these medications.
- Advise patient to inform health care professional if pregnancy is planned or suspected.
Evaluation

**Effectiveness of therapy can be demonstrated by:**
- Improvement in sleep patterns
- Decrease in anxiety level
- Control of seizures
- Decrease in muscle spasm
- Decrease in tremulousness
- More rational ideation when used for alcohol withdrawal.

Anti-anxiety and Sedative/Hypnotic Agents Included in *Davis’s Drug Guide for Nurses*, 7th edition,

<table>
<thead>
<tr>
<th>Anti-histamines</th>
<th>Flurazepam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine 300</td>
<td>lorazepam 588</td>
</tr>
<tr>
<td>Hydroxyzine 493</td>
<td>midazolam 645</td>
</tr>
<tr>
<td>Promethazine 893</td>
<td>oxazepam 735</td>
</tr>
</tbody>
</table>

**Barbiturates**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Uses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pentobarbital 776</td>
<td></td>
</tr>
<tr>
<td>Phenobarbital 784</td>
<td></td>
</tr>
</tbody>
</table>

**Benzodiazepines**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Uses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprazolam 23</td>
<td></td>
</tr>
<tr>
<td>Chlordiazepoxide 188</td>
<td></td>
</tr>
<tr>
<td>Diazepam 279</td>
<td></td>
</tr>
</tbody>
</table>

ANTIARRHYTHMIC AGENTS

PHARMACOLOGIC PROFILE

**General Use:**
Suppression of cardiac arrhythmias.

**General Action and Information:**
Correct cardiac arrhythmias by a variety of mechanisms, depending on the group used. The therapeutic goal is decreased symptomatology and increased hemodynamic performance. Choice of agent depends on etiology of arrhythmia and individual patient characteristics. Treatable causes of arrhythmias should be corrected before therapy is initiated (e.g., electrolyte disturbances). Major antiarrhythmics are generally classified by their effects on cardiac conduction tissue (see the following table). Adenosine, atropine, and digitalis glycosides (digoxin, digoxin) are also used as antiarrhythmics.

**MECHANISM OF ACTION OF MAJOR ANTIARRHYTHMIC DRUGS**

<table>
<thead>
<tr>
<th>Group</th>
<th>Drugs</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Moricizine</td>
<td>Shares properties of IA, IB, and IC agents</td>
</tr>
<tr>
<td>IA</td>
<td>Disopyramide, procainamide, quinidine</td>
<td>Depress Na conductance, increase APD and ERP, decrease membrane responsiveness</td>
</tr>
<tr>
<td>IB</td>
<td>Lidocaine, mexiletine, phenytoin, tocainide,</td>
<td>Increase K conductance, decrease APD and ERP</td>
</tr>
<tr>
<td>IC</td>
<td>Flecainide, propafenone</td>
<td>Profound slowing of conduction, markedly depress phase 0</td>
</tr>
<tr>
<td>II</td>
<td>Acebutolol, esmolol, propranolol</td>
<td>Interfere with Na conductance, depress cell membrane, decrease automaticity, and increase ERP of the AV node, block excess sympathetic activity</td>
</tr>
<tr>
<td>III</td>
<td>Amiodarone, bretylium, ibutilide, sotalol</td>
<td>Interfere with norepinephrine, increase APD and ERP</td>
</tr>
<tr>
<td>IV</td>
<td>Diltiazem, verapamil</td>
<td>Increase AV nodal ERP, Ca channel blocker</td>
</tr>
</tbody>
</table>

APD = action-potential duration; Ca = calcium; ERP = effective refractory period; K = potassium; Na = sodium.

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
Contraindications:
Differ greatly among various agents. See individual drugs.

Precautions:
Differ greatly among agents used. Appropriate dosage adjustments should be made in elderly patients and those with renal or hepatic impairment, depending on agent chosen. Correctable causes (electrolyte abnormalities, drug toxicity) should be evaluated. See individual drugs.

Interactions:
Differ greatly among agents used. See individual drugs.

NURSING IMPLICATIONS

Assessment
- Monitor ECG, pulse, and blood pressure continuously throughout IV administration and periodically throughout oral administration.

Potential Nursing Diagnoses
- Cardiac output, decreased (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Take apical pulse before administration of oral doses. Withhold dose and notify physician or other health care professional if heart rate is <50 bpm.
- Administer oral doses with a full glass of water. Most sustained-release preparations should be swallowed whole. Do not crush, break, or chew tablets or open capsules, unless specifically instructed.

Patient/Family Teaching
- Instruct patient to take oral doses around the clock, as directed, even if feeling better.
- Instruct patient or family member on how to take pulse. Advise patient to report changes in pulse rate or rhythm to health care professional.
- Caution patient to avoid taking OTC medications without consulting health care professional.
- Advise patient to carry identification describing disease process and medication regimen at all times.
- Emphasize the importance of follow-up exams to monitor progress.

Evaluation
Effectiveness of therapy can be demonstrated by: Resolution of cardiac arrhythmias without detrimental side effects.

Antiarrhythmic Agents Included in *Davis’s Drug Guide for Nurses*

<table>
<thead>
<tr>
<th>group I</th>
<th>group IA</th>
</tr>
</thead>
<tbody>
<tr>
<td>moricizine 665</td>
<td>disopyramide 306</td>
</tr>
</tbody>
</table>
ANTICHOLINERGIC AGENTS

PHARMACOLOGIC PROFILE

General Use:

Atropine—Bradyarrhythmias. Scopolamine—Nausea and vomiting related to motion sickness and vertigo. Propantheline and glycopyrrolate—Decreasing gastric secretory activity and increasing esophageal sphincter tone. Atropine and scopolamine are also used as ophthalmic mydriatics.

General Action and Information:

Competitively inhibit the action of acetylcholine. In addition, atropine, glycopyrrolate, propantheline, and scopolamine are antimuscarinic in that they inhibit the action of acetylcholine at sites innervated by postganglionic cholinergic nerves.

Contraindications:

Hypersensitivity, narrow-angle glaucoma, severe hemorrhage, tachycardia (due to thyrotoxicosis or cardiac insufficiency), or myasthenia gravis.

Precautions:

Geriatric and pediatric patients are more susceptible to adverse effects. Use cautiously in patients with urinary tract pathology; those at risk for GI obstruction; and those with chronic renal, hepatic, pulmonary, or cardiac disease.

Interactions:

Additive anticholinergic effects (dry mouth, dry eyes, blurred vision, constipation) with other agents possessing anticholinergic activity, including antihistamines, antidepressants, quinidine, and disopyramide. May alter GI absorption of other drugs by inhibiting GI motility and increasing transit time. Antacids may decrease absorption of anticholinergics.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
NURSING IMPLICATIONS

Assessment

- Assess vital signs and ECG frequently during IV drug therapy. Report any significant changes in heart rate or blood pressure or increase in ventricular ectopy or angina promptly.
- Monitor intake and output ratios in elderly or surgical patients; may cause urinary retention.
- Assess patient regularly for abdominal distention and auscultate for bowel sounds. Constipation may become a problem. Increasing fluids and adding bulk to the diet may help alleviate constipation.

Potential Nursing Diagnoses

- Cardiac output, decreased (Indications).
- Oral mucous membrane, altered (Side Effects).
- Constipation (Side Effects).

Implementation

- **PO:** Administer oral doses of atropine, glycopyrrolate, propantheline, or scopolamine 30 min before meals.
- Scopolamine transdermal patch should be applied at least 4 hr before travel.

Patient/Family Teaching

- **General Info:** Instruct patient that frequent rinses, sugarless gum or candy, and good oral hygiene may help relieve dry mouth.
- May cause drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
- **Ophth:** Advise patients that ophthalmic preparations may temporarily blur vision and impair ability to judge distances. Dark glasses may be needed to protect eyes from bright light.

Evaluation

**Effectiveness of therapy can be demonstrated by:** ■ Increase in heart rate ■ Decrease in nausea and vomiting related to motion sickness or vertigo ■ Dryness of mouth ■ Dilation of pupils ■ Decrease in GI motility ■ Resolution of signs and symptoms of Parkinson's disease.

Anticholinergic Agents Included in *Davis's Drug Guide for Nurses*

- atropine 81
- glycopyrrolate 444
- propantheline 843
- scopolamine 913

ANTICOAGULANTS

PHARMACOLOGIC PROFILE

General Use:

Prevention and treatment of thromboembolic disorders including deep vein thrombosis, pulmonary embolism, and atrial fibrillation with embolization.
General Action and Information:
Anticoagulants are used to prevent clot extension and formation. They do not dissolve clots. The two types of anticoagulants in common use are parenteral heparins and oral warfarin. Therapy is usually initiated with heparin because of its rapid onset of action, while maintenance therapy consists of warfarin. Warfarin takes several days to produce therapeutic anticoagulation. In serious or severe thromboembolic events, heparin therapy may be preceded by thrombolytic therapy (alteplase, anistreplase, streptokinase, or urokinase). Low doses of heparin, low-molecular-weight heparins, and heparin-like compounds (ardaparin, danaparoid, dalteparin, enoxaparin) are mostly used to prevent deep vein thrombosis after certain surgical procedures and in similar situations in which prolonged bedrest increases the risk of thromboembolism.

Contraindications:
Underlying coagulation disorders, ulcer disease, malignancy, recent surgery, or active bleeding.

Precautions:
Anticoagulation should be undertaken cautiously in any patient with a potential site for bleeding. Pregnant or lactating patients should not receive warfarin. Heparin does not cross the placenta. Heparin and heparin-like agents should be used cautiously in patients receiving epidural analgesia.

Interactions:
Warfarin is highly protein bound and may displace or be displaced by other highly protein-bound drugs. The resultant interactions depend on which drug is displaced. Bleeding may be potentiated by aspirin or large doses of penicillins or penicillin-like drugs, cefamandole, cepofuran, cefotetan, cefoperazone, plicamycin, valproic acid, or NSAIDs.

NURSING IMPLICATIONS
Assessment
- Assess patient taking anticoagulants for signs of bleeding and hemorrhage (bleeding gums; nosebleed; unusual bruising; tarry, black stools; hematuria; fall in hematocrit or blood pressure; guaiac-positive stools; urine; or nasogastric aspirate).
- Assess patient for evidence of additional or increased thrombosis. Symptoms will depend on area of involvement.
- Lab Test Considerations: Monitor activated partial thromboplastin time (aPTT) or international normalized ratio (INR) with full-dose heparin therapy, prothrombin time (PT) with warfarin therapy, and hematocrit and other clotting factors frequently during therapy.
- Monitor bleeding time throughout antiplatelet therapy. Prolonged bleeding time, which is time- and dose-dependent, is expected.
- Toxicity and Overdose: If overdose occurs or anticoagulation needs to be immediately reversed, the antidote for heparins is protamine sulfate; for warfarin, the antidote is vitamin K (phytonadione [AquaMEPHYTON]). Administration of whole blood or plasma may also be required in severe bleeding due to warfarin because of the delayed onset of vitamin K.

Potential Nursing Diagnoses
- Tissue perfusion, altered (Indications).
Injury, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Inform all personnel caring for patient of anticoagulant therapy. Venipunctures and injection sites require application of pressure to prevent bleeding or hematoma formation.
- Use an infusion pump with continuous infusions to ensure accurate dosage.

Patient/Family Teaching
- Caution patient to avoid activities leading to injury, to use a soft toothbrush and electric razor, and to report any symptoms of unusual bleeding or bruising to health care professional immediately.
- Instruct patient not to take OTC medications, especially those containing aspirin, NSAIDs, or alcohol, without advice of health care professional.
- Review foods high in vitamin K (see Appendix L) with patients on warfarin. Patient should have consistent limited intake of these foods, as vitamin K is the antidote for warfarin and greatly alternating intake of these foods will cause PT levels to fluctuate.
- Emphasize the importance of frequent lab tests to monitor coagulation factors.
- Instruct patient to carry identification describing medication regimen at all times and to inform all health care personnel caring for patient of anticoagulant therapy before lab tests, treatment, or surgery.

Evaluation
Clinical response can be evaluated by:
- Prevention of undesired clotting and its sequelae without signs of hemorrhage
- Prevention of stroke, myocardial infarction, and vascular death in patients at risk.

Anticoagulants Included in Davis's Drug Guide for Nurses
- ardeparin 469
- dalteparin 469
- danaparoid 469
- enoxaparin 469
- heparin 465
- warfarin 1057

ANTICONVULSANTS

PHARMACOLOGIC PROFILE

General Use:
See the following table.

General Action and Information:
Anticonvulsants include a variety of agents, all capable of depressing abnormal neuronal discharges in the CNS that may result in seizures. They may work by preventing the spread of seizure activity, depressing the motor cortex, raising seizure threshold, or altering levels of neurotransmitters, depending on the group. See individual drugs.
Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.

## MAJOR ANTICONVULSANT CLASSES, DRUGS, AND MOST COMMON USES

<table>
<thead>
<tr>
<th>CLASS</th>
<th>DRUGS</th>
<th>TYPE OF SEIZURE CONTROLLED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbiturates</td>
<td>phenobarbital</td>
<td>Tonic-clonic and partial seizures, prophylaxis of febrile seizures</td>
</tr>
<tr>
<td></td>
<td>clonazepam</td>
<td>Absence seizures, akinetic seizures, myoclonic seizures</td>
</tr>
<tr>
<td></td>
<td>clorazepate</td>
<td>Partial seizures</td>
</tr>
<tr>
<td></td>
<td>diazepam (IV)</td>
<td>Status epilepticus, tonic-clonic seizures</td>
</tr>
<tr>
<td></td>
<td>lorazepam (IV)</td>
<td>Status epilepticus</td>
</tr>
<tr>
<td>Hydantoins</td>
<td>fosphenytoin</td>
<td>Short-term parenteral management of seizures, treatment/prevention of seizures during neurosurgery</td>
</tr>
<tr>
<td></td>
<td>phenytoin</td>
<td>Tonic-clonic and partial seizures with complex symptomatology</td>
</tr>
<tr>
<td>Succinimides</td>
<td>ethosuximide</td>
<td>Absence seizures</td>
</tr>
<tr>
<td></td>
<td>acetoazolamide</td>
<td>Refractory seizures</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>carbamazepine</td>
<td>Tonic-clonic seizures, complex partial seizures, mixed seizures</td>
</tr>
<tr>
<td></td>
<td>gabapentin</td>
<td>Adjunctive treatment of partial seizures</td>
</tr>
<tr>
<td></td>
<td>lamotrigine</td>
<td>Adjunctive treatment of partial seizures</td>
</tr>
<tr>
<td></td>
<td>magnesium sulfate</td>
<td>Eclamptic seizures</td>
</tr>
<tr>
<td></td>
<td>oxcarbazepine</td>
<td>Adjunctive therapy of partial seizures</td>
</tr>
<tr>
<td></td>
<td>tiagabine</td>
<td>Adjunct treatment of partial seizures</td>
</tr>
<tr>
<td></td>
<td>topiramate</td>
<td>Adjunctive therapy of partial-onset seizures</td>
</tr>
<tr>
<td></td>
<td>valproates</td>
<td>Simple and complex partial seizures</td>
</tr>
</tbody>
</table>

**Contraindications:**

Previous hypersensitivity.

**Precautions:**

Use cautiously in patients with severe hepatic or renal disease; dosage adjustment may be required. Choose agents carefully in pregnant and lactating women. Fetal hydantoin syndrome may occur in offspring of patients who receive phenytoin during pregnancy.

**Interactions:**

Barbiturates stimulate the metabolism of other drugs that are metabolized by the liver, decreasing their effectiveness. Hydantoins are highly protein-bound and may displace or be displaced by other highly protein-bound drugs. Lamotrigine, tiagabine, and topiramate are capable of interacting with several other anticonvulsants. For more specific interactions, see individual drugs. Many drugs are capable of lowering seizure threshold and may decrease the effectiveness of anticonvulsants, including tri cyclic antidepressants and phenothiazines.

**NURSING IMPLICATIONS**

**Assessment**

- Assess location, duration, and characteristics of seizure activity.
- **Toxicity and Overdose:** Monitor serum drug levels routinely throughout anticonvulsant therapy, especially when adding or discontinuing other agents.

**Potential Nursing Diagnoses**

- Injury, risk for (Indications, Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
Implementation

- Administer anticonvulsants around the clock. Abrupt discontinuation may precipitate status epilepticus.
- Implement seizure precautions.

Patient/Family Teaching

- Instruct patient to take medication every day, exactly as directed.
- May cause drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known. Do not resume driving until physician gives clearance based on control of seizures.
- Advise patient to avoid taking alcohol or other CNS depressants concurrently with these medications.
- Advise patient to carry identification describing disease process and medication regimen at all times.

Evaluation

Effectiveness of therapy can be demonstrated by: ■ Decrease or cessation of seizures without excessive sedation.

Anticonvulsants Included in Davis's Drug Guide for Nurses

<table>
<thead>
<tr>
<th>Barbiturates</th>
<th>Valproates</th>
</tr>
</thead>
<tbody>
<tr>
<td>phenobarbital 784</td>
<td>divalproex sodium 1030</td>
</tr>
<tr>
<td>benzodiazepines</td>
<td>valproate sodium 1030</td>
</tr>
<tr>
<td>clonazepam 211</td>
<td>valproic acid 1030</td>
</tr>
<tr>
<td>clorazepate 216</td>
<td>miscellaneous</td>
</tr>
<tr>
<td>diazepam 279</td>
<td>carbamazepine 149</td>
</tr>
<tr>
<td>lorazepam 588</td>
<td>gabapentin 433</td>
</tr>
<tr>
<td>hydantoins</td>
<td>lamotrigine 561</td>
</tr>
<tr>
<td>phenytoin/ fosphenytoin 790</td>
<td>magnesium sulfate 595</td>
</tr>
<tr>
<td>succinamide</td>
<td>oxcarbazepine 736</td>
</tr>
<tr>
<td>ethosuximide 1175</td>
<td>tiagabine 989</td>
</tr>
<tr>
<td></td>
<td>topiramate 1006</td>
</tr>
</tbody>
</table>

ANTIDEPRESSANTS

PHARMACOLOGIC PROFILE

General Use:

Used in the treatment of various forms of endogenous depression, often in conjunction with psychotherapy. Other uses include: ■ Treatment of anxiety (doxepin) ■ Enuresis (imipramine) ■ Chronic pain syndromes (amitriptyline, doxepin, imipramine, and nortriptyline) ■ Smoking cessation (bupropion) ■ Bulimia (fluoxetine) ■ Obsessive-compulsive disorder (fluoxetine, sertraline).

General Action and Information:

Antidepressant activity most likely due to preventing the reuptake of dopamine, norepinephrine, and serotonin by presynaptic neurons, resulting in accumulation of these neurotransmitters.
The two major classes of antidepressants are the tricyclic antidepressants and the SSRI(s). Most tricyclic agents possess significant anticholinergic and sedative properties, which explains many of their side effects (amitriptyline, doxepin, imipramine, nortriptyline). The SSRIs are more likely to cause insomnia (fluoxetine, fluvoxamine, paroxetine, sertraline).

Contraindications:
Hypersensitivity. Should not be used in narrow-angle glaucoma. Should not be used in pregnancy or lactation or immediately after myocardial infarction.

Precautions:
Use cautiously in older patients and those with pre-existing cardiovascular disease. Elderly men with prostatic enlargement may be more susceptible to urinary retention. Anticholinergic side effects (dry eyes, dry mouth, blurred vision, and constipation) may require dosage modification or drug discontinuation. Dosage requires slow titration; onset of therapeutic response may be 2–4 wk. May decrease seizure threshold, especially bupropion.

Interactions:
Tricyclic antidepressants—May cause hypertension, tachycardia, and convulsions when used with MAO inhibitors. May prevent therapeutic response to some antihypertensives. Additive CNS depression with other CNS depressants. Sympathomimetic activity may be enhanced when used with other sympathomimetics. Additive anticholinergic effects with other drugs possessing anticholinergic properties. MAO inhibitors—Hypertensive crisis may occur with concurrent use of MAO inhibitors and amphetamines, methyldopa, levodopa, dopamine, epinephrine, norepinephrine, desipramine, imipramine, guanethidine, reserpine, vasoconstrictors, or ingestion of tyramine-containing foods. Hypertension or hypotension, coma, convulsions, and death may occur with meperidine or other opioid analgesics and MAO inhibitors. Additive hypotension with antihypertensives or spinal anesthesia and MAO inhibitors. Fluoxetine, fluvoxamine, bupropion, citalopram, paroxetine, sertraline, or venlafaxine should not be used in combination with or within weeks of MAO inhibitors (see individual monographs). Risk of adverse reactions may be increased by rizatriptan, naratriptan, sumatriptan, or zolmitriptan.

NURSING IMPLICATIONS
Assessment
- Monitor mental status and affect. Assess for suicidal tendencies, especially during early therapy. Restrict amount of drug available to patient.
- Toxicity and Overdose: Concurrent ingestion of monamine oxidase inhibitors and tyramine-containing foods may lead to hypertensive crisis. Symptoms include chest pain, severe headache, nuchal rigidity, nausea and vomiting, photosensitivity, and enlarged pupils. Treatment includes IV phentolamine.

Potential Nursing Diagnoses
- Coping, ineffective individual (Indications).
- Injury, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Implementation

- Administer drugs that are sedating at bedtime to avoid excessive drowsiness during waking hours, and administer drugs that cause insomnia (fluoxetine, fluvoxamine, paroxetine, sertraline, MAO inhibitors) in the morning. Bupropion must be given in divided doses.

Patient/Family Teaching

- Caution patient to avoid alcohol and other CNS depressants. Patients receiving MAO inhibitors should also avoid OTC drugs and foods or beverages containing tyramine (see Appendix L for foods) during and for at least 2 wk after therapy has been discontinued, as they may precipitate a hypertensive crisis. Health care professional should be contacted immediately if symptoms of hypertensive crisis develop.
- Inform patient that dizziness or drowsiness may occur. Caution patient to avoid driving and other activities requiring alertness until response to the drug is known.
- Caution patient to make position changes slowly to minimize orthostatic hypotension.
- Advise patient to notify health care professional if dry mouth, urinary retention, or constipation occurs. Frequent rinses, good oral hygiene, and sugarless candy or gum may diminish dry mouth. An increase in fluid intake, fiber, and exercise may prevent constipation.
- Advise patient to notify health care professional of medication regimen before treatment or surgery. MAO inhibitor therapy usually needs to be withdrawn at least 2 wk before use of anesthetic agents.
- Emphasize the importance of participation in psychotherapy and follow-up exams to evaluate progress.

Evaluation

Effectiveness of therapy can be demonstrated by: ■ Resolution of depression ■ Decrease in anxiety ■ Control of bedwetting in children over 6 yr of age ■ Management of chronic neurogenic pain.

Antidepressants Included in Davis's Drug Guide for Nurses

<table>
<thead>
<tr>
<th>tricyclic antidepressants</th>
<th>monoamine oxidase (MAO) inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>amitriptyline 39</td>
<td>phenelzine 661</td>
</tr>
<tr>
<td>doxepin 330</td>
<td>tranylcypromine 661</td>
</tr>
<tr>
<td>imipramine 509</td>
<td></td>
</tr>
<tr>
<td>nortriptyline 719</td>
<td></td>
</tr>
<tr>
<td>selective serotonin reuptake</td>
<td>miscellaneous</td>
</tr>
<tr>
<td>inhibitors</td>
<td></td>
</tr>
<tr>
<td>citalopram 202</td>
<td>bupropion 129</td>
</tr>
<tr>
<td>fluoxetine 417</td>
<td>mirtazapine 654</td>
</tr>
<tr>
<td>fluvoxamine 426</td>
<td>nefazodone 690</td>
</tr>
<tr>
<td>paroxetine 752</td>
<td>trazodone 1015</td>
</tr>
<tr>
<td>sertraline 916</td>
<td>venlafaxine 1035</td>
</tr>
</tbody>
</table>
ANTIDIABETIC AGENTS

PHARMACOLOGIC PROFILE

General Use:
Insulin is used in the management of insulin-dependent diabetes mellitus (IDDM, type 1). It may also be used in non-insulin-dependent diabetes mellitus (NIDDM, type 2) when diet and/or oral hypoglycemic therapy fails to adequately control blood sugar. The choice of insulin preparation (rapid-acting, intermediate-acting, long-acting) and source (beef, beef/pork, pork, semisynthetic, human recombinant DNA) depend on the degree of control desired, daily blood sugar fluctuations, and history of previous reactions. Oral hypoglycemics can be used only in NIDDM, type 2. Oral agents are used when diet therapy alone fails to control blood sugar or symptoms or when patients are not amenable to using insulin. Some oral agents may be used with insulin.

General Action and Information:
Insulin, a hormone produced by the pancreas, lowers blood glucose by increasing transport of glucose into cells and promotes the conversion of glucose to glycogen. It also promotes the conversion of amino acids to proteins in muscle, stimulates triglyceride formation, and inhibits the release of free fatty acids. Sulfonylureas, repaglinide, and metformin lower blood sugar by stimulating endogenous insulin secretion by beta cells of the pancreas and by increasing sensitivity to insulin at intracellular receptor sites. Intact pancreatic function is required. Miglitol delays digestion of ingested carbohydrates, thus lowering blood sugar, especially after meals. It may be combined with sulfonylureas.

Contraindications:
Insulin—Hypoglycemia. Oral hypoglycemic agents—Hypersensitivity (cross-sensitivity with other sulfonylureas and sulfonamides may exist). Hypoglycemia. IDDM, type 1. Avoid use in patients with severe kidney, liver, thyroid, and other endocrine dysfunction. Should not be used in pregnancy or lactation.

Precautions:
Insulin—Infection, stress, or changes in diet may alter requirements. Oral hypoglycemic agents—Use cautiously in geriatric patients. Dosage reduction may be necessary. Infection, stress, or changes in diet may alter requirements. Use with sulfonylureas with caution in patients with a history of cardiovascular disease. Metformin may cause lactic acidosis.

Interactions:
Insulin—Additive hypoglycemic effects with oral hypoglycemic agents. Oral hypoglycemic agents—Ingestion of alcohol may result in disulfiram-like reaction with some agents. Alcohol, corticosteroids, rifampin, glucagon, and thiazide diuretics may decrease effectiveness. Anabolic steroids, chloramphenicol, clofibrate, MAO inhibitors, most NSAIDs, salicylates, sulfonamides, and warfarin may increase hypoglycemic effect. Beta-adrenergic blocking agents may produce hypoglycemia and mask signs and symptoms.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
NURSING IMPLICATIONS

Assessment

- Observe patient for signs and symptoms of hypoglycemic reactions.
- Miglitol and pioglitazone do not cause hypoglycemia when taken alone but may increase the hypoglycemic effect of other hypoglycemic agents.
- Patients who have been well controlled on metformin but develop illness or laboratory abnormalities should be assessed for ketoacidosis or lactic acidosis. Assess serum electrolytes, ketones, glucose, and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If either form of acidosis is present, discontinue metformin immediately and treat acidosis.

**Lab Test Considerations:** Serum glucose and glycosylated hemoglobin should be monitored periodically throughout therapy to evaluate effectiveness of treatment.

Potential Nursing Diagnoses

- Nutrition, altered: more than body requirements (Indications).
- Knowledge deficit: related to medication regimen (Patient/Family Teaching).
- Noncompliance (Patient/Family Teaching).

Implementation

- **General Info:** Patients stabilized on a diabetic regimen who are exposed to stress, fever, trauma, infection, or surgery may require sliding scale insulin. Withhold metformin and reinstitute after resolution of acute episode.
- Patients switching from daily insulin dose may require gradual conversion to oral hypoglycemics.
- **Insulin:** Available in different types and strengths and from different species. Check type, species’ source, dose, and expiration date with another licensed nurse. Do not interchange insulins without physician’s order. Use only insulin syringes to draw up dose. Use only U100 syringes to draw up insulin lispro dose.

Patient/Family Teaching

- **General Info:** Explain to patient that medication controls hyperglycemia but does not cure diabetes. Therapy is long-term.
- Review signs of hypoglycemia and hyperglycemia with patient. If hypoglycemia occurs, advise patient to take a glass of orange juice or 2–3 tsp of sugar, honey, or corn syrup dissolved in water (glucose, not table sugar, if taking miglitol), and notify health care professional.
- Encourage patient to follow prescribed diet, medication, and exercise regimen to prevent hypoglycemic or hyperglycemic episodes.
- Instruct patient in proper testing of serum glucose and ketones.
- Advise patient to notify health care professional if nausea, vomiting, or fever develops; if unable to eat usual diet; or if blood sugar levels are not controlled.
- Advise patient to carry sugar or a form of glucose and identification describing medication regimen at all times.
- Insulin is the recommended method of controlling blood sugar during pregnancy. Counsel female patients to use a form of contraception other than oral contraceptives and to notify health care professional promptly if pregnancy is planned or suspected.
- **Insulin:** Instruct patient on proper technique for administration; include type of insulin, equipment (syringe and cartridge pens), storage, and syringe disposal. Discuss the importance of not changing brands of insulin or syringes, selection and rotation of injection sites, and compliance with therapeutic regimen.
Because of space limitations, additional classes or drugs not represented in Davis's Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.

**Sulfonylureas:** Advise patient that concurrent use of alcohol may cause a disulfiram-like reaction (abdominal cramps, nausea, flushing, headache, and hypoglycemia).

**Metformin:** Explain to patient the risk of lactic acidosis and the potential need for discontinuation of metformin therapy if a severe infection, dehydration, or severe or continuing diarrhea occurs or if medical tests or surgery is required.

**Evaluation**

**Effectiveness of therapy can be demonstrated by:**  
Control of blood glucose levels without the appearance of hypoglycemic or hyperglycemic episodes.

**Antidiabetic Agents Included in Davis's Drug Guide for Nurses**

- **alpha-glucosidase inhibitor**
  miglitol 649

- **biguanide**
  metformin 619

- **insulin mixture**
  NPH/regular insulin mixture 520

- **intermediate-acting insulin**
  insulin, NPH (isophane insulin suspension) 520
  insulin zinc suspension (lente insulin) 520

- **long-acting insulin**
  insulin zinc suspension, extended (ultralenle insulin) 520

- **rapid-acting insulin**
  insulin, lispro, rDNA origin 520
  regular insulin (insulin injection, crystalline zinc insulin) 520

- **sulfonylureas**
  glimepiride 495
  glipizide 495
  glyburide 495

- **miscellaneous**
  pioglitazone 801
  repaglinide 877
  rosiglitazone P–105

**ANTIDIARRHEAL AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
For the control and symptomatic relief of acute and chronic nonspecific diarrhea.

**General Action and Information:**
Diphenoxylate/atropine, difenoxin/atropine, and loperamide slow intestinal motility and propulsion. Kaolin/pectin and bismuth subsalicylate affect fluid content of the stool. Polycarbophil acts as an antidiarrheal by taking on water within the bowel lumen to create a formed stool. Octreotide is used specifically for diarrhea associated with GI endocrine tumors.

**Contraindications:**
Previous hypersensitivity. Severe abdominal pain of unknown cause, especially when associated with fever.

---

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Precautions:
Use cautiously in patients with severe liver disease or inflammatory bowel disease. Safety in pregnancy and lactation not established (diphenoxylate/atropine and loperamide). Octreotide may aggravate gallbladder disease.

Interactions:
Kaolin/pectin may decrease absorption of digoxin. Polycarbophil decreases the absorption of tetracycline. Octreotide may alter the response to insulin or oral hypoglycemic agents.

NURSING IMPLICATIONS
Assessment
■ Assess the frequency and consistency of stools and bowel sounds before and throughout therapy.
■ Assess patient’s fluid and electrolyte status and skin turgor for dehydration.

Potential Nursing Diagnoses
■ Diarrhea (Indications).
■ Constipation (Side Effects).
■ Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
■ Shake liquid preparations before administration.

Patient/Family Teaching
■ Instruct patient to notify health care professional if diarrhea persists; or if fever, abdominal pain, or palpitations occur.

Evaluation
Effectiveness of therapy can be demonstrated by: ■ Decrease in diarrhea.

Antidiarrheal Agents Included in Davis’s Drug Guide for Nurses
- attapulgite 1171
- bismuth subsalicylate 110
- difenoxin/atropine 303
- diphenoxylate/atropine 303
- kaolin/pectin 547
- loperamide 585
- octreotide 723
- polycarbophil 811

ANTIDOTES
PHARMACOLOGIC PROFILE
General Use:
See the following table.
General Action and Information:

Antidotes are used in accidental and intentional overdoses of medications or toxic substances. The goal of antidotal therapy is to decrease systemic complications of the overdosage while supporting vital functions. Obtaining a precise history will determine aggressiveness of therapy, choice, and dose of agent. Some antidotes are designed to aid removal of the offending agent before systemic absorption occurs or to speed elimination (activated charcoal). Other agents are more specific and require more detailed history as to type and amount of agent ingested.

POISONS AND SPECIFIC ANTIDOTES

<table>
<thead>
<tr>
<th>POISON</th>
<th>ANTIDOTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen</td>
<td>acetylcysteine</td>
</tr>
<tr>
<td>anticholinesterases</td>
<td>atropine, pralidoxime</td>
</tr>
<tr>
<td>benzodiazepines</td>
<td>flumazenil</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>meprobamate</td>
</tr>
<tr>
<td>doxorubicin</td>
<td>diphenhydramine</td>
</tr>
<tr>
<td>fluorouracil</td>
<td>leucovorin calcium</td>
</tr>
<tr>
<td>heparin</td>
<td>protamine sulfate</td>
</tr>
<tr>
<td>iron</td>
<td>deferoxamine</td>
</tr>
<tr>
<td>lead</td>
<td>succimer</td>
</tr>
<tr>
<td>methotrexate</td>
<td>leucovorin calcium</td>
</tr>
<tr>
<td>opioid analgesics, heroin</td>
<td>naloxone</td>
</tr>
<tr>
<td>warfarin</td>
<td>phytonadione (vitamin K)</td>
</tr>
</tbody>
</table>

Contraindications:

See individual drugs.

Precautions:

See individual drugs.

Interactions:

See individual drugs.

NURSING IMPLICATIONS

Assessment

■ Inquire as to the type of drug or poison and time of ingestion.
■ Consult reference, poison control center, or physician for symptoms of toxicity of ingested agent(s) and antidote. Monitor vital signs, affected systems, and serum levels closely.
■ Monitor for suicidal ideation; institute suicide precautions as necessary.

Potential Nursing Diagnoses

■ Coping, ineffective individual (Indications).
■ Injury, risk for: poisoning (Patient/Family Teaching).
■ Knowledge deficit, related to medication regimen (Patient/Family Teaching).

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Implementation

- May be used in conjunction with induction of emesis or gastric aspiration and lavage, cathartics, agents to modify urine pH, and supportive measures for respiratory and cardiac effects of overdose or poisoning.

Patient/Family Teaching

- When counseling about poisoning in the home, discuss methods of prevention and the need to confer with poison control center, physician, or emergency department prior to administering syrup of ipecac and the need to bring ingested substance to the hospital for identification. Reinforce need to keep all medications and hazardous substances out of the reach of children.

Evaluation

**Effectiveness of therapy is demonstrated by:**

- Prevention or resolution of toxic side effects of ingested agent.

Antidotes Included in *Davis's Drug Guide for Nurses*

<table>
<thead>
<tr>
<th>Acetaminophen 5</th>
<th>Leucovorin calcium 567</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amyl nitrate 1170</td>
<td>Mesna 616</td>
</tr>
<tr>
<td>Deferoxamine 268</td>
<td>Naloxone 685</td>
</tr>
<tr>
<td>Dextromethorphan 274</td>
<td>Prolidase 1180</td>
</tr>
<tr>
<td>Digoxin immune Fab 291</td>
<td>Prothrombin 854</td>
</tr>
<tr>
<td>Dexamethasone 1175</td>
<td>Sodium nitrate 1181</td>
</tr>
<tr>
<td>Flumazenil 406</td>
<td>Sodium thiosulfate 1181</td>
</tr>
<tr>
<td>Succimer 939</td>
<td></td>
</tr>
</tbody>
</table>

**ANTIEMETIC AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**

Phenothiazines, dolasetron, granisetron, metoclopramide, trimethobenzamide, and ondansetron are used to manage nausea and vomiting of many causes, including surgery, anesthesia, and antineoplastic and radiation therapy. Dimenhydrinate, scopolamine, and meclizine are used almost exclusively to prevent motion sickness.

**General Action and Information:**

Phenothiazines act on the chemoreceptor trigger zone to inhibit nausea and vomiting. Dimenhydrinate, scopolamine, and meclizine act as antiemetics mainly by diminishing motion sickness. Metoclopramide decreases nausea and vomiting by its effects on gastric emptying. Dolasetron, granisetron, and ondansetron block the effects of serotonin.

**Contraindications:**

Previous hypersensitivity.
Precautions:
Use phenothiazines cautiously in children who may have viral illnesses. Choose agents carefully in pregnant patients (no agents are approved for safe use).

Interactions:
Additive CNS depression with other CNS depressants including antidepressants, antihistamines, opioid analgesics, and sedative/hypnotics. Phenothiazines may produce hypotension when used with antihypertensives, nitrates, or acute ingestion of alcohol.

NURSING IMPLICATIONS
Assessment
■ Assess nausea, vomiting, bowel sounds, and abdominal pain before and following administration.
■ Monitor hydration status and intake and output. Patients with severe nausea and vomiting may require IV fluids in addition to antiemetics.

Potential Nursing Diagnoses
■ Fluid volume deficit (Indications).
■ Nutrition, altered: less than body requirements (Indications).
■ Injury, risk for (Side Effects).

Implementation
■ For prophylactic administration, follow directions for specific drugs so that peak effect corresponds to time of anticipated nausea.
■ Phenothiazines should be discontinued 48 hr before and not resumed for 24 hr following myelography, as they lower seizure threshold.

Patient/Family Teaching
■ Advise patient and family to use general measures to decrease nausea (begin with sips of liquids and small, nongreasy meals; provide oral hygiene; and remove noxious stimuli from environment).
■ May cause drowsiness. Advise patient to call for assistance when ambulating and to avoid driving or other activities requiring alertness until response to medication is known.
■ Advise patient to make position changes slowly to minimize orthostatic hypotension.

Evaluation
Effectiveness of therapy can be demonstrated by: ■ Prevention of, or decrease in, nausea and vomiting.

Antiemetic Agents Included in Davis’s Drug Guide for Nurses
anticholinergic
scopolamine 913

antihistamines
dimenhydrinate 296
meclizine 604

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
**ANTIFUNGAL AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
Treatment of fungal infections. Infections of skin or mucous membranes may be treated with topical or vaginal preparations. Deep-seated or systemic infections require oral or parenteral therapy. New parenteral formulations of amphotericin employ lipid encapsulation technology designed to decrease toxicity.

**General Action and Information:**
Kill (fungicidal) or stop growth of (fungistatic) susceptible fungi by affecting the permeability of the fungal cell membrane or protein synthesis within the fungal cell itself.

**Contraindications:**
Previous hypersensitivity.

**Precautions:**
Because most systemic antifungals may have adverse effects on bone marrow function, use cautiously in patients with depressed bone marrow reserve. Amphotericin B commonly causes renal impairment. Fluconazole requires dosage adjustment in the presence of renal impairment. Adverse reactions to fluconazole may be more severe in HIV-positive patients.

**Interactions:**
Differ greatly among various agents. See individual drugs.

**NURSING IMPLICATIONS**

**Assessment**
- Assess patient for signs of infection and assess involved areas of skin and mucous membranes before and throughout therapy. Increased skin irritation may indicate need to discontinue medication.

**Potential Nursing Diagnoses**
- Infection, risk for (Indications).
- Skin integrity, impaired (Indications).
Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- **General Info:** Available in various dosage forms. Refer to specific drugs for directions for administration.
- **Topical:** Consult physician or other health care professional for cleansing technique before applying medication. Wear gloves during application. Do not use occlusive dressings unless specified by physician or other health care professional.

Patient/Family Teaching

- Instruct patient on proper use of medication form.
- Instruct patient to continue medication as directed for full course of therapy, even if feeling better.
- Advise patient to report increased skin irritation or lack of therapeutic response to health care professional.

Evaluation

**Effectiveness of therapy can be demonstrated by:**

- Resolution of signs and symptoms of infection. Length of time for complete resolution depends on organism and site of infection.
- Deep-seated fungal infections may require prolonged therapy (weeks–months). Recurrent fungal infections may be a sign of serious systemic illness.

Antifungal Agents Included in *Davis’s Drug Guide for Nurses*

**ophthalmic antifungal**
- natamycin 1158

**systemic antifungals**
- amphotericin B cholesteryl sulfate 48
- amphotericin B deoxycholate 48
- amphotericin B lipid complex 48
- amphotericin B liposome 48
- dapsone 1173
- fluconazole 402
- griseofulvin 450
- itraconazole 543
- ketoconazole 548

**topical antifungals**
- amphotericin B deoxycholate 48
- butenafine 70
- ciclopirox 70
- clotrimazole 70

- econazole 70
- haloprogin 70
- ketoconazole 548
- miconazole 70
- naftifine 70
- nystatin 721
- oxiconazole 70
- sulconazole 70
- tolnaftate 70

- **vaginal antifungals**
- butoconazole 73
- clotrimazole 73
- miconazole 73
- nystatin 721
- terconazole 73
- tioconazole 73

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
ANTIHISTAMINES

PHARMACOLOGIC PROFILE

General Use:
Relief of symptoms associated with allergies, including rhinitis, urticaria, and angioedema, and as adjunctive therapy in anaphylactic reactions. Some antihistamines are used to treat motion sickness (dimenhydrinate and meclizine), insomnia (diphenhydramine), Parkinson-like reactions (diphenhydramine), and other nonallergic conditions.

General Action and Information:
Antihistamines block the effects of histamine at the H₁ receptor. They do not block histamine release, antibody production, or antigen-antibody reactions. Most antihistamines have anticholinergic properties and may cause constipation, dry eyes, dry mouth, and blurred vision. In addition, many antihistamines cause sedation. Some phenothiazines have strong antihistaminic properties (hydroxyzine and promethazine).

Contraindications:
Hypersensitivity and narrow-angle glaucoma. Should not be used in premature or newborn infants.

Precautions:
Elderly patients may be more susceptible to adverse anticholinergic effects of antihistamines. Use cautiously in patients with pyloric obstruction, prostatic hypertrophy, hyperthyroidism, cardiovascular disease, or severe liver disease. Use cautiously in pregnancy and lactation.

Interactions:
Additive sedation when used with other CNS depressants, including alcohol, antidepressants, opioid analgesics, and sedative/hypnotics. MAO inhibitors prolong and intensify the anticholinergic properties of antihistamines.

NURSING IMPLICATIONS

Assessment
- **General Info:** Assess allergy symptoms (rhinitis, conjunctivitis, hives) before and periodically throughout therapy.
- Monitor pulse and blood pressure before initiating and throughout IV therapy.
- Assess lung sounds and character of bronchial secretions. Maintain fluid intake of 1500–2000 ml/day to decrease viscosity of secretions.
- **Nausea and Vomiting:** Assess degree of nausea and frequency and amount of emesis when administering for nausea and vomiting.
- **Anxiety:** Assess mental status, mood, and behavior when administering for anxiety.
- **Pruritus:** Observe the character, location, and size of affected area when administering for pruritic skin conditions.

Potential Nursing Diagnoses
- Airway clearance, ineffective (Indications).
Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.

Implementation

- When used for prophylaxis of motion sickness, administer at least 30 min and preferably 1–2 hr before exposure to conditions that may precipitate motion sickness.
- When administering concurrently with opioid analgesics (hydroxyzine, promethazine), supervise ambulation closely to prevent injury secondary to increased sedation.

Patient/Family Teaching

- Inform patient that drowsiness may occur. Avoid driving or other activities requiring alertness until response to drug is known.
- Caution patient to avoid using concurrent alcohol or CNS depressants.
- Advise patient that good oral hygiene, frequent rinsing of mouth with water, and sugarless gum or candy may help relieve dryness of mouth.
- Instruct patient to contact health care professional if symptoms persist.

Evaluation

Effectiveness of therapy can be demonstrated by:
- Decrease in allergic symptoms
- Prevention or decreased severity of nausea and vomiting
- Decrease in anxiety
- Relief of pruritus
- Sedation when used as a sedative/hypnotic.

Antihistamines Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>Antihistamine</th>
<th>84</th>
<th>118</th>
<th>183</th>
<th>190</th>
<th>254</th>
<th>296</th>
</tr>
</thead>
<tbody>
<tr>
<td>azatadine</td>
<td>84</td>
<td>118</td>
<td>183</td>
<td>190</td>
<td>254</td>
<td>296</td>
</tr>
<tr>
<td>brompheniramine</td>
<td>118</td>
<td>183</td>
<td>190</td>
<td>254</td>
<td>296</td>
<td>296</td>
</tr>
<tr>
<td>cetirizine</td>
<td>183</td>
<td>190</td>
<td>254</td>
<td>296</td>
<td>84</td>
<td>118</td>
</tr>
<tr>
<td>chlorpheniramine</td>
<td>190</td>
<td>254</td>
<td>296</td>
<td>296</td>
<td>84</td>
<td>118</td>
</tr>
<tr>
<td>cyproheptadine</td>
<td>254</td>
<td>296</td>
<td>84</td>
<td>118</td>
<td>183</td>
<td>190</td>
</tr>
<tr>
<td>dimenhydrinate</td>
<td>296</td>
<td>84</td>
<td>118</td>
<td>183</td>
<td>190</td>
<td>254</td>
</tr>
<tr>
<td>diphenhydramine</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fexofenadine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hydroxyzine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>loratadine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>meclizine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>promethazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ANTIHYPERTENSIVE AGENTS

PHARMACOLOGIC PROFILE

General Use:

Treatment of hypertension of many causes, most commonly essential hypertension. Parenteral products are used in the treatment of hypertensive emergencies. Oral treatment should be initiated as soon as possible and individualized to ensure compliance for long-term therapy. Therapy is initiated with agents having minimal side effects. When such therapy fails, more potent drugs with different side effects are added in an effort to control blood pressure while causing minimal patient discomfort.

General Action and Information:

As a group, the antihypertensives are used to lower blood pressure to a normal level (<90 mm Hg diastolic) or to the lowest level tolerated. The goal of antihypertensive therapy is prevention of end-organ damage. Antihypertensives are classified into groups according to their site of action.
action. These include peripherally acting antiadrenergics; centrally acting alpha adrenergics; beta-adrenergic blockers; vasodilators; ACE inhibitors; angiotensin II antagonists; calcium channel blockers; diuretics; and indapamide, a diuretic with vasodilatory properties. Hypertensive emergencies may be managed with parenteral vasodilators such as nitroprusside or enalaprilat.

Contraindications:
Hypersensitivity to individual agents.

Precautions:
Choose agents carefully in pregnancy, during lactation, or in patients receiving cardiac glycosides. ACE inhibitors and angiotensin II antagonists should be avoided during pregnancy. Alpha-adrenergic agonists and beta-adrenergic blockers should be used only in patients who will comply, because abrupt discontinuation of these agents may result in rapid and excessive rise in blood pressure (rebound phenomenon). Thiazide diuretics may increase the requirement for insulin, diet therapy, or oral hypoglycemic agents in diabetics. Vasodilators may cause tachycardia if used alone and are commonly used in combination with beta-adrenergic blocking agents. Most antihypertensives (except for beta-adrenergic blockers, ACE inhibitors, angiotensin II receptor antagonists, and calcium channel blockers) cause sodium and water retention and are usually combined with a diuretic.

Interactions:
Many drugs can negate the therapeutic effectiveness of antihypertensives, including antihistamines, NSAIDs, sympathomimetic bronchodilators, decongestants, appetite suppressants, antidepressants, and MAO inhibitors. Hypokalemia from diuretics may increase the risk of cardiac glycoside toxicity. Potassium supplements and potassium-sparing diuretics may cause hyperkalemia when used with ACE inhibitors.

NURSING IMPLICATIONS

Assessment
- Monitor blood pressure and pulse frequently during dosage adjustment and periodically throughout therapy.
- Monitor intake and output ratios and daily weight.
- Monitor frequency of prescription refills to determine compliance.

Potential Nursing Diagnoses
- Tissue perfusion, altered (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
- Noncompliance (Patient/Family Teaching).

Implementation
- Many antihypertensive agents are available as combination products to enhance compliance (see Appendix B).
Patient/Family Teaching

- Instruct patient to continue taking medication, even if feeling well. Abrupt withdrawal may cause rebound hypertension. Medication controls but does not cure hypertension.
- Encourage patient to comply with additional interventions for hypertension (weight reduction, low-sodium diet, regular exercise, discontinuation of smoking, moderation of alcohol consumption, and stress management).
- Instruct patient and family on proper technique for monitoring blood pressure. Advise them to check blood pressure weekly and report significant changes.
- Caution patient to make position changes slowly to minimize orthostatic hypotension. Advise patient that exercise or hot weather may enhance hypotensive effects.
- Advise patient to consult health care professional before taking any OTC medications, especially cold remedies.
- Advise patient to inform health care professional of medication regimen before treatment or surgery.
- Patients taking ACE inhibitors or angiotensin II antagonists should notify health care professional if pregnancy is planned or suspected.
- Emphasize the importance of follow-up exams to monitor progress.

Evaluation

Effectiveness of therapy can be demonstrated by: ■ Decrease in blood pressure.

Antihypertensive Agents Included in Davis’s Drug Guide for Nurses

- **alpha-adrenergic blocking agent**
  - phenoxybenzamine 1179
- **angiotensin-converting enzyme (ACE) inhibitors**
  - benazepril 63
  - captopril 63
  - enalapril, enalaprilat 63
  - fosinopril 64
  - lisinopril 64
  - moexipril 64
  - perindopril 64
  - quinapril 64
  - ramipril 64
  - trandolapril 64
- **angiotensin II antagonists**
  - candesartan 61
  - irbesartan 61
  - losartan 61
  - valsartan 61
- **beta-adrenergic blocking agents**
  - acebutolol 1
  - atenolol 79
  - betaxolol 100
  - carteolol 160
  - carvedilol 162
  - labetalol 555
  - metoprolol 638
  - nadolol 678
  - penbutolol 758
  - pindolol 799
  - propranolol 849
  - timolol 996
- **calcium channel blockers**
  - amlodipine 41
  - diltiazem 293
  - felodipine 384
  - isradipine 541
  - nicardipine 699
  - nifedipine 705
  - nisoldipine 711
  - verapamil 1037
- **centrally acting adrenergics**
  - clonidine 212
  - guanabenz 455
  - guanfacine 459
  - methyldopa P–96
- **diuretics**
  - chlorothiazide 315
  - chlorothalidone 315
  - furosemide 308

---

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
**ANTI-INFECTIVE AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
Treatment and prophylaxis of various bacterial infections. See specific drugs for spectrum and indications. Some infections may require additional surgical intervention and supportive therapy.

**General Action and Information:**
Kill (bactericidal) or inhibit the growth of (bacteriostatic) susceptible pathogenic bacteria. Not active against viruses or fungi. Anti-infective agents are subdivided into categories depending on chemical similarities and antimicrobial spectrum.

**Contraindications:**
Known hypersensitivity to individual agents. Cross-sensitivity among related agents may occur.

**Precautions:**
Culture and susceptibility testing are desirable to optimize therapy. Dosage modification may be required in patients with hepatic or renal insufficiency. Use cautiously in pregnant and lactating women. Prolonged inappropriate use of broad spectrum anti-infective agents may lead to superinfection with fungi or resistant bacteria.

**Interactions:**
Penicillins and aminoglycosides chemically inactivate each other and should not be physically admixed. Erythromycins may decrease hepatic metabolism of other drugs. Probenecid increases serum levels of penicillins and related compounds. Highly protein-bound anti-infectives such as sulfonamides may displace or be displaced by other highly bound drugs. See individual drugs. Extended-spectrum penicillins (ticarcillin, piperacillin) and some cephalosporins (ceftamandole, cefoperazone, cefotetan) may increase the risk of bleeding with anticoagulants, antiplatelet agents, or NSAIDs. Fluoroquinolone absorption is decreased by antacids, bismuth subsalicylate, iron salts, sucralfate, and zinc salts.

**NURSING IMPLICATIONS**

**Assessment**

- Assess patient for signs and symptoms of infection prior to and throughout therapy.
- Determine previous hypersensitivities in patients receiving penicillins or cephalosporins.
- Obtain specimens for culture and sensitivity prior to initiating therapy. First dose may be given before receiving results.
Potential Nursing Diagnoses
- Infection, risk for (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
- Noncompliance (Patient/Family Teaching).

Implementation
- Most anti-infectives should be administered around the clock to maintain therapeutic serum drug levels.

Patient/Family Teaching
- Instruct patient to continue taking medication around the clock until finished completely, even if feeling better.
- Advise patient to report the signs of superinfection (black, furry overgrowth on the tongue; vaginal itching or discharge; loose or foul-smelling stools) and allergy to health care professional.
- Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains pus, blood, or mucus. Advise patient not to treat diarrhea without consulting health care professional.
- Instruct patient to notify health care professional if symptoms do not improve.

Evaluation
Effectiveness of therapy can be demonstrated by: Resolution of the signs and symptoms of infection. Length of time for complete resolution depends on organism and site of infection.

Anti-infective Agents Included in *Davis's Drug Guide for Nurses*

<table>
<thead>
<tr>
<th>aminoglycosides</th>
<th>cephalosporins—second generation</th>
</tr>
</thead>
<tbody>
<tr>
<td>amikacin 30</td>
<td>cefaclor 171</td>
</tr>
<tr>
<td>gentamicin 30</td>
<td>cefamandole 171</td>
</tr>
<tr>
<td>kanamycin 30</td>
<td>cefmetazole 171</td>
</tr>
<tr>
<td>neomycin 30</td>
<td>cefonicid 171</td>
</tr>
<tr>
<td>netilminic 30</td>
<td>cefotetan 171</td>
</tr>
<tr>
<td>streptomycin 30</td>
<td>cefoxitin 171</td>
</tr>
<tr>
<td>tobramycin 30</td>
<td>ceprozil 171</td>
</tr>
<tr>
<td></td>
<td>cefuroxime 171</td>
</tr>
<tr>
<td></td>
<td>loracarbef 171</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>antimalarial</th>
<th>cephalosporins—third generation</th>
</tr>
</thead>
<tbody>
<tr>
<td>quinine P–103</td>
<td>cediranir 176</td>
</tr>
<tr>
<td></td>
<td>cefepime 176</td>
</tr>
<tr>
<td></td>
<td>cefixime 176</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>antiprotozoal</th>
<th>cephalexin 177</th>
</tr>
</thead>
<tbody>
<tr>
<td>pentamide 771</td>
<td>cefadroxil 167</td>
</tr>
<tr>
<td></td>
<td>cefazolin 167</td>
</tr>
<tr>
<td></td>
<td>cephalaxin 167</td>
</tr>
<tr>
<td></td>
<td>cephamycin 167</td>
</tr>
</tbody>
</table>

*Because of space limitations, additional classes or drugs not represented in *Davis's Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
ANTINEOPLASTIC AGENTS

PHARMACOLOGIC AGENTS

General Use:
Used in the treatment of various solid tumors, lymphomas, and leukemias. Also used in some autoimmune disorders such as rheumatoid arthritis (cyclophosphamide, methotrexate). Often used in combinations to minimize individual toxicities and increase response. Chemotherapy may be combined with other treatment modalities such as surgery and radiation therapy. Dosages vary greatly, depending on extent of disease, other agents used, and patient’s condition. Some new formulations (daunorubicin, doxorubicin) encapsulated in a lipid membrane have less toxicity with greater efficacy.

General Action and Information:
Act by many different mechanisms (see the following table). Most commonly affect DNA synthesis or function. Action may not be limited to neoplastic cells.
Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.

### MECHANISM OF ACTION OF VARIOUS ANTEOPLASTIC AGENTS

<table>
<thead>
<tr>
<th>MECHANISM OF ACTION</th>
<th>AGENT</th>
<th>EFFECTS ON CELL CYCLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALKYLATING AGENTS</td>
<td>busulfan</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>carboplatin</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>chlorambucil</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>cyclophosphamide</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>dacarbazine</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>ifosfamide</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>melphalan</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>procarbazine</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>temozolamide</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>thiotepa</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td>ANTIANGIOGENIC AGENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANTHOCYCLINES</td>
<td>daunorubicin</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>doxorubicin</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td></td>
<td>idarubicin</td>
<td>Cell cycle–nonspecific</td>
</tr>
<tr>
<td>ANTIMETABOLITES</td>
<td>capecitabine</td>
<td>Cell cycle–specific, work mostly in S phase (DNA synthesis)</td>
</tr>
<tr>
<td></td>
<td>cytarabine</td>
<td>Cell cycle–specific, work mostly in S phase (DNA synthesis)</td>
</tr>
<tr>
<td></td>
<td>fluorouracil</td>
<td>Cell cycle–specific, work mostly in S phase (DNA synthesis)</td>
</tr>
<tr>
<td></td>
<td>fludarabine</td>
<td>Cell cycle–specific, work mostly in S phase (DNA synthesis)</td>
</tr>
<tr>
<td></td>
<td>hydroxyurea</td>
<td>Cell cycle–specific, work mostly in S phase (DNA synthesis)</td>
</tr>
<tr>
<td></td>
<td>mercaptopurine</td>
<td>Cell cycle–specific, work mostly in S phase (DNA synthesis)</td>
</tr>
<tr>
<td></td>
<td>methotrexate</td>
<td>Cell cycle–specific, work mostly in S phase (DNA synthesis)</td>
</tr>
<tr>
<td>ANTITUMOR ANTIBIOTICS</td>
<td>bleomycin</td>
<td>Cell cycle–nonspecific (except bleomycin)</td>
</tr>
<tr>
<td></td>
<td>dactinomycin</td>
<td>Cell cycle–nonspecific (except bleomycin)</td>
</tr>
<tr>
<td></td>
<td>mitomycin</td>
<td>Cell cycle–nonspecific (except bleomycin)</td>
</tr>
<tr>
<td></td>
<td>mitoxantrone</td>
<td>Cell cycle–nonspecific (except bleomycin)</td>
</tr>
<tr>
<td></td>
<td>plicamycin</td>
<td>Cell cycle–nonspecific (except bleomycin)</td>
</tr>
<tr>
<td></td>
<td>streptozocin</td>
<td>Cell cycle–nonspecific (except bleomycin)</td>
</tr>
<tr>
<td>ENZYMES</td>
<td>asparaginase</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td>ENZYME INHIBITORS</td>
<td>pegaspargase</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td></td>
<td>irinotecan</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td></td>
<td>topotecan</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td>HORMONAL AGENTS</td>
<td>bicalutamide</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>estramustine</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>flutamide</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>leuprolide</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>megestrol</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>nilutamide</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>tamoxifen</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>testosterone</td>
<td>Unknown</td>
</tr>
<tr>
<td>HORMONAL AGENTS—AROMATASE INHIBITORS</td>
<td>anastrazole</td>
<td>Unknown</td>
</tr>
<tr>
<td>IMMUNE MODULATORS</td>
<td>letrazole</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>aldesleukin</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>BSG</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>trastuzumab</td>
<td>Unknown</td>
</tr>
<tr>
<td>PODOPHILLOTOXIN DERIVATIVES</td>
<td>etoposide</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td></td>
<td>teniposide</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td></td>
<td>docetaxel</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td>TAUROSIDE</td>
<td>paclitaxel</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td></td>
<td>nabpaclitaxel</td>
<td>Cell cycle–specific</td>
</tr>
<tr>
<td></td>
<td>vinblastine</td>
<td>Cell cycle–specific, work during M phase (mitosis)</td>
</tr>
<tr>
<td></td>
<td>vincristine</td>
<td>Cell cycle–specific, work during M phase (mitosis)</td>
</tr>
<tr>
<td></td>
<td>vinorelbine</td>
<td>Cell cycle–specific, work during M phase (mitosis)</td>
</tr>
<tr>
<td></td>
<td>aldesleukin</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>altretamine</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Contraindications:**

Previous bone marrow depression or hypersensitivity. Contraindicated in pregnancy and lactation.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Precautions:
Use cautiously in patients with active infections, decreased bone marrow reserve, radiation therapy, or other debilitating illnesses. Use cautiously in patients with childbearing potential.

Interactions:
Allopurinol decreases metabolism of mercaptopurine. Toxicity from methotrexate may be increased by other nephrotoxic drugs or larger doses of aspirin or NSAIDs. Bone marrow depression is additive. See individual drugs.

NURSING IMPLICATIONS

Assessment
- Monitor for bone marrow depression. Assess for bleeding (bleeding gums, bruising, petechiae, guaiac stools, urine, and emesis) and avoid IM injections and rectal temperatures if platelet count is low. Apply pressure to venipuncture sites for 10 min. Assess for signs of infection during neutropenia. Anemia may occur. Monitor for increased fatigue, dyspnea, and orthostatic hypotension.
- Monitor intake and output ratios, appetite, and nutritional intake. Prophylactic antiemetics may be used. Adjusting diet as tolerated may help maintain fluid and electrolyte balance and nutritional status.
- Monitor IV site carefully and ensure patency. Discontinue infusion immediately if discomfort, erythema along vein, or infiltration occurs. Tissue ulceration and necrosis may result from infiltration.
- Monitor for symptoms of gout (increased uric acid, joint pain, and edema). Encourage patient to drink at least 2 liters of fluid each day. Allopurinol may be given to decrease uric acid levels. Alkalization of urine may be ordered to increase excretion of uric acid.

Potential Nursing Diagnoses
- Infection, risk for (Side Effects).
- Nutrition, altered: less than body requirements (Adverse Reactions).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Solutions for injection should be prepared in a biologic cabinet. Wear gloves, gown, and mask while handling medication. Discard equipment in designated containers (see Appendix J for guidelines for safe handling).
- Check dose carefully. Fatalities have resulted from dosing errors.

Patient/Family Teaching
- Caution patient to avoid crowds and persons with known infections. Health care professional should be informed immediately if symptoms of infection occur.
- Instruct patient to report unusual bleeding. Advise patient of thrombocytopenia precautions.
- These drugs may cause gonadal suppression; however, patient should still use birth control, as most antineoplastics are teratogenic. Advise patient to inform health care professional immediately if pregnancy is suspected.
- Discuss with patient the possibility of hair loss. Explore methods of coping.
- Instruct patient to inspect oral mucosa for erythema and ulceration. If ulceration occurs, advise patient to use sponge brush and to rinse mouth with water after eating and drinking.
Topical agents may be used if mouth pain interferes with eating. Stomatitis pain may require treatment with opioid analgesics.

- Instruct patient not to receive any vaccinations without advice of health care professional.
- Antineoplastics may decrease antibody response and increase risk of adverse reactions.
- Advise patient of need for medical follow-up and frequent lab tests.

Evaluation

**Effectiveness of therapy can be demonstrated by:**
- Decrease in size and spread of tumor
- Improvement in hematologic status in patients with leukemia.

**Antineoplastic Agents Included in *Davis’s Drug Guide for Nurses***

<table>
<thead>
<tr>
<th>Alkylating Agents</th>
<th>Enzyme Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>busulfan 132</td>
<td>pegaspargase 754</td>
</tr>
<tr>
<td>carboplatin 154</td>
<td>irinotecan 530</td>
</tr>
<tr>
<td>chlorambucil 186</td>
<td>pentostatin 1179</td>
</tr>
<tr>
<td>cisplatin 199</td>
<td>topotecan 1008</td>
</tr>
<tr>
<td>cyclophosphamide 249</td>
<td>estramustine 1175</td>
</tr>
<tr>
<td>ifosfamide 505</td>
<td>ifosfamide 954</td>
</tr>
<tr>
<td>mechlorethamine 602</td>
<td>melphalan 609</td>
</tr>
<tr>
<td>procarbazine 830</td>
<td>procarbazine 830</td>
</tr>
<tr>
<td>temozolamide 959</td>
<td>temozolamide 1182</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anthracyclines</th>
<th>Enzyme Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>daunorubicin citrate liposome 265</td>
<td>pegaspargase 754</td>
</tr>
<tr>
<td>daunorubicin hydrochloride 265</td>
<td>irinotecan 530</td>
</tr>
<tr>
<td>doxorubicin 332</td>
<td>pentostatin 1179</td>
</tr>
<tr>
<td>doxorubicin hydrochloride liposome 333</td>
<td>topotecan 1008</td>
</tr>
<tr>
<td>idarubicin 502</td>
<td>estramustine 1175</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antimetabolites</th>
<th>Enzyme Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>cytarabine 256</td>
<td>irinotecan 530</td>
</tr>
<tr>
<td>floxuridine 1176</td>
<td>pentostatin 1179</td>
</tr>
<tr>
<td>fludarabine 1176</td>
<td>topotecan 1008</td>
</tr>
<tr>
<td>fluorouracil 414</td>
<td>estramustine 1175</td>
</tr>
<tr>
<td>hydroxyurea 491</td>
<td>ifosfamide 954</td>
</tr>
<tr>
<td>metacaptopurine 1178</td>
<td>melphalan 609</td>
</tr>
<tr>
<td>methotrexate 627</td>
<td>procarbazine 830</td>
</tr>
<tr>
<td>thioguanine 1182</td>
<td>temozolamide 1182</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antitumor Antibiotics</th>
<th>Enzyme Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>bleomycin 114</td>
<td>pegaspargase 754</td>
</tr>
<tr>
<td>mitomycin 656</td>
<td>irinotecan 530</td>
</tr>
<tr>
<td>mitoxantrone 659</td>
<td>pentostatin 1179</td>
</tr>
<tr>
<td>plicamycin 809</td>
<td>topotecan 1008</td>
</tr>
<tr>
<td>streptozocin 1182</td>
<td>estramustine 1175</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Enzymes</th>
<th>Enzyme Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>asparaginase 77</td>
<td>pegaspargase 754</td>
</tr>
</tbody>
</table>

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this *Pocket Companion*. 
**ANTIPARKINSON AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
Used in the treatment of parkinsonism of various causes: degenerative, toxic, infective, neoplastic, or drug-induced.

**General Action and Information:**
Drugs used in the treatment of the parkinsonian syndrome and other dyskinesias are aimed at restoring the natural balance of two major neurotransmitters in the CNS: acetylcholine and dopamine. The imbalance is a deficiency in dopamine that results in excessive cholinergic activity. Drugs used are either anticholinergics (benztropine, biperiden, and trihexyphenidyl) or dopaminergic agonists (bromocriptine, levodopa, and pergolide). Pramipexole and ropinerole are two new nonergot dopamine agonists. Entacapone inhibits the enzyme that breaks down levodopa, thereby enhancing its effects.

**Contraindications:**
Anticholinergics should be avoided in patients with narrow-angle glaucoma.

**Precautions:**
Use cautiously in patients with severe cardiac disease, pyloric obstruction, or prostatic enlargement.

**Interactions:**
Pyridoxine, MAO inhibitors, benzodiazepines, phenytoin, phenothiazines, and haloperidol may antagonize the effects of levodopa. Agents that antagonize dopamine (phenothiazines, metoclopramide) may decrease effectiveness of dopamine agonists.

**NURSING IMPLICATIONS**

**Assessment**
- Assess parkinsonian and extrapyramidal symptoms (akinesia, rigidity, tremors, pill rolling, mask faces, shuffling gait, muscle spasms, twisting motions, and drooling) before and throughout course of therapy. On-off phenomenon may cause symptoms to appear or improve suddenly.
- Monitor blood pressure frequently during therapy. Instruct patient to remain supine during and for several hours after 1st dose of bromocriptine, as severe hypotension may occur.

**Potential Nursing Diagnoses**
- Physical mobility, impaired (Indications).
- Injury, risk for (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
Implementation

- In the carbidopa/levodopa combination, the number following the drug name represents the milligram of each drug.

Patient/Family Teaching

- May cause drowsiness or dizziness. Advise patient to avoid driving or other activities that require alertness until response to medication is known.
- Caution patient to make position changes slowly to minimize orthostatic hypotension.
- Instruct patient that frequent rinsing of mouth, good oral hygiene, and sugarless gum or candy may decrease dry mouth. Patient should notify health care professional if dryness persists (saliva substitutes may be used). Also notify the dentist if dryness interferes with use of dentures.
- Advise patient to confer with health care professional before taking OTC medications, especially cold remedies, or drinking alcoholic beverages. Patients receiving levodopa should avoid multivitamins. Vitamin B6 (pyridoxine) may interfere with levodopa's action.
- Caution patient that decreased perspiration may occur. Overheating may occur during hot weather. Patients should remain indoors in an air-conditioned environment during hot weather.
- Advise patient to increase activity, bulk, and fluid in diet to minimize constipating effects of medication.
- Advise patient to notify health care professional if confusion, rash, urinary retention, severe constipation, visual changes, or worsening of parkinsonian symptoms occur.

Evaluation

Effectiveness of therapy can be demonstrated by:

- Resolution of parkinsonian signs and symptoms
- Resolution of drug-induced extrapyramidal symptoms.

Antiparkinson Agents Included in Davis’s Drug Guide for Nurses

**anticholinergics**
- benztropine 96
- biperiden 107
- trihexyphenidyl 1021

**catechol-O-methyltransferase inhibitor**
- entacapone 341

**dopamine agonists**
- amantadine 1169
- bromocriptine 116
- carbidopa/levodopa 574
- levodopa 574
- pergolide 780
- pramipexole 823
- ropinirole 899

ANTIPLATELET AGENTS

PHARMACOLOGIC PROFILE

General Use:

Antiplatelet agents are used to treat and prevent thromboembolic events such as stroke and myocardial infarction. Dipyridamole is commonly used after cardiac surgery.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
General Action and Information:
Inhibit platelet aggregation, prolongs bleeding time, and are used to prevent myocardial infarction or stroke (aspirin, clopidogrel, dipyridamole, ticlopidine). Abciximab, eptifibatide, and tirofiban are used in the management of various acute coronary syndromes. These agents have been used concurrently/sequentially with anticoagulants and thrombolytic agents.

Contraindications:
Hypersensitivity, ulcer disease, active bleeding, and recent surgery.

Precautions:
Use cautiously in patients at risk for bleeding (trauma, surgery). History of GI bleeding or ulcer disease. Safety not established in pregnancy, lactation, or children.

Interactions:
Concurrent use with NSAIDs, heparin, thrombolytic agents, or warfarin may increase the risk of bleeding.

NURSING IMPLICATIONS

Assessment
- Assess patient taking anticoagulants for signs of bleeding and hemorrhage (bleeding gums; nosebleed; unusual bruising; tarry, black stools; hematuria; fall in hematocrit or blood pressure; guaiac-positive stools; urine; or nasogastric aspirate).
- Assess patient for evidence of additional or increased thrombosis. Symptoms will depend on area of involvement.
- Assess patient taking antiplatelet agents for symptoms of stroke, peripheral vascular disease, or myocardial infarction periodically throughout therapy.
- Lab Test Considerations: Monitor activated partial thromboplastin time (aPTT) or international normalized ratio (INR) with full-dose heparin therapy, prothrombin time (PT) with warfarin therapy, and hematocrit and other clotting factors frequently during therapy.
- Monitor bleeding time throughout antiplatelet therapy. Prolonged bleeding time, which is time- and dose-dependent, is expected.
- Toxicity and Overdose: If overdose occurs or anticoagulation needs to be immediately reversed, the antidote for heparin is protamine sulfate; for warfarin, the antidote is vitamin K (phytonadione [AquaMEPHYTON]). Administration of whole blood or plasma may also be required in severe bleeding due to warfarin because of the delayed onset of vitamin K.

Potential Nursing Diagnoses
- Tissue perfusion, altered (Indications).
- Injury, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Inform all personnel caring for patient of anticoagulant therapy. Venipunctures and injection sites require application of pressure to prevent bleeding or hematoma formation.
- Use an infusion pump with continuous infusions to ensure accurate dosage.
Patient/Family Teaching

- Caution patient to avoid activities leading to injury, to use a soft toothbrush and electric razor, and to report any symptoms of unusual bleeding or bruising to health care professional immediately.
- Instruct patient not to take OTC medications, especially those containing aspirin, NSAIDs, or alcohol, without advice of health care professional.
- Review foods high in vitamin K (see Appendix L) with patients on warfarin. Patient should have consistent limited intake of these foods, as vitamin K is the antidote for warfarin and greatly alternating intake of these foods will cause PT levels to fluctuate.
- Emphasize the importance of frequent lab tests to monitor coagulation factors.
- Instruct patient to carry identification describing medication regimen at all times and to inform all health care personnel caring for patient of anticoagulant therapy before laboratory tests, treatment, or surgery.

Evaluation

**Effectiveness of therapy can be demonstrated by:**
- Prevention of undesired clotting and its sequelae without signs of hemorrhage
- Prevention of stroke, myocardial infarction, and vascular death in patients at risk.

**Antiplatelet Agents Included in Davis’s Drug Guide for Nurses**

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>abciximab</td>
<td>1168</td>
</tr>
<tr>
<td>aspirin</td>
<td>903</td>
</tr>
<tr>
<td>clopidogrel</td>
<td>215</td>
</tr>
<tr>
<td>dipyriramole</td>
<td>304</td>
</tr>
<tr>
<td>eptifibatide</td>
<td>354</td>
</tr>
<tr>
<td>ticlopidine</td>
<td>993</td>
</tr>
<tr>
<td>tirofiban</td>
<td>998</td>
</tr>
</tbody>
</table>

**ANTIPSYCHOTIC AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
Treatment of acute and chronic psychoses, particularly when accompanied by increased psychomotor activity. Use of clozapine is limited to schizophrenia unresponsive to conventional therapy. Selected agents are also used as antihistamines or antiemetics. Chlorpromazine is also used in the treatment of intractable hiccups.

**General Action and Information:**
Block dopamine receptors in the brain; also alter dopamine release and turnover. Peripheral effects include anticholinergic properties and alpha-adrenergic blockade. Most antipsychotics are phenothiazines except for haloperidol, which is a butyrophenone, and clozapine, which is a miscellaneous compound. Newer agents such as olanzapine, quetiapine, and risperidone may have fewer adverse reactions. Phenothiazines differ in their ability to produce sedation (greatest with chlorpromazine and thioridazine), extrapyramidal reactions (greatest with prochlorperazine and trifluoperazine), and anticholinergic effects (greatest with chlorpromazine).

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Contraindications:

Hypersensitivity. Cross-sensitivity may exist among phenothiazines. Should not be used in narrow-angle glaucoma. Should not be used in patients who have CNS depression.

Precautions:

Safety in pregnancy and lactation not established. Use cautiously in patients with symptomatic cardiac disease. Avoid exposure to extremes in temperature. Use cautiously in severely ill or debilitated patients, diabetics, and patients with respiratory insufficiency, prostatic hypertrophy, or intestinal obstruction. May lower seizure threshold. Clozapine may cause agranulocytosis. Most agents are capable of causing neuroleptic malignant syndrome.

Interactions:

Additive hypotension with acute ingestion of alcohol, antihypertensives, or nitrates. Antacids may decrease absorption. Phenobarbital may increase metabolism and decrease effectiveness. Additive CNS depression with other CNS depressants, including alcohol, antihistamines, antidespressants, opioid analgesics, or sedative/hypnotics. Lithium may decrease blood levels and effectiveness of phenothiazines. May decrease the therapeutic response to levodopa. May increase the risk of agranulocytosis with antithyroid agents.

NURSING IMPLICATIONS

Assessment

- Assess patient’s mental status (orientation, mood, behavior) before and periodically throughout therapy.
- Monitor blood pressure (sitting, standing, lying), pulse, and respiratory rate before and frequently during the period of dosage adjustment.
- Observe patient carefully when administering medication to ensure medication is actually taken and not hoarded.
- Monitor patient for onset of akathisia (restlessness or desire to keep moving) and extrapyramidal side effects (parkinsonian—difficulty speaking or swallowing, loss of balance control, pill rolling, mask-like face, shuffling gait, rigidity, tremors; and dystonia—muscle spasms, twisting motions, twitching, inability to move eyes, weakness of arms or legs) every 2 mo during therapy and 8–12 wk after therapy has been discontinued. Parkinsonian effects are more common in geriatric patients and dystonias are more common in younger patients. Notify health care professional if these symptoms occur, as reduction in dosage or discontinuation of medication may be necessary. Trihexyphenidyl or diphenhydramine may be used to control these symptoms.
- Monitor for tardive dyskinesia (uncontrolled rhythmic movement of mouth, face, and extremities; lip smacking or puckering; puffing of cheeks; uncontrolled chewing; rapid or worm-like movements of tongue). Notify health care professional immediately if these symptoms occur; these side effects may be irreversible.
- Monitor for development of neuroleptic malignant syndrome (fever, respiratory distress, tachycardia, convulsions, diaphoresis, hypertension or hypotension, pallor, tiredness, severe muscle stiffness, loss of bladder control.) Notify health care professional immediately if these symptoms occur.

Potential Nursing Diagnoses

- Thought processes, altered (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.

Noncompliance (Patient/Family Teaching).

**Implementation**

- **General Info**: Keep patient recumbent for at least 30 min following parenteral administration to minimize hypotensive effects.
- To prevent contact dermatitis, avoid getting solution on hands.
- Phenothiazines should be discontinued 48 hr before and not resumed for 24 hr following myelography, as they lower the seizure threshold.
- **PO**: Administer with food, milk, or a full glass of water to minimize gastric irritation.
- Dilute most concentrates in 120 ml of distilled or acidified tap water or fruit juice just before administration.

**Patient/Family Teaching**

- Advise patient to take medication exactly as directed and not to skip doses or double up on missed doses. Abrupt withdrawal may lead to gastritis, nausea, vomiting, dizziness, headache, tachycardia, and insomnia.
- Advise patient to make position changes slowly to minimize orthostatic hypotension.
- Medication may cause drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to the medication is known.
- Caution patient to avoid taking alcohol or other CNS depressants concurrently with this medication.
- Advise patient to use sunscreen and protective clothing when exposed to the sun to prevent photosensitivity reactions. Extremes of temperature should also be avoided, as these drugs impair body temperature regulation.
- Advise patient that increasing activity, bulk, and fluids in the diet helps minimize the constipating effects of this medication.
- Instruct patient to use frequent mouth rinses, good oral hygiene, and sugarless gum or candy to minimize dry mouth.
- Advise patient to notify health care professional of medication regimen before treatment or surgery.
- Emphasize the importance of routine follow-up exams and continued participation in psychotherapy as indicated.

**Evaluation**

Effectiveness of therapy can be demonstrated by: ■ Decrease in excitable, paranoic, or withdrawn behavior ■ Relief of nausea and vomiting ■ Relief of intractable hiccups.

**Antipsychotic Agents Included in *Davis’s Drug Guide for Nurses***

- **butoyropheneone**
  - haloperidol 463

- **phenothiazines**
  - chlorpromazine 191
  - fluphenazine 419
  - prochlorperazine 833
  - thioridazine 978
  - trifluoperazine 1018

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
**miscellaneous**
clozapine 218
olanzapine 725

**ANTIPYRETIC AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
Used to lower fever of many causes (infection, inflammation, and neoplasms).

**General Action and Information:**
Antipyretics lower fever by affecting thermoregulation in the CNS and by inhibiting the action of prostaglandins peripherally. Aspirin has the most profound effect on platelet function as compared with other salicylates, ibuprofen, or ketoprofen.

**Contraindications:**
Avoid aspirin, ibuprofen, or ketoprofen in patients with bleeding disorders (risk of bleeding is less with other salicylates). Aspirin and other salicylates should be avoided in children and adolescents.

**Precautions:**
Use aspirin, ibuprofen, or ketoprofen cautiously in patients with ulcer disease. Avoid chronic use of large doses of acetaminophen.

**Interactions:**
Large doses of aspirin may displace other highly protein-bound drugs. Additive GI irritation with aspirin, ibuprofen, ketoprofen, and other NSAIDs or corticosteroids. Aspirin, ibuprofen, ketoprofen, or naproxen may increase the risk of bleeding with other agents affecting hemostasis (anticoagulants, thrombolytics, antineoplastics, and certain anti-infectives).

**NURSING IMPLICATIONS**

**Assessment**
- Assess fever; note presence of associated symptoms (diaphoresis, tachycardia, and malaise).

**Potential Nursing Diagnoses**
- Body temperature, altered, risk for (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

**Implementation**
- Administration with food or antacids may minimize GI irritation (aspirin, ibuprofen, ketoprofen, naproxen).
- Available in oral and rectal dosage forms and in combination with other drugs.
Patient/Family Teaching

- Advise patient to consult health care professional if fever is not relieved by routine doses or if greater than 39.5°C (103°F) or lasts longer than 3 days.
- Centers for Disease Control and Prevention warns against giving aspirin to children or adolescents with varicella (chickenpox) or influenza-like or viral illnesses because of a possible association with Reye’s syndrome.

Evaluation

**Effectiveness of therapy can be demonstrated by:** ■ Reduction of fever.

Antipyretic Agents Included in *Davis’s Drug Guide for Nurses*

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen</td>
<td>3</td>
</tr>
<tr>
<td>aspirin</td>
<td>903</td>
</tr>
<tr>
<td>choline and magnesium salicylates</td>
<td>903</td>
</tr>
<tr>
<td>choline salicylate</td>
<td>903</td>
</tr>
<tr>
<td>ibuprofen</td>
<td>499</td>
</tr>
<tr>
<td>ketoprofen</td>
<td>550</td>
</tr>
<tr>
<td>salsalate</td>
<td>903</td>
</tr>
</tbody>
</table>

**ANTIRETROVIRAL AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
The goal of antiretroviral therapy in the management of HIV infection is to improve CD4 cell counts and decrease viral load. If accomplished, this generally results in slowed progression of the disease, improved quality of life, and decreased opportunistic infections. Perinatal use of agents also prevents transmission of the virus to the fetus. Postexposure prophylaxis with antiretrovirals is also recommended.

**General Action and Information:**
Because of the rapid emergence of resistance and toxicities of individual agents, HIV infection is almost always managed by a combination of agents. Selections and doses are based on individual toxicities, underlying organ system disease, concurrent drug therapy, and severity of illness. Various combinations are used; up to 4 agents may be used simultaneously. More than 100 agents are currently being tested in addition to those already approved by the Food and Drug Administration (FDA).

**Contraindications:**
Hypersensitivity. Because of highly varying toxicities among agents, see individual monographs for more specific information.

**Precautions**
Many agents require modification for renal impairment. Protease inhibitors may cause hyperglycemia and should be used cautiously in patients with diabetes. Hemophiliacs may also be at risk of bleeding when taking protease inhibitors. See individual monographs for specific information.

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
Interactions:
There are many significant interactions among the antiretrovirals. They are affected by drugs that alter metabolism; some agents themselves affect metabolism. See individual agents.

NURSING IMPLICATIONS

Assessment
- Assess patient for change in severity of symptoms of HIV and for symptoms of opportunistic infections throughout therapy.
- **Lab Test Considerations:** Monitor viral load and CD4 counts prior to and periodically during therapy.

Potential Nursing Diagnoses
- Infection, risk for (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
- Noncompliance (Patient/Family Teaching).

Implementation
- Administer doses around the clock.

Patient/Family Teaching
- Instruct patient to take medication exactly as directed, around the clock, even if sleep is interrupted. Emphasize the importance of complying with therapy, not taking more than prescribed amount, and not discontinuing without consulting health care professional. Missed doses should be taken as soon as remembered unless almost time for next dose; patient should not double doses. Inform patient that long-term effects are unknown at this time.
- Instruct patient that antiretrovirals should not be shared with others.
- Inform patient that antiretroviral therapy does not cure HIV and does not reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Caution patient to use a condom during sexual contact and to avoid sharing needles or donating blood to prevent spreading the AIDS virus to others.
- Advise patient to avoid taking any Rx or OTC medications without consulting health care professional.
- Emphasize the importance of regular follow-up exams and blood counts to determine progress and monitor for side effects.

Evaluation
**Effectiveness of therapy can be demonstrated by:**
- Decrease in viral load and increase in CD4 counts in patients with HIV.

Antiretroviral Agents Included in *Davis’s Drug Guide for Nurses*

<table>
<thead>
<tr>
<th>non-nucleoside reverse transcriptase inhibitors</th>
<th>nucleoside reverse transcriptase inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>delavirdine 270</td>
<td>didanosine 284</td>
</tr>
<tr>
<td>efavirenz 339</td>
<td>lamivudine 559</td>
</tr>
<tr>
<td>nevirapine 695</td>
<td>stavudine 937</td>
</tr>
<tr>
<td></td>
<td>zalcitabine 1062</td>
</tr>
</tbody>
</table>
Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.

ANTITHYROID AGENTS

PHARMACOLOGIC PROFILE

General Use:
Used in the treatment of hyperthyroidism of various causes (Graves’ disease, multinodular goiter, thyroiditis, and thyrotoxic crisis) in children, pregnant women, and other patients in whom hyperthyroidism is not expected to be permanent. These agents are also used to prepare patients for thyroidectomy or for patients in whom thyroidectomy is contraindicated. Beta-adrenergic blockers (propranolol) are sometimes used in conjunction with antithyroid agents to control symptoms (tachycardia and tremor) but have no effect on thyroid status. Iodine and iodides are also used as radiation protectants.

General Action and Information:
Inhibit thyroid hormone formation (iodine) or inhibit oxidation of iodine (methimazole and propylthiouracil).

Contraindications:
Hypersensitivity. Previous bone marrow depression.

Precautions:
Use methimazole cautiously in patients with decreased bone marrow reserve.

Interactions:
Lithium may cause thyroid abnormalities and interfere with the response to antithyroid therapy. Phenothiazines may increase the risk of agranulocytosis.

NURSING IMPLICATIONS

Assessment
- **General Info:** Monitor response of symptoms of hyperthyroidism or thyrotoxicosis (tachycardia, palpitations, nervousness, insomnia, fever, diaphoresis, heat intolerance, tremors, weight loss, diarrhea).
- Assess patient for development of hypothyroidism (intolerance to cold, constipation, dry skin, headache, listlessness, tiredness, or weakness). Dosage adjustment may be required.
- Assess patient for skin rash or swelling of cervical lymph nodes. Treatment may be discontinued if this occurs.
- Monitor thyroid function studies before and periodically throughout therapy.
- **Iodides:** Assess for signs and symptoms of iodism (metallic taste, stomatitis, skin lesions, cold symptoms, severe GI upset) or anaphylaxis. Report these symptoms promptly to physician or other health care provider.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Potential Nursing Diagnoses

- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Mix iodide solutions in a full glass of fruit juice, water, or milk. Administer after meals to minimize GI irritation.

Patient/Family Teaching

- Instruct patient to take medication exactly as directed. Missing doses may precipitate hyperthyroidism.
- Advise patient to consult health care professional regarding dietary sources of iodine (iodized salt, shellfish, cabbage, kale, turnips).
- Advise patient to carry identification describing medication regimen at all times and to notify health care professional of medical regimen before treatment or surgery.
- Emphasize the importance of routine exams to monitor progress and check for side effects.

Evaluation

Effectiveness of therapy can be demonstrated by:

- Decrease in severity of symptoms of hyperthyroidism
- Decrease in vascularity and friability of the thyroid gland before preparation for surgery
- Protection of the thyroid gland during radiation emergencies.

Antithyroid Agents Included in *Davis’s Drug Guide for Nurses*

- methimazole 624
- potassium iodide, saturated solution 525
- propylthiouracil 855
- strong iodine solution 525

**ANTITUBERCULAR AGENTS**

**PHARMACOLOGIC PROFILE**

General Use:

Used in the treatment and prevention of tuberculosis and diseases caused by other mycobacteria, including *Mycobacterium avium* complex (MAC), seen mostly in HIV patients. Combinations are used in the treatment of active disease tuberculosis to rapidly decrease the infectious state and delay or prevent the emergence of resistant strains. In selected situations, intermittent (twice weekly) regimens may be employed. Streptomycin is also used as an antitubercular agent. The anti-infective agents, azithromycin and clarithromycin, are useful in the prevention and management of MAC disease. Rifampin is used in the prevention of meningococcal meningitis and *Haemophilus influenzae* type b disease.

General Action and Information:

Kill (tuberculocidal) or inhibit the growth of (tuberculostatic) mycobacteria responsible for causing tuberculosis. Combination therapy with two or more agents is required, unless used as prophylaxis (isoniazid alone).

Contraindications:

Hypersensitivity. Severe liver disease.
Precautions:
Use cautiously in patients with a history of liver disease or in elderly or debilitated patients. Ethambutol requires ophthalmologic follow-up. Safety in pregnancy and lactation not established, although selected agents have been used without adverse effects on the fetus. Compliance is required for optimal response.

Interactions:
Isoniazid inhibits the metabolism of phenytoin. Rifampin significantly decreases saquinavir levels (combination should be avoided).

NURSING IMPLICATIONS

Assessment
- Mycobacterial studies and susceptibility tests should be performed prior to and periodically throughout therapy to detect possible resistance.
- Assess lung sounds and character and amount of sputum periodically throughout therapy.

Potential Nursing Diagnoses
- Infection, risk for (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
- Noncompliance (Patient/Family Teaching).

Implementation
- Most medications can be administered with food or antacids if GI irritation occurs.

Patient/Family Teaching
- Advise patient of the importance of continuing therapy even after symptoms have subsided.
- Emphasize the importance of regular follow-up examinations to monitor progress and check for side effects.
- Inform patients taking rifampin that saliva, sputum, sweat, tears, urine, and feces may become red-orange to red-brown and that soft contact lenses may become permanently discolored.

Evaluation
**Effectiveness of therapy can be demonstrated by:**
- Resolution of the signs and symptoms of tuberculosis
- Negative sputum cultures.

Antitubercular Agents Included in *Davis’s Drug Guide for Nurses*

- ethambutol 374
- isoniazid 537
- pyrazinamide 859
- rifampin 886
- rifapentine 888

*Because of space limitations, additional classes or drugs not represented in *Davis's Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
ANTITUSSIVE AGENTS

PHARMACOLOGIC PROFILE

General Use:
Used for the symptomatic relief of cough due to various causes, including viral upper respiratory infections. Not intended for chronic use.

General Action and Information:
Antitussives (codeine, dextromethorphan, diphenhydramine, hydrocodone, and hydromorphone) suppress cough by central mechanisms. Benzonatate decreases cough by a local anesthetic action. Productive cough should not be suppressed unless it interferes with sleeping or other activities of daily living. Increasing fluid intake probably serves as the best expectorant, decreasing the viscosity of secretions so that they may be more easily mobilized.

Contraindications:
Hypersensitivity.

Precautions:
Use cautiously in children. Should not be used for prolonged periods unless under the advice of a physician or other health care professional.

Interactions:
Centrally acting antitussives may have additive CNS depression with other CNS depressants.

NURSING IMPLICATIONS

Assessment
- Assess frequency and nature of cough, lung sounds, and amount and type of sputum produced.

Potential Nursing Diagnoses
- Airway clearance, ineffective (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Unless contraindicated, maintain fluid intake of 1500–2000 ml to decrease viscosity of bronchial secretions.

Patient/Family Teaching
- Instruct patient to cough effectively, sit upright, and take several deep breaths before attempting to cough.
- Advise patient to minimize cough by avoiding irritants (cigarette smoke, fumes, dust). Humidification of environmental air, frequent sips of water, and sugarless hard candy may also decrease the frequency of dry, irritating cough.
Caution patient to avoid taking concurrent alcohol or CNS depressants.

May cause dizziness or drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.

Advise patient that any cough lasting over 1 wk or accompanied by fever, chest pain, persistent headache, or skin rash warrants medical attention.

Evaluation

**Effectiveness of therapy can be demonstrated by:** Decrease in frequency and intensity of cough without eliminating patient's cough reflex.

**Antitussive Agents Included in *Davis's Drug Guide for Nurses***

<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>benzonatate 95</td>
<td>diphenhydramine 300</td>
</tr>
<tr>
<td>codeine 221</td>
<td>hydrocodone 483</td>
</tr>
<tr>
<td>dextromethorphan 277</td>
<td>hydromorphone 486</td>
</tr>
</tbody>
</table>

**ANTI-ULCER AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**

Treatment and prophylaxis of peptic ulcer and gastric hypersecretory conditions such as Zollinger-Ellison syndrome. Histamine H2-receptor antagonists and gastric and pump inhibitors are also used in the management of GERD.

**General Action and Information:**

Because a great majority of peptic ulcer disease may be traced to GI infection with the organism *Helicobacter pylori*, eradication of the organism decreases symptomatology and recurrence. Anti-infectives with significant activity against the organism include amoxicillin, clarithromycin, metronidazole, and tetracycline. Bismuth also has anti-infective activity against *H. pylori*. Regimens may include 2 anti-infectives plus a gastric acid–pump inhibitor (lansoprazole, omeprazole) or 3 anti-infectives or 3 anti-infectives plus a gastric acid–pump inhibitor.
Other medications used in the management of gastric/duodenal ulcer disease are aimed at neutralizing gastric acid (antacids), decreasing acid secretion (histamine H₂ antagonists, lansoprazole, misoprostol, omeprazole), or protecting the ulcer surface from further damage (misoprostol, sucralfate). Histamine H₂-receptor antagonists (blockers) competitively inhibit the action of histamine at the H₂ receptor, located primarily in gastric parietal cells, resulting in inhibition of gastric acid secretion. Misoprostol decreases gastric acid secretion and increases production of protective mucus. Omeprazole and lansoprazole prevent the transport of hydrogen ions into the gastric lumen.

Contraindications:
- Hypersensitivity.

Precautions:
- Most histamine H₂ antagonists require dosage reduction in renal impairment and in elderly patients. Magnesium-containing antacids should be used cautiously in patients with renal impairment. Misoprostol should be used cautiously in women with childbearing potential.

Interactions:
- Calcium and magnesium-containing antacids decrease the absorption of tetracycline and fluoroquinolones. Cimetidine inhibits the ability of the liver to metabolize several drugs, increasing the risk of toxicity from warfarin, tricyclic antidepressants, theophylline, metoprolol, phenytoin, propranolol, and lidocaine. Omeprazole decreases metabolism of phenytoin, diazepam, and warfarin. All agents that increase gastric pH will decrease the absorption of ketoconazole.

**NURSING IMPLICATIONS**

Assessment
- **General Info:** Assess patient routinely for epigastric or abdominal pain and frank or occult blood in the stool, emesis, or gastric aspirate.
Antacids: Assess for heartburn and indigestion as well as the location, duration, character, and precipitating factors of gastric pain.

Histamine H₂ Antagonists: Assess elderly and severely ill patients for confusion routinely. Notify physician or other health care professional promptly should this occur.

Misoprostol: Assess women of childbearing age for pregnancy. Medication is usually begun on 2nd or 3rd day of menstrual period following a negative serum pregnancy test within 2 wk of beginning therapy.

Lab Test Considerations: Histamine H₂ antagonists antagonize the effects of pentagastrin and histamine during gastric acid secretion test. Avoid administration during the 24 hr preceding the test.

May cause false-negative results in skin tests using allergen extracts. These drugs should be discontinued 24 hr prior to the test.

Potential Nursing Diagnoses

- Pain (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Antacids: Antacids cause premature dissolution and absorption of enteric-coated tablets and may interfere with absorption of other oral medications. Separate administration of antacids and other oral medications by at least 1 hr.
- Shake liquid preparations well before pouring. Follow administration with water to ensure passage to stomach. Liquid and powder dosage forms are considered to be more effective than chewable tablets.
- Chewable tablets must be chewed thoroughly before swallowing. Follow with half a glass of water.
- Administer 1 and 3 hr after meals and at bedtime for maximum antacid effect.
- Misoprostol: Administer with meals and at bedtime to reduce the severity of diarrhea.
- Pantoprazole, Rabeprazole, Omeprazole, and Lansoprazole: Administer before meals, preferably in the morning. Capsules should be swallowed whole; do not open, crush, or chew.
- May be administered concurrently with antacids.
- Sucralfate: Administer on an empty stomach 1 hr before meals and at bedtime. Do not crush or chew tablets. Shake suspension well prior to administration. If nasogastric administration is required, consult pharmacist, as protein-binding properties of sucralfate have resulted in formation of a bezoar when administered with enteral feedings and other medications.

Patient/Family Teaching

- General Info: Instruct patient to take medication as directed for the full course of therapy, even if feeling better. If a dose is missed, it should be taken as soon as remembered but not if almost time for next dose. Do not double doses.
- Advise patient to avoid alcohol, products containing aspirin, NSAIDs, and foods that may cause an increase in GI irritation.
- Advise patient to report onset of black, tarry stools to the physician or other health care professional promptly.
- Inform patient that cessation of smoking may help prevent the recurrence of duodenal ulcers.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Antacids: Caution patient to consult health care professional before taking antacids for more than 2 wk or if problem is recurring. Advise patient to consult health care professional if relief is not obtained or if symptoms of gastric bleeding (black, tarry stools; coffee-ground emesis) occur.

Misoprostol: Emphasize that sharing of this medication may be dangerous.

Inform patient that misoprostol may cause spontaneous abortion. Women of childbearing age must be informed of this effect through verbal and written information and must use contraception throughout therapy. If pregnancy is suspected, the woman should stop taking misoprostol and immediately notify her health care professional.

Sucralfate: Advise patient to continue with course of therapy for 4–8 wk, even if feeling better, to ensure ulcer healing.

Advise patient that an increase in fluid intake, dietary bulk, and exercise may prevent drug-induced constipation.

Evaluation

Effectiveness of therapy can be demonstrated by:

- Decrease in GI pain and irritation
- Prevention of gastric irritation and bleeding. Healing of duodenal ulcers can be seen by x-rays or endoscopy. Therapy with histamine H2 antagonists is continued for at least 6 wk after initial episode
- Decreased symptoms of GERD
- Increase in the pH of gastric secretions (antacids)
- Prevention of gastric ulcers in patients receiving chronic NSAID therapy (misoprostol only).

Anti-ulcer Agents Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>antacids</th>
<th>gastric acid–pump inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>aluminum hydroxide 26</td>
<td>lansoprazole 563</td>
</tr>
<tr>
<td>magaldrate 591</td>
<td>omeprazole 727</td>
</tr>
<tr>
<td>magnesium hydroxide/aluminum hydroxide 591</td>
<td>pantoprazole 751</td>
</tr>
<tr>
<td>sodium bicarbonate 926</td>
<td>rabeprazole 875</td>
</tr>
</tbody>
</table>

anti-infectives

| amoxicillin 43 | cimetidine 472 |
| bismuth subsalicylate 110 | famotidine 472 |
| clarithromycin 204 | nizatidine 472 |
| metronidazole 641 | ranitidine 472 |
| tetracycline 969 | |

miscellaneous

| misoprostol 655 | |
| sucralfate 941 | |

ANTIVIRAL AGENTS

PHARMACOLOGIC PROFILE

General Use:

Acyclovir, famciclovir, and valacyclovir are used in the management of herpesvirus infections. Acyclovir also is used in the management of chickenpox. Zanamivir is used primarily in the prevention of influenza A viral infections. Cidofovir, ganciclovir, and foscarnet are used in the treatment of cytomegalovirus (CMV) retinitis.

General Action and Information:

Most agents inhibit viral replication.
Contraindications:
Previous hypersensitivity.

Precautions:
All except zanamivir require dosage adjustment in renal impairment. Acyclovir may cause renal impairment. Acyclovir may cause CNS toxicity. Foscarnet increases risk of seizures.

Interactions:
Acyclovir may have additive CNS and nephrotoxicity with drugs causing similar adverse reactions.

NURSING IMPLICATIONS

Assessment

- **General Info:** Assess patient for signs and symptoms of infection before and throughout therapy.
- **Ophth:** Assess eye lesions before and daily during therapy.
- **Topical:** Assess lesions before and daily during therapy.

Potential Nursing Diagnoses

- Infection, risk for (Indications).
- Skin integrity, impaired (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Most systemic antiviral agents should be administered around the clock to maintain therapeutic serum drug levels.

Patient/Family Teaching

- Instruct patient to continue taking medication around the clock for full course of therapy, even if feeling better.
- Advise patient that antivirals and antiretrovirals do not prevent transmission to others. Precautions should be taken to prevent spread of virus.
- Instruct patient in correct technique for topical or ophthalmic preparations.
- Instruct patient to notify health care professional if symptoms do not improve.

Evaluation

**Effectiveness of therapy can be demonstrated by:**
Prevention or resolution of the signs and symptoms of viral infection. Length of time for complete resolution depends on organism and site of infection.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Antiviral Agents Included in *Davis's Drug Guide for Nurses*

- acyclovir 8
- amantadine 1169
- cidofovir 196
- famciclovir 383
- foscarnet 430
- ganciclovir 436
- rimantadine 1181
- trifuradine 1158
- valacyclovir 1029
- zanamivir 1065

**BRONCHODILATORS**

**PHARMACOLOGIC PROFILE**

**General Use:**

Used in the treatment of reversible airway obstruction due to asthma or COPD. Recently revised recommendations for management of asthma recommend that rapid-acting inhaled beta-agonist bronchodilators (not salmeterol) be reserved as acute relievers of bronchospasm; repeated or chronic use indicates the need for additional long-term control agents including inhaled corticosteroids, mast cell stabilizers, and long-acting bronchodilators (oral theophylline or beta-agonists) and leukotriene modifiers (montelukast, zafirlukast). The place of the new agent zafirlukast has not yet been established.

**General Action and Information:**

Beta-adrenergic agonists (albuterol, epinephrine, isoproterenol, metaproterenol, pirbuterol, and terbutaline) produce bronchodilation by stimulating the production of cyclic adenosine monophosphate (cAMP). Newer agents (albuterol, metaproterenol, pirbuterol, and terbutaline) are relatively selective for pulmonary (beta_2_) receptors, whereas older agents produce cardiac stimulation (beta_2-adrenergic effects) in addition to bronchodilation. Onset of action allows use in management of acute attacks except for salmeterol, which has delayed onset. Phosphodiesterase inhibitors (aminophylline, dyphylline, oxtriphylline, and theophylline) inhibit the breakdown of cAMP. Ipratropium is an anticholinergic compound that produces bronchodilation by blocking the action of acetylcholine in the respiratory tract. Montelukast and zafirlukast are leukotriene modifiers. Leukotrienes are components of slow-reacting substance of anaphylaxis A (SRS-A), which may be a cause of bronchospasm.

**Contraindications:**

Hypersensitivity to agents, preservatives (bisulfites), or propellants used in their formulation. Avoid use in uncontrolled cardiac arrhythmias.

**Precautions:**

Use cautiously in patients with diabetes, cardiovascular disease, or hyperthyroidism.

**Interactions:**

Therapeutic effectiveness may be antagonized by concurrent use of beta-adrenergic blocking agents. Additive sympathomimetic effects with other adrenergic (sympathetic) drugs, including vasopressors and decongestants. Cardiovascular effects may be potentiated by antidepressants and MAO inhibitors.

---

NURSING IMPLICATIONS

Assessment
- Assess blood pressure, pulse, respiration, lung sounds, and character of secretions before and throughout therapy.
- Patients with a history of cardiovascular problems should be monitored for ECG changes and chest pain.

Potential Nursing Diagnoses
- Airway clearance, ineffective (Indications).
- Activity intolerance (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Administer around the clock to maintain therapeutic plasma levels.

Patient/Family Teaching
- Emphasize the importance of taking only the prescribed dose at the prescribed time intervals.
- Encourage the patient to drink adequate liquids (2000 ml/day minimum) to decrease the viscosity of the airway secretions.
- Advise patient to avoid OTC cough, cold, or breathing preparations without consulting health care professional and to minimize intake of xanthine-containing foods or beverages (colas, coffee, and chocolate), as these may increase side effects and cause arrhythmias.
- Caution patient to avoid smoking and other respiratory irritants.
- Instruct patient on proper use of metered-dose inhaler (see Appendix I).
- Advise patient to contact health care professional promptly if the usual dose of medication fails to produce the desired results, symptoms worsen after treatment, or toxic effects occur.
- Patients using other inhalation medications and bronchodilators should be advised to use bronchodilator first and allow 5 min to elapse before administering the other medication, unless otherwise directed by health care professional.

Evaluation
Effectiveness of therapy can be demonstrated by:
- Decreased bronchospasm
- Increased ease of breathing.

Bronchodilators Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>beta-adrenergic agonists</th>
<th>leukotriene antagonists</th>
<th>phosphodiesterase inhibitors (xanthines)</th>
</tr>
</thead>
<tbody>
<tr>
<td>albuterol 13</td>
<td>montelukast 664</td>
<td>aminophylline 120</td>
</tr>
<tr>
<td>epinephrine 345</td>
<td>zafirlukast 1061</td>
<td>dyphylline 120</td>
</tr>
<tr>
<td>isoproterenol 1177</td>
<td></td>
<td>oxtriphylline 120</td>
</tr>
<tr>
<td>metaproterenol 617</td>
<td></td>
<td>theophylline 120</td>
</tr>
<tr>
<td>pirbuterol 805</td>
<td></td>
<td></td>
</tr>
<tr>
<td>salmeterol 907</td>
<td></td>
<td></td>
</tr>
<tr>
<td>terbutaline 964</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
anticholinergic agent

ipratropium 528

CARDIOTONIC AND INOTROPIC AGENTS*

PHARMACOLOGIC PROFILE

General Use:

Management of congestive heart failure or cardiac decompensation unresponsive to conventional therapy with cardiac glycosides, diuretics, or vasodilators. Also used during cardiac surgery.

General Action and Information:

Increase cardiac output mainly by direct myocardial effects and some peripheral vascular effects. Myocardial contractility is increased by inhibiting cyclic adenosine monophosphate (cAMP) phosphodiesterase, which increases intracellular cAMP.

Contraindications:


Precautions:

Safety in pregnancy, lactation, and children not established.

Interactions:

Amrinone may produce excessive hypotension when given with disopyramide. Agents that cause hypokalemia, hypomagnesemia, or hypercalcemia increase the risk of cardiac glycoside toxicity. Bradycardia from beta blockers may be additive with digitalis glycosides. Quinidine increases serum digoxin levels.

NURSING IMPLICATIONS

Assessment

- Monitor blood pressure, pulse, and respiration before and periodically throughout therapy.
- Monitor intake and output ratios and daily weights. Assess patient for signs and symptoms of congestive heart failure (peripheral edema, rales/crackles, dyspnea, weight gain, jugular vein distentions) throughout therapy.
- Before administering initial loading dose, determine if patient has taken any cardiac glycoside preparations in the preceding 2–3 wk.
- Lab Test Considerations: Serum electrolyte levels, especially potassium, magnesium, and calcium, and renal and hepatic function should be evaluated periodically during therapy.
- Toxicity and Overdose: Patients taking digitalis glycosides should have serum levels measured regularly.

Potential Nursing Diagnoses

- Cardiac output, decreased (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
Implementation

- Hypokalemia should be corrected before administration of amrinone, milrinone, digoxin, or digitoxin.
- Hypovolemia should be corrected with volume expanders before administrations.

Patient/Family Teaching

- Advise patient to notify health care professional if symptoms are not relieved or worsen.
- Instruct patient to notify nurse immediately if pain or discomfort at the insertion site occurs during IV administration.

Evaluation

**Effectiveness of therapy can be demonstrated by:**
- Increased cardiac output
- Decrease in severity of congestive heart failure
- Increased urine output

Cardiotonic and Inotropic Agents Included in *Davis’s Drug Guide for Nurses*

- amrinone 58
- digoxin 2287
- dopamine 326
- milrinone 650
- dobutamine 317

**CENTRAL NERVOUS SYSTEM STIMULANTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
CNS stimulants are used as an adjunct in the treatment of ADHD and in the treatment of narcolepsy.

**General Action and Information:**
CNS stimulation results in increased attention span in ADHD, increased motor activity, mental alertness, and decreased fatigue in narcoleptic patients.

**Contraindications:**
Hypersensitivity. Pregnancy or lactation. Should not be used in patients with psychiatric illness or chemical dependence.

**Precautions:**
Use cautiously in patients with cardiovascular disease, hypertension, diabetes, and seizure disorders.

**Interactions:**
Additive sympathomimetic effects with other adrenergic agents. Use with MAO inhibitors results in hypertensive crisis.

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
NURSING IMPLICATIONS

Assessment
- Monitor blood pressure, pulse, and respiration before and periodically throughout therapy.
- In treatment of ADHD, monitor weight biweekly and inform prescriber of significant loss.
- Monitor height periodically in children; report growth inhibition.
- In narcolepsy, observe and document frequency of narcoleptic episodes.
- Assess attention span, motor, or vocal tics; impulse control; and interactions with others for children with ADHD.
- May produce a false sense of euphoria and well-being. Monitor and provide rest periods.
- These agents have a high dependence abuse potential. Tolerance to medication occurs rapidly; do not increase dose.

Potential Nursing Diagnoses
- Thought processes, altered (Side Effects).
- Sleep pattern disturbance (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Therapy should use the lowest possible dose.
- Sustained-release capsules should be swallowed whole; do not break, crush, or chew.
- Chewable tablets should be chewed thoroughly before swallowing.
- ADHD: When symptoms are under control, dose reduction or interruption of therapy may be possible during the summer, or may be given on each of the 5 school days, with medication-free days on weekends and holidays.

Patient/Family Teaching
- Instruct patient to take medication at least 6 hr before bedtime to avoid sleep disturbances
- Inform patient that the side effect of dry mouth can be minimized with frequent mouth rinses with water or by chewing sugarless gum or candies.
- Advise patient to avoid caffeine.
- Medication may impair judgment, cause dizziness or blurred vision. Advise patient to use caution when driving or during other activities requiring mental alertness.
- Instruct patient to inform health care professional if nervousness, restlessness, insomnia, anorexia, or dry mouth becomes severe.
- Inform patient that periodic holiday from the drug may be ordered to assess progress and decrease dependence.
- Advise the patient to take weight measurements twice weekly and report weight loss to health care professional.
- In children receiving the medication for ADHD, inform school nurse of regimen.
- In patients taking pemoline, instruct about signs of hepatitis and to report promptly to the health care professional if they occur.

Evaluation
Effectiveness of therapy can be demonstrated by:
- Calming effect with decreased hyperactivity and prolonged attention span in children with ADHD
- Decrease in the frequency of narcolepsy symptoms.
Central Nervous System Stimulants Included in *Davis’s Drug Guide for Nurses*

- amphetamine 1170
- methylphenidate 632
- pemoline 756

**CHOLINERGIC AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**
Used in the treatment of nonobstructive urinary retention (bethanechol) and in the diagnosis and treatment (neostigmine and pyridostigmine) of myasthenia gravis. Cholinesterase inhibitors may be used to reverse nondepolarizing neuromuscular blocking agents.

**General Action and Information:**
Cholinergic agents intensify and prolong the action of acetylcholine by either mimicking its effects at cholinergic receptor sites (bethanechol) or preventing the breakdown of acetylcholine by inhibiting cholinesterases (neostigmine). Effects include increased tone in GU and skeletal muscle, decreased intraocular pressure, increased secretions, and decreased bladder capacity.

**Contraindications:**
Hypersensitivity. Avoid use in patients with possible obstruction of the GI or GU tract.

**Precautions:**
Use with extreme caution in patients with a history of asthma, peptic ulcer disease, cardiovascular disease, epilepsy, or hyperthyroidism. Safety in pregnancy and lactation not established. Atropine should be available to treat excessive dosage.

**Interactions:**
Additive cholinergic effects. Do not use with depolarizing neuromuscular blocking agents. Use with ganglionic blocking agents may result in severe hypotension.

**NURSING IMPLICATIONS**

**Assessment**

- **General Info:** Monitor pulse, respiratory rate, and blood pressure frequently throughout parenteral administration.
- **Myasthenia Gravis:** Assess neuromuscular status (ptosis, diplopia, vital capacity, ability to swallow, and extremity strength) before and at time of peak effect.
- **Assess patient for overdosage and underdosage or resistance.** Both have similar symptoms (muscle weakness, dyspnea, and dysphagia), but symptoms of overdosage usually occur within 1 hr of administration, while underdosage symptoms occur 3 hr or more after administration. A Tensilon test (edrophonium chloride) may be used to distinguish between overdosage and underdosage.

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
Antidote to Nondepolarizing Neuromuscular Blocking Agents: Monitor reversal of effects of neuromuscular blocking agents with a peripheral nerve stimulator.

Urinary Retention: Monitor intake and output ratios. Palpate abdomen for bladder distention. Catheterization may be done to assess postvoid residual.

Glaucoma: Monitor patient for changes in vision, eye irritation, and persistent headache.

Toxicity and Overdose: Atropine is the specific antidote.

Potential Nursing Diagnoses

- Urinary elimination, altered (Indications).
- Breathing pattern, ineffective (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Myasthenia Gravis: For patients who have difficulty chewing, medication may be administered 30 min before meals.

Patient/Family Teaching

- General Info: Instruct patients with myasthenia gravis to take medication exactly as ordered. Taking the dose late may result in myasthenic crisis. Taking the dose early may result in a cholinergic crisis. This regimen must be continued as a lifelong therapy.
- Ophth: Instruct patient on correct method of application of drops or ointment (see Appendix I).
- Explain to patient that pupil constriction and temporary stinging and blurring of vision are expected. Notify health care professional if blurred vision and brow ache persist.
- Caution patient that night vision may be impaired.
- Advise patient of the need for regular eye exams to monitor intraocular pressure and visual fields.

Evaluation

Effectiveness of therapy can be demonstrated by: ■ Reversal of CNS symptoms secondary to anticholinergic excess resulting from drug overdose or ingestion of poisonous plants ■ Control of elevated intraocular pressure ■ Increase in bladder function and tone ■ Decrease in abdominal distention ■ Relief of myasthenic symptoms ■ Differentiation of myasthenic from cholinergic crisis ■ Reversal of paralysis after anesthesia ■ Resolution of supraventricular tachycardia.

Cholinergic Agents Included in Davis's Drug Guide for Nurses

- **Cholinomimetic**
  - bethanechol 102

- **Cholinesterase inhibitors**
  - demercarium 1161
  - echothiophate 1161
  - isoflurophate 1161
  - neostigmine 693
  - physostigmine 1161, 1179
  - pyridostigmine 860
  - tacrine 951
**CORTICOSTEROIDS**

**PHARMACOLOGIC PROFILE**

**General Use:**
Used in replacement doses (20 mg of hydrocortisone or equivalent) to treat adrenocortical insufficiency. Larger doses are usually used for their anti-inflammatory, immunosuppressive, or antineoplastic activity. Used adjunctively in many other situations, including hypercalcemia and autoimmune diseases. Topical corticosteroids are used in a variety of inflammatory and allergic conditions. Inhalant corticosteroids are used in the chronic management of reversible airway disease (asthma); intranasal and ophthalmic corticosteroids are used in the management of chronic allergic and inflammatory conditions.

**General Action and Information:**
Produce profound and varied metabolic effects, in addition to modifying the normal immune response and suppressing inflammation. Available in a variety of dosage forms, including oral, injectable, topical, and inhalation. Prolonged use of large amounts of topical or inhaled agent may result in systemic absorption and/or adrenal suppression.

**Contraindications:**
Serious infections (except for certain forms of meningitis). Do not administer live vaccines to patients on larger doses.

**Precautions:**
Prolonged treatment will result in adrenal suppression. Do not discontinue abruptly. Additional doses may be needed during stress (surgery and infection). Safety in pregnancy and lactation not established. Long-term use in children will result in decreased growth. May mask signs of infection. Use lowest dose possible for shortest time possible. Alternate-day therapy is preferable during long-term treatment.

**Interactions:**
Additive hypokalemia with amphotericin B, potassium-losing diuretics, mezlocillin, piperacillin, and ticarcillin. Hypokalemia may increase the risk of cardiac glycoside toxicity. May increase requirements for insulin or oral hypoglycemic agents. Phenytoin, phenobarbital, and rifampin stimulate metabolism and may decrease effectiveness. Oral contraceptives may block metabolism. Cholestyramine and colestipol may decrease absorption.

**NURSING IMPLICATIONS**

**Assessment**
- These drugs are indicated for many conditions. Assess involved systems prior to and periodically throughout course of therapy.
- Assess patient for signs of adrenal insufficiency (hypotension, weight loss, weakness, nausea, vomiting, anorexia, lethargy, confusion, restlessness) prior to and periodically throughout course of therapy.
- Children should have periodic evaluations of growth.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Potential Nursing Diagnoses

- Infection, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
- Body image disturbance (Side Effects).

Implementation

- **General Info:** If dose is ordered daily or every other day, administer in the morning to coincide with the body’s normal secretion of cortisol.
- **PO:** Administer with meals to minimize gastric irritation.

Patient/Family Teaching

- Emphasize need to take medication exactly as directed. Review symptoms of adrenal insufficiency that may occur when stopping the medication and that may be life-threatening.
- Encourage patients on long-term therapy to eat a diet high in protein, calcium, and potassium and low in sodium and carbohydrates.
- These drugs cause immunosuppression and may mask symptoms of infection. Instruct patient to avoid people with known contagious illnesses and to report possible infections. Advise patient to consult health care professional before receiving any vaccinations.
- Discuss possible effects on body image. Explore coping mechanisms.
- Advise patient to carry identification in the event of an emergency in which patient cannot relate medical history.

Evaluation

**Effectiveness of therapy can be demonstrated by:**

- Suppression of the inflammatory and immune responses in autoimmune disorders, allergic reactions, and organ transplants
- Replacement therapy in adrenal insufficiency
- Resolution of skin inflammation, pruritus, or other dermatologic conditions.

Corticosteroids Included in *Davis’s Drug Guide for Nurses*

- **Corticosteroids, inhalation**
  - beclomethasone 229
  - budesonide 229
  - flunisolide 229
  - fluticasone 229
  - triamcinolone 229

- **Corticosteroids, nasal**
  - beclomethasone 233
  - budesonide 233
  - dexamethasone 233
  - flunisolide 233

- **Corticosteroids, ophthalmic**
  - dexamethasone 1161
  - fluromethalone 1161
  - loteprednol 1161
  - medrysone 1161
  - prednisone 236
  - rimexolone 1161
Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.

### Corticosteroids, Systemic
- **(Short-Acting)**
  - Cortisone 236
  - Hydrocortisone 236
- **(Intermediate-Acting)**
  - Methylprednisolone 236
  - Prednisolone 236
  - Prednisone 236
  - Triamcinolone 236
- **(Long-Acting)**
  - Betamethasone 236
  - Dexamethasone 236

### Corticosteroids, Topical/Local
- Alclometasone 244
- Amcinonide 244
- Betamethasone 244
- Clobetasol 244
- Clocortolone 244
- Desonide 244
- Desoximetasone 244
- Dexamethasone 244
- Diflorasone 244
- Flucinolone 244
- Flucinonide 244
- Flurandrenolide 244
- Fluticasone 244
- Halcinonide 244
- Halobetasol 244
- Hydrocortisone 244
- Methylprednisolone 244
- Mometasone 245
- Prednicarbate 245
- Triamcinolone 245

### Diuretics
**Pharmacologic Profile**

**General Use:**
Thiazide and loop diuretics are used alone or in combination in the treatment of hypertension or edema due to congestive heart failure or other causes. Potassium-sparing diuretics have weak diuretic and antihypertensive properties and are used mainly to conserve potassium in patients receiving thiazide or loop diuretics. Osmotic diuretics are often used in the management of cerebral edema.

**General Action and Information:**
Enhance the selective excretion of various electrolytes and water by affecting renal mechanisms for tubular secretion and reabsorption. Groups commonly used are thiazide diuretics and thiazide-like diuretics (chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide, and metolazone), loop diuretics (bumetanide, furosemide, and toremifene), potassium-sparing diuretics (amiloride, spironolactone, and triamterene), and osmotic diuretics (mannitol). Mechanisms vary, depending on agent.

**Contraindications:**
Hypersensitivity. Thiazide diuretics may exhibit cross-sensitivity with other sulfonamides.

**Precautions:**
Use with caution in patients with renal or hepatic disease. Safety in pregnancy and lactation not established.
Interactions:
Additive hypokalemia with corticosteroids, amphotericin B, mezlocillin, piperacillin, or ticarcillin. Hypokalemia enhances digitalis glycoside toxicity. Potassium-losing diuretics decrease lithium excretion and may cause toxicity. Additive hypotension with other antihypertensives or nitrates. Potassium-sparing diuretics may cause hyperkalemia when used with potassium supplements or ACE inhibitors.

NURSING IMPLICATIONS

Assessment
- **General Info:** Assess fluid status throughout therapy. Monitor daily weight, intake and output ratios, amount and location of edema, lung sounds, skin turgor, and mucous membranes.
- Assess patient for anorexia, muscle weakness, numbness, tingling, paresthesia, confusion, and excessive thirst. Notify physician or other health care professional promptly if these signs of electrolyte imbalance occur.
- **Hypertension:** Monitor blood pressure and pulse before and during administration. Monitor frequency of prescription refills to determine compliance in patients treated for hypertension.
- **Increased Intracranial Pressure:** Monitor neurologic status and intracranial pressure readings in patients receiving osmotic diuretics to decrease cerebral edema.
- **Increased Intraocular Pressure:** Monitor for persistent or increased eye pain or decreased visual acuity.
- **Lab Test Considerations:** Monitor electrolytes (especially potassium), blood glucose, BUN, and serum uric acid levels before and periodically throughout course of therapy.
- Thiazide diuretics may cause increased serum cholesterol, LDL, and triglyceride concentrations.

Potential Nursing Diagnoses
- Fluid volume excess (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Administer oral diuretics in the morning to prevent disruption of sleep cycle.
- Many diuretics are available in combination with antihypertensives or potassium-sparing diuretics.

Patient/Family Teaching
- **General Info:** Instruct patient to take medication exactly as directed. Advise patients on antihypertensive regimen to continue taking medication, even if feeling better. Medication controls but does not cure hypertension.
- Caution patient that use of alcohol, exercise during hot weather, or standing for long periods during therapy may enhance orthostatic hypotension.
- Instruct patient to consult health care professional regarding dietary potassium guidelines.
- Instruct patient to monitor weight weekly and report significant changes.
- Caution patient to use sunscreen and protective clothing to prevent photosensitivity reactions.
- Advise patient to consult health care professional before taking OTC medication concurrently with this therapy.
Instruct patient to notify health care professional of medication regimen before treatment or surgery.

Advise patient to contact health care professional immediately if muscle weakness, cramps, nausea, dizziness, or numbness or tingling of extremities occurs.

Emphasize the importance of routine follow-up.

**Hypertension:** Reinforce the need to continue additional therapies for hypertension (weight loss, regular exercise, restricted sodium intake, stress reduction, moderation of alcohol consumption, and cessation of smoking).

Instruct patients with hypertension in the correct technique for monitoring weekly blood pressure.

**Evaluation**

**Effectiveness of therapy can be demonstrated by:**
- Decreased blood pressure
- Increased urine output
- Decreased edema
- Reduced intracranial pressure
- Prevention of hypokalemia in patients taking diuretics
- Treatment of hyperaldosteronism.

### Diuretics Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>Loop diuretic</th>
<th>Thiazide and thiazide-like diuretics</th>
</tr>
</thead>
<tbody>
<tr>
<td>bumetanide 124</td>
<td>chlorothiazide 315</td>
</tr>
<tr>
<td>furosemide 315</td>
<td>chlorthalidone 315</td>
</tr>
<tr>
<td>toresemide 315</td>
<td>hydrochlorothiazide 315</td>
</tr>
<tr>
<td>Mannitol 597</td>
<td>indapamide 512</td>
</tr>
<tr>
<td>Potassium-sparing diuretics</td>
<td></td>
</tr>
<tr>
<td>amiloride 312</td>
<td>methyclothiazide 809</td>
</tr>
<tr>
<td>spironolactone 312</td>
<td>metolazone 636</td>
</tr>
<tr>
<td>trichlormethiazide 1176</td>
<td></td>
</tr>
</tbody>
</table>

### ESTROGENS/PROGESTINS/HORMONAL CONTRACEPTIVES*

**PHARMACOLOGIC PROFILE**

**General Use:**

Used to treat hormonal deficiency states in menopausal women to minimize vasomotor symptoms and to prevent and treat osteoporosis. Estrogens and/or progestins are effective as oral contraceptives for women during the reproductive years.

**General Action and Information:**

Hormonal contraceptives block the ovulatory cycle through a negative feedback mechanism on the hypothalamus, by suppressing the production of follicle-stimulating hormone and luteinizing hormone. In addition to suppressing ovulation, these agents affect the movement of the ovum and sperm and creates an environment that is unfavorable for the implantation of a fertilized ovum. Estrogens promote the growth and development of female sex organs and the maintenance of secondary sex characteristics. Estrogens inhibit bone resorption in the prevention and treatment of osteoporosis.

---

*Because of space limitations, additional classes or drugs not represented in *Davis’s Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
Contraindications:
Should not be used in thromboembolic disease, cerebrovascular accident or patients with a history of coronary artery or ischemic heart disease, pregnancy, breast cancer or patients with a history of breast cancer, and severe liver disease.

Precautions:
Use cautiously in women over age 35 who smoke heavily and in patients with hypertension, diabetes, renal disease, lactation, and family history of hyperlipidemia.

Interactions:
May alter requirement for warfarin, oral hypoglycemic agents, or insulin. Antibiotics and anticonvulsants (except valproic acid) may decrease effectiveness. Cigarette smoking increases the risk of adverse cardiovascular effects.

NURSING IMPLICATIONS

Assessment
- Assess blood pressure prior to the start of and periodically during therapy.
- Exclude thrombophlebitis and breast cancer by history or physical exam prior to initiating therapy.
- Exclude pregnancy prior to starting therapy.
- Assess smoking habits and encourage individuals to stop smoking while on hormonal therapy.
- Assess for history of gallbladder disease, hypertension, impaired liver function, obesity, and conditions that may be aggravated by fluid retention. Monitor these individuals at more frequent intervals.

Potential Nursing Diagnoses
- Noncompliance (Family/Patient Teaching).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Oral doses may be administered with or immediately after food to reduce nausea.
- Implant is inserted subdermally in midportion of upper arm about 8–10 cm above the elbow crease.
- Administer IM doses deep into the gluteal or deltoid muscle.

Patient/Family Teaching
- Instruct patient to take oral medication as directed at the same time each day. Pills should be taken in proper sequence and kept in the original container.
- Advise patient of need to use another form of contraception for the first 3 wk when beginning to use oral contraceptives
- Warn patient that many other medications (e.g., certain antibiotics) may interfere with the action of oral contraceptives and to remind their health care professional that he or she is taking birth control pills whenever any other medications are prescribed for them.
- If nausea is a problem, advise patient that eating solid food often provides relief.
Advise patient to report signs of fluid retention, thromboembolic disorders, mental depression, hepatic dysfunction, or abnormal vaginal bleeding.
Inform patient to stop taking medication and to contact their health care professional if pregnancy is suspected.
Caution patient that cigarette smoking during estrogen therapy may increase the risk of serious side effects, especially for women over age 35.
Warn patient to wear sunscreen and protective clothing to prevent increased pigmentation.
Caution patient that oral contraceptives do not protect against HIV and other sexually transmitted diseases.
Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
Emphasize the importance of routine follow-up exams, including blood pressure, breast, abdomen, pelvic, and PAP smears, every 6–12 mo.

Evaluation

Effectiveness of therapy can be demonstrated by:
- Prevention of pregnancy
- Regulation of menstrual cycle
- Decrease in acne
- Control of menopausal symptoms.

Estrogens/Progestins/Hormonal Contraceptives Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>Estrogens</th>
<th>Contraceptives, Bormonal (Triphasic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>estrogens</td>
<td>ethinyl estradiol/norethindrone 225</td>
</tr>
<tr>
<td>estropipate</td>
<td>ethinyl estradiol/norgestrel 225</td>
</tr>
<tr>
<td>progestins</td>
<td>ethinyl estradiol/norgestimate 225</td>
</tr>
<tr>
<td>medroxyprogesterone 605</td>
<td>progestin only</td>
</tr>
<tr>
<td>progesterone 837</td>
<td>norethindrone 226</td>
</tr>
<tr>
<td>contraceptives, Bormonal (Mono-Phasic)</td>
<td>norgestrel 225</td>
</tr>
<tr>
<td>ethinyl estradiol/desogestrel 225</td>
<td>contraceptive implant</td>
</tr>
<tr>
<td>ethinyl estradiol/ethynodiol 225</td>
<td>levonorgestrel 226</td>
</tr>
<tr>
<td>ethinyl estradiol/norethindrone 225</td>
<td>contraceptives, Bormonal (Emergency Contraceptives)</td>
</tr>
<tr>
<td>ethinyl estradiol/norgestrel 225</td>
<td>ethinyl estradiol/levonorgestrel 225</td>
</tr>
<tr>
<td>contraceptives, Bormonal (Biphasic)</td>
<td></td>
</tr>
<tr>
<td>ethinyl estradiol/northindrone 225</td>
<td></td>
</tr>
</tbody>
</table>

IMMUNOSUPPRESSANT AGENTS*

PHARMACOLOGIC PROFILE

General Use:
Azathioprine, basiliximab, cyclosporine, daclizumab, mycophenolate, sirolimus, and tacrolimus are used with glucocorticoids in the prevention of transplantation rejection reactions. Muromonab-CD3 is used to manage rejection reactions not controlled by other agents. Azathioprine, cyclophosphamide, and methotrexate are used in the management of selected autoimmune diseases (nephrotic syndrome of childhood and severe rheumatoid arthritis).

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
General Action and Information:
Inhibit cell-mediated immune responses by different mechanisms. In addition to azathioprine and cyclosporine, which are used primarily for their immunomodulating properties, cyclophosphamide and methotrexate are used to suppress the immune responses in certain disease states (nephrotic syndrome of childhood and severe rheumatoid arthritis). Muromonab-CD3 is a recombinant immunoglobulin antibody that alters T-cell function. Basiliximab and daclizumab are monoclonal antibodies.

Contraindications:
Hypersensitivity to drug or vehicle.

Precautions:
Use cautiously in patients with infections. Safety in pregnancy and lactation not established.

Interactions:
Allopurinol inhibits the metabolism of azathioprine. Drugs that alter liver-metabolizing processes may change the effect of cyclosporine. The risk to toxicity of methotrexate may be increased by other nephrotoxic drugs, large doses of aspirin, or NSAIDs. Muromonab-CD3 has additive immunosuppressive properties; concurrent immunosuppressive doses should be decreased or eliminated.

NURSING IMPLICATIONS

Assessment

- **General Info:** Monitor for infection (vital signs, sputum, urine, stool, WBC). Notify physician or other health care professional immediately if symptoms occur.
- **Organ Transplant:** Assess for symptoms of organ rejection throughout therapy.
- **Lab Test Considerations:** Monitor CBC and differential throughout therapy.

Potential Nursing Diagnoses

- Infection, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Protect transplant patients from staff and visitors who may carry infection.
- Maintain protective isolation as indicated.

Patient/Family Teaching

- Reinforce the need for lifelong therapy to prevent transplant rejection. Review symptoms of rejection for transplanted organ and stress need to notify health care professional immediately if they occur.
- Advise patient to avoid contact with contagious persons and those who have recently taken oral poliovirus vaccine. Patients should not receive vaccinations without first consulting with health care professional.
- Emphasize the importance of follow-up exams and lab tests.
Evaluation

Effectiveness of therapy can be demonstrated by: ■ Prevention or reversal of rejection of organ transplants or decrease in symptoms of autoimmune disorders.

Immunosuppressant Agents Included in Davis's Drug Guide for Nurses

- azathioprine 85
- basiliximab 92
- cyclophosphamide 249
- cyclosporine 252
- methotrexate 627
- muromonab-CD3 672
- sirolimus 924

LAXATIVES

PHARMACOLOGIC PROFILE

General Use:
Used to treat or prevent constipation or to prepare the bowel for radiologic or endoscopic procedures.

General Action and Information:
Induce one or more bowel movements per day. Groups include stimulants (bisacodyl, senna), saline laxatives (magnesium salts and phosphates), stool softeners (docusate), bulk-forming agents (polycarbophil and psyllium), and osmotic cathartics (lactulose, polyethylene glycol/electrolyte). Increasing fluid intake, exercising, and adding more dietary fiber are also useful in the management of chronic constipation.

Contraindications:
Hypersensitivity. Contraindicated in persistent abdominal pain, nausea, or vomiting of unknown cause, especially if accompanied by fever or other signs of an acute abdomen.

Precautions:
Excessive or prolonged use may lead to dependence. Should not be used in children unless advised by a physician or other health care professional.

Interactions:
Theoretically may decrease the absorption of other orally administered drugs by decreasing transit time.

NURSING IMPLICATIONS

Assessment
■ Assess patient for abdominal distention, presence of bowel sounds, and usual pattern of bowel function.
■ Assess color, consistency, and amount of stool produced.
Potential Nursing Diagnoses

- Constipation (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Many laxatives may be administered at bedtime for morning results.
- Taking oral doses on an empty stomach will usually produce more rapid results.
- Do not crush or chew enteric-coated tablets. Take with a full glass of water or juice.
- Stool softeners and bulk laxatives may take several days for results.

Patient/Family Teaching

- Advise patients, other than those with spinal cord injuries, that laxatives should be used only for short-term therapy. Long-term therapy may cause electrolyte imbalance and dependence.
- Advise patient to increase fluid intake to a minimum of 1500–2000 ml/day during therapy to prevent dehydration.
- Encourage patients to use other forms of bowel regulation: increasing bulk in the diet, increasing fluid intake, and increasing mobility. Normal bowel habits are individualized and may vary from 3 times/day to 3 times/wk.
- Instruct patients with cardiac disease to avoid straining during bowel movements (Valsalva maneuver).
- Advise patient that laxatives should not be used when constipation is accompanied by abdominal pain, fever, nausea, or vomiting.

Evaluation

Effectiveness of therapy can be demonstrated by:

- A soft, formed bowel movement
- Evacuation of colon.

Laxatives Included in Davis’s Drug Guide for Nurses

- **bulk-forming agents**
  - polycarbophil 811
  - psyllium 858
- **osmotic agents**
  - lactulose 557
  - polyethylene glycol/electrolyte 813
- **saline laxatives**
  - magnesium citrate 593
- **stimulants**
  - bisacodyl 108
  - senna, sennosides 915
- **stool softener**
  - docusate 322

LIPID-LOWERING AGENTS

PHARMACOLOGIC PROFILE

General Use:

Used as a part of a total plan including diet and exercise to reduce blood lipids in an effort to reduce the morbidity and mortality of atherosclerotic cardiovascular disease and its sequelae.
General Action and Information:
HMG-CoA reductase inhibitors (fluvastatin, lovastatin, pravastatin, simvastatin) inhibit an enzyme involved in cholesterol synthesis. Bile acid sequestrants (cholestyramine, colestipol) bind cholesterol in the GI tract. Niacin and gemfibrozil act by other mechanisms (see individual monographs).

Contraindications:
Hypersensitivity.

Precautions:
Safety in pregnancy, lactation, and children not established. See individual drugs. Dietary therapy should be given a 2–3 mo trial before drug therapy is initiated.

Interactions:
Bile acid sequestrants (cholestyramine and colestipol) may bind lipid-soluble vitamins (A, D, E, and K) and other concurrently administered drugs in the GI tract. The risk of myopathy from HMG-CoA reductase inhibitors is increased by niacin, erythromycin, gemfibrozil, and cyclosporine.

NURSING IMPLICATIONS

Assessment
- Obtain a diet history, especially in regard to fat and alcohol consumption.
- **Lab Test Considerations:** Serum cholesterol and triglyceride levels should be evaluated before initiating and periodically throughout therapy. Medication should be discontinued if paradoxical increase in cholesterol level occurs.
- Liver function tests should be assessed before and periodically throughout therapy. May cause an increase in levels.

Potential Nursing Diagnoses
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
- Noncompliance (Patient/Family Teaching).

Implementation
- See specific medications to determine timing of doses in relation to meals.

Patient/Family Teaching
- Advise patient that these medications should be used in conjunction with diet restrictions (fat, cholesterol, carbohydrates, and alcohol), exercise, and cessation of smoking.

Evaluation
**Effectiveness of therapy can be demonstrated by:**
- Decreased serum triglyceride and LDL cholesterol levels and improved high-density lipoprotein HDL cholesterol ratios. Therapy is usually discontinued if the clinical response is not evident after 3 mo of therapy.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
Lipid-Lowering Agents Included in Davis’s Drug Guide for Nurses

**bile acid sequestrants**
- cholestyramine 105
- colestipol 105

**HMG-CoA reductase inhibitors**
- atorvastatin 478
- cerivastatin 478
- fluvastatin 478
- lovastatin 478
- pravastatin 478
- simvastatin 478
- cerivastatin 478
- niacin, niacinamide 697

**PHARMACOLOGIC PROFILE**

**General Use:**
Electrolytes are used to prevent or treat fluid and electrolyte imbalances and to maintain acid-base balance and osmotic pressure. Minerals are used to prevent or treat deficiencies in trace minerals.

**General Action and Information:**
Electrolytes are essential for homeostasis in the body. Maintenance of electrolyte levels within normal limits is necessary for many physiologic processes, such as cardiac, nerve, and muscle function, bone growth and stability; and others. Minerals are needed for normal growth and function; as cofactors in enzymatic reactions; and as stabilizing factors in hemoglobin synthesis, protein synthesis, and many other physiologic processes.

**Contraindications:**
Contraindicated in situations in which replacement would cause excess or when risk factors for fluid retention are present.

**Precautions:**
Use cautiously in disease states in which electrolyte imbalances are common, such as hepatic or renal disease, adrenal disorders, pituitary disorders, and diabetes mellitus.

**Interactions:**
See individual agents.

**NURSING IMPLICATIONS**

**Assessment**
- Observe patient carefully for evidence of electrolyte excess or insufficiency. Monitor lab values before and periodically throughout therapy.
- Nutrition, altered: less than body requirements (Indications).
- Knowledge deficit, related to medication and dietary regimens (Patient/Family Teaching).

**Implementation**
- **Potassium Chloride:** Do not administer parenteral potassium chloride undiluted.
Patient/Family Teaching

- Review diet modifications with patients with chronic electrolyte disturbances.

Evaluation

Effectiveness of therapy can be demonstrated by:

- Return to normal serum electrolyte concentrations and resolution of clinical symptoms of electrolyte imbalance
- Changes in pH or composition of urine, which prevent formation of renal calculi

Minerals/Electrolytes Included in Davis’s Drug Guide for Nurses

calcium supplements
- calcium acetate 142
- calcium carbonate 142
- calcium chloride 142
- calcium citrate 142
- calcium gluconate 142
- calcium lactate 142
- tricalcium phosphate 142

iron supplements
- carbonyl iron 532
- ferrous fumarate 533
- ferrous gluconate 533
- ferrous sulfate 533
- iron dextran 533
- iron polysaccharide 533
- sodium ferric gluconate complex 533

magnesium salts
- magnesium salts (oral) 593

phosphate supplements
- potassium phosphate 817
- potassium and sodium phosphates 815
- sodium phosphate 932

potassium supplements
- potassium acetate 819
- potassium bicarbonate 819
- potassium chloride, 819
- potassium citrate 819
- potassium gluconate 820
- trikates 820

miscellaneous
- sodium bicarbonate 926
- sodium chloride 928

NON-OPIOID ANALGESICS*

PHARMACOLOGIC PROFILE

General Use:

Used to control mild to moderate pain and/or fever. Phenazopyridine is used only to treat urinary tract pain, and capsaicin is used topically for a variety of painful syndromes.

General Action and Information:

Most non-opioid analgesics inhibit prostaglandin synthesis peripherally for analgesic effect and centrally for antipyretic effect.

Contraindications:

Hypersensitivity and cross-sensitivity among NSAIDs may occur.

Precautions:

Use cautiously in patients with severe hepatic or renal disease, chronic alcohol use/abuse, or malnutrition. Tramadol has CNS depressant properties.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
Interactions:
Chronic use of acetaminophen with NSAIDs may increase the risk of adverse renal effects. Chronic high-dose acetaminophen may increase the risk of bleeding with warfarin. Hepatotoxicity may be additive with other hepatotoxic agents, including alcohol. NSAIDs increase the risk of bleeding with warfarin, thrombolytic agents, antiplatelet agents, some cephalosporins, and valproates (effect is greatest with aspirin). NSAIDs may also decrease the effectiveness of diuretics and antihypertensives. The risk of CNS depression with tramadol is increased by concurrent use of other CNS depressants, including alcohol, antihistamines, sedative/hypnotics, and some antidepressants.

NURSING IMPLICATIONS

Assessment
- **General Info:** Patients who have asthma, allergies, and nasal polyps or who are allergic to tartrazine are at an increased risk for developing hypersensitivity reactions.
- **Pain:** Assess pain and limitation of movement; note type, location, and intensity prior to and at the peak (see Time/Action Profile) following administration.
- **Fever:** Assess fever and note associated signs (diaphoresis, tachycardia, malaise, chills).
- **Lab Test Considerations:** Hepatic, hematologic, and renal function should be evaluated periodically throughout prolonged, high-dose therapy. Aspirin and most NSAIDs prolong bleeding time due to suppressed platelet aggregation and, in large doses, may cause prolonged prothrombin time. Monitor hematocrit periodically in prolonged high-dose therapy to assess for GI blood loss.

Potential Nursing Diagnoses
- Pain (Indications).
- Body temperature, altered (Indications).
- Knowledge deficit related to medication regimen (Patient/Family Teaching).

Implementation
- **PO:** Administer salicylates and NSAIDs after meals or with food or an antacid to minimize gastric irritation.

Patient/Family Teaching
- Instruct patient to take salicylates and NSAIDs with a full glass of water and to remain in an upright position for 15–30 min after administration.
- Adults should not take acetaminophen longer than 10 days and children not longer than 5 days unless directed by health care professional. Short-term doses of acetaminophen with salicylates or NSAIDs should not exceed the recommended daily dose of either drug alone.
- Caution patient to avoid concurrent use of alcohol with this medication to minimize possible gastric irritation; 3 or more glasses of alcohol per day may increase the risk of GI bleeding with salicylates or NSAIDs. Caution patient to avoid taking acetaminophen, salicylates, or NSAIDs concurrently for more than a few days, unless directed by health care professional to prevent analgesic nephropathy.
- Advise patients on long-term therapy to inform health care professional of medication regimen prior to surgery. Aspirin, salicylates, and NSAIDs may need to be withheld prior to surgery.
**Evaluation**

**Effectiveness of therapy can be demonstrated by:**
- Relief of mild to moderate discomfort
- Reduction of fever.

**Non-opioid Analgesics Included in Davis’s Drug Guide for Nurses**

<table>
<thead>
<tr>
<th><strong>nonsteroidal anti-inflammatory drugs</strong></th>
<th>choline and magnesium salicylates</th>
<th>choline salicylate</th>
<th>salsalate</th>
</tr>
</thead>
<tbody>
<tr>
<td>etodolac 379</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ibuprofen 499</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ketorolac 552</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>naproxen P–98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>salicylates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aspirin 903</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>miscellaneous</strong></th>
<th>acetaminophen 3</th>
<th>phenazopyridine 783</th>
<th>tramadol 1011</th>
</tr>
</thead>
</table>

**NONSTEROIDAL ANTI-INFLAMMATORY AGENTS**

**PHARMACOLOGIC PROFILE**

**General Use:**

NSAIDs are used to control mild to moderate pain, fever, and various inflammatory conditions, such as rheumatoid arthritis and osteoarthritis. Ophthalmic NSAIDs are used to decrease postoperative ocular inflammation, to inhibit perioperative miosis, and to decrease inflammation due to allergies.

**General Action and Information:**

NSAIDs have analgesic, antipyretic, and anti-inflammatory properties. Analgesic and anti-inflammatory effects are due to inhibition of prostaglandin synthesis. Antipyretic action is due to vasodilation and inhibition of prostaglandin synthesis in the CNS.

**Contraindications:**

Hypersensitivity to aspirin is a contraindication for the whole group of NSAIDs. Cross-sensitivity may occur.

**Precautions:**

Use cautiously in patients with a history of bleeding disorders, GI bleeding, and severe hepatic, renal, or cardiovascular disease. Safe use in pregnancy is not established and, in general, should be avoided during the second half of pregnancy.

**Interactions:**

NSAIDs prolong bleeding time and potentiate the effect of warfarin, thrombolytic agents, plicamycin, some cephalosporins, antiplatelet agents, and valproates. Chronic use with aspirin may result in increased GI side effects and decreased effectiveness. NSAIDs may also decrease response to diuretics or antihypertensive therapy.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
NURSING IMPLICATIONS

Assessment

- **General Info:** Patients who have asthma, allergies, and nasal polyps or who are allergic to tartrazine are at an increased risk for developing hypersensitivity reactions.
- **Pain:** Assess pain and limitation of movement; note type, location, and intensity prior to and at the peak (see Time/Action Profile) following administration.
- **Fever:** Assess fever and note associated signs (diaphoresis, tachycardia, malaise, chills).
- **Lab Test Considerations:** Most NSAIDs prolong bleeding time due to suppressed platelet aggregation and, in large doses, may cause prolonged prothrombin time. Monitor periodically in prolonged high-dose therapy to assess for GI blood loss.

Potential Nursing Diagnoses

- Pain (Indications).
- Body temperature, altered (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- **PO:** Administer NSAIDs after meals or with food or an antacid to minimize gastric irritation.

Patient/Family Teaching

- Instruct patient to take NSAIDs with a full glass of water and to remain in an upright position for 15–30 min after administration.
- Caution patient to avoid concurrent use of alcohol with this medication to minimize possible gastric irritation; 3 or more glasses of alcohol per day may increase the risk of GI bleeding with salicylates or NSAIDs. Caution patient to avoid taking acetaminophen, salicylates, or NSAIDs concurrently for more than a few days, unless directed by health care professional to prevent analgesic nephropathy.
- Advise patient on long-term therapy to inform health care professional of medication regimen prior to surgery. NSAIDs may need to be withheld prior to surgery.

Evaluation

**Effectiveness of therapy can be demonstrated by:**

- Relief of mild to moderate discomfort.
- Reduction of fever.

Nonsteroidal Anti-inflammatory Agents Included in *Davis’s Drug Guide for Nurses*

**nonsteroidal anti-inflammatory drugs**

- aspirin 903
- celecoxib 166
- choline and magnesium salicylates 903
- choline salicylate 903
- diclofenac 282
- etodolac 378
- flurbiprofen 423
- ibuprofen 499
- ketoprofen 550
- ketorolac 522
- nabumetone 677
- naproxen P-98
- oxaprozin 733
- piroxicam 807
- rofecoxib 898
- salsalate 903
- sulindac 946
- tolmetin 1003

**ophthalmic NSAIDs**
OPIOID ANALGESICS*

PHARMACOLOGIC PROFILE

General Use:
Management of moderate to severe pain. Fentanyl is used as a general anesthetic adjunct.

General Action and Information:
Opioids bind to opiate receptors in the CNS, where they act as agonists of endogenously occurring opioid peptides (eukephalins and endorphins). The result is alteration to the perception of and response to pain.

Contraindications:
Hypersensitivity to individual agents.

Precautions:
Use cautiously in patients with undiagnosed abdominal pain, head trauma or pathology, liver disease, or history of addiction to opioids. Use smaller doses initially in the elderly and those with respiratory diseases. Chronic use may result in tolerance and the need for larger doses to relieve pain. Psychological or physical dependence may occur.

Interactions:
Increases the CNS depressant properties of other drugs, including alcohol, antihistamines, antidepressants, sedative/hypnotics, phenothiazines, and MAO inhibitors. Use of partial-antagonist opioid analgesics (buprenorphine, butorphanol, dezocine, nalbuphine, and pentazocine) may precipitate opioid withdrawal in physically dependent patients. Use with MAO inhibitors or procarbazine may result in severe paradoxical reactions (especially with meperidine). Nalbuphine or pentazocine may decrease the analgesic effects of other concurrently administered opioid analgesics.

NURSING IMPLICATIONS

Assessment

- Assess type, location, and intensity of pain prior to and at peak following administration. When titrating opioid doses, increases of 25–50% should be administered until there is either a 50% reduction in the patient's pain rating on a numerical or visual analogue scale or the patient reports satisfactory pain relief. A repeat dose can be safely administered at the time of the peak if previous dose is ineffective and side effects are minimal. Patients requiring higher doses of opioid agonist-antagonists should be converted to an opioid agonist. Opioid agonist-antagonists are not recommended for prolonged use or as first-line therapy for acute or cancer pain.

- An equianalgesic chart (see Appendix C) should be used when changing routes or when changing from one opioid to another.

*Because of space limitations, additional classes or drugs not represented in Davis's Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
Assess blood pressure, pulse, and respirations before and periodically during administration. If respiratory rate is <10/min, assess level of sedation. Physical stimulation may be sufficient to prevent significant hypoventilation. Dose may need to be decreased by 25–50%. Initial drowsiness will diminish with continued use.

Assess prior analgesic history. Antagonistic properties of agonist-antagonists may induce withdrawal symptoms (vomiting, restlessness, abdominal cramps, and increased blood pressure and temperature) in patients physically dependent on opioids.

Prolonged use may lead to physical and psychological dependence and tolerance. This should not prevent patient from receiving adequate analgesia. Most patients who receive opioid analgesics for pain do not develop psychological dependence. Progressively higher doses may be required to relieve pain with long-term therapy.

Assess bowel function routinely. Prevention of constipation should be instituted with increased intake of fluids and bulk, stool softeners, and laxatives to minimize constipating effects. Stimulant laxatives should be administered routinely if opioid use exceeds 2–3 days, unless contraindicated.

Monitor intake and output ratios. If significant discrepancies occur, assess for urinary retention and inform physician or other health care professional.

Toxicity and Overdose: If an opioid antagonist is required to reverse respiratory depression or coma, naloxone (Narcan) is the antidote. Dilute the 0.4-mg ampule of naloxone in 10 ml of 0.9% NaCl and administer 0.5 ml (0.02 mg) by direct IV push every 2 min. For children and patients weighing <40 kg, dilute 0.1 mg of naloxone in 10 ml of 0.9% NaCl for a concentration of 10 mcg/ml and administer 0.5 mcg/kg every 1–2 min. Titrate dose to avoid withdrawal, seizures, and severe pain.

Potential Nursing Diagnoses

- Pain (Indications).
- Sensory-perceptual alteration: visual, auditory (Side Effects).
- Injury, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Do not confuse morphine with hydromorphone or meperidine; errors have resulted in fatalities.
- Explain therapeutic value of medication before administration to enhance the analgesic effect.
- Regularly administered doses may be more effective than prn administration. Analgesic is more effective if given before pain becomes severe.
- Coadministration with nonopioid analgesics may have additive analgesic effects and may permit lower doses.
- Medication should be discontinued gradually after long-term use to prevent withdrawal symptoms.

Patient/Family Teaching

- Instruct patient on how and when to ask for pain medication.
- Medication may cause drowsiness or dizziness. Caution patient to call for assistance when ambulating or smoking and to avoid driving or other activities requiring alertness until response to medication is known.
- Advise patient to make position changes slowly to minimize orthostatic hypotension.
- Caution patient to avoid concurrent use of alcohol or other CNS depressants with this medication.
Encourage patient to turn, cough, and breathe deeply every 2 hr to prevent atelectasis.

Evaluation

Effectiveness of therapy can be demonstrated by: Decreased severity of pain without a significant alteration in level of consciousness or respiratory status.

Opioid Analgesics Included in Davis’s Drug Guide for Nurses

**opioid agonists**  
codeine 221  
fentanyl (parenteral) 391  
fentanyl (transdermal) 394  
fentanyl (transmucosal) 1176  
hydromorphone 482  
morphine 666  

**opioid agonists/antagonists**  
buprenorphine 127  
butorphanol 137  
dezocine 1120  
hydromorphone 1119  

**SKELETAL MUSCLE RELAXANTS**

**PHARMACOLOGIC PROFILE**

**General Use:**  
Two major uses are spasticity associated with spinal cord diseases or lesions (baclofen and dantrolene) or adjunctive therapy in the symptomatic relief of acute painful musculoskeletal conditions (cyclobenzaprine, diazepam, and methocarbamol). IV dantrolene is also used to treat and prevent malignant hyperthermia.

**General Action and Information:**  
Act either centrally (baclofen, carisoprodol, cyclobenzaprine, diazepam, and methocarbamol) or directly (dantrolene).

**Contraindications:**  
Baclofen and oral dantrolene should not be used in patients in whom spasticity is used to maintain posture and balance.

**Precautions:**  
Safety in pregnancy and lactation not established. Use cautiously in patients with a previous history of liver disease.

**Interactions:**  
Additive CNS depression with other CNS depressants, including alcohol, antihistamines, antidepressants, opioid analgesics, and sedative/hypnotics.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.*
NURSING IMPLICATIONS

Assessment
- Assess patient for pain, muscle stiffness, and range of motion before and periodically throughout therapy.

Potential Nursing Diagnoses
- Pain (Indications).
- Physical mobility, impaired (Indications).
- Injury, risk for (Side Effects).

Implementation
- Provide safety measures as indicated. Supervise ambulation and transfer of patients.

Patient/Family Teaching
- Encourage patient to comply with additional therapies prescribed for muscle spasm (rest, physical therapy, heat).
- Medication may cause drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to drug is known.
- Advise patient to avoid concurrent use of alcohol or other CNS depressants with these medications.

Evaluation
Effectiveness of therapy can be demonstrated by:
- Decreased musculoskeletal pain
- Decreased muscle spasticity
- Increased range of motion
- Prevention or decrease in temperature and skeletal rigidity in malignant hyperthermia.

Skeletal Muscle Relaxants Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>centrrally acting</th>
<th>methocarbamol 626</th>
</tr>
</thead>
<tbody>
<tr>
<td>baclofen 91</td>
<td>orphenadrine 1178</td>
</tr>
<tr>
<td>carisoprodol 157</td>
<td></td>
</tr>
<tr>
<td>chlorzoxazone 195</td>
<td></td>
</tr>
<tr>
<td>cyclobenzaprine 247</td>
<td></td>
</tr>
<tr>
<td>diazepam 279</td>
<td></td>
</tr>
</tbody>
</table>

| direct-acting     | dantrolene 262 |

THROMBOLYTIC AGENTS*

PHARMACOLOGIC PROFILE

General Use:
Acute management of coronary thrombosis (myocardial infarction). Streptokinase and urokinase are used in the management of massive pulmonary embolus, deep vein thrombosis, and arterial thromboembolism. Alteplase is used in the management of acute ischemic stroke.
General Action and Information:
Converts plasminogen to plasmin, which then degrades fibrin in clots. Alteplase, reteplase, and urokinase directly activate plasminogen. Anistreplase and streptokinase bind with plasminogen to form activator complexes, which then convert plasminogen to plasmin. Results in lysis of thrombi in coronary arteries, pulmonary emboli, or deep vein thrombosis, or clearing of clots in cannulae/catheters.

Contraindications:
Hypersensitivity. Cross-sensitivity with anistreplase and streptokinase may occur. Contraindicated in active internal bleeding, history of cerebrovascular accident, recent CNS trauma or surgery, neoplasm, or arteriovenous malformation. Severe uncontrolled hypertension and known bleeding tendencies.

Precautions:
Recent (within 10 days) major surgery, trauma, GI or GU bleeding. Severe hepatic or renal disease. Subacute bacterial endocarditis or acute pericarditis. Use cautiously in geriatric patients. Safety not established in pregnancy, lactation, or children.

Interactions:
Concurrent use with aspirin, NSAIDs, warfarin, heparins, abciximab, ticlopidine, or dypridamone may increase the risk of bleeding, although these agents are frequently used together or in sequence. Risk of bleeding may also be increased by concurrent use with cefamandole, cefotetan, cefoperazone, plicamycin, and valproic acid.

NURSING IMPLICATIONS
Assessment
- Begin therapy as soon as possible after the onset of symptoms.
- Monitor vital signs, including temperature, continuously for coronary thrombosis and at least every 4 hr during therapy for other indications. Do not use lower extremities to monitor blood pressure.
- Assess patient carefully for bleeding every 15 min during the 1st hr of therapy, every 15–30 min during the next 8 hr, and at least every 4 hr for the duration of therapy. Frank bleeding may occur from sites of invasive procedures or from body orifices. Internal bleeding may also occur (decreased neurologic status; abdominal pain with coffee-ground emesis or black, tarry stools; hematuria; joint pain). If uncontrolled bleeding occurs, stop medication and notify physician immediately.
- Inquire about previous reaction to anistreplase or streptokinase therapy. Assess patient for hypersensitivity reaction (rash, dyspnea, fever, changes in facial color, swelling around the eyes, wheezing). If these occur, inform physician promptly. Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
- Inquire about recent streptococcal infection. Anistreplase and streptokinase may be less effective if administered between 5 days and 6 mo of a streptococcal infection.
- Assess neurologic status throughout therapy.
- Altered sensorium or neurologic changes may be indicative of intracranial bleeding.
- Coronary Thrombosis: Monitor ECG continuously. Notify physician if significant arrhythmias occur. IV lidocaine or procainamide (Promestyl) may be ordered prophylactically. Cardiac
enzymes should be monitored. Radionuclide myocardial scanning and/or coronary angiography may be ordered 7–10 days following therapy to monitor effectiveness of therapy.

- Monitor heart sounds and breath sounds frequently. Inform physician if signs of congestive heart failure occur (rales/crackles, dyspnea, S3 heart sound, jugular venous distention, relieved CVP).
- Monitor heart sounds and breath sounds frequently. Inform physician if signs of congestive heart failure occur (rales/crackles, dyspnea, S3 heart sound, jugular venous distention, relieved CVP).
- **Pulmonary Embolism:** Monitor pulse, blood pressure, hemodynamics, and respiratory status (rate, degree of dyspnea, ABGs).
- **Deep Vein Thrombosis/Acute Arterial Occlusion:** Observe extremities and palpate pulses of affected extremities every hour. Notify physician immediately if circulatory impairment occurs. Computerized axial tomography, impedance plethysmography, quantitative Doppler effect determination, and/or angiography or venography may be used to determine restoration of blood flow and duration of therapy; however, repeated venograms are not recommended.
- **Cannula/Catheter Occlusion:** Monitor ability to aspirate blood as indicator of patency. Ensure that patient exhales and holds breath when connecting and disconnecting IV syringe to prevent air embolism.
- **Acute Ischemic Stroke:** Assess neurologic status. Determine time of onset of stroke symptoms. Alteplase must be administered within 3 hr of onset.
- **Lab Test Considerations:** Hematocrit, hemoglobin, platelet count, fibrin/fibrin degradation product (FDP/fdp) titer, fibrinogen concentration, prothrombin time, thrombin time, and activated partial thromboplastin time may be evaluated prior to and frequently throughout therapy. Bleeding time may be assessed prior to therapy if patient has received platelet aggregation inhibitors. Obtain type and crossmatch and have blood available at all times in case of hemorrhage. Stools should be tested for occult blood loss and urine for hematuria periodically during therapy
- **Toxicity and Overdose:** If local bleeding occurs, apply pressure to site. If severe internal bleeding occurs, discontinue infusion. Clotting factors and/or blood volume may be restored through infusions of whole blood, packed RBCs, fresh frozen plasma, or cryoprecipitate. Do not administer dextran, as it has antiplatelet activity. Aminocaproic acid (Amicar) may be used as an antidote.

**Potential Nursing Diagnoses**

- Tissue perfusion (Indications).
- Injury, risk for (Side effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

**Implementation**

- This medication should be used only in settings in which hematologic function and clinical response can be adequately monitored.
- Starting two IV lines prior to therapy is recommended: one for the thrombolytic agent, the other for any additional infusions.
- Avoid invasive procedures, such as IM injections or arterial punctures, with this therapy. If such procedures must be performed, apply pressure to all arterial and venous puncture sites for at least 30 min. Avoid venipunctures at noncompressible sites (jugular vein, subclavian site).
- Systemic anticoagulation with heparin is usually begun several hours after the completion of thrombolytic therapy.
- Acetaminophen may be ordered to control fever.
Patient/Family Teaching

- Explain purpose of medication and the need for close monitoring to patient and family.
- Instruct patient to report hypersensitivity reactions (rash, dyspnea) and bleeding or bruising.
- Explain need for bedrest and minimal handling during therapy to avoid injury. Avoid all unnecessary procedures such as shaving and vigorous tooth brushing.

Evaluation

**Effectiveness of therapy can be demonstrated by:**
- Lysis of thrombi and restoration of blood flow
- Prevention of neurologic sequelae in acute ischemic stroke
- Cannula or catheter patency.

Thrombolytic Agents Included in *Davis's Drug Guide for Nurses*

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>alteplase</td>
<td>980</td>
</tr>
<tr>
<td>anistreplase</td>
<td>980</td>
</tr>
<tr>
<td>reteplase</td>
<td>980</td>
</tr>
<tr>
<td>streptokinase</td>
<td>980</td>
</tr>
<tr>
<td>urokinase</td>
<td>980</td>
</tr>
</tbody>
</table>

VASCULAR HEADACHE SUPPRESSANTS

PHARMACOLOGIC PROFILE

General Use:

Used for acute treatment of vascular headaches (migraine, cluster headaches, migraine variants). Other agents such as some beta-adrenergic blockers and some calcium channel blockers are used for suppression of frequently occurring vascular headaches.

General action and information:

Ergot derivative agents (ergotamine, dihydroergotamine) directly stimulate alpha-adrenergic and serotoninergic receptors, producing vascular smooth muscle vasoconstriction. Sumatriptan and zolmitriptan produce vasoconstriction by acting as serotonin agonists.

Contraindications:

Avoid using these agents in patients with ischemic cardiovascular disease.

Precautions:

Use cautiously in patients with a history of or risk for cardiovascular disease.

Interactions:

Avoid concurrent use of ergot derivative agents with serotonin agonist agents; see also individual agents.

*Because of space limitations, additional classes or drugs not represented in *Davis's Drug Guide for Nurses*, 7th edition, are provided in this Pocket Companion.*
NURSING IMPLICATIONS

Assessment

- Assess pain location, intensity, duration, and associated symptoms (photophobia, phonophobia, nausea, vomiting) during migraine attack.

Potential Nursing Diagnoses

- Pain (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation

- Medication should be administered at the first sign of a headache.

Patient/Family Teaching

- Inform patient that medication should be used only during a migraine attack. It is meant to be used for relief of migraine attacks but not to prevent or reduce the number of attacks.
- Advise patient that lying down in a darkened room following medication administration may further help relieve headache.
- May cause dizziness or drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
- Advise patient to avoid alcohol, which aggravates headaches.

Evaluation

Effectiveness of therapy can be demonstrated by: ■ Relief of migraine attack.

Vascular Headache Suppressants Included in Davis's Drug Guide for Nurses

**Ergot Derivatives**
- Dihydroergotamine 357
- Ergotamine 357
- Naratriptan 688
- Rizatriptan 896

**Serotonin Agonists**
- Sumatriptan 947
- Zolmitriptan 1070

VITAMINS

PHARMACOLOGIC PROFILE

General Use:

Used in the prevention and treatment of vitamin deficiencies and as supplements in various metabolic disorders.

General Action and Information:

Serve as components of enzyme systems that catalyze numerous varied metabolic reactions. Necessary for homeostasis. Water-soluble vitamins (B-vitamins and vitamin C) rarely cause toxicity. Fat-soluble vitamins (vitamins D and E) may accumulate and cause toxicity.
Contraindications:
Hypersensitivity to additives, preservatives, or colorants.

Precautions:
Dosage should be adjusted to avoid toxicity, especially for fat-soluble vitamins.

Interactions:
Pyridoxine in large amounts may interfere with the effectiveness of levodopa. Cholestyramine, colestipol, and mineral oil decrease absorption of fat-soluble vitamins.

NURSING IMPLICATIONS

Assessment
- Assess patient for signs of vitamin deficiency before and periodically throughout therapy.
- Assess nutritional status through 24-hr diet recall. Determine frequency of consumption of vitamin-rich foods.

Potential Nursing Diagnoses
- Nutrition, altered: less than body requirements (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

Implementation
- Because of infrequency of single vitamin deficiencies, combinations are commonly administered.

Patient/Family Teaching
- Encourage patients to comply with diet recommendations of physician or other health care professional. Explain that the best source of vitamins is a well-balanced diet with foods from the four basic food groups.
- Patients self-medicating with vitamin supplements should be cautioned not to exceed RDA (see Appendix M). The effectiveness of megadoses for treatment of various medical conditions is unproved and may cause side effects and toxicity.

Evaluation
Effectiveness of therapy may be demonstrated by: Prevention of or decrease in the symptoms of vitamin deficiencies.

Vitamins Included in Davis’s Drug Guide for Nurses

<table>
<thead>
<tr>
<th>Fat-soluble vitamins</th>
<th>Water-soluble vitamins</th>
</tr>
</thead>
<tbody>
<tr>
<td>calcitriol 1050</td>
<td>vitamin D compounds 1050</td>
</tr>
<tr>
<td>dihydrotachysterol 1050</td>
<td>vitamin E 1053</td>
</tr>
<tr>
<td>ergocalciferol 1050</td>
<td></td>
</tr>
<tr>
<td>paricalcitol 1050</td>
<td></td>
</tr>
<tr>
<td>phytonadione (vitamin K) 795</td>
<td>ascorbic acid (vitamin C) 75</td>
</tr>
<tr>
<td></td>
<td>cyanocobalamin (vitamin B12) 1047</td>
</tr>
<tr>
<td></td>
<td>folic acid 428</td>
</tr>
</tbody>
</table>

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
<table>
<thead>
<tr>
<th>Compound</th>
<th>Classification</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>hydroxocobalamin (vitamin B₁₂)</td>
<td>1048</td>
<td></td>
</tr>
<tr>
<td>niacin, niacinamide (vitamin B₃)</td>
<td>697</td>
<td></td>
</tr>
<tr>
<td>pyridoxine (vitamin B₆)</td>
<td>863</td>
<td></td>
</tr>
<tr>
<td>riboflavin (vitamin B₂)</td>
<td>883</td>
<td></td>
</tr>
<tr>
<td>thiamine (vitamin B₁)</td>
<td>974</td>
<td></td>
</tr>
</tbody>
</table>
SECTION II
Drugs Not Represented in
Davis’s Drug Guide for Nurses, 7th Edition*

CALCITONIN (human)
(kal-si-toe-nin)
Cibacalcin

CALCITONIN (salmon)
Calcimar, Micalcin, Osteocalcin, Salmonine

CLASSIFICATION(S):
Calcium/phosphorous regulating hormones (hypocalcemic)

Pregnancy Category C

INDICATIONS
■ IM, SC: Treatment of Paget’s disease of bone

ACTION
■ Decreases serum calcium by a direct effect on bone, kidney, and GI tract ■ Promotes renal excretion of calcium. Therapeutic Effects:
■ Decreased rate of bone turnover ■ Lowering of serum calcium.

PHARMACOKINETICS
Absorption: Completely absorbed from IM and SC sites. Rapidly absorbed from nasal mucosa; absorption is 3% compared with parenteral administration.
Distribution: Unknown.
Metabolism and Excretion: Rapidly metabolized in kidneys, blood, and tissues.
Half-life: 70–90 min.

CONTRAINDICATIONS AND PRECAUTIONS
Contraindicated in: ■ Hypersensitivity to salmon protein or gelatin diluent■ Pregnancy or lactation (use not recommended).
Use Cautionally in: ■ Children (safety not established).

ADVERSE REACTIONS AND SIDE EFFECTS†
CNS: headaches.
EENT: nasal only—epistaxis, nasal irritation, rhinitis.
GI: IM, SC—nausea, vomiting, altered taste, diarrhea.
GU: IM, SC—urinary frequency.
Derm: rashes.
Local: injection site reactions.
MS: nasal—arthralgia, back pain.
Misc: allergic reactions including ANAPHYLAXIS, facial flushing, swelling, tingling, and tenderness in the hands.

INTERACTIONS
Drug-Drug: ■ Previous bisphosphonate therapy, including alendronate etidronate and pamidronate may decrease response to calcitonin.

ROUTE AND DOSAGE
Postmenopausal osteoporosis
■ IM, SC (Adults): 100 IU/day
■ Intranasal (Adults): 200 IU/day.
Paget’s disease
■ IM, SC (Adults): 100 IU/day initially, after titration, maintenance dose is usually 50IU/day or every other day.

*Because of space limitations, additional classes or drugs not represented in Davis’s Drug Guide for Nurses, 7th edition, are provided in this Pocket Companion.
[] = Available in Canada only.
†CAPITALS indicate life-threatening; underlines indicate most frequent.
CALCITONIN

- **Hypercalcemia**
  - **IM, SC (Adults):** 4 IU/kg q 12 hr; may be increased after 1–2 days to 8 IU/kg q 12 hr, and if necessary after 2 more days may be increased to 8 IU q 6 hr.

**AVAILABILITY**

- **Injection:** 200 IU/ml in 2 ml vials
  - **Cost:** $34.00-53.40/vial
- **Nasal spray:** 200 IU/actuation in 2 ml bottles
  - **Cost:** $56.72/bottle.

**TIME/ACTION PROFILE**

<table>
<thead>
<tr>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM, SC†</td>
<td>Unknown</td>
<td>2 hr</td>
</tr>
<tr>
<td>Intranasal†</td>
<td>rapid</td>
<td>31–39 min</td>
</tr>
</tbody>
</table>

†Effects on serum calcium.

PATIENT/FAMILY TEACHING

- **General Info:** Advise patient to take medication exactly as directed. If dose is missed and medication is scheduled for twice a day, take only if possible within 2 hr of correct time. If scheduled for daily dose, take only if remembered that day. If scheduled for every other day, take when remembered and restart alternate day schedule. If taking 1 dose 3 times weekly (Mon, Wed, Fri), take missed dose the next day and set each injection back 1 day; resume regular schedule the following week. Do not double doses.


- Advise patient to report signs of hypercalcemic relapse (deep bone or flank pain, renal calculi, anorexia, nausea, vomiting, thirst, lethargy) or allergic response promptly.

- Reassure patient that flushing and warmth following injection are transient and usually last about 1 hr.

- Explain that nausea following injection tends to decrease even with continued therapy.

- Instruct patient to follow low-calcium diet if recommended by health care professional (see Appendix L). Women with postmenopausal osteoporosis should adhere to a diet high in calcium and vitamin D.

- **Osteoporosis:** Advise patients receiving calcitonin for the treatment of osteoporosis that exercise has been found to arrest and reverse bone loss. The patient should discuss any exercise limitations with health care professional before beginning program.

**NURSING IMPLICATIONATIONS**

**ASSESSMENT**

- Observe patient for signs of hypersensitivity (skin rash, fever, hives, anaphylaxis, serum sickness). Keep epinephrine, antihistamines, and oxygen nearby in the event of a reaction.

- Assess patient for signs of hypocalcemic tetany (nervousness, irritability, paresthesia, muscle twitching, tetanic spasms, convulsions) during the first several doses of calcitonin. Parenteral calcium, such as calcium gluconate, should be available in case of this event.

- **Lab Test Considerations:** Serum calcium and alkaline phosphatase should be monitored periodically throughout therapy. These levels should normalize within a few months of initiation of therapy.

- Urine hydroxyproline (24 hr) may be monitored periodically in patients with Paget’s disease.

**POTENTIAL NURSING DIAGNOSES**

- **Pain (Indications).**
- **Injury, risk for (Indications, Side Effects).**
- **Knowledge deficit, related to medication regimen (Patient/Family Teaching).**

**IMPLEMENTATION**

- **General Info:** Assess for sensitivity to calcitonin-salmon by administering an intradermal test dose on the inner aspect of the forearm prior to initiating therapy. Test dose is prepared in a dilution of 10 IU/ml by withdrawing 0.05 ml in a tuberculin syringe and filling to 1 ml with 0.9% NaCl for injection. Mix well and discard 0.9 ml. Administer 0.1 ml and observe site for 15 min. More than mild erythema or wheal constitutes positive response.

- Store solution in refrigerator.

- **IM, SC:** Inspect injection site for the appearance of redness, swelling, or pain. Rotate injection sites. SC is the preferred route. Use IM route if dose exceeds 2 ml in volume. Use multiple sites to minimize inflammatory reaction.

- Do not administer solutions that are discolored or contain particulate matter.

- **General Info:** Advise patient to take medication exactly as directed. If dose is missed and medication is scheduled for twice a day, take only if possible within 2 hr of correct time. If scheduled for daily dose, take only if remembered that day. If scheduled for every other day, take when remembered and restart alternate day schedule. If taking 1 dose 3 times weekly (Mon, Wed, Fri), take missed dose the next day and set each injection back 1 day; resume regular schedule the following week. Do not double doses.


- Advise patient to report signs of hypercalcemic relapse (deep bone or flank pain, renal calculi, anorexia, nausea, vomiting, thirst, lethargy) or allergic response promptly.

- Reassure patient that flushing and warmth following injection are transient and usually last about 1 hr.

- Explain that nausea following injection tends to decrease even with continued therapy.

- Instruct patient to follow low-calcium diet if recommended by health care professional (see Appendix L). Women with postmenopausal osteoporosis should adhere to a diet high in calcium and vitamin D.

- **Osteoporosis:** Advise patients receiving calcitonin for the treatment of osteoporosis that exercise has been found to arrest and reverse bone loss. The patient should discuss any exercise limitations with health care professional before beginning program.
FEXOFENADINE
(fex-oh-fen-a-deen)
Allegra
CLASSIFICATION(S):
Antihistamines
Pregnancy Category C

INDICATIONS
■ Relief of symptoms of seasonal allergic rhinitis.

ACTION
■ Antagonizes the effects of histamine at periph-
eral histamine-1 (H) receptors, including pruri-
tus and urticaria ■ Also has a drying effect on
the nasal mucosa. Therapeutic Effects:
■ Decreased sneezing, rhinorrhea, itchy eyes,
nerve, and throat associated with seasonal aller-
gies.

PHARMACOKINETICS
Absorption: Rapidly absorbed after oral admin-
istration.
Distribution: Unknown.
Metabolism and Excretion: 80% excreted in
urine, 11% excreted in feces.
Half-life: 14.4 hr (increased in renal impair-
ment).

CONTRAINDICATIONS AND
PRECAUTIONS
Contraindicated in: ■ Hypersensitivity.
Use Cautiously in: ■ Impaired renal function
(increased dosing interval recommended)
■ Pregnancy, lactation, or children <12 yr (safe-
ty not established).

ADVERSE REACTIONS AND SIDE
EFFECTS†
CNS: drowsiness, fatigue.
GI: dyspepsia.
Endo: dysmenorrhea.

INTERACTIONS
Drug-Drug: ■ None significant.

ROUTE AND DOSAGE
■ PO (Adults and Children ≥12 yr): 60 mg
twice daily.
❑ Renal Impairment
■ PO (Adults): 60 mg once daily.

AVAILABILITY
■ Capsules: 60 mgRx ■ Cost: $99.42/100 ■
In combination with: pseudoephedrine (Al-
legra-D®). See Appendix B.

TIME/ACTION PROFILE (antihistaminic effect)
<table>
<thead>
<tr>
<th></th>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>within 1 hr</td>
<td>2–3 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

NURSING IMPLICATIONS

ASSESSMENT
❑ Assess allergy symptoms (rhinitis, conjunctivi-
tis, hives) before and periodically throughout
therapy.
❑ Assess lung sounds and character of bronchial
secretions. Maintain fluid intake of 1500–
2000 ml/day to decrease viscosity of secre-
tions.
■ Lab Test Considerations: Will cause false-
negative reactions on allergy skin tests; dis-
continue 3 days before testing.

\[
\text{C} \rightarrow \text{Available in Canada only.}
\]

†CAPITALS indicate life-threatening; underlines indicate most frequent.
POTENTIAL NURSING DIAGNOSES

- Ineffective airway clearance (Indications).
- Injury, risk for (Adverse Reactions).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

IMPLEMENTATION

- PO: Administer with food or milk to decrease GI irritation.

PATIENT/FAMILY TEACHING

- Instruct patient to take medication as directed. If a dose is missed, take as soon as remembered unless almost time for next dose.
- Inform patient that drug may cause drowsiness, although it is less likely to occur than with other antihistamines. Avoid driving or other activities requiring alertness until response to drug is known.
- Instruct patient to contact health care professional if symptoms persist.

EVALUATION

Effectiveness of therapy can be demonstrated by:
- Decrease in allergic symptoms.

METHYLDOPA

(meth-ill-doe-pa)

Aldomet, (Apo-Methyldopa), (Dopamet), (Novamedopa), (Nu-Medopa)

CLASSIFICATION(S):
Antihypertensive agents (centrally acting alpha-adrenergic agonist)

Pregnancy Category B

INDICATIONS

- Management of moderate to severe hypertension (with other agents).

ACTION

- Stimulates CNS alpha-adrenergic receptors, producing a decrease in sympathetic outflow to heart, kidneys, and blood vessels. Result is decreased blood pressure and peripheral resistance, a slight decrease in heart rate, and no change in cardiac output. Therapeutic Effects: ■ Lowering of blood pressure.

PHARMACOKINETICS

Absorption: 50% absorbed from the GI tract. Parenteral form, methyldopate hydrochloride, is slowly converted to methyldopa.

Distribution: Crosses the blood-brain barrier. Crosses the placenta; small amounts enter breast milk.

Metabolism and Excretion: Partially metabolized by the liver, partially excreted unchanged by the kidneys.

Half-life: 1.7 hr.

CONTRAINDICATIONS AND PRECAUTIONS

Contraindicated in:
- Hypersensitivity
- Active liver disease
- Some products contain alcohol or bisulfites and should be avoided in patients with known intolerance.

Use Cautiously in:
- Previous history of liver disease
- Geriatric patients (increased risk of adverse reactions)
- Pregnancy (has been used safely)
- Lactation.

ADVERSE REACTIONS AND SIDE EFFECTS

- CNS: sedation, decreased mental acuity, depression.
- EENT: nasal stuffiness.
- CV: myoccarditis, bradycardia, edema, orthostatic hypotension.
- GI: drug-induced hepatitis, diarrhea, dry mouth.
- GU: impotence.
- Hemat: eosinophilia, hemolytic anemia.
- Misc: fever.

INTERACTIONS

Drug-Drug: ■ Additive hypotension with other antihypertensive agents, acute ingestion of alcohol, anesthesia, and nitrates ■ Amphetamines, barbiturates, tricyclic antidepressants, NSAIDs, and phenothiazines may decrease antihypertensive effect of methyldopa ■ Increased effects and risk of psychoses with haloperidol ■ Excess sympathetic stimulation may occur with concurrent use of MAO inhibitors or sympathomimetics ■ May increase the effects of tolbutamide ■ May increase lithium toxicity ■ Additive hypotension and CNS toxicity with levodopa ■ Additive CNS depression may occur with alcohol, antihistamines, sedative/hypnotics, some antidepressants, and opioids ■ Concurrent use with
nonselective beta-blockers may rarely cause paradoxical hypertension.

ROUTE AND DOSAGE
- **PO (Adults):** 250–500 mg 2–3 times daily (not to exceed 500 mg/day if used with other agents); may be increased q 2 days as needed; usual maintenance dose is 500 mg–2 g/day (not to exceed 3 g/day).
- **PO (Children):** 10 mg/kg/day (300 mg/m²/day); may be increased q 2 days up to 65 mg/kg/day in divided doses (not to exceed 3 g/day).
- **IV (Adults):** 250–500 mg q 6 hr (up to 1 g q 6 hr).
- **IV (Children):** 5–10 mg/kg q 6 hr; up to 65 mg/kg/day in divided doses (not to exceed 3 g/day).

AVAILABILITY
- **Tablets:** 125 mgRx, 250 mgRx, 500 mgRx
- **Cost:** Aldomet—125 mg $29.85/100, 250 mg $38/100, 500 mg $69.44/100; generic—125 mg $9.75–$26.72/100, 250 mg $12.50–$34.01/100, 500 mg $22.50–$62.25/100
- **Oral suspension (orange-pineapple flavor):** 250 mg/5 mlRx
- **Injection:** 250 mg/5 ml in 5- and 10-ml vialsRx
- **In combination with:** hydrochlorothiazide (Aldoril)Rx or chlorothiazide (Aldoclor)Rx. See Appendix B.

TIME/ACTION PROFILE (antihypertensive effect)

<table>
<thead>
<tr>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>12–24 hr</td>
<td>4–6 hr</td>
</tr>
<tr>
<td>IV</td>
<td>4–6 hr</td>
<td>unknown</td>
</tr>
</tbody>
</table>

NURSING IMPLICATIONS

ASSESSMENT
- Monitor blood pressure and pulse frequently during initial dosage adjustment and periodically throughout therapy. Report significant changes.
- Monitor frequency of prescription refills to determine compliance.
- Monitor intake and output ratios and weight and assess for edema daily, especially at beginning of therapy. Report weight gain or edema; sodium and water retention may be treated with diuretics.
- Assess patient for depression or other alterations in mental status. Notify physician or other health care professional promptly if these symptoms develop.
- Monitor temperature during therapy. Drug fever may occur shortly after initiation of therapy and may be accompanied by eosinophilia and hepatic function changes. Monitor hepatic function test if unexplained fever occurs.

Lab Test Considerations: Renal and hepatic function and CBC should be monitored before and periodically throughout therapy.
- Monitor direct Coombs’ test before and after 6 and 12 mo of therapy. May cause a positive direct Coombs’ test, rarely associated with hemolytic anemia.
- May cause increased BUN, serum creatinine, potassium, sodium, prolactin, uric acid, AST, ALT, alkaline phosphatase, and bilirubin concentrations.
- May cause prolonged prothrombin times.
- May interfere with serum creatinine and AST measurements.

POTENTIAL NURSING DIAGNOSES
- Injury, risk for (Side Effects).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).
- Noncompliance (Patient/Family Teaching).

IMPLEMENTATION
- **General Info:** Fluid retention and expanded volume may cause tolerance to develop within 2–3 mo after initiation of therapy. Diuretics may be added to regimen at this time to maintain control.
- Dosage increases should be made with the evening dose to minimize drowsiness.
- When changing from IV to oral forms, dosage should remain consistent.
- **PO:** Shake suspension before administration.
- **Intermittent Infusion:** Dilute in 100 ml of D5W, 0.9% NaCl, D5/0.9% NaCl, 5% sodium bicarbonate, or Ringer’s solution.
- **Rate:** Infuse slowly over 30–60 min.
### INDICATIONS
- Mild to moderate pain
- Dysmenorrhea
- Fever
- Inflammatory disorders, including:
  - Rheumatoid arthritis
  - Osteoarthritis

### ACTION
- Inhibit prostaglandin synthesis.

#### Therapeutic Effects:
- Decreased pain
- Reduction of fever
- Suppression of inflammation

### PHARMACOKINETICS
- **Absorption:** Completely absorbed from the GI tract. Sodium salt (Anaprox) is more rapidly absorbed.
- **Distribution:** Crosses the placenta; enters breast milk in low concentrations.
- **Protein Binding:** >99%
- **Metabolism and Excretion:** Mostly metabolized by the liver.
- **Half-life:** 10–20 hr.

### CONTRAINDICATIONS AND PRECAUTIONS
- Contraindicated in:
  - Hypersensitivity
  - Cross-sensitivity may occur with other NSAIDs, including aspirin
  - Active GI bleeding
  - Ulcer disease
Use Cautiously in: ■ Severe cardiovascular, renal, or hepatic disease ■ History of ulcer disease ■ Chronic alcohol use/abuse ■ Pregnancy or lactation (safety not established; avoid using during 2nd half of pregnancy).

ADVERSE REACTIONS AND SIDE EFFECTS†
CNS: dizziness, drowsiness, headache.
EENT: tinnitus.
Resp: dyspnea.
CV: edema, palpitations, tachycardia.
GI: DRUG-INDUCED HEPATITIS, GI BLEEDING, constipation, dyspepsia, nausea, anorexia, diarrhea, discomfort, flatulence, vomiting.
GU: cystitis, hematuria, renal failure.
Derm: photosensitivity, rash, sweating.
Hemat: blood dyscrasias, prolonged bleeding time.
Misc: allergic reactions including ANAPHYLAXIS.

INTERACTIONS
Drug-Drug: ■ Concurrent use with aspirin decreases naproxen blood levels and may decrease effectiveness ■ Increased risk of bleeding with anticoagulants, thrombolytic agents, eptifibatide, tirofiban, cefamandole, cefotetan, ceftiraxone, valproic acid, clopidogrel, ticlopidine, plicamycin ■ Additive adverse GI side effects with aspirin, corticosteroids, and other NSAIDs ■ Probenecid increases blood levels and may increase toxicity ■ Increased risk of photosensitivity with other photosensitizing agents ■ May increase the risk of toxicity from methotrexate, antineoplastic agents, or radiation therapy ■ May increase serum levels and risk of toxicity from lithium ■ Increased risk of adverse renal effects with cyclosporine or chronic use of acetaminophen ■ May decrease response to antihypertensives or diuretics ■ May increase risk of hypoglycemia with insulin or oral hypoglycemic agents.

ROUTE AND DOSAGE
275 mg naproxen sodium is equivalent to 250 mg naproxen.

PO (Analgesic): Naproxen—250–500 mg naproxen bid (up to 1.5 g/day). Delayed-release naproxen—375–500 mg twice daily. Naproxen sodium—275–500 mg twice daily (up to 1.65 g/day).
PO (Children): 5 mg/kg/day twice daily as naproxen suspension.

PO (Adults): Naproxen—750 mg naproxen initially, then 250 mg q 8 hr. Naproxen sodium—825 mg initially, then 275 mg q 8 hr.
OTC Use PO (Adults): 200 mg q 8–12 hr or 400 mg followed by 200 mg q 12 hr (not to exceed 600 mg/24 hr).
PO (Geriatric Patients >65 yr): Not to exceed 200 mg q 12 hr.

AVAILABILITY
Naproxen (generic available)
Tablets (Naprosyn, [Apo-Naproxen, Naxen, Novo-Naprox, Ne-Napro]): {125 mgRX}, 250 mgRX, 375 mgRX, 500 mgRX
Controlled-release tablets (Naprelan): 375 mgRX, 500 mgRX ■ Delayed-release tablets (EC-Naprosyn, [Naprosyn-E]): {250 mgRX}, 375 mgRX, 500 mgRX ■ Extended-release tablets (Naprosyn-SR): {750 mgRX}
Oral suspension (Naprosyn): 125 mg/5 mlRX ■ Suppositories (Naprosyn, [Naxen]): {500 mgRX}.
Naproxen Sodium
Tablets (Aleve, Anapro, Anaprox DS, [Apo-Naprox-Na, Novo-Naprox Sodium, Novo-Naprox Sodium DS, Synaflex, Synaflex DS]): 220 mgOTC, 275 mgRX, 550 mgRX.

TIME/ACTION PROFILE
ONSET PEAK DURATION
PO (Analgesic) 1 hr Unknown up to 7 hr
PO (Anti-inflammatory) 14 days 2–4 wk Unknown

CAPITALS indicate life-threatening; underline indicate most frequent.
NURSING IMPLICATIONS

ASSESSMENT

- **General Info:** Patients who have asthma, aspirin-induced allergy, and nasal polyps are at increased risk for developing hypersensitivity reactions. Assess for rhinitis, asthma, and urticaria.

- **Pain:** Assess pain (note type, location, and intensity) prior to and 1–2 hr following administration.

- **Arthritis:** Assess pain and range of motion prior to and 1–2 hr following administration.

- **Fever:** Monitor temperature; note signs associated with fever (diaphoresis, tachycardia, malaise).

- **Lab Test Considerations:** BUN, serum creatinine, CBC, and liver function tests should be evaluated periodically in patients receiving prolonged courses of therapy.

  - Serum potassium, BUN, serum creatinine, alkaline phosphatase, LDH, AST, and ALT tests may show increased levels. Blood glucose, hemoglobin, and hematocrit concentrations, leukocyte and platelet counts, and CrCl may be decreased.

  - Bleeding time may be prolonged up to 4 days following discontinuation of therapy.

  - May alter test results for urine 5-HIAA and urine steroid determinations.

POTENTIAL NURSING DIAGNOSES

- **Pain (Indications).**

- **Impaired physical mobility (Indications).**

- **Knowledge deficit, related to medication regimen (Patient/Family Teaching).**

IMPLEMENTATION

- **General Info:** Administration in higher than recommended doses does not provide increased effectiveness but may cause increased side effects.

  - Coadministration with opioid analgesics may have additive analgesic effects and may permit lower opioid doses.

  - Analgesic is more effective if given before pain becomes severe.

- **PO:** For rapid initial effect, administer 30 min before or 2 hr after meals. May be administered with food, milk, or antacids to decrease GI irritation. Food slows but does not reduce the extent of absorption. Do not mix suspension with antacid or other liquid prior to administration.

- **Dysmenorrhea:** Administer as soon as possible after the onset of menses. Prophylactic treatment has not been shown to be effective.

PATIENT/FAMILY TEACHING

- Advise patient to take this medication with a full glass of water and to remain in an upright position for 15–30 min after administration.

- Instruct patient to take medication exactly as directed. If a dose is missed, it should be taken as soon as remembered but not if almost time for the next dose. Do not double doses.

- May cause drowsiness or dizziness. Advise patient to avoid driving or other activities requiring alertness until response to the medication is known.

- Caution patient to avoid the concurrent use of alcohol, aspirin, acetaminophen, or other OTC medications without consulting health care professional. Use of naproxen with 3 or more glasses of alcohol per day may increase risk of GI bleeding.

- Advise patient to inform health care professional of medication regimen prior to treatment or surgery.

- Caution patient to wear sunscreen and protective clothing to prevent photosensitivity reactions.

- Instruct patients not to take OTC naproxen preparations for more than 3 days for fever and to consult health care professional if symptoms persist or worsen.

- Advise patient to consult health care professional if rash, itching, visual disturbances, tinnitus, weight gain, edema, black stools, persistent headache, or influenza-like syndrome (chills, fever, muscle aches, pain) occurs.

EVALUATION

Effectiveness of therapy can be demonstrated by:

- Relief of pain
- Improved joint mobility. Partial arthritic relief is usually seen within 2 wk, but maximum effectiveness may require 2–4 wk of continuous therapy. Patients who do not respond to one NSAID may respond to another
- Reduction of fever.
OXYCODONE
(ox-i-koe-done)
Endocodon, Oxycontin, OxyFAST,
OxyIR, Percolone, Roxicodon,
Roxicodon SR, (SPEEDul)

OXYCODONE/ACETAMINOPHEN
(See also acetaminophen monograph on page 3.)
(Endocet), (Oxycet), Percocet,
(Percocet), Roxicet, Roxilox, Tylox

OXYCODONE/ASPIRIN
(See also salicylates monograph on page 903.)
(Endodan), (Oxycodan), Percodan,
Percodan-Demi, Roxiprin

CLASSIFICATION(S):
Opioid analgesic (agonist)

Pregnancy Category C
(oxycodeone alone)

INDICATIONS
■ Management of moderate to severe pain.

ACTION
■ Bind to opiate receptors in the CNS ■ Alter the perception of and response to painful stimuli, while producing generalized CNS depression.

Therapeutic Effects:
■ Decreased pain.

PHARMACOKINETICS
Absorption: Well absorbed from the GI tract.
Distribution: Widely distributed. Cross the placentia; enter breast milk.
Metabolism and Excretion: Mostly metabolized by the liver.
Half-life: 2–3 hr.

CONTRAINdications and PRECAUTIONS
Contraindicated in:
■ Hypersensitivity
■ Pregnancy or lactation (avoid chronic use)
■ Some products contain alcohol or bisulfites and should be avoided in patients with known intolerance or hypersensitivity.

Use Cautiously in:
■ Head trauma
■ Increased intracranial pressure ■ Severe renal, hepatic, or pulmonary disease ■ Hypothyroidism ■ Adrenal insufficiency ■ Alcoholism ■ Geriatric or debilitated patients (initial dosage reduction recommended) ■ Undiagnosed abdominal pain ■ Prostatic hypertrophy.

ADVERSE REACTIONS AND SIDE EFFECTS
CNS: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams.
EENT: blurred vision, diplopia, miosis.
Resp: RESPIRATORY DEPRESSION.
CV: orthostatic hypotension.
GI: constipation, dry mouth, nausea, vomiting.
GU: urinary retention.
Derm: flushing, sweating.
Misc: physical dependence, psychological dependence, tolerance.

INTERACTIONS
Drug-Drug:
■ Use with caution in patients receiving MAO inhibitors (may result in unpredictable reactions—decrease initial dose of oxycodeone to 25% of usual dose) ■ Additive CNS depression with alcohol, antihistamines, and sedative/hypnotics ■ Administration of partial-antagonist opioid analgesics may precipitate withdrawal in physically dependent patients ■ Nalbuphine, buprenorphine, dezocine, or pentazocine may decrease analgesia.

ROUTE AND DOSAGE
Larger doses may be required during chronic therapy. Consider cumulative effects of additional acetaminophen/ aspirin; if toxic levels are exceeded, change to pure oxycodone product.
■ PO (Adults ≥50 kg): 5–10 mg q 3–4 hr initially, as needed. Controlled-release tablets (Oxycontin) may be given q 12 hr.
■ PO (Adults <50 kg or Children): 0.2 mg/kg q 3–4 hr initially, as needed.
■ Rect (Adults): 10–40 mg 3–4 times daily initially, as needed.

}) = Available in Canada only.
†CAPITALS indicate life-threatening; Underlines indicate most frequent.
OXYCODONE

AVAILABILITY

❑ Oxycodone

■ Tablets: 5 mg (Percolone, Roxicodone, Supeudol)Rx ■ Cost: Percolone—$68.75/100; Roxicodone—$31.04/100; generic—$27.00–41.99/100 ■ Immediate-release capsules: 5 mg (OxyIR)Rx ■ Controlled-release tablets: 10 mgRx, 20Rx, 40 mgRx, 80 mg (Oxycontin, Roxicodone SR)Rx, 160 mg (Oxycontin) ■ Cost: Oxycontin—10 mg $117.10/100, 20 mg $224.11/100, 40 mg $397.66/100, 80 mg $747.79/100; Roxicodone SR ■ Oral solution (burgundy cherry): 5 mg/5 ml in 500-ml bottle (Roxicodone) Rx ■ Cost: $41.65/500 ml ■ Concentrated oral solution: 20 mg/ml in 30-ml bottle with dropper (Roxicodone Intensol, OxyFAST)Rx ■ Cost: Roxicodone Intensol $40.56/30 ml; OxyFAST $33.75/30 ml

❑ Oxycodone/Acetaminophen

■ Tablets: 2.5 mg oxycodone with 325 mg acetaminophen (Percocet 2.5)Rx, 5 mg oxycodone with 325 mg acetaminophen (Endocet, Oxyelt, Percocet, Roxicet)Rx, 7.5 mg oxycodone with 500 mg acetaminophen (Percocet 7.5)Rx, 10 mg oxycodone with 650 mg acetaminophen (Percocet 10)Rx ■ Cost: Endocet—$107.72/100; Percocet 5—$83.75/100, Roxicet—$25.73/100, 25.73/100 ■ Capsules: 5 mg oxycodone with 500 mg acetaminophen (Roxilox, Tylox)Rx ■ Cost: Roxilox—$57.72/100; Tylox—$87.63/100 ■ Caplets: 5 mg oxycodone with 500 mg acetaminophen (Roxicet 5/500)Rx ■ Cost: $57.60/100 ■ Oral solution (mint): 5 mg oxycodone with 325 mg acetaminophen/5 ml (Roxicet Solution) in 500-ml bottlesRx ■ Cost: $37.57/500 ml

❑ Oxycodone/Aspirin

■ Tablets: 2.44 mg oxycodone with 325 mg aspirin (Percodan-Demi)Rx, 4.88 mg oxycodone with 325 mg aspirin (Endodan, Oxydol, Pera- codan, Roxiprin)Rx

TIME/ACTION PROFILE (analgesic effects)

<table>
<thead>
<tr>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>10–15 min</td>
<td>60–90 min</td>
</tr>
<tr>
<td>PO-CR</td>
<td>10–15 min</td>
<td>3 hr</td>
</tr>
</tbody>
</table>

NURSING IMPLICATIONS

ASSESSMENT

❑ Assess type, location, and intensity of pain prior to and 1 hr (peak) after administration. When titrating opioid doses, increases of 25–50% should be administered until there is either a 50% reduction in the patient’s pain rating on a numerical or visual analogue scale or the patient reports satisfactory pain relief. A repeat dose can be safely administered at the time of the peak if previous dose is ineffective and side effects are minimal.

❑ Patients taking controlled-release tablets should also be given supplemental short-acting opioid doses for breakthrough pain.

❑ An equianalgesic chart (see Appendix C) should be used when changing routes or when changing from one opioid to another.

❑ Assess blood pressure, pulse, and respirations before and periodically during administration. If respiratory rate is <10/min, assess level of sedation. Physical stimulation may be sufficient to prevent significant hypoventilation. Dose may need to be decreased by 25–50%. Initial drowsiness will diminish with continued use.

❑ Prolonged use may lead to physical and psychological dependence and tolerance. This should not prevent patient from receiving adequate analgesia. Most patients who receive oxycodone for pain do not develop psychological dependence. Progressively higher doses may be required to relieve pain with long-term therapy.

❑ Assess bowel function routinely. Prevention of constipation should be instituted with increased intake of fluids and bulk, and laxatives to minimize constipating effects. Stimulant laxatives should be administered routinely if opioid use exceeds 2–3 days, unless contraindicated.

❑ Lab Test Considerations: May increase plasma amylase and lipase levels.

❑ Toxicity and Overdose: If an opioid antagonist is required to reverse respiratory depression or coma, naloxone (Narcan) is the antidote. Dilute the 0.4-mg ampule of naloxone in 10 ml of 0.9% NaCl and administer 0.5 ml (0.02 mg) by direct IV push every 2 min. For children and patients weighing <40 kg, dilute 0.1 mg of naloxone in 10 ml of 0.9%
NaCl for a concentration of 10 mcg/ml and administer 0.5 mcg/kg every 2 min. Titrate dose to avoid withdrawal, seizures, and severe pain.

POTENTIAL NURSING DIAGNOSES
- Pain (Indications).
- Sensory-perceptual alterationsvisual, auditory (Side Effects).
- Injury, risk for (Side Effects).

IMPLEMENTATION
- **General Info:** Explain therapeutic value of medication prior to administration to enhance the analgesic effect.
- Regularly administered doses may be more effective than prn administration. Analgesic is more effective if given before pain becomes severe.
- Coadministration with nonopioid analgesics may have additive analgesic effects and may permit lower doses.
- Medication should be discontinued gradually after long-term use to prevent withdrawal symptoms.
- **PO:** May be administered with food or milk to minimize GI irritation.
- Administer solution with properly calibrated measuring device.
- Controlled-release tablets should be swallowed whole; do not crush, break, or chew.
- **Controlled Release:** Dose should be based on 24-hr opioid requirement determined with short-acting opioids then converted to controlled-release form.

PATIENT/FAMILY TEACHING
- Instruct patient on how and when to ask for pain medication.
- Medication may cause drowsiness or dizziness. Advise patient to call for assistance when ambulating or smoking. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
- Advise patients taking Oxycontin tablets that empty matrix tablets may appear in stool.
- Advise patient to make position changes slowly to minimize orthostatic hypotension.
- Advise patient to avoid concurrent use of alcohol or other CNS depressants with this medication.
- Encourage patient to turn, cough, and breathe deeply every 2 hr to prevent atelectasis.

EVALUATION
Effectiveness of therapy can be demonstrated by:
- Decrease in severity of pain without a significant alteration in level of consciousness or respiratory status.

QUININE (kwı-nine)

CLASSIFICATION(S):
Anti-infective agents (antimalarial)

Pregnancy Category X

INDICATIONS
- Combination with other agents in the treatment of chloroquine-resistant malaria. Unlabeled Uses: ■ Prophylaxis and treatment of nocturnal recumbency leg cramps, including those associated with arthritis, diabetes, varicose veins, thrombophlebitis, arteriosclerosis, and static foot deformities.

ACTION
- Disrupts metabolism of the erythrocytic phase of *Plasmodia falciparum* ■ Increases the refractory period of skeletal muscle, increases the distribution of calcium within muscle fibers, decreases the excitability of motor end-plate regions, resulting in decreased response to repetitive nerve stimulation and acetylcholine. **Therapeutic Effects:** ■ Death of *P. falciparum* ■ Decreased severity of leg cramps.

PHARMACOKINETICS
Absorption: Rapidly and almost completely (80%) absorbed following oral administration.
Distribution: Varies with condition and patient; does not enter CSF well. Crosses the placenta and enters breast milk.
Protein Binding: >90% in patients with cerebral malaria, pregnant women and children, 85–
90% in patients with uncomplicated malaria, 70% in healthy adults.

**Metabolism and Excretion:** >80% metabolized by the liver; metabolites have less activity than quinine; metabolites excreted in urine. 20% excreted unchanged in urine. Excretion increased in acidic urine.

**Half-life:** 11 hr (increased in patients with malaria).

**CONTRAINDICATIONS AND PRECAUTIONS**

Contraindicated in:
- Hypersensitivity
- Pregnancy or lactation.

Use Cautiously in:
- Recurrent or interrupted malaria therapy
- History of arrhythmias, especially QT prolongation
- G6PD deficiency
- Hypoglycemia
- Myasthenia gravis
- History of thrombocytopenic purpura.

**ADVERSE REACTIONS AND SIDE EFFECTS†**

**GI:** abdominal cramps/pain, diarrhea, nausea, vomiting, hepatotoxicity.

**Derm:** rash.

**Endo:** hypoglycemia.

**Hemat:** bleeding, blood dyscrasias.

**Misc:** cinchonism, hypersensitivity reactions including fever and HEMOLYTIC UREMIC SYNDROME.

**INTERACTIONS**

Drug-Drug:
- May increase serum digoxin levels
- May increase the risk of hemolytic, ototoxic, or neurotoxic reactions when used concurrently with agents sharing these toxicities

- Concurrent use with quinidine may increase the risk of adverse cardiovascular reactions

- May increase the risk of bleeding with warfarin

- Concurrent use with mefloquine increases the risk of seizures and adverse cardiovascular reactions.

**ROUTE AND DOSAGE**

**PO (Adults):** Malaria—600–650 mg q 8 hr for 3 days (7 days in southeast Asia) with tetracycline or doxycycline or sulfadoxine/pyramethamine or clindamycin; leg cramps (unlabeled)—200–300 mg at bedtime, if needed an additional 200–300 mg may be given with supper.

**PO (Children):** 8.3 mg/kg q 8 hr for 3 days (7 days in southeast Asia) with tetracycline or doxycycline (if child is over 8 yr) or sulfadoxine/pyramethamine or clindamycin.

**AVAILABILITY**

- **Capsules:** 200 mgRx, 300 mgRx, 325 mgRx
  - **Cost:** 325 mg $5.15–$8.28/30

- **Tablets:** 200 mgRx, 325 mgRx
  - **Cost:** 260 mg $3.89–$3.95/30.

**TIME/ACTION PROFILE (antimalarial blood levels)**

<table>
<thead>
<tr>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO unknown</td>
<td>3.2–5.9 hr</td>
<td>8 hr</td>
</tr>
</tbody>
</table>

**NURSING IMPLICATIONS**

**ASSESSMENT**

- **Malaria:** Assess patient for improvement in signs and symptoms of condition daily throughout therapy.

- **Nocturnal recumbency leg cramps:** Assess frequency and severity of nocturnal leg cramps. If cramps do not occur for several consecutive nights, may be discontinued to determine if continued use is required.

  **Lab Test Considerations:** May cause elevated urinary 17-ketogenic steroids when metyrapone or Zimmerman method is used.

- **Toxicity and Overdose:** Plasma quinine levels of >10 mcg/ml may cause tinnitus and impaired hearing.

  - Signs of toxicity or cinchonism include tinnitus, headache, nausea, and slightly disturbed vision; usually disappear rapidly upon discontinuing quinine.

**POTENTIAL NURSING DIAGNOSES**

- Infection, risk for (Indications).
- Pain, chronic (Indications).
- Knowledge deficit, related to medication regimen (Patient/Family Teaching).

**IMPLEMENTATION**

- **PO:** Administer with or after meals to minimize GI distress. Aluminum-containing antacids will decrease and delay absorption; avoid concurrent use.

**PATIENT/FAMILY TEACHING**

- Instruct patient to take medication exactly as directed and continue full course of therapy, even if feeling better. Missed doses should be
taken as soon as remembered, unless almost time for the next dose. Do not double doses or take more than recommended.

- Review methods of minimizing exposure to mosquitoes with patients receiving chloroquine prophylactically (use repellent, wear long-sleeved shirt and long trousers, use screen or netting).
- Quinine may cause visual changes. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
- May cause diarrhea, nausea, stomach cramps or pain, vomiting, or ringing in the ears. Advise patient to notify health care professional promptly if these become pronounced.
- Advise patient to stop quinine and notify health care professional of any evidence of allergy (flushing, itching, rash, fever, stomach pain, difficult breathing, ringing in the ears, visual problems).

EVALUATION
Effectiveness of therapy can be demonstrated by:
- Prevention of or improvement in signs and symptoms of malaria
- Decrease in frequency and severity of nocturnal redundancy leg cramps.

INDICATIONS
- Used as an adjunct to diet and exercise in the management of type 2 diabetes mellitus; may also be used with metformin when the combination of diet, exercise, and metformin does not achieve glycemic control.

ACTION
- Improves sensitivity to insulin by acting as an agonist at receptor sites involved in insulin responsiveness and subsequent glucose production and utilization
- Requires insulin for activity

Therapeutic Effects:
- Decreased insulin resistance, resulting in glycemic control without hypoglycemia.

PHARMACOKINETICS
Absorption: Well absorbed (99%) following oral administration.
Distribution: Unknown.
Protein Binding: 99.8% bound to plasma proteins.
Metabolism and Excretion: Entirely metabolized by the liver.
Half-life: 3.2–3.6 hr (increased in liver disease).

CONTRAINDICATIONS AND PRECAUTIONS
Contraindicated in:
- Hypersensitivity
- Pregnancy or lactation (not recommended for use during pregnancy or lactation; insulin should be used)
- Children <18 yr or type 1 diabetes (requires insulin for activity)
- Diabetic ketoacidosis
- Clinical evidence of active liver disease or increased ALT (>2.5 times upper limit of normal).

Use Cautiously in:
- Edema
- Congestive heart failure (avoid use in moderate to severe CHF unless benefits outweigh risks)
- Hepatic impairment
- Women with child-bearing potential (may restore ovulation and risk of pregnancy).

ADVERSE REACTIONS AND SIDE EFFECTS†
- CV: edema.
- Hemat: anemia.
- Metab: increased total cholesterol, LDL and HDL, weight gain.

INTERACTIONS
Drug-Drug: None known.

ROUTE AND DOSAGE
- PO (Adults): 4 mg as a single dose once daily or 2 mg twice daily; after 12 weeks, may be increased if necessary to 8 mg once daily or 4 mg twice daily.

†CAPITALS indicate life-threatening; underlines indicate most frequent.
ROSIGLITAZONE

AVAILABILITY
■ Tablets: 2 mgRx, 4 mgRx, 8 mgRx.

TIME/ACTION PROFILE (effects on blood glucose)

<table>
<thead>
<tr>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>unknown</td>
<td>unknown</td>
</tr>
</tbody>
</table>

NURSING IMPLICATIONS

ASSESSMENT

■ Observe patient taking current insulin for signs and symptoms of hypoglycemic reactions (sweating, hunger, weakness, dizziness, tremor, tachycardia, anxiety).

■ Lab Test Considerations: Serum glucose and glycosylated hemoglobin should be monitored periodically throughout therapy to evaluate effectiveness of treatment.

■ Monitor CBC with differential periodically throughout therapy. May cause decrease in hemoglobin, hematocrit, and WBC, usually during the first 4–8 wk of therapy; then levels stabilize.

■ Monitor AST and ALT every 2 months during the first 12 months of therapy and periodically thereafter or if jaundice or symptoms of hepatic dysfunction occur. May cause irreversible elevations in AST and ALT or hepatic failure (rare). If ALT increases to >3 times the upper limit of normal, recheck ALT promptly. Discontinue rosiglitazone if ALT remains >3 times normal.

■ May cause increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.

POTENTIAL NURSING DIAGNOSES

■ Nutrition: altered, more than body requirements (Indications).

■ Knowledge deficit (Patient/Family Teaching).

IMPLEMENTATION

■ General Info: Patients stabilized on a diabetic regimen who are exposed to stress, fever, trauma, infection, or surgery may require administration of insulin.

■ PO: May be administered with or without meals.

PATIENT/FAMILY TEACHING

■ Instruct patient to take medication exactly as directed. If dose for 1 day is missed, do not double dose the next day.

■ Explain to patient that this medication controls hyperglycemia but does not cure diabetes. Therapy is long-term.

■ Review signs of hypoglycemia and hyperglycemia with patient. If hypoglycemia occurs, advise patient to take a glass of orange juice or 2–3 tsp of sugar, honey, or corn syrup dissolved in water and notify health care professional.

■ Encourage patient to follow prescribed diet, medication, and exercise regimen to prevent hypoglycemic or hyperglycemic episodes.

■ Instruct patient in proper testing of serum glucose and ketones. These tests should be closely monitored during periods of stress or illness and health care professional notified if significant changes occur.

■ Advise patient to notify health care professional immediately if signs of hepatic dysfunction (nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, jaundice) occur.

■ Insulin is the preferred method of controlling blood sugar during pregnancy. Counsel female patients that higher doses of oral contraceptives or a form of contraception other than oral contraceptives may be required and to notify health care professional promptly if pregnancy is planned or suspected.

■ Advise patient to inform health care professional of medication regimen prior to treatment or surgery.

■ Advise patient to carry a form of sugar (sugar packets, candy) and identification describing disease process and medication regimen at all times.

■ Emphasize the importance of routine follow-up exams.

EVALUATION

Effectiveness of therapy can be demonstrated by:
■ Control of blood glucose levels.
COMPREHENSIVE INDEX*

generic / Trade / classification

A

A-200 Shampoo, 1099
AbboKinase, 980
AbboKinase Open-Cath, 980
abciximab, 1168, P±45
Abelcet, 48
Abenol, 3
ABORTIFACIENTS, P±2
Accolate, 1061
Accupril, 64
Accuretic 10/12.5, 1099
Accuretic 20/12.5, 1099
Accuretic 20/25, 1099
Accutane, 1177
acebutolol, 1, C4, C24, P±13, P±15, P±35
ACE INHIBITORS. See ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
Acecol-Imune, 1151
acellular pertussis vaccine, 1151
Acephn, 3
Aceta, 3
acetaminophen, 3, C36, P±49, P±81.
See also oxycodone/acetaminophen
Acetazolam, 152
acetazolamide, 152, P±19
acetazolamide, see DrugGuide.com
acetelycysteine, 5, C17, P±27, P±28
acetylsalicylic acid, 903
Acriflomycin, 969
Acid-X, 1099
Aciphex, 875
Aclor, 244
Acta-Char Liquid-A, 7
Actagen-C Cough Syrup, 1099
Actagen Syrup, 1099
Actagen Tablets, 1099
ACTH, 1172
Asthcart, 1172
A undertaken HIB, 1151
Acticin, 781
Acticor, 245
Actidose-Aqua, 7
Actifed, 1099
Actifed Allergy, Nighttime, 1099
Actifed Cold and Sinus Caplets, 1099
Actifed Cold and Sinus Tablets, 1099
Actifed Plus, 1099
Actifed Plus Extra Strength Caplets, 1099
Actifed Sinus Daytime, 1099
Actifed Sinus Nighttime, 1099
Actifed Syrup, 1099
Actifed with Codeine, 1099
Actifed with Codein Cough Syrup, 1099
Actigall, 1183
Actimmune, 1177
Actimol, 3
Actinex, 1177
Actiprofen, 499
Actiq, 389
Activase, 980, 1125
Activase rt-PA, 980
activated charcoal, 7
Activelle Tablets, 1099
Actional, 890
Action, 801
Actron, 550
Acele, 1164
Acurin, 903
Acutrin 16 hr, 788
Acutrine II Maximum Strength, 788
Acutrine Late Day, 788
acyclovir, 8, C6, P±60
Adalat, 705
Adenoscan, 11
adenosine, 11, C4, P±15
Adipex-P, 1179
Adrenalin, 345
ADRENERGIC BRONchodilator,
INFREQUENTLY USED, 1177
ADRENERGICS, CENTRALLY ACTING, C25, P±35

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon ( //= ), and web references are underlined. A "C" and a boldface page number following a generic name identify the page in the "Classification" section on which that drug is listed.

P-107
<table>
<thead>
<tr>
<th>P±108</th>
<th>COMPREHENSIVE INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adriamycin PBS, 332</td>
<td>aclometasone, 244, P±69</td>
</tr>
<tr>
<td>Adriamycin RDF, 332</td>
<td>Alcohol Abuse Deterrent, 1174</td>
</tr>
<tr>
<td>Adrucil, 414</td>
<td>Alcomicin, 1157</td>
</tr>
<tr>
<td>Adsorbecarpine, 1160</td>
<td>Aldactazide 25/25, 1099</td>
</tr>
<tr>
<td>Adsorboteur, 1159</td>
<td>Aldactazide 50/50, 1099</td>
</tr>
<tr>
<td>Adult TD, 1154</td>
<td>Aldactone, 312</td>
</tr>
<tr>
<td>Aldol, 499</td>
<td>aldesleukin, 15, C30, P−39, P−41</td>
</tr>
<tr>
<td>Adrif Cold &amp; Sinus, 1099</td>
<td>Aldoclor-250, 1099</td>
</tr>
<tr>
<td>AeroBild, 229</td>
<td>Aldomet, P−96</td>
</tr>
<tr>
<td>Aerodilate, 120</td>
<td>Aldoril-15, 1099</td>
</tr>
<tr>
<td>Aerosedh-Dex, 244</td>
<td>Aldoril-25, 1099</td>
</tr>
<tr>
<td>Aerosedh-HC, 245</td>
<td>alendronate, 18</td>
</tr>
<tr>
<td>Ak-Lube, 322</td>
<td>Alesse, 225</td>
</tr>
<tr>
<td>Aldrin Syrup, 1099</td>
<td>Aleve, P−98</td>
</tr>
<tr>
<td>Aldrin Tablets, 1099</td>
<td>Alev Cold &amp; Sinus, 1099</td>
</tr>
<tr>
<td>Aftenil, 70</td>
<td>allantoin, see DrugGuide.com</td>
</tr>
<tr>
<td>Agenerase, 56</td>
<td>Allergan, 609</td>
</tr>
<tr>
<td>Aggrastat, 998</td>
<td>allantoin, see DrugGuide.com</td>
</tr>
<tr>
<td>Aggrenox, 1099</td>
<td>Alk-Seltzer Effervescent, Original, 1100</td>
</tr>
<tr>
<td>Agrylif, 1170</td>
<td>Alka-Seltzer Plus Allergy Liqui-Gels, 1100</td>
</tr>
<tr>
<td>Aire, 13</td>
<td>Alka-Seltzer Plus Cold &amp; Cough Liqui-Gels, 1100</td>
</tr>
<tr>
<td>Akarpine, 1160</td>
<td>Alka-Seltzer Plus Cold Liqui-Gels, 1100</td>
</tr>
<tr>
<td>AKBeta, 1159</td>
<td>Alka-Seltzer Plus Cold Medicine, 1100</td>
</tr>
<tr>
<td>AK-Chlor, 1157</td>
<td>Alka-Seltzer Plus Flu &amp; Body Aches Non-</td>
</tr>
<tr>
<td>AK-Dilate, 1164</td>
<td>Drowsy Liqui-Gels, 1100</td>
</tr>
<tr>
<td>AK-Con, 1164</td>
<td>Alka-Seltzer Plus Night-Time Cold, 1100</td>
</tr>
<tr>
<td>AK-Dex, 236, 1164</td>
<td>Alka-Seltzer Plus Night-Time Cold Liqui-</td>
</tr>
<tr>
<td>AK-Dilate, 1164</td>
<td>Gels, 1100</td>
</tr>
<tr>
<td>Akineton, 107</td>
<td>Alka-Seltzer Plus Sinus, 1100</td>
</tr>
<tr>
<td>AK-Nefrin, 1164</td>
<td>Alleron, 609</td>
</tr>
<tr>
<td>Akine-Mycin, 360</td>
<td>allantoin, see DrugGuide.com</td>
</tr>
<tr>
<td>AK-Pentolate, 1162</td>
<td>Alk-Seltzer Plus Flu &amp; Body Aches Non-</td>
</tr>
<tr>
<td>AK-Pred, 1162</td>
<td>Drowsy Liqui-Gels, 1100</td>
</tr>
<tr>
<td>AK-Sulf, 1158</td>
<td>Alka-Seltzer Plus Sinus, 1100</td>
</tr>
<tr>
<td>AK-Taine, 1156</td>
<td>Alka-Seltzer Plus Sinus, 1100</td>
</tr>
<tr>
<td>Alk-Tears, 1159</td>
<td>Alka-Seltzer Plus Sinus, 1100</td>
</tr>
<tr>
<td>AK-Zol, 152</td>
<td>Allergy, P−95</td>
</tr>
<tr>
<td>Ala-Cort, 245</td>
<td>Allegra-D, 1100</td>
</tr>
<tr>
<td>Alamag, 591</td>
<td>Allegra-HR, 190</td>
</tr>
<tr>
<td>Ala-Scalp, 245</td>
<td>Alleron Tablets, 1100</td>
</tr>
<tr>
<td>Alatrofloxacin, 408, P−38</td>
<td>Allerdyr, 300</td>
</tr>
<tr>
<td>Albutarol, 1164</td>
<td>Allerest, 1164</td>
</tr>
<tr>
<td>Albendazole, 1168</td>
<td>Allerest Headache Strength Advanced For-</td>
</tr>
<tr>
<td>Albenza, 1168</td>
<td>mula, 1100</td>
</tr>
<tr>
<td>albendazole, see DrugGuide.com</td>
<td>Allerest Maximum Strength, 1100</td>
</tr>
<tr>
<td>albuterol, 13, C48, P−61</td>
<td>Allerest Maximum Strength 12 Hour, 1100</td>
</tr>
<tr>
<td>Alcaine, 1156</td>
<td>Allerest No-Drowsiness, 1100</td>
</tr>
<tr>
<td>Allerest Sinus Pain Formula, 1100</td>
<td>Allerest Sinus Pain Formula, 1100</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (†), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
Ampicin, 51
amrinone, 58, 1126, P–63
and nitrate, see DrugGuide.com
amyl nitrite, 1170, P–28
Anacin, 1100
Anacin Maximum Strength, 1100
Anacin PM (Aspirin Free), 1100
Anacolin, 1047
Analex, 903
Analfrin, 209
Ana-Gard, 345
anagralide, 1170
analex, 1090
Anaflex, 903
W
anise, 1090
Anafranil, 209
anisoylated plasminogen–streptokinase activator complex, 980
Anasial, 406
ANTANGINAL AGENTS, 1170
angiotensin-converting enzyme (ACE) inhibitors, 63, C1, C24, P–8, P–35
angiotensin II antagonists, P–35
angiotensin II receptor antagonists, 61, anileridine, see DrugGuide.com
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
COMPREHENSIVE INDEX

Cyanide, 1181
Antimetic Agents, C18, P–28
Anticholinergic, C19
Antiergic, C19
Infrequently Used, 1171, 1173
Phenothiazine, C19
Serotonin Antagonist, C19
Antihistaminics, 1183
Antifungal Agents, C19
Infrequently Used, 1173
Ophthalmic, 1157, 1158, P–31
Systemic, C20
Topical, 70, C20
Drug Release Update, 1167
Vaginal, 73, C21
Antiguatamates, 1181
Antihelments, 1168
Antihemophilic Factor, see DrugGuide.com
Antihistamines, C21, P–13, P–29, P–32, P–33
Antiemetic, C19
Ophthalmic, 1157
Antibist-D, 1101
Antihypertensive Agents, C23, P–33
Infrequently Used, 1178, 1179, 1183
Anti-Infective Agents, C25, P–36, P–58
Anti-Tuss, 454
Infrequently Used, 1180
Antitussive Agents, C41, P–54
Infrequently Used, 1171
Anti-Elder Agents, C42, P–55
Antizyme, 504
Antiviral Agents, C45, P–58
Infrequently Used, 1180
Ophthalmic, 1157, 1158, 1183
Antrizine, 604
Antase, 245
Anerget, 323
Apacet, 3
APAP, 3
Aptizyme, 504
Apo-Acetaminophen, 5
Apo-Acetazolamide, 152
Apo-Allopurinol, 21
Apo-Alprazolam, 23
Apo-Almitriptiline, 39
Apo-Amitriptyline, 43
Apo-Atenolol, 79
Apo-Ampicillin, 51
Apo-ASA, 903
Apo-ASEN, 903
Apo-Apomorphine, 79
Apo-Benztropine, 96
Apo-Bromocriptine, 116
Apo-Cephalexin, 167
Apo-Chlordiazepoxide, 188

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. And a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
### COMPREHENSIVE INDEX

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apo-Chlorpropamide</td>
<td>1172</td>
</tr>
<tr>
<td>Apo-Chlorthalidone</td>
<td>315</td>
</tr>
<tr>
<td>Apo-Cimetidine</td>
<td>472</td>
</tr>
<tr>
<td>Apo-Clorazepate</td>
<td>216</td>
</tr>
<tr>
<td>Apo-Diazepam</td>
<td>279</td>
</tr>
<tr>
<td>Apo-Diltaiz</td>
<td>293</td>
</tr>
<tr>
<td>Apo-Dimethazine</td>
<td>296</td>
</tr>
<tr>
<td>Apo-Dipyriramole</td>
<td>304</td>
</tr>
<tr>
<td>Apo-Doxyl S</td>
<td>969</td>
</tr>
<tr>
<td>Apo-Erythromycin</td>
<td>360</td>
</tr>
<tr>
<td>Apo-Fluphenazine</td>
<td>419</td>
</tr>
<tr>
<td>Apo-Flurbiprofen</td>
<td>423</td>
</tr>
<tr>
<td>Apo-Gain</td>
<td>1178</td>
</tr>
<tr>
<td>Apo-Glibride</td>
<td>495</td>
</tr>
<tr>
<td>Apo-Haloperidol</td>
<td>463</td>
</tr>
<tr>
<td>Apo-Hydroxyzine</td>
<td>493</td>
</tr>
<tr>
<td>Apo-Ibuprofen</td>
<td>499</td>
</tr>
<tr>
<td>Apo-Impazine</td>
<td>509</td>
</tr>
<tr>
<td>Apo-Iodoxacin</td>
<td>515</td>
</tr>
<tr>
<td>Apo-ISDN</td>
<td>539</td>
</tr>
<tr>
<td>Apo-K</td>
<td>819</td>
</tr>
<tr>
<td>Apo-Keto</td>
<td>550</td>
</tr>
<tr>
<td>Apo-Lorazepam</td>
<td>588</td>
</tr>
<tr>
<td>Apo-Methylphenidate</td>
<td>634</td>
</tr>
<tr>
<td>Apo-Meteoridazole</td>
<td>641</td>
</tr>
<tr>
<td>Apo-Naprosyn</td>
<td>98</td>
</tr>
<tr>
<td>Apo-Naprosyn DS</td>
<td>98</td>
</tr>
<tr>
<td>Apo-Nifedipine</td>
<td>705</td>
</tr>
<tr>
<td>Apo-Nitrofurantoin</td>
<td>712</td>
</tr>
<tr>
<td>Apo-Oxazepam</td>
<td>755</td>
</tr>
<tr>
<td>Apo-Piroxicam</td>
<td>807</td>
</tr>
<tr>
<td>Apo-Propranolol</td>
<td>849</td>
</tr>
<tr>
<td>Apo-Ranitidine</td>
<td>472</td>
</tr>
<tr>
<td>Apo-Sulfamethoxazole</td>
<td>942</td>
</tr>
<tr>
<td>Apo-Sulfatrim</td>
<td>1025</td>
</tr>
<tr>
<td>Apo-Sulfatrim DS</td>
<td>1025</td>
</tr>
<tr>
<td>Apo-Sulfinyl</td>
<td>946</td>
</tr>
<tr>
<td>Apo-Tetra</td>
<td>969</td>
</tr>
<tr>
<td>Apo-Theo LA</td>
<td>120</td>
</tr>
<tr>
<td>Apo-Thioridazine</td>
<td>978</td>
</tr>
<tr>
<td>Apo-Timol</td>
<td>986</td>
</tr>
<tr>
<td>Apo-Timop</td>
<td>1160</td>
</tr>
<tr>
<td>Apo-Tolbutamide</td>
<td>1182</td>
</tr>
<tr>
<td>Apo-Triam</td>
<td>1016</td>
</tr>
<tr>
<td>Apo-Trilex</td>
<td>1021</td>
</tr>
<tr>
<td>Apo-Trihex</td>
<td>1021</td>
</tr>
<tr>
<td>Apo-Trizalt</td>
<td>1021</td>
</tr>
<tr>
<td>Apo-Zidovudine</td>
<td>1066</td>
</tr>
<tr>
<td>A.P.P</td>
<td>1176</td>
</tr>
<tr>
<td>APPETITE SUPPRESSANTS</td>
<td>1179</td>
</tr>
<tr>
<td>Apreclonidine</td>
<td>1165</td>
</tr>
<tr>
<td>Aprexazide</td>
<td>25/25, 1101</td>
</tr>
<tr>
<td>Aprexazide 50/50</td>
<td>1101</td>
</tr>
<tr>
<td>Aprexazide 50/50</td>
<td>1110</td>
</tr>
<tr>
<td>Aprosinol</td>
<td>481</td>
</tr>
<tr>
<td>Aprotinin</td>
<td>1171</td>
</tr>
<tr>
<td>APSAC</td>
<td>980</td>
</tr>
<tr>
<td>Aquachloral</td>
<td>184</td>
</tr>
<tr>
<td>Aquasite</td>
<td>1159</td>
</tr>
<tr>
<td>Aquasol E</td>
<td>1053</td>
</tr>
<tr>
<td>Aqueous Charcoal</td>
<td>7</td>
</tr>
<tr>
<td>Ara-G</td>
<td>256</td>
</tr>
<tr>
<td>Arava</td>
<td>564</td>
</tr>
<tr>
<td>Arctostaphylos ura-ursi</td>
<td>1097</td>
</tr>
</tbody>
</table>
| Ardeparin | 469, P-18 | [Ardeparin see DrugGuide.com](http://www.drugguide.com)
| Ardeparin | 745 |
| Aricept | 325 |
| Arimex | 60 |
| Aristocor | 256, 245 |
| Aristospan | 256 |
| A.R.M. | 1101 |
| Armour thyroid | 986 |
| Arnica | 1090 |
| Arnica montana | 1090 |
| Aromatase Inhibitors | 39, P-41 |
| Artestin | 1022 |
| Artane | 1021 |
| Artemisia vulgaris | 1095 |

*Entries for generic names appear in **boldface type**, trade names appear in regular type, classifications appear in **boldface small caps**, combination drugs appear in *italics*, herbal products are preceded by a leaf icon (_leaf_), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
Arthritis, 903
Arthrinol, 903
Arthrotene, 1101
Articolose, 236
Articolose IA, 236
Atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Arthrisin, 903
P±15, P±16, P±27.
See also difenoxylate/atropine; diphenoxylate/atropine;
Arthritis Foundation Pain Reliever Aspirin-Free, 3
Arthritis Pain Formula, 1101
Arthropan, 903
Articulose, 236
Atropisol, 1162
Arthritis Pain Formula, 1101
Atrovent, 528
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropine Free, 3
Isopto Atropine
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
atropine, 81, 1162, C4, C5, C6, 1162, P±16, P±27.
Atropisol, 1162
Arthritis Pain Formula, 1101
Atropisol, 1162
Arthritis Pain Formula, 1101
Articulose, 236
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Bayer Timed-Release Arthritic Pain Formula, 903
BCG, P–39
BCG-Connaught Strain, 1171, P–41
BCG-Tice Strain, 1171, P–41
BGN, 158
Bears, 97
Bee, 244
beclaspermin, 94
beclomethasone, 229, 239, P–68
beclomethasone (inhaled), see DrugGuide.com
Beez, 1047
Bellal, 1102
Bellergal-S, 1102
Bel-Phen-Ergot-SR, 1102
Benadryl, 300
Benadryl Allergy Decongestant Liquid, 1102
Benadryl Allergy/Sinus Headache Caplets, 1102
Benadryl Decongestant Allergy, 1102
Benadryl Itch Children’s, 300
Benadryl Itch Stopping Gel Children’s Formula, 300
Benadryl Itch Stopping Gel Maximum Strength, 300
benazepril, 63, C1, C24, P–8, P–35
benazepril, 63, C1, C24, P–8, P–35
Benylin Expectorant Liquid, 1102
Benylin Multi-Symptom Liquid, 1102
Benylin Pediatric, 277
Benzacot, 1022
Benzamycin, 1102
benzathine penicillin G, 764, P–38
benzodiazepines, 1123, P–13, P–19, P–20
ANTICONVULSANT, G8, C10
INFREQUENTLY USED, 1182
ULTRA-SHORT ACTING, 1178
Barbiturates, 1123, P–13, P–19, P–20
ANTICONVULSANT, G8, C10
INFREQUENTLY USED, 1182
ULTRA-SHORT ACTING, 1178
Baridium, 783
Barriere-HC, 245
Basalgel, 36, 591
Basalximab, 94, P–74
Baycol, 478
Bayer Aspirin, 903
Bayer Plus, Extra Strength, 1101
Bayer Select Chest Cold, 1101
Bayer Select Flu Relief, 1101
Bayer Select Head & Chest Cold, Aspirin Free Caplets, 1101
Bayer Select Head Cold, 1101
Bayer Select Ibuprofen Pain Relief, 499
Bayer Select Maximum Strength Headache, 1101
Bayer Select Maximum Strength Night Time Pain Relief, 1101
Bayer Select Maximum Strength Sinus Pain Relief, 1101
Bayer Select Night Time Cold, 1101
Bayer Select Night Time Cold, 1101
8-Hour Bayer Timed Release, 903

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>CLASSIFICATION</th>
<th>TRADE NAME</th>
<th>GENEric NAME</th>
<th>PAGE NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betaxol, 100, 1159, C25, P-35</td>
<td>Betaxol, 1159</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betaxin, 974</td>
<td>Betaxin, 974</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>betaxol, 100, 1159, C25, P-35</td>
<td>Betaxol, 1159</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>betaxin, 974</td>
<td>Betaxin, 974</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betanecol, 102, C50, P-66</td>
<td>Betanecol, 102, C50, P-66</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betimol, 1160</td>
<td>Betimol, 1160</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betnesol, 236</td>
<td>Betnesol, 236</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>betnesol, 236</td>
<td>Betnesol, 236</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betnovate, 244</td>
<td>Betnovate, 244</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betoptic, 1159</td>
<td>Betoptic, 1159</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betoptic S, 1159</td>
<td>Betoptic S, 1159</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Betron, 974</td>
<td>Betron, 974</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>bexarotene, 1166</td>
<td>bexarotene, 1166</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Blaxin, 1160</td>
<td>Blaxin, 1160</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Bicalutamide, 103, C30, P-39, P-41</td>
<td>Bicalutamide, 103, C30, P-39, P-41</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>bicarbonate. See sodium bicarbonate</td>
<td>bicarbonate. See sodium bicarbonate</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Bicillin, 764</td>
<td>Bicillin, 764</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Bicillin LA, 764</td>
<td>Bicillin LA, 764</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Bicitra, 930</td>
<td>Bicitra, 930</td>
<td></td>
</tr>
<tr>
<td>BETA-ADRENERGIC BLOCKERS, C1, C2, P-11, P-35</td>
<td>Bicitra Solution, 1102</td>
<td>Bicitra Solution, 1102</td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A "C" and a boldface page number following a generic name identify the page in the "Classification" section on which that drug is listed.
COMPREHENSIVE INDEX

Butalgen, 135

butafine, 70, C20, P–31

Butibel, 1102

butoconazole, 73, C21, P–31

butoconazole, vaginal, C21

butorphanol, 137, 1120, 1124, P–85

butyrophenone, C35, P–47

Hydramine Congel, 300

C

cabergoline, 141, 1172

Cafiatine PB, 1102

Gafefrol, 1102

Gafefrol Supps, 1102

Galadryl Lotion, 1102

Calan, 1037

Calan SR, 1037

Calcarb, 142

Calcit, 1102

Calci-Chew, 142

Calcidey, 142

Calciferol, 1050

Calcijex, 1050

Calcilac, 142

Calcinean, 465

Calcinam, P–93

Calcimix, 142

Calciparine, 465

calcipotriene, 1172

Calci, 142

calcitriol, see DrugGuide.com

calcitonin, see DrugGuide.com

calcitonin (human), P–93

calcitonin (salmon), P–93

calcitriol, 1050, C59, P–91

calcium, 1149

calcium acetate, 142, P–79

calcium carbonate, 142, P–79

calcium channel blockers, C1, C2, P–11, P–35

antihypertensive, C25

calcium chloride, 142, P–79

calcium citrate, 142, P–79

Calcium Disodium Versenate, 1175

Calcium EDTA, 1175

calcium gluconate, 142, P–29

calcium gluconate, 142, P–79

calcium lactate, 142, P–79

*Entries for generic names appear in boldface type, trade names appear in regular type, classificaiions appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
## COMPREHENSIVE INDEX

| Calcium Salts, 142 | Cardene SR, 699 |
| Calcium-Sandoz, 142 | Cardioquin, 869 |
| Calcium-Supplements, P–79 | Carditome, 293 |
| Cardizem, 293 | Cardura, 328 |
| Cardizem, 293 | Carisoprodol, 157, C57, P–86 |
| Calcfty ant, see DrugGuide.com | Carmol HC, 245 |
| Calgynine, 142 | Carmustine, 158 |
| Calm X, 296 | Carvedilol, 162, C25, P–35 |
| Calmylin #1, 277 | Cefadroxil, 167, P–37 |
| Calmylin Expectorant, 454 | Cefadyl, 167 |
| Calphron, 142 | Cefazolin, 167, P–37 |
| Calprate, 142 | Cefdinir, 176, C27, P–37 |
| Caltrate 600+D, 1102 | Cefepime, 176, C27, P–37 |
| Caltrate, 142 | Cefixime, 176, C27, P–37 |
| Calglycine, 142 | Cefotaxime, 176, C27, P–37 |
| Calmylin #1, 277 | Cefoperazone, 176, C27, P–37 |
| Calmylin Expectorant, 454 | Cefotaxime, 177 |
| Calprate, 142 | Cefpodoxime, C27, P–37 |
| Calrute 600+D, 1102 | Cefpodoxime, 177 |
| Cama Arthritis Pain Reliever, 1102 | Cefuroxime, 177 |
| Camphor tree, 1091 | Cefuroxime, 177 |
| Camsonsar, 530 | Cefuroxime, 177 |
| candesartan, 61, P–35 | Cefuroxime, 177 |
| Ganzent, 70, 73 | Cefuroxime, 177 |
| capcicatidine, 146, P–39 | Cefuroxime, 177 |
| Captopril, 63 | Cefuroxime, 177 |
| Captopril, 63 | Cefuroxime, 177 |
| Captopril 25/15, 1102 | Cefuroxime, 177 |
| Captopril 25/25, 1102 | Cefuroxime, 177 |
| Captopril 50/15, 1102 | Cefuroxime, 177 |
| Captopril 50/25, 1102 | Cefuroxime, 177 |
| Capricolin, 148 | Cefuroxime, 177 |
| Caprini, 148 | Cefuroxime, 177 |
| Captopril, 63, C1, C24, P–8, P–35 | Cefuroxime, 177 |
| Capanil, 148 | Cefuroxime, 177 |
| Carafate, 941 | Cefuroxime, 177 |
| carcachol, 1160. See also Isoto Carba- | Cefuroxime, 177 |
| chol | Cefuroxime, 177 |
| Carbacor, 626 | Cefuroxime, 177 |
| carbamazepine, 149, P–19, P–20 | Cefuroxime, 177 |
| carbamazepine, C10 | Cefuroxime, 177 |
| CARBAPENEM, P–37 | Cefuroxime, 177 |
| Carbatrol, 149 | Cefuroxime, 177 |
| Carbidopa/levodopa, 574, C32, P–43 | Cefuroxime, 177 |
| Carbolith, 583 | Cefuroxime, 177 |
| CARBONIC ANHYDROGEN INHIBITORS, ORAL, 152, 1160 | Cefuroxime, 177 |
| Carbonyl iron, 532, P–79 | Cefuroxime, 177 |
| Carboplatin, 154, C30, P–39, P–41 | Cefuroxime, 177 |
| Carboprost, 1172, P–2 | Cefuroxime, 177 |
| Cardec DM Syrup, 1102 | Cefuroxime, 177 |
| Cardene, 699 | Cefuroxime, 177 |
| Cardene IV, 699 | Cefuroxime, 177 |

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in BOLDFACE SMALL CAPS, combination drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
COMPREHENSIVE INDEX

P±118

ceftibuten, 177, C27, P±37
Cefin, 171
ceftizoxime, 177, C27, P±38
ceftriaxone, 177, C27, P±38
cefuroxime, 171, C27, P±37
Cefzil, 171
Celebrex, 166
celecoxib, 166, P±82
gcelestrine, 244
Gelsestone, 236
Celestra, 202
gelfoam, 67
Gelfoam Fresh, 1159
Gelvivio, 1159
Gemil, 75
Genafo, 856
Cenafo Plus Tablets, 1102
Cena-K, 819
Genestin, 368
Genocort, 236
Gonolate, 75
cephalexin, 167, C26, P±37
cephalsporins
FIRST GENERATION, C26, P±37
SECOND GENERATION, C26, P±37
THIRD GENERATION, C27, P±37
Cephapirin, 167, C26, P±37
Cephradine, 167, C26, P±37
Cephalac, 557
Cepaz, 177
gerebsys, 790
gerespan, 1179
gerezyme, 1177
cerivastatin, 478, C55, P±77
gemfibrozil, 265
gemidil Vaginal Insert, 297
C.E.S., 368
Getaeaine Topical, 1103
Getacont, 245
getaeine, 75
Geta Plus, 1103
Cetaeapsy Ophthalmic Ointment, 1103
cetirizine, 183, C22, P±33
cetirizine, 183, C22, P±33
getal, 75
Cev-Bid, 75
cesimeline, 1166
chamomile, 1091
Charac-50, 7
Charcolaid 2000, 7
Charcoaste, 7
Chemnet, 993
Gberacol Cough Syrup, 1103
Gberacol Plus Liquid, 1103
Chibroxin, 1157
Children’s Advil, 499
Children’s Cepacol Liquid, 1103
Children’s Bold, 277
Children’s Motrin, 499
Chirocaine, 542
Chlo-Amine, 190
chloral hydrate, 184, 1124
chlorambucil, 186, C30, P±39, P±41
cilorphenicol, 1157, P±38
cilorphenicol, see DrugGuide.com
Chlorate, 190
chlorhiazepoxide, 188, 1124, P±13
chloride. See strontium-89 chloride
Chlorofair, 1157
Chloromag, 593
Chloroptic, 1157
chlorquinine, see DrugGuide.com
chlorothiazide, 315, C52, P±35, P±71
chlorpheniranine, 190, C22, P±33
Chlorpromamyl, 191
chlorpromazine, 191, C19, C35, P±30, P±47
chlorpropamide, 1172
chlorpropamide, see DrugGuide.com
chlorothalidone, 315, C52, P±35, P±71
Chlor-Trimeton, 190
Chlor-Trimeton 12 Hour Relief, 1103
Chlor-Trimeton 4 Hour Relief, 1103
Chlor-Trimeton Allergy 12 Hour, 190
Chlor-Trimeton Allergy 4 Hour, 190
Chlor-Trimeton Allergy 8 Hour, 190
Chlor-Trimeton Allergy-Sinus Caplets, 1103
Chlor-Tripolon, 190
chlorzoxazone, 195, C57, 1172, P±86
Cholac, 557
Choleodys SA, 120
cholestyramine, 105, C55, P±78
cholesterol, 1149
choline and magnesium salicylates, 903, P±81, P±82
cholinergic, anticholinesterase agent, 1179

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (_leaf_), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
**Cholinergic Agents, C49, P–65**

**Cholinomimetic, C50**

**Drug Release Update, 1166**

**Ophthalmic, 1161**

**Direct-Acting, 1160**

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codimal DH Syrup</td>
<td>1103</td>
</tr>
<tr>
<td>Codimal DM Syrup</td>
<td>1103</td>
</tr>
<tr>
<td>Codimal-LA</td>
<td>1103</td>
</tr>
<tr>
<td>Codimal PH Syrup</td>
<td>1103</td>
</tr>
<tr>
<td>Colatrin</td>
<td>1025</td>
</tr>
<tr>
<td>Cogenit</td>
<td>96</td>
</tr>
<tr>
<td>Co-Gesic</td>
<td>483, 1103</td>
</tr>
<tr>
<td>Cognex</td>
<td>951</td>
</tr>
<tr>
<td>Golacl</td>
<td>322</td>
</tr>
<tr>
<td>ColBenemid</td>
<td>1103</td>
</tr>
<tr>
<td>colchicine</td>
<td>223</td>
</tr>
<tr>
<td>ColDryne</td>
<td>1103</td>
</tr>
<tr>
<td>Coledrild</td>
<td>105</td>
</tr>
<tr>
<td>colfosceril</td>
<td>1172</td>
</tr>
<tr>
<td>Collyrium Fresh</td>
<td>1164</td>
</tr>
<tr>
<td>Colorage</td>
<td>813</td>
</tr>
<tr>
<td>Col-Probenecid</td>
<td>1103</td>
</tr>
<tr>
<td>Colty-Mycin S Otic Suspension</td>
<td>1103</td>
</tr>
<tr>
<td>Colyte</td>
<td>813</td>
</tr>
<tr>
<td>combination drugs</td>
<td>1099</td>
</tr>
<tr>
<td>Combipatch 0.05/0.14</td>
<td>1103</td>
</tr>
<tr>
<td>Combipatch 0.05/0.25</td>
<td>1103</td>
</tr>
<tr>
<td>CombiPres 0.1</td>
<td>1103</td>
</tr>
<tr>
<td>CombiPres 0.2</td>
<td>1103</td>
</tr>
<tr>
<td>Combivent</td>
<td>1103</td>
</tr>
<tr>
<td>Comfort Eye Drops</td>
<td>1164</td>
</tr>
<tr>
<td>Comfort Tears</td>
<td>1159</td>
</tr>
<tr>
<td>Contrafex</td>
<td>1092</td>
</tr>
<tr>
<td>Comp-A-Z</td>
<td>833</td>
</tr>
<tr>
<td>Compazine</td>
<td>833</td>
</tr>
<tr>
<td>Compodaz</td>
<td>390</td>
</tr>
<tr>
<td>Comtan</td>
<td>541</td>
</tr>
<tr>
<td>Comtrex Allergy-Sinus</td>
<td>1103</td>
</tr>
<tr>
<td>Comtrex Liquid</td>
<td>1103</td>
</tr>
<tr>
<td>Comtrex Liqui-Gels</td>
<td>1103</td>
</tr>
<tr>
<td>Comtrex Maximum Strength Caplets</td>
<td>1103</td>
</tr>
<tr>
<td>Comtrex Maximum Strength Liqui-Gels</td>
<td>1104</td>
</tr>
<tr>
<td>Comtrex Maximum Strength Multi-Symptom Cold &amp; Flu Relief</td>
<td>1104</td>
</tr>
<tr>
<td>Comtrex Maximum Strength Multi-Symptom Cold &amp; Flu Relief Liqui-Gels</td>
<td>1104</td>
</tr>
<tr>
<td>Comtrex Maximum Strength Non-Drowsy Caplets</td>
<td>1104</td>
</tr>
<tr>
<td>ComVax</td>
<td>1151</td>
</tr>
<tr>
<td>concentrated regular insulin</td>
<td>520</td>
</tr>
<tr>
<td>Comfortex</td>
<td>1092</td>
</tr>
<tr>
<td>Corlopam</td>
<td>388</td>
</tr>
<tr>
<td>Coronec</td>
<td>539</td>
</tr>
<tr>
<td>Correctol Stool Softener Soft Gels</td>
<td>322</td>
</tr>
<tr>
<td>Cortact</td>
<td>245</td>
</tr>
<tr>
<td>Cortaid</td>
<td>245</td>
</tr>
<tr>
<td>Cortate</td>
<td>245</td>
</tr>
<tr>
<td>Cort-Done</td>
<td>245</td>
</tr>
<tr>
<td>Cortel</td>
<td>236</td>
</tr>
<tr>
<td>Cortef</td>
<td>245</td>
</tr>
<tr>
<td>Cortenem</td>
<td>236</td>
</tr>
<tr>
<td>Corticine</td>
<td>245</td>
</tr>
<tr>
<td>CORTICOSTEROIDS</td>
<td>67</td>
</tr>
<tr>
<td>INHALATION</td>
<td>68</td>
</tr>
<tr>
<td>NASAL</td>
<td>68</td>
</tr>
<tr>
<td>OPHTHALMIC</td>
<td>1161, 1162</td>
</tr>
<tr>
<td>SYSTEMIC</td>
<td>69</td>
</tr>
<tr>
<td>INTERMEDIATE-ACTING</td>
<td>69</td>
</tr>
<tr>
<td>LONG-ACTING</td>
<td>69</td>
</tr>
<tr>
<td>SHORT-ACTING</td>
<td>69</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (_leaf_), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.

---

**P-120 COMPREHENSIVE INDEX**

Codimal DH Syrup, 1103  Congress SR, 1104
Codimal DM Syrup, 1103  Congest, 368
Codimal-LA, 1103  Congestac, 1104
Codimal PH Syrup, 1103  Constilac, 557
Colatrin, 1025  Constulose, 557
Cogenit, 96  Contac 12 Hour, 1104
Co-Gesic, 483, 1103  Contac Cough & Chest Cold Liquid, 1104
Cognex, 951  Contac Cough & Sore Throat Liquid, 1104
Golacl, 322  Contac Day Allergy/Sinus, 1104
ColBenemid, 1103  Contac Day Cold and Flu, 1104
Colchicine, 223  Contac Maximum Strength 12 Hour, 1104
Coldrine, 1103  Contac Night Allergy Sinus, 1104
Colestid, 105  Contac Night Cold and Flu Caplets, 1104
colfosceril, 1172  Contac Severe Cold & Flu Nighttime Liquid, 1104
Collyrium Fresh, 1164  Conten, 135
Colorage, 813  CONTRACEPTIVE IMPLANT, P-73
Col-Probenecid, 1103  CONTRACEPTIVES, HORMONAL, 225, P-71,
Colty-Mycin S Otic Suspension, 1103  P-73
Colyte, 813  Control, 788
combination drugs, 1099  Contilase, 557
Combipatch 0.05/0.14, 1103  Cordarone, 35, 1126
Combipatch 0.05/0.25, 1103  Cordran, 244
CombiPres 0.1, 1103  Coreg, 162
CombiPres 0.2, 1103  Corgard, 678
Combivent, 1103  Corgidin, 1104
Comfort Eye Drops, 1164  Cortidin D, 1104
Comfort Tears, 1159  Cortidin Maximum Strength Sinus Headache Caplets, 1104
Contrafex, 1092  Corlopam, 388
Comp-A-Z, 833  Coronex, 539
Compazine, 833  Correctol Stool Softener Soft Gels, 322
Compodaz, 390  Cortact, 245
Comtan, 541  Cortaid, 245
Comtrex Allergy-Sinus, 1103  Cortate, 245
Comtrex Liquid, 1103  Cort-Done, 245
Comtrex Liqui-Gels, 1103  Cortel, 236
Comtrex Maximum Strength Caplets, 1103  Cortef Feminine Itch, 245
Comtrex Maximum Strength Liqui-Gels, 1104  Cortenem, 236
Comtrex Maximum Strength Multi-Symptom Cold & Flu Relief, 1104  Corticine, 245
Comtrex Maximum Strength Multi-Symptom Cold & Flu Relief Liqui-Gels, 1104  corticosteroids, p-67
Comtrex Maximum Strength Non-Drowsy Caplets, 1104
ComVax, 1151

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (_leaf_), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>TOPICAL/LOCAL, P–69</th>
</tr>
</thead>
<tbody>
<tr>
<td>corticotropin, 1172</td>
</tr>
<tr>
<td>Corticrome, 245</td>
</tr>
<tr>
<td>Cortifair, 245</td>
</tr>
<tr>
<td>Cortifoam, 236</td>
</tr>
<tr>
<td>cortisone, 236, P–69</td>
</tr>
<tr>
<td>cortisone, see DrugGuide.com</td>
</tr>
<tr>
<td>Cortisporin Ophthalmic Ointment, 1104</td>
</tr>
<tr>
<td>Cortisporin Ophthalmic (Suspension)/Otic (Solution/Suspension), 1104</td>
</tr>
<tr>
<td>Cortisporin Topical Cream, 1104</td>
</tr>
<tr>
<td>Cortisporin Topical Ointment, 1104</td>
</tr>
<tr>
<td>Cortizone, 245</td>
</tr>
<tr>
<td>Cortone, 236</td>
</tr>
<tr>
<td>Cortone Acetate, 236</td>
</tr>
<tr>
<td>Cortroyn, 1173</td>
</tr>
<tr>
<td>Convert, 501</td>
</tr>
<tr>
<td>Goryphen, 903</td>
</tr>
<tr>
<td>Corzide 40/5, 1104</td>
</tr>
<tr>
<td>cosyntropin, 1173</td>
</tr>
<tr>
<td>Gotazym, 747</td>
</tr>
<tr>
<td>Gotazym-65 B, 747</td>
</tr>
<tr>
<td>Gotazym E.C.S. 20, 747</td>
</tr>
<tr>
<td>Gotazym E.C.S. 8, 747</td>
</tr>
<tr>
<td>Gotazym-S, 747</td>
</tr>
<tr>
<td>Gotrazine, 833</td>
</tr>
<tr>
<td>Gotrim, 1025</td>
</tr>
<tr>
<td>Gotrim DS, 1025</td>
</tr>
<tr>
<td>Cough-X, 1104</td>
</tr>
<tr>
<td>Guomadin, 1057</td>
</tr>
<tr>
<td>Guvera-BS, 1037</td>
</tr>
<tr>
<td>Gozzar, 61</td>
</tr>
<tr>
<td>Cramp End, 499</td>
</tr>
<tr>
<td>Crataegus species, 1085</td>
</tr>
<tr>
<td>creatinine clearance, calculation of, 1134</td>
</tr>
<tr>
<td>Creon, 1104</td>
</tr>
<tr>
<td>Creo-Terpin, 277</td>
</tr>
<tr>
<td>Grinone, 837, 1180</td>
</tr>
<tr>
<td>Grixvan, 514</td>
</tr>
<tr>
<td>Groloom, 1163</td>
</tr>
<tr>
<td>cromolyn, 598, 1163</td>
</tr>
<tr>
<td>oral, 1173</td>
</tr>
<tr>
<td>crystalline zinc insulin, C15</td>
</tr>
<tr>
<td>Crystamine, 1047</td>
</tr>
<tr>
<td>Cystic-1000, 1047</td>
</tr>
<tr>
<td>Crysticillin A.S., 764</td>
</tr>
<tr>
<td>C/T/S, 206</td>
</tr>
<tr>
<td>Cuprimine, 761</td>
</tr>
<tr>
<td>Garreth, 605</td>
</tr>
<tr>
<td>Cytarine, 244</td>
</tr>
<tr>
<td>CYANIDE ANTIDOTE, 1181</td>
</tr>
<tr>
<td>cyanocobalamin, 1047, C59, P–91</td>
</tr>
<tr>
<td>Cyanject, 1047</td>
</tr>
<tr>
<td>cyclizine, 1173, P–30</td>
</tr>
<tr>
<td>cyclobenzaprine, 247, C57, P–86</td>
</tr>
<tr>
<td>Cyclocort, 244</td>
</tr>
<tr>
<td>Cycloflex, 247</td>
</tr>
<tr>
<td>Cyclogyl, 1162</td>
</tr>
<tr>
<td>Cyclomen, 261</td>
</tr>
<tr>
<td>Cyclomydril Ophthalmic Solution, 1104</td>
</tr>
<tr>
<td>Cyclosporine, 252, P–75</td>
</tr>
<tr>
<td>Cyclosporine immune globulin, 1173</td>
</tr>
<tr>
<td>Cytomel, 985</td>
</tr>
<tr>
<td>Cytosar, 256</td>
</tr>
<tr>
<td>Cytosar-U, 256</td>
</tr>
<tr>
<td>cytosine arabinoside, 256</td>
</tr>
<tr>
<td>Cytosporin, 1104</td>
</tr>
<tr>
<td>Cytovene, 436</td>
</tr>
<tr>
<td>Cytovan, 249</td>
</tr>
<tr>
<td>Cytomel, 985</td>
</tr>
<tr>
<td>Cytosar, 256</td>
</tr>
<tr>
<td>Cytosar-U, 256</td>
</tr>
<tr>
<td>cytomegalovirus immune globulin, 1173</td>
</tr>
<tr>
<td>D</td>
</tr>
<tr>
<td>d4T, 937</td>
</tr>
<tr>
<td>dacarbazine, P–39</td>
</tr>
<tr>
<td>dacarbazine, see DrugGuide.com</td>
</tr>
<tr>
<td>Dacodyl, 108</td>
</tr>
<tr>
<td>dactinomycin, P–39</td>
</tr>
<tr>
<td>dactinomycin, see DrugGuide.com</td>
</tr>
<tr>
<td>Dakrin, 1159</td>
</tr>
<tr>
<td>Dalacin C, 206</td>
</tr>
<tr>
<td>Dalacin T, 206</td>
</tr>
<tr>
<td>Dalalone, 236</td>
</tr>
<tr>
<td>Dalgan, 1120</td>
</tr>
<tr>
<td>Dallergy Caplets, 1104</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in **boldface type**, trade names appear in regular type, **classifications** appear in **boldface small caps**, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (_leaf_), and web references are underlined. A “C” and a **boldface** page number following a generic name identify the page in the “Classification” section on which that drug is listed.
COMPREHENSIVE INDEX

Dallergy-D Syrup, 1104
Dallergy Syrup, 1104
Dallergy Tablets, 1104
Dalmane, 422
dalteparin, 469, P–18
Damason-P, 483, 1105
D-aminogluthimide, see DrugGuide.com
danaparoid, 469, P–18
danazol, 261, P–5, P–6
Danocrine, 261
Dantrium, 262
dantrene, 262, C57, P–86
Dapacta, 5
dapiprazole, 1156
dapsone, 1173, P–31, P–38
Daranide, 152
Daraprim, 864
darocet-N, 847
darocet-N 100, 1105
darvon, 847, 1122
Darvon Compound-65, 847, 1105
darvon-N, 847
darvon-N Compound, 847
darvon-N with ASA, 847
daunorubicin, P–39
daunorubicin citrate liposome, 265, C30, P–41
daunorubicin hydrochloride, 265, C30, P–41
daunoXome, 265
daypro, 735
Dazamide, 152
DC Softgels, 322
DDAVP, 272
DDAVP Rhinal Tube, 272
DDAVP Rinyle Drops, 272
ddC, 1062
ddl, 284
decadrol, 236
decadron, 233, 236, 244, 1161
deca-Durabolin, 687
decaject, 236
decaspray, 244
decloxytocin, 1173
decofed, 856
decomamine, 1105
decomamine CX, 1105
decomamine SR, 1105
Deconamine Syrup, 1105
deferoxamine, 268, C17, P–27, P–28
deficocin, 108
defesol, 1164
defelastin, 966
defelastin, 966
delavirdine, 270, 1173, C38, P–50
delavirdine, 270
deflazacort, 270
Delestrogen, 365
edemycin, 360
delgocitin, 277
delta-Cortef, 236
deltalin, 1090
deltasone, 236
delta-Triox, 245
demadex, 308
Demazin, 1105
demecicarium, 1161
demeclocycline, 1173, P–38
demicarcium, P–66
demi-Broston, 1105
demulcin, 225
demulcin 1/55, 225
Demulcin 1/50, 1105
denazol, 760
denileukin difftox, see DrugGuide.com
deoxyribonuclease. See fibrinolytic
sin/deoxyribonuclease
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Dermacort, 245
Dermalex, 577
Dermamycin, 300
Dermaflex, 244
Dermatop, 245
Dermatog, 244
Dermag, 244
Dermex HC, 245
Dermoplast, 244
Dialume, 26, 591
Diamox, 152
Diamox Sequels, 152
Diasorb, 1171
Diastat, 279
Diazemuls, 279
diazepam, 279, 1124, C10, C57, P±13, P±19, P±20, P±86
Dibenzyline, 1170
Dicarbosil, 142
dichlorphenamide, 152
dichlorphenamide, see DrugGuide.com
diclofenac, 282, 1164, P±82
diclofenac potassium, 282
diclofenac sodium, 282
dicloxacillin, 767, C27, P±38
dicloxacillin, see DrugGuide.com
didanosine, 284, C38, P±50
dideoxyctidine, 1062
dideoxyinosine, 284
didronel, 376
dienestrol, 1174
dietary guidelines for food sources, 1147
diethylstilbesetrol, P±39
diefemin, 407
difenoxin/atropine, 303, 1124, C16, P±26
diflunisal, see DrugGuide.com
diltiazem, 1105
diltiazem, see DrugGuide.com
diptan, 303
diphenhydramine, 275
diflunisal, see DrugGuide.com
digoxin, 287, C4, P±15, P±63
digoxin immune Fab, 291, C17, P±27, P±28
dibasone, 244, P±69
dihydrotachysterol, 1050, C59, P±91
dihydroergotamine, 357, C58, P±90
dihydroergotamine-Sandoz, 357
dihydroxycholecalciferol, 1050
Dilacor XR, 293
Dilantin, 790
Dilatone, 1164
Dilatrate-SR, 539
Dilaudid, 486, 1119
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, and web references are underlined. A "C" and a boldface page number following a generic name identify the page in the "Classification" section on which that drug is listed.
P-124

COMPREHENSIVE INDEX

Dilaudid Cough Syrup, 1105
Dilaudid-HP, 486

Dill, 1092

Dilucaine, 577
Dilor, 120
Dilor-G, 1105
Dilutax, 293

dimethyldronate, 296, C19, C22, P–29, P–33
dimercaprol, 1174, P–28
Dimetane, 118
Dimetane-DC Cough Syrup, 1105
Dimetane Decongestant, 1105
Dimetane-DX Cough Syrup, 1105
Dimetapp, 1105
Dimetapp Cold & Allergy Cough, 1105
Dimetapp Cold & Flu, 1105
Dimetapp DM Elixir, 1105
Dimetapp Elixir, 1105
Dimetapp Exenteral, 1105
Dinate, 296

dinoprost, 297, P–2
Diocane, 1156
Diocot, 322
Diocotcal, 322
Diocot-T, 322
Diozec, 1161
Diozec, 322
Dionex Softgels, 322
Diosuccin, 322
Diowal, 365
Diowan, 61
Diowal, 591
Diowal ES, 591
Diphen Gough, 300
Diphenhist, 300

diphenhydramine, 300, C22, C42, P–13, P–33, P–55
diphenoxylate/atropine, 303, C16, 1124, P–26

diphenhydramine, 790

diphenylhydantoin, 1126
Diphenhexyl, 1165
Dipridol, 304
Diprivan, 844

Dipotone, 244
Diprosone, 244
diphtheria vaccine. See tetanus-diphtheria vaccine
dipyriramol, 304, P–45
dirithromycin, 1174
Disalid, 903
discontinued drugs, 1167
Disipal, 1178
disopropyl, 844
disopyramide, 306, C4, P–13, P–14
disufluram, 1174

Diuril, 315

Dissati-R, 1105
divalproex sodium, 1030, C10, P–20
Dixanit, 212
Ditzac, 279
Dizmoss, 604
DM Syrup, 277
Doan’s Backache Pills, 903
Doan’s PM Extra Strength, 1105
Doan’s Regular Strength Tablets, 903
dobutamine, 317, 1127, P–63
Dobutrex, 317, 1127
docetaxel, 319, C30, P–39, P–41
docusate, 322, C54, P–76
docusate calcium, 322
docusate potassium, 322
docusate sodium, 322
Dodd’s Extra Strength, 903
Dodd’s Pils, 903
dofetilde, 1166

Dolacet, 483, 1105
Dolagist, 483
dolasetron, 323, C19, P–30
Dolorna, 847
Dologest, 499
Dolmar, 135
Dolophine, 621, 1119
Dolorac, 148

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (\(\mathcal{W}\)), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
donepezil, 325
Donnatal, 1105
Donnatal Elixir, 1105
Donnatal Extentabs, 1105
Dorazyme, 1106
Doramez, P–96
dopamine, 326, 1128, P–63
dopamine agonists, C32, P–43
Dopar, 574
Doral, 1180
Dorcol Children’s Cold Formula Liquid, 1106
Dorcol Children’s Decongestant Liquid, 1116
dornase alfa, 1174
Dorsys, 969
dorzolamide, 1160
dosage, formulas for calculating, 1133
doSS, 322
dosage forms, 322
Dowsymes, 1172
doxazosin, 328, C25, P–36
doxepin, 330, C12, P–13, P–22
doxercalciferol, 1050
Doxidan, 1106
Doxil, 333
Doxil, 1106
doxorubicin, 332, C21, P–39, P–41
doxorubicin hydrochloride, 332, C30, P–14
doxorubicin hydrochloride liposome, 333, C30, P–41
doxycycline, 969, C27, P–38
DPhl, 700
Dramamine, 969
Dramamine II, 964
Dramamine, 296
Dr. Caldwell Senna Laxative, 915
Dreiser, 244
Dristan, 1050
Dristan Cold, 1106
Dristan Cold Maximum Strength Caplets, 1106
Dristan Cold Multi-Symptom Formula, 1106
Dristan Sinus, 1106
Drixoral Allergy Sinus, 1106
Drixoral Cold & Allergy, 1106
Drixoral Cold & Flu, 1106
Drixoral Cough & Congestion Liquid Caps, 1106
Drixoral Cough & Sore Throat Liquid Caps, 1106
Drixoral Liquid Cough Caps, 1106
Drixoral Non-Drowsy Formula, 1106
Drixoral Plus, 1106
dronabinol, 1123
droperidol, 337, 1123
droxiga, 491
Dr. Scholl’s Athlete’s Foot, 70
Dr. Scholl’s Maximum Strength Tritin, 70
drug release update, 1166
Dry Eye Therapy, 1159
Dry Eye Therapy, 70
DSS, 1106
dTP diphtheria toxoid, 1151
DTP Vaccine, 1106
DT Vaccine, 1106
Dulcolax, 108
Dulcolax, 108
Duraclon, 577
Duracert, 212
Dura-Estrin, 1106
Duragen, 366
Duragesic, 394
Duramephin, 583
Duramephin, 1106
Duramephrin, 666
Duramephin, 868
Duramephrin, 966
Duramephrin, 454
Dura-Vent, 1106
Dura-Vent/A, 1106
Dura-Vent/DA, 1106
Duricef, 167
Durodol, 1106
D-Val, 279
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th><strong>E</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>E-200, 1053</td>
<td>E-400, 1053</td>
</tr>
<tr>
<td>E-1000, 1053</td>
<td>Easprin, 903</td>
</tr>
<tr>
<td>E-base, 360</td>
<td></td>
</tr>
</tbody>
</table>

**echinacea, 1077**  
**Echinacea purpurea herba, 1077**  
**echothiophate, 1161, P–66**  
**EC-Naprosyn, P–98**  
**E-Complex-600, 1053**  
**econazole, 70, C21, P–31**  
**Econochlor, 1157**  
**Econopred, 1162**  
**Ectosone, 244**  
**E-Cypionate, 365**  
**Edathamil calcium disodium, 1175**  
**edetate calcium disodium, 1175, P–28**  
**Edex, 1168**  
**ED-IN-SOL, 533**  
**edrophonium, see DrugGuide.com**  
**Eldon-Acin, 697**  
**E.E.S., 360**  
**efavirenz, 339, C38, P–50**  
**Elfer-K, 819**  
**Elfer-Syllium, 858**  
**Effexor, 1035**  
**Effexor XR, 1045**  
**Etidac/24, 856**  
**Elioidex, 414**  

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (Ŵ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
## COMPREHENSIVE INDEX

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Classification</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>entacapone</td>
<td>Ergot Derivatives</td>
<td>P–43</td>
</tr>
<tr>
<td>Entertainers' Secret</td>
<td></td>
<td>1181</td>
</tr>
<tr>
<td>Entex</td>
<td></td>
<td>1106</td>
</tr>
<tr>
<td>Entex LA</td>
<td></td>
<td>1106</td>
</tr>
<tr>
<td>Entex PSE</td>
<td></td>
<td>1106</td>
</tr>
<tr>
<td>Entropen</td>
<td></td>
<td>903</td>
</tr>
<tr>
<td>Enulose</td>
<td></td>
<td>557</td>
</tr>
<tr>
<td>Enzymase-16</td>
<td></td>
<td>747</td>
</tr>
<tr>
<td>ENZYME INHIBITORS</td>
<td></td>
<td>C–39, P–41</td>
</tr>
<tr>
<td>ENZYME INHIBITORS</td>
<td></td>
<td>P–39, P–41</td>
</tr>
<tr>
<td>ANTI NEOPLASTIC</td>
<td></td>
<td>C–28, C–30</td>
</tr>
<tr>
<td>INFREQUENTLY USED</td>
<td></td>
<td>1168, 1179</td>
</tr>
<tr>
<td>ENZYMES</td>
<td></td>
<td>P–39, P–41</td>
</tr>
<tr>
<td>ANTI NEOPLASTIC</td>
<td></td>
<td>C–28, C–30</td>
</tr>
<tr>
<td>INFREQUENTLY USED</td>
<td></td>
<td>1174, 1176, 1177</td>
</tr>
<tr>
<td>Ephedra sinica</td>
<td></td>
<td>1094</td>
</tr>
<tr>
<td>EPINEPHRINE</td>
<td></td>
<td>345, 1165, C–48, P–61</td>
</tr>
<tr>
<td>Epipen</td>
<td></td>
<td>345</td>
</tr>
<tr>
<td>eNoprin</td>
<td></td>
<td>349</td>
</tr>
<tr>
<td>epirubicin</td>
<td></td>
<td>149</td>
</tr>
<tr>
<td>Epivir</td>
<td></td>
<td>1030</td>
</tr>
<tr>
<td>Epivir HBV</td>
<td></td>
<td>559</td>
</tr>
<tr>
<td>EPO</td>
<td></td>
<td>351</td>
</tr>
<tr>
<td>epoetin</td>
<td></td>
<td>351</td>
</tr>
<tr>
<td>epoetin</td>
<td></td>
<td>351</td>
</tr>
<tr>
<td>epoprostenol</td>
<td></td>
<td>1175</td>
</tr>
<tr>
<td>Eppy/N</td>
<td></td>
<td>1165</td>
</tr>
<tr>
<td>Epres</td>
<td></td>
<td>351</td>
</tr>
<tr>
<td>eNoprin</td>
<td></td>
<td>354</td>
</tr>
<tr>
<td>Equanil</td>
<td></td>
<td>811</td>
</tr>
<tr>
<td>equianalgesic tables</td>
<td></td>
<td>1119</td>
</tr>
<tr>
<td>Equilet</td>
<td></td>
<td>142</td>
</tr>
<tr>
<td>ergocalciferol</td>
<td></td>
<td>1050, C–59, P–91</td>
</tr>
<tr>
<td>Ergomar</td>
<td></td>
<td>357</td>
</tr>
<tr>
<td>ergonovine</td>
<td></td>
<td>356</td>
</tr>
<tr>
<td>Ergostat</td>
<td></td>
<td>357</td>
</tr>
<tr>
<td>ergotamine</td>
<td></td>
<td>357, C–58, P–90</td>
</tr>
<tr>
<td>Ergotrate</td>
<td></td>
<td>356</td>
</tr>
<tr>
<td>Erido</td>
<td></td>
<td>783</td>
</tr>
<tr>
<td>Erycid</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Eryc</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erycety</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erygel</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>EryMax</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>EryPed</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erysol</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Ery-Tab</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erythro</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erythromycin</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erythromycin estolate</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erythromycin lactobionate</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Erythromycin stearate</td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>erythropoietin</td>
<td></td>
<td>351</td>
</tr>
<tr>
<td>Eserine Salicylate</td>
<td></td>
<td>1161</td>
</tr>
<tr>
<td>Esiq</td>
<td></td>
<td>135</td>
</tr>
<tr>
<td>Esiq-Plus</td>
<td></td>
<td>135, 1106</td>
</tr>
<tr>
<td>Esiqest</td>
<td></td>
<td>315</td>
</tr>
<tr>
<td>Eserol</td>
<td></td>
<td>583</td>
</tr>
<tr>
<td>Eserol-CR</td>
<td></td>
<td>583</td>
</tr>
<tr>
<td>esmolol</td>
<td></td>
<td>363, 1128, C–4, P–13, P–15</td>
</tr>
<tr>
<td>Estin II</td>
<td></td>
<td>1164</td>
</tr>
<tr>
<td>Estrace</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>Estrogen</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol cypionate</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol/norgestimate</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol transdermal system</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol vaginal ring</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol vaginal tablet</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol valerate</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>Estragen LA 5</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>Estragen L</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>Estramustine</td>
<td></td>
<td>1175, P–39, P–41</td>
</tr>
<tr>
<td>Estrane</td>
<td></td>
<td>1106</td>
</tr>
<tr>
<td>Estrastem</td>
<td></td>
<td>365</td>
</tr>
<tr>
<td>estradiol</td>
<td></td>
<td>365</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A "C" and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrofem</td>
<td>365</td>
</tr>
<tr>
<td><strong>ESTROGEN BLOCKERS, C28, C30, P–41</strong></td>
<td></td>
</tr>
<tr>
<td>Estrogens, conjugated (synthetic A), 368, P–73</td>
<td></td>
</tr>
<tr>
<td><strong>ESTROGENS, P–71</strong></td>
<td></td>
</tr>
<tr>
<td>Estroject LA, 365</td>
<td></td>
</tr>
<tr>
<td>Estro-L.A., 365</td>
<td></td>
</tr>
<tr>
<td>Estropipate, 371, P–73</td>
<td></td>
</tr>
<tr>
<td>Estro-Span, 365</td>
<td></td>
</tr>
<tr>
<td>Estrostep, 226</td>
<td></td>
</tr>
<tr>
<td>Estrostep Fe, 226</td>
<td></td>
</tr>
<tr>
<td>Excedrin P.M.</td>
<td>1107</td>
</tr>
<tr>
<td>Excedrin P.M. Liquid</td>
<td>1107</td>
</tr>
<tr>
<td>Excedrin Migraine</td>
<td>1107</td>
</tr>
<tr>
<td>Excedrin PMI. Liquid</td>
<td>1107</td>
</tr>
<tr>
<td>Excedrin Sinus Extra Strength</td>
<td>1107</td>
</tr>
<tr>
<td>Exdol, 3</td>
<td></td>
</tr>
<tr>
<td>Exederm, 70</td>
<td></td>
</tr>
<tr>
<td>Ex-Lax Gentle Nature Laxative Pills, 915</td>
<td></td>
</tr>
<tr>
<td>Exosurf Neonatal, 1172</td>
<td></td>
</tr>
<tr>
<td>Extra Strength Gas-X, 923</td>
<td></td>
</tr>
<tr>
<td>Extra Strength Maalox Anti-Gas, 923</td>
<td></td>
</tr>
<tr>
<td>Extra Strength Maalox GRF Gas Relief Formula, 923</td>
<td></td>
</tr>
<tr>
<td>Eye-Lube-X, 1159</td>
<td></td>
</tr>
<tr>
<td>Eze-DMS, 195, 1172</td>
<td></td>
</tr>
<tr>
<td>Ezol, 135</td>
<td></td>
</tr>
<tr>
<td><strong>ESTROGENS/PROGESTINS, 1167</strong></td>
<td></td>
</tr>
<tr>
<td>Estroject LA, 365</td>
<td></td>
</tr>
<tr>
<td>Estro-L.A., 365</td>
<td></td>
</tr>
<tr>
<td>Estropipate, 371, P–73</td>
<td></td>
</tr>
<tr>
<td>Ethambutol, 374, C41, P–53</td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol/desogestrel, P–73</td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol/ethynodiol, 225, P–73</td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol/levonorgestrel, 225, P–73</td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol/norethindrone, 225, P–73</td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol/norgestimate, P–73</td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol/norgestrel, 225, P–73</td>
<td></td>
</tr>
<tr>
<td>Ethmozine, 665</td>
<td></td>
</tr>
<tr>
<td><strong>ETHOXYMIDE, see DrugGuide.com</strong></td>
<td></td>
</tr>
<tr>
<td>Ethosuximide, 1175, P–20</td>
<td></td>
</tr>
<tr>
<td>Ethynodiol. See ethinyl estradiol/ethynodiol</td>
<td></td>
</tr>
<tr>
<td>Ethynol, 28</td>
<td></td>
</tr>
<tr>
<td>Ethil, 374</td>
<td></td>
</tr>
<tr>
<td>Etiadronate, 376</td>
<td></td>
</tr>
<tr>
<td>Etodolac, 378, P–81, P–82</td>
<td></td>
</tr>
<tr>
<td>Etopophos, 380</td>
<td></td>
</tr>
<tr>
<td>Etoposide, 380, C30, P–39, P–41</td>
<td></td>
</tr>
<tr>
<td>Etoposide phosphate, 380</td>
<td></td>
</tr>
<tr>
<td>Etoposides, 380</td>
<td></td>
</tr>
<tr>
<td>Etrafon, 1106</td>
<td></td>
</tr>
<tr>
<td>Etrafon-Forte, 1107</td>
<td></td>
</tr>
<tr>
<td>ETS, 360</td>
<td></td>
</tr>
<tr>
<td><strong>EUCALYPTUS, 1092</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Eucalyptus globulus, 1092</strong></td>
<td></td>
</tr>
<tr>
<td>Euglucon, 495</td>
<td></td>
</tr>
<tr>
<td>Eulexin, 425</td>
<td></td>
</tr>
<tr>
<td>Evalose, 557</td>
<td></td>
</tr>
<tr>
<td>Everone, 966</td>
<td></td>
</tr>
<tr>
<td>Evista, 876</td>
<td></td>
</tr>
<tr>
<td>E-Vitamin, 1053</td>
<td></td>
</tr>
<tr>
<td>Evocax, 1106</td>
<td></td>
</tr>
<tr>
<td>Excedrin IB, 499</td>
<td></td>
</tr>
<tr>
<td><strong>Excedrin Migraine, 1107</strong></td>
<td></td>
</tr>
<tr>
<td>Excedrin P.M., 1107</td>
<td></td>
</tr>
<tr>
<td>Excedrin P.M. Liquid, 1107</td>
<td></td>
</tr>
<tr>
<td>Excedrin PMI. Liquid, 1107</td>
<td></td>
</tr>
<tr>
<td>Excedrin Sinus Extra Strength, 1107</td>
<td></td>
</tr>
<tr>
<td>Exdol, 3</td>
<td></td>
</tr>
<tr>
<td>Exederm, 70</td>
<td></td>
</tr>
<tr>
<td>Ex-Lax Gentle Nature Laxative Pills, 915</td>
<td></td>
</tr>
<tr>
<td>Exosurf Neonatal, 1172</td>
<td></td>
</tr>
<tr>
<td>Extra Strength Gas-X, 923</td>
<td></td>
</tr>
<tr>
<td>Extra Strength Maalox Anti-Gas, 923</td>
<td></td>
</tr>
<tr>
<td>Extra Strength Maalox GRF Gas Relief Formula, 923</td>
<td></td>
</tr>
<tr>
<td>Eye-Lube-X, 1159</td>
<td></td>
</tr>
<tr>
<td>Eze-DMS, 195, 1172</td>
<td></td>
</tr>
<tr>
<td>Ezol, 135</td>
<td></td>
</tr>
<tr>
<td><strong>factor IX, see DrugGuide.com</strong></td>
<td></td>
</tr>
<tr>
<td>Fanciclovir, 383, C46, P–60</td>
<td></td>
</tr>
<tr>
<td>Famotidine, 472, C45, P–58</td>
<td></td>
</tr>
<tr>
<td>Famotidine orally disintegrating tablets, 1167</td>
<td></td>
</tr>
<tr>
<td>Famvir, 383</td>
<td></td>
</tr>
<tr>
<td>Fansidar, 1107</td>
<td></td>
</tr>
<tr>
<td>Fareston, 1100</td>
<td></td>
</tr>
<tr>
<td>Fasict, 1179</td>
<td></td>
</tr>
<tr>
<td>FDA. See Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>Fe50, 533</td>
<td></td>
</tr>
<tr>
<td>Fedahist, 1107</td>
<td></td>
</tr>
<tr>
<td>Fedahist Espectorant Syrup, 1107</td>
<td></td>
</tr>
<tr>
<td>Fedahist Gyrocaps, 1107</td>
<td></td>
</tr>
<tr>
<td>Fedahist Timecaps, 1107</td>
<td></td>
</tr>
<tr>
<td>Feen-A-Mint Pills, 1107</td>
<td></td>
</tr>
<tr>
<td>Felbamate, 1175</td>
<td></td>
</tr>
<tr>
<td>Felbatol, 1175</td>
<td></td>
</tr>
<tr>
<td>Feldene, 807</td>
<td></td>
</tr>
<tr>
<td>Felodipine, 384, C25, P–35</td>
<td></td>
</tr>
<tr>
<td>Fem-1, 1107</td>
<td></td>
</tr>
<tr>
<td>Femara, 566</td>
<td></td>
</tr>
<tr>
<td>FemCare, 73</td>
<td></td>
</tr>
<tr>
<td>Femet, 135</td>
<td></td>
</tr>
<tr>
<td>Fem-Ets, 3</td>
<td></td>
</tr>
<tr>
<td>Femhrt 1/5, 1107</td>
<td></td>
</tr>
<tr>
<td>Femiron, 533</td>
<td></td>
</tr>
<tr>
<td>Femizole, 73</td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination drugs appear in italics, herbal products are preceded by a leaf icon (,unsigned), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Femogex, 365</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FemPatch, 365</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femstat, 73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenesin, 454</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenicol, 1157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fennel, 1093</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenofozen, see DrugGuide.com</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentany, 1123</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl (oral transmucosal), 389, 1176, P–85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl (parenteral), 391, P–85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl (transdermal), 394, 1121, P–85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fesol, 532, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feostat, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feratab, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fer-gen-sol, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fergon, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fer-In-Sol, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fer-Iron, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fero-Grad, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferradil, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrlecit, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferro-Sequels, 1107</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous Fumarate, 533, P–79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous Gluconate, 533, P–79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous Sulfate, 533, P–79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fertinic, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feverall, 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feverfew, 1093</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fexofenadine, P–33, P–95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fiberall, 811, 858</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FiberCon, 811</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fiber-Lax, 811</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrepur, 858</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrinolysin/deoxyribonuclease, 1176</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filgrastim, 396</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finasteride, 399</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florgen, 135</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Floricet, 135, 1107</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Floricate w/Codetine, 1107</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florinal, 135, 1107</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florinal w/Codetine, 1107</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florap, 135</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flortal, 135</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flugel, 641</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flagel ER, 641</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flamaizine, 1181</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flarex, 1161</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flavox, 923</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flavorco, 75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flecaainide, 400, C4, P–13, P–15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fleet Bisacodyl, 108</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fleet Enema, 794</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fleet Phospho-Soda, 794</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fleet Soflax Gelcaps, 322</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fletchers’ Castoria, 915</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flexeril, 247</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flint SSD, 1181</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flolan, 1175</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flonase, 229</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flonase, 233</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florinef, 404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florone, 244</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Floropryl, 1161</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flovent, 229</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flexin, 408</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Floxuridine, 1176, P–41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluconazole, 402, C20, P–31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fludara, 1176</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocinonide, 404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flu-Imune, 1154</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocinolone, 244, P–69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocinonide, 244, P–69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flunisolide, 229, 233, P–68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocet, 244</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocin, 244</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocinolone, 244, P–69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocinonide, 244, P–69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorinef, 404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluridate, 244</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoride, 1149</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoride supplements, see DrugGuide.com</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorometholone, 1161, P–68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluor-Op, 1161</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorquinolone, 1167</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorouracil, 208, C27, P–37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorouracil, 414, C30, P–39, P–41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine, 417, C12, P–22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluphenazine, 419, P–47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluphenazine Decanoate, 419</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in **boldface type**, trade names appear in regular type, classifications appear in **boldface small caps**, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a **boldface** page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Phenazine enanthate, 419
Phenazine hydrochloride, 419
Flurandrenolide, 244, P–69
Flurazepam, 422, 1124, P–13
Flurbiprofen, 423, 1164, P–82
Flutamide, 425, C30, P–39, P–41
Flunitrazepam, 229, 233, 244, P–68, P–69
Fluvastatin, 478, C55, P–78
Fluvaxamine, 426, C12, P–22
Fluzone, 1154
FML, 1161
FML-S Ophthalmic Suspension, 1107
Foeniculum vulgare, 1093
Folinic acid, 428, C59, P–91
Folic acid, 428, C59, P–91
Folivite, 428
Food and Drug Administration
Food sources, dietary guidelines, 1147
Fortabs, 135
Fortaz, 177
Fortovase, 909
Fosamys, 18
Fosinopril, 430, C46, P–60
Foscarnet, 430, C46, P–60
Foscavir, 430
Folinic acid, see DrugGuide.com
Gemcitabine, 438
Gemfibrozil, 440, C55, P–78
Gemzar, 438
Genacid, 1179
Genac Tablets, 1107
Genalex, 856
Genalex, 300
Gen-Allerate, 190
Genapap, 3
Genasyne, 923
Genattus, 454
Genattus DM Syrup, 1107
Gencale, 142
Genels, 3
Geneeye, 1164
Gen-Glybe, 495
Gen-K, 819
Gen-Minosidil, 1178
Genoptic, 1157
Genora 0.5/35, 225
Genora 1/35, 225
Genor 1/50, 225
Genotropin, 451
Genpril, 499
Gen-Salbutamol, 13
Gentacidin, 1157
Gentafir, 1157
Gentak, 1157
gentamicin, 30, 1157, C27, P±37
Gentrasul, 1157
Gen-Triazolam, 1016
Gen-XENE, 216
Geridlum, 785
Gestril, 1180
GG-Gen, 454
ginger, 1078
Ginkgo, 1080
Ginkgo biloba, 1080
Gin Pain Pills, 905
Ginseng, 1082
Glaxcon, 1165
Gliadel, 158
Glyburide, 495, C15, P–25
gliclazide, 495, P–25
GlucaGen, 411
glucagon, 441
glucophage, 619
Glucotrol, 495
Glucotrol XL, 495
Glytate, 454
glibride, 495, C15, P–25
glycerin, 1164
Glycerin, see DrugGuide.com
glycopyrrolate, 444, C5, C6, P–15, P–16
Glycous, 454
Glymase PresTab, 495
Glyset, 649
Glytuss, 454
G–Myx, 30
GOLDENSEAL, 1083
GoldTELY, 813
gonadotropin, see DrugGuide.com
GONADOTROPIN CHORIONIC, 1176
INFREQUENTLY USED, 1176, 1177
GONADOTROPIN-RELEASING HORMONE, 1176
goserelin, 446
granisetron, 448, C19, P–30
Granules, Aerosol, 1107
granulocyte-colony stimulating factor, 396
Gravol, 296
Griselin V, 450
Grisactin, 450
Grisactin Ultra, 450
grisofulvin, 450, C20, P±31
gentamicin, 30, 1157, C26, P±37
Gris-PEG, 450
Grossvitz-FP, 450
GROWTH HORMONES, 451
guaifenesin, 454
Guainfenesin LA, 454
Guainfenesin PPA 75, 1107
Guainfenesin PSE 60, 1107
Guainfenesin PSE 120, 1107
guanadrel, 455, C25, P–35
guanabenz, 455, C25, P–35
guanafacine, 454, C25, P–35
Gyauss, 454
G–Well, 581
Gynergen, 245
Gynotropin, 454
Gyne-Lotrimin, 73
Gyne-Trosyd, 73
Gynogen L.A., 365
Habitrol, 702
HAIR GROWTH STIMULANT, 1178
halcinonide, 244, P–69
Haircon, 1016
Halol, 463
Haldol Decanoate, 463
Haldol LA, 463
Hal-Nov, 3
Haley's M-O Liquid, 1107
Halfprin, 903
halobetasol, 244, P–69
Halofed, 856
Halog, 244
haloperidol, 463, C35, P–47
haloprin, 70, C21, P–31
Halotex, 70
Halotussin-DM Sugar Free Liquid, 1107
*Entries for generic names appear in boldface type, trade names appear in regular type, classification appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Haltran, 499
Havrix, 1152, 1154
Hawthorn, 1085
hazardous drugs, safe handling of, 1141
HB, 1151
H-BIG, 1176
HCTZ, 315
HEADACHE SUPPRESSANT, VASCULAR, C57
Headache Tablets, 903
Healthprin, 903
HEAVY METAL ANTAGONISTS, 1174
Hect bordel, 1050
Helix, 1107
Hemabate, 1172
Hemocyte, 533
hemophilia b conjugate vaccine, 1151
HEMOSTATIC AGENTS, 1169, 1171, 1183
Hemrrt-BC, 245
Hepalexan, 465
heparin, 465, 1129, C6, C8, P-18
Heparin Lev, 465
heparins (low molecular weight)/heparinoids, 469
hepatitis A vaccine, 1152, 1154
hepatitis B immune globulin, 1176
hepatitis B vaccine, 1151, 1154
Hep-B-Gammagee, 1176
Hep-Lock, 465
Hep-Lock U/P, 465
Heptalar, 557
Herceptin, 1013
heroin, 1123
hetastarch, see DrugGuide.com
Hexadrol, 236
Hexalen, 24
hexamethylmelamine, 24
Hexastat, 24
Hexit, 581
Hi-Cor, 245
Hismenal, 1167
HISTAMINE H 2-RECEPTOR ANTAGONISTS, 472, C45, P-57, P-58
DRUG RELEASE UPDATE, 1167
Histanil, 839
Histrelin, 966
HIVID, 1062
HMG-GA REDUCTASE INHIBITORS, LIPID-LOWERING, 478, C55, P-78
HMS, 1161
Hold, 277
homatropine, 1162
HORMONAL CONTRACEPTIVES, P-71
HORMONE/ALKYLATING AGENTS, 1175
HORMONES, P-39, P-41
ADRENOCORTICOTROPIC, 1172, 1173
ANTINEOPLASTIC, C28, C30
INFREQUENTLY USED, 1176, 1177, 1180, 1183
HORMONES±AROMATASE INHIBITORS, C28, C30,
P-39, P-41
5-HT3 RECEPTOR ANTAGONIST, 1166
Humalog, 520
Humatin, 1179
Humatrope, 451
Humibid DM Sprinkle Caps, 1107
Humibid DM Tablets, 1107
Humibid LA, 454
Humibid Sprinkle, 454
Humorosol, 1161
Humulin 50/50, 520
Humulin 70/30, 520
Humulin L, 520
Humulin N, 520
Humulin R, 520
Humulin U Ultralente, 520
Hybodin Decanone, 687
Hyctamin, 1008
Hycoan, 483, 1107
Hydrocan, 1107
Hyctamin Compound, 1107
Hycomine Syrup, 1107
Hyco-Pap, 483
Hyco-Pap, 483
Hydrea, 491
Hydrochlorothiazide, 315
Hydrocortisone, 245
Hydrocort, 245
Hydrocet, 483
Hydrochlorothiazide, 315, C52, P-36
Hydrocortisone, 245
Hydrocort, 245
Hydrocortisone, 245
Hydrocort, 245
Hydrocort, 245
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination drugs appear in italics. Herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocodone, 483, 1119, 1122, 1123, C42, P-55, P-85</td>
<td>C42, P±55, P±85</td>
</tr>
<tr>
<td>Hydrocodone/acetaminophen, 483</td>
<td></td>
</tr>
<tr>
<td>Hydrocodone/aspirin, 483</td>
<td></td>
</tr>
<tr>
<td>Hydrocodone/ibuprofen, 483</td>
<td></td>
</tr>
<tr>
<td>Hydrocortone, 236</td>
<td></td>
</tr>
<tr>
<td>Hydro-Crystil-12, 1048</td>
<td></td>
</tr>
<tr>
<td>Hydro-D, 315</td>
<td></td>
</tr>
<tr>
<td>HydroDERIL, 315</td>
<td></td>
</tr>
<tr>
<td>Hydrogesic, 483, 1107</td>
<td></td>
</tr>
<tr>
<td>Hydroxyzine, 493, C22, P-13, P-33</td>
<td></td>
</tr>
<tr>
<td>I-Chlor, 1157</td>
<td></td>
</tr>
<tr>
<td>Idamycin, 502</td>
<td></td>
</tr>
<tr>
<td>idarubicin, 502, C30, P-39, P-41</td>
<td></td>
</tr>
<tr>
<td>Ilosone, 360</td>
<td></td>
</tr>
<tr>
<td>Hydropres-50, 1107</td>
<td></td>
</tr>
<tr>
<td>HyperHep, 1176</td>
<td></td>
</tr>
<tr>
<td>HYPOGLYCEMIC AGENTS, ORAL, 495, 1172, 1182</td>
<td></td>
</tr>
<tr>
<td>HypoTears, 1159</td>
<td></td>
</tr>
<tr>
<td>HypoTears PF, 1159</td>
<td></td>
</tr>
<tr>
<td>Hypono-D, 879</td>
<td></td>
</tr>
<tr>
<td>Hypono-D Mini-Dose, 879</td>
<td></td>
</tr>
<tr>
<td>Hytakerol, 1050</td>
<td></td>
</tr>
<tr>
<td>Hytine, 533</td>
<td></td>
</tr>
<tr>
<td>Hytine, 245</td>
<td></td>
</tr>
<tr>
<td>Hytrin, 960</td>
<td></td>
</tr>
<tr>
<td>Hytuss, 454</td>
<td></td>
</tr>
<tr>
<td>Hytuss-2X, 454</td>
<td></td>
</tr>
<tr>
<td>Hyzaar, 1108</td>
<td></td>
</tr>
<tr>
<td>Hyzine-50, 493</td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (🌱), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>indinavir</td>
<td>P-51</td>
</tr>
<tr>
<td>Indochron E-R</td>
<td>515</td>
</tr>
<tr>
<td>Indocid</td>
<td>515</td>
</tr>
<tr>
<td>Indocin</td>
<td>515</td>
</tr>
<tr>
<td>Indocin I.V.</td>
<td>515</td>
</tr>
<tr>
<td>Indocin SR</td>
<td>515</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>515</td>
</tr>
<tr>
<td>InFeD</td>
<td>533</td>
</tr>
<tr>
<td>Intramuscular injection sites</td>
<td>1140</td>
</tr>
<tr>
<td>intravenous drip rate, calculation of</td>
<td>1134</td>
</tr>
<tr>
<td>Intropin</td>
<td>326, 1128</td>
</tr>
<tr>
<td>Invirase</td>
<td>909</td>
</tr>
<tr>
<td>iodide</td>
<td>525</td>
</tr>
<tr>
<td>iodine</td>
<td>525</td>
</tr>
<tr>
<td>iodine solution, strong</td>
<td>C39, P-52</td>
</tr>
<tr>
<td>Iodopen</td>
<td>525</td>
</tr>
<tr>
<td>Iofed</td>
<td>1108</td>
</tr>
<tr>
<td>Iofed PD</td>
<td>1108</td>
</tr>
<tr>
<td>Iophen-C Liquid</td>
<td>1108</td>
</tr>
<tr>
<td>Iophen-DM Liquid</td>
<td>1108</td>
</tr>
<tr>
<td>Iophosphate</td>
<td>1161</td>
</tr>
<tr>
<td>Irbesartan</td>
<td>P-35</td>
</tr>
<tr>
<td>irinotecan</td>
<td>530, 539, P-39, P-41</td>
</tr>
<tr>
<td>iron dextran</td>
<td>533, P-79</td>
</tr>
<tr>
<td>iron polysaccharide</td>
<td>533, P-79</td>
</tr>
<tr>
<td>iron supplements</td>
<td>532, P-79</td>
</tr>
<tr>
<td>insulin(s)</td>
<td>C14, P-25</td>
</tr>
<tr>
<td>insulin lispro, rDNA origin</td>
<td>520, C14, P-25</td>
</tr>
<tr>
<td>Insulin-Toronto</td>
<td>520</td>
</tr>
<tr>
<td>insulin zinc suspension, extended</td>
<td>520, C14, P-25</td>
</tr>
<tr>
<td>insulin zinc suspension, 520, C14, P-25</td>
<td></td>
</tr>
<tr>
<td>Intal</td>
<td>598</td>
</tr>
<tr>
<td>Integrim</td>
<td>554</td>
</tr>
<tr>
<td>interferon beta-1a</td>
<td>523</td>
</tr>
<tr>
<td>interferon beta-1b</td>
<td>523</td>
</tr>
<tr>
<td>interferon gamma-1b</td>
<td>1177</td>
</tr>
<tr>
<td>interferons, beta</td>
<td>523</td>
</tr>
<tr>
<td>interferons alpha, see DrugGuide.com</td>
<td></td>
</tr>
<tr>
<td>interferon-2,15</td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
COMPREHENSIVE INDEX

P–135

Isopto Cetamide, 1158
Isopto Eserin, 1161
Isopto Frin, 1164
Isopto Homatropine, 1162
Isopto Hyoscine, 913, 1163
Isopto Plain, 1159
Isorbid, 539
Isordil, 539
isosorbide dinitrate, 539, C2, P–11
isosorbide DNSP, see DrugGuide.com
isosorbide mononitrate, 539, C2, P–11
Isotamine, 537
Isotrate, 539
Isotrate ER, 539
isotretiloin, 1177
Isradipine, 541, C25, P–35
I-Sulfacet, 1158
Isuprel, 1177
Itraconazole, 543, P–31
I-Tropine, 1162

J
Jenamicin, 30
Junior Strength Advil, 499
Just Tears, 1159

K
K+ 10, 819
K+ Care, 819
K+Care ET, 819
Kabbikinase, 980
Kabolin, 687
Kadian, 666
Kalcinate, 142
Kalium Durules, 819
kanamycin, 30, P–37
Kantrex, 30
Kaochlor, 819
Kaochlor Eff, 820
Kaochlor SF, 819
kaolin/pectin, 547, C16, P–26
Kao, 820
Kao-Cl, 819
Kaopectate, 1171
Kaopectate Advanced Formula, 1171
Kaopectate II Caplets, 585
Kaopectate Maximum Strength, 1171
Kao-Spen, 547
Kapectolin, 547
Karacil, 858
Kasof, 322
kava-kava, 1086
Kay Gel, 819
Kayexalate, 933
Kayfizer, 820
K Cl, 819
K-Dur, 819
Keflex, 167
Keftab, 167
Kefurox, 171
Kefzol, 167
K- Electrolyte, 819
Kenacort, 236
Kenject, 236
Kenalog, 236, 245
Kenoval, 245
Kerlone, 100
Ketalar, 1177
ketamine, 1177, P–8
ketoconazole, 70, 548, P–31
systemic, C20
topical, C21
ketoprofen, 550, C36, P–49, P–82
ketoion, 1163
K-Exit, 934
K-Film, 820
K-Ide, 819
K-Dur, 819
Klor-Con, 819
Klor-Con/EF, 819
Klorvess, 819
Klorvess Effervescent Granules, 819
Klorvess Liquid, 819
Klortix, 819
K-Lyte, 819
K-Lyte/Cl, 819

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “º” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
COMPREHENSIVE INDEX

K-Lyte/C Powder, 819
K-Lyte IS, 819
K-Med, 819
K-Norm, 819
Koflex, 277
Kolvum, 820
Koudreau t/wBenphosbate, 1108
Konsyl, 858
Konsyl Fiber, 811
K-P, 547
K-Pek, 1171
K-Phos M.E., 815
K-Phos Neutral, 815
K-Phos No. 2, 815
K-Phos Original, 817
K-Sol, 819
K-Tab, 819
Ku-Zyme HP, 747
K-Vescent, 819
Kwilda, 581
Kytril, 448

L
LA-12, 1048
labetalol, 555, C25, P–35
laboratory tests, normal values of, 1145
Lacril, 1159
Lacrifilm S.O.P., 1159
Lacrisert, 1159
Lactilose, 557
lactulose, 557, C54, P–76
Lactulose PSE, 557
Lamictal, 546
Lamisal, 962
Lamisil, 70
lamivudine, 559, C38, P–50
lamotrigine, 561, C10, P–19, P–20
Lanacort 9-1-1, 245
Lanazid, 537
Lanotrol, 135
Lanoxin, 135
Lanoxcaps, 287
Lanoxin, 287
lansoprazole, 563, C45, P–56, P–57, P–58
Lanvis, 1182
Largactil, 191
larodopa, 574
Lasix, 308
Lasix Special, 308
lataurus, 1165
LAXITIVES, C53, P–75
SALINE, C54, P–76
Laxinate, 322
Laxit, 108
t-dopa, 574
LEAD CHELATORS, 1175
Ledercellin NK, 764
leflunomide, 564
Lemoderm, 245
lemon verbena, 1093
Lente Iletin I, 520
Lente Iletin II, 520
lente insulin. See insulin zinc suspen-
sion
Lente L, 520
lepirudin rDNA, see DrugGuide.com
Lescol, 478
letrozole, 566, C30, P–39, P–41
leucovorin calcium, 567, C17, P–27, P–28
Leukeran, 186
Leukane, 911
leukotriene antagonists, C48, P–61
leuprolide, 570, C30, P–39, P–41
Leustatin, 1172
levobuterol, 573
levaquin, 408, 1167
Levarterenol, 1178
LactiCare-HC, 245
levalbuterol, 573
Lactinex, 1108
Levate, 39
levol, 758
Levestrajectum, see DrugGuide.com
levisticum officinale, 1094
Levlen, 225
levobetaxolol, 1159
levobunolol, 1159
levobupivacaine, 342, P–8
levocabastine, 1157
levo
dopa, 574, C32, P–43. See also car-

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (<W>), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
levonorgestrel, 226, P–73. See also ethinyl estradiol/levonorgestrel
levonorgestrel/ethinyl estradiol, 226
Levophed, 1178
levorphanol, 1119
levorphanol, see DrugGuide.com
Levo-T, 985
Levotiroid, 985
levothyroxine, 985
Levosyl, 985
Lessinex, 1176
Lester PB Drops, 1108
Lester w/Phenobarbital, 1108
Levexel 1, 1108
Levexel 2, 1108
Librax, 1108
Libritabs, 188
Librium, 188
Licon, 244
Lida-Mantle-HC Cream, 1108
Lidemol, 244
Lidex, 244
lidocaine, 1129, C4, P–8, P–13, P–15
lidocaine (local anesthetic), 577
lidocaine (mucosal), 577
lidocaine (parenteral), 577
lidocaine/prilocaine, 579, P–7, P–8
lidocaine (topical), 577
Lidject, 577
LidoPen, 577
Limbitrol DS 10-25, 1108
lindane, 581
Lioresal, 91
Biothyroxine, 985
Biotrix, 986
LIPID-LOWERING AGENTS, C54, P–76
Lipitor, 478
Liquibid, 454
Liqui-Cal, 142
Liqui-Char, 7
Liqui-Cal-600, 142
Liquid Pred, 236
Liqui-E, 1053
Liquifilm Forte, 1159
Liquitum, 3
Lisinopril, 64, C1, C24, P–8, P–35
Lithane, 583
lithium, 583
Lithazine, 583
Lithonate, 583
Lithotabs, 583
Livostin, 1157
Lobac, 1108
LoCHOLEST, 105
LoCHOLEST Light, 105
Locoid, 245
Lodine, 378
Lodine XL, 378
lodoxamide, 1163
Loestrin 21 1/20, 225
Loestrin 21 1.5/30, 225
Loestrin Fe 1.5/30, 1108
Lofene, 303
Lomen, 303
lomefloxacin, 408, C27, P–38
Lomocot, 303
Lomotil, 303
Lomotil Liquid, 1108
Lomustine, see DrugGuide.com
Lomiten, 652
Loracarbef, 171, C27, P–37
loratadine, 587, C22, P–33
lorazepam, 588, C10, 1124, P–13, P–19, P–20
Loracet, 483, 1119, 1122
Loracet 10/650, 1108
Lortab, 483, 1119, 1122
Lortab 10/500, 1108
Lortab 2.5/500, 1108
Lortab 3/500, 1108
Lortab 7.5/500, 1108
Lortab ASA, 483, 1108
Lortab Elixir, 1108
Losartan, 61, P–35

*Entries for generic names appear in boldface type, trade names appear in regular type, CLASSIFICATIONS appear in BOLD FACE SMALL CAPS, combination drugs appear in italics, herbal products are preceded by a leaf icon (¥), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
**COMPREHENSIVE INDEX**

<table>
<thead>
<tr>
<th>Losopan, 591</th>
<th>Maalox Antidiarrheal Caplets, 585</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lotemax, 1161</td>
<td>Maalox Anti-Gas, 923</td>
</tr>
<tr>
<td>Lotensin, 63</td>
<td>Maalox GRF Gas Relief Formula, 923</td>
</tr>
<tr>
<td>Lotensin HCT 10/12.5, 1108</td>
<td>Maalox Plus, 1109</td>
</tr>
<tr>
<td>Lotensin HCT 20/12.5, 1108</td>
<td>Maalox Plus Extra Strength Suspension, 1109</td>
</tr>
<tr>
<td>Lotensin HCT 20/25, 1108</td>
<td>Maalox Suspension, 1109</td>
</tr>
<tr>
<td>Lotensin HCT 5/6.25, 1108</td>
<td>Maalox TC, 591</td>
</tr>
<tr>
<td>Loteprednol, 1161, P±68</td>
<td>Macrobid, 712</td>
</tr>
<tr>
<td>Maalox Antacid Caplets, 142</td>
<td>Macrodantin, 712</td>
</tr>
<tr>
<td>Lotrel 2.5/10, 1108</td>
<td>MACROLOIDES, C27, P±38</td>
</tr>
<tr>
<td>Lotrel 5/10, 1108</td>
<td>INFREQUENTLY USED, 1174</td>
</tr>
<tr>
<td>Lotrel 5/20, 1108</td>
<td>magaldrate, 903</td>
</tr>
<tr>
<td>Lotrimin, 70</td>
<td>magnesium, 1149</td>
</tr>
<tr>
<td>Lotrimin AF, 70</td>
<td>magnesium and aluminum salts, 591</td>
</tr>
<tr>
<td>Lotrimin Topical, 1108</td>
<td>magnesium and saline salicylates, C36</td>
</tr>
<tr>
<td>L-triiodothyronine, 985</td>
<td>magnesium chloride, 593</td>
</tr>
<tr>
<td>LubriTears, 1159</td>
<td>magnesium citrate, 593, C54, P±76</td>
</tr>
<tr>
<td>Lufillin, 120</td>
<td>magnesium hydroxide, 593, C54, P±76</td>
</tr>
<tr>
<td>Lufillin-EPG Elixir, 1108</td>
<td>magnesium hydroxide/aluminum hydroxide, 591, C45, P±58</td>
</tr>
<tr>
<td>Lufillin-GG, 1108</td>
<td>magnesium oxide, 593</td>
</tr>
<tr>
<td>Lugol's solution, 525</td>
<td>magnesium salicylate, 903</td>
</tr>
<tr>
<td>Lysine, 784</td>
<td>magnesium salts (oral), 593, P–79</td>
</tr>
<tr>
<td>Lupron, 570</td>
<td>magnesium sulfate (IV), 595, C10, P–19, P–20</td>
</tr>
<tr>
<td>Lupron Depot, 570</td>
<td>Mag-Ox 400, 593</td>
</tr>
<tr>
<td>Lupron Depot-3 Month, 570</td>
<td>ma-huang, 1094</td>
</tr>
<tr>
<td>Lupron Depot-PED, 570</td>
<td>Malagesic PM, 1109</td>
</tr>
<tr>
<td>Luvox, 426</td>
<td>Mallamint, 142</td>
</tr>
<tr>
<td>Luxiq, 244</td>
<td>Mallazine, 1164</td>
</tr>
<tr>
<td>Nydrom, 244</td>
<td>Malogen, 966</td>
</tr>
<tr>
<td>Lyme disease vaccine, 1154</td>
<td>Malogenesis, 966</td>
</tr>
<tr>
<td>Lyme disease vaccine, see DrugGuide.com</td>
<td>Mandol, 171</td>
</tr>
<tr>
<td>Mannitol, 597, C52, P–71</td>
<td>mannose, 595</td>
</tr>
<tr>
<td>MAO INHIBITORS. See monoamine oxidase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Mapap, 3</td>
<td>Mapap Cold Formula, 1109</td>
</tr>
<tr>
<td>Mapap, 3</td>
<td>Marax, 1109</td>
</tr>
<tr>
<td>Marcafine, 342</td>
<td>Marcaine, 342</td>
</tr>
<tr>
<td>Marcillin, 51</td>
<td>Marsid, 342</td>
</tr>
<tr>
<td>Marecine, 1173</td>
<td>Marjestic-H, 483</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
COMPREHENSIVE INDEX  P–139

Marnal, 135
Marthinic, 903
Marzine, 1173
masopropol, 1177, P–42
Mast cell stabilizers, 598
Infrequently used, 1173
Ophthalmic, 1163
Matricaria chamomilla, 1091
Matulane, 830
Mavik, 64
Maxair, 805
Maxalt, 896
Maxalt-MLT, 896
Maxaquin, 408
Maxifen, 634
Maxidex, 1161
Maxilair, 244
Maximum Strength Benadryl Itch Relief, 300
Maximum Strength Desenex Antifungal, 70
Maximum Strength Gas Relief, 923
Maximum Strength Mylanta Gas Relief, 923
Maximum Strength Phazyme, 923
Maxipime, 176
Maxitrol Ophthalmic Suspension/Ointment, 1109
Maxivate, 244
Mazindol, 135
Meda, 3
medication error and adverse reaction medications with, 1138
Medi-Flu-Liquid, 1109
Medigesic, 135
Medipren, 499
Mediquell, 277
Medralone, 236
Medrol, 236, 245
medroxyprogesterone, 226, 605
medrysone, 1161, P–68
Med Tamoxifen, 954
Medrol, 236, 245
medroxyprogesterone, 226, 605
medrysone, 1161, P–68
Med Tamoxifen, 954
Mefoxin, 171
Mega-C/A Plus, 75
Mega, 608
Megacillin, 764
megestrol, 608, C30, P–39, P–41
Mellaril, 978
mellucid-S, 978
melphalan, 609, C30, P–39, P–41
Menadione, 499
Menaval, 365
Meni-D, 604
mestranol/norethindrone, 225
mesna, 616, C14, P–25
mesnax, 616, C17, P–27, P–28
Mesnex, 616
mesoridazine, see DrugGuide.com
Mestinon, 860
Mestinon SR, 860
Mestinon Timespan, 860
mestranol/norethindrone, 225
Meda, 3
medication error and adverse reaction medications with, 1138
Medi-Flu-Liquid, 1109
Medigesic, 135
Medipren, 499
Mediquell, 277
Medralone, 236
Medrol, 236, 245
medroxyprogesterone, 226, 605
medrysone, 1161, P–68
Med Tamoxifen, 954
Mefoxin, 171
Mega-C/A Plus, 75
Mega, 608
Megacillin, 764
megestrol, 608, C30, P–39, P–41
Mellaril, 978
mellucid-S, 978
melphalan, 609, C30, P–39, P–41
Menadione, 499
Menaval, 365
Meni-D, 604
mestranol/norethindrone, 225
mesna, 616, C14, P–25
mesnax, 616, C17, P–27, P–28
Mesnex, 616
mesoridazine, see DrugGuide.com
Mestinon, 860
Mestinon SR, 860
Mestinon Timespan, 860
mestranol/norethindrone, 225
Meda, 3
medication error and adverse reaction medications with, 1138
Medi-Flu-Liquid, 1109
Medigesic, 135
Medipren, 499
Mediquell, 277
Medralone, 236
Medrol, 236, 245
medroxyprogesterone, 226, 605
medrysone, 1161, P–68
Med Tamoxifen, 954
Mefoxin, 171
Mega-C/A Plus, 75
Mega, 608
Megacillin, 764
megestrol, 608, C30, P–39, P–41
Mellaril, 978
mellucid-S, 978
melphalan, 609, C30, P–39, P–41
Menadione, 499
Menaval, 365
Meni-D, 604
mestranol/norethindrone, 225
mesna, 616, C14, P–25
mesnax, 616, C17, P–27, P–28
Mesnex, 616
mesoridazine, see DrugGuide.com
Mestinon, 860
Mestinon SR, 860
Mestinon Timespan, 860
mestranol/norethindrone, 225
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
P–140

methylgonovine, 631, P–1, P–2
Methyl, 632
methylphenidate, 632, 1123, P–65
methylprednisolone, 236, 245, P–69
methylprednisolone, see DrugGuide.com
Metocorten, 230
Metimyd Ophthalmic Suspension/Ointment, 1109
Metipranolol, 1160
metoclopramide, 634, C19, P–30
metolazone, 636, C25, C52, P–36, P–71
Metric 21, 641
MetroCream, 641
MetroGel, 641
MetroGel-Vaginal, 641
Metro IV, 641
MetroLotion, 641
metronidazole, 641, C27, C45, P–38, P–56, P–58
Metyl, 641
Mevacor, 478
mexiletine, 644, C4, P–13, P–15
Mexitil, 644
mezlocillin, see DrugGuide.com
Miacalcin, P–93
micardis, 61
Mictin, 70
miconazole
  topical, 70, C21, P–31
  vaginal, 73, C21, P–31
MICRoGAM, 879
Micro-K, 819
Micro-K ExtentCaps, 819
Micro-LS, 819
Micronase, 495
microNefrin, 345
Micronor, 226
Microzide, 345
Midamor, 312
Midamor, 312
midazolam, 645, 1124, P–13
MIDol, Teen, 1109
MIDol IB, 499
MIDol Maximum Strength Multi-Symptom
  Menstrual Gelcaps, 1109
  MIDEol PM, 1109

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
**COMPREHENSIVE INDEX**

<table>
<thead>
<tr>
<th>Classifications</th>
<th>P–141</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moditen HCl, 419</td>
<td></td>
</tr>
<tr>
<td>Moditen HCl-HP, 419</td>
<td></td>
</tr>
<tr>
<td>Mosatrexite, 1109</td>
<td></td>
</tr>
<tr>
<td>moxipril, 64, C1, C24, P–8, P–35</td>
<td></td>
</tr>
<tr>
<td>Moisture Drops, 1159</td>
<td></td>
</tr>
<tr>
<td>Motizol, 322</td>
<td></td>
</tr>
<tr>
<td>MOM, 593</td>
<td></td>
</tr>
<tr>
<td>mometasone, 233, 245, P–68, P–69</td>
<td></td>
</tr>
<tr>
<td>Monafed, 454</td>
<td></td>
</tr>
<tr>
<td>Monistat, 70</td>
<td></td>
</tr>
<tr>
<td>Monistat-Derm, 70</td>
<td></td>
</tr>
<tr>
<td>Monitan, 1</td>
<td></td>
</tr>
<tr>
<td>MEGA-AMINE OXIDASE (MAO) INHIBITORS, 661, C11, C12, P–22</td>
<td></td>
</tr>
<tr>
<td>monobasic potassium and sodium phosphates, 815</td>
<td></td>
</tr>
<tr>
<td>monobasic potassium phosphate, 817</td>
<td></td>
</tr>
<tr>
<td>Monocid, 171</td>
<td></td>
</tr>
<tr>
<td>Monodox, 903</td>
<td></td>
</tr>
<tr>
<td>Mone-Gesic, 903</td>
<td></td>
</tr>
<tr>
<td>Monoket, 64</td>
<td></td>
</tr>
<tr>
<td>montelukast, 664, C48, P–61</td>
<td></td>
</tr>
<tr>
<td>moricizine, 665, C4, P–13, P–14</td>
<td></td>
</tr>
<tr>
<td>morphine, 666, 1119, 1121, 1123, P–85</td>
<td></td>
</tr>
<tr>
<td>Morphine H.P., 666</td>
<td></td>
</tr>
<tr>
<td>morphine-like agonists, 1122</td>
<td></td>
</tr>
<tr>
<td>Morphitec, 666</td>
<td></td>
</tr>
<tr>
<td>M.O.S., 666</td>
<td></td>
</tr>
<tr>
<td>M.O.S.-S.R., 666</td>
<td></td>
</tr>
<tr>
<td>Motofen, 305</td>
<td></td>
</tr>
<tr>
<td>Motrin, 499</td>
<td></td>
</tr>
<tr>
<td>Motrin Drops, 499</td>
<td></td>
</tr>
<tr>
<td>Motrin IB, 499</td>
<td></td>
</tr>
<tr>
<td>Motrin IB Sinus, 1109</td>
<td></td>
</tr>
<tr>
<td>Motrin Junior Strength, 499</td>
<td></td>
</tr>
<tr>
<td>Mouthkote, 1181</td>
<td></td>
</tr>
<tr>
<td>moxifloxacin, 408, P–38</td>
<td></td>
</tr>
<tr>
<td>M-R-Vax II, 1108</td>
<td></td>
</tr>
<tr>
<td>MS, 666</td>
<td></td>
</tr>
<tr>
<td>MS Contin, 666</td>
<td></td>
</tr>
<tr>
<td>MSIR, 666</td>
<td></td>
</tr>
<tr>
<td>MSIR Capsules, 666</td>
<td></td>
</tr>
<tr>
<td>MS/L Concentrate, 666</td>
<td></td>
</tr>
<tr>
<td>MSA, 666</td>
<td></td>
</tr>
<tr>
<td>MSX, 666</td>
<td></td>
</tr>
<tr>
<td>MucodefenuLA, 454</td>
<td></td>
</tr>
<tr>
<td>mucosteril, 5</td>
<td></td>
</tr>
<tr>
<td>Mucostat, 5</td>
<td></td>
</tr>
<tr>
<td>mupirocin, 670</td>
<td></td>
</tr>
<tr>
<td>multiple vitamins, see DrugGuide.com</td>
<td></td>
</tr>
<tr>
<td>Muroxol, 1159</td>
<td></td>
</tr>
<tr>
<td>Murocoll-2 Ophthalmic Drops, 1109</td>
<td></td>
</tr>
<tr>
<td>murumonab-CD3, 672, P–75</td>
<td></td>
</tr>
<tr>
<td>MUSCLE RELAXANTS</td>
<td></td>
</tr>
<tr>
<td>CENTRALLY ACTING, 1172, 1178</td>
<td></td>
</tr>
<tr>
<td>SKELLETAL, C56, P–85</td>
<td></td>
</tr>
<tr>
<td>Muse, 1168</td>
<td></td>
</tr>
<tr>
<td>Mustargen, 602</td>
<td></td>
</tr>
<tr>
<td>Mutamycin, 656</td>
<td></td>
</tr>
<tr>
<td>Myambutol, 374</td>
<td></td>
</tr>
<tr>
<td>Mycelex, 70, 73</td>
<td></td>
</tr>
<tr>
<td>Mycelex OTC, 70</td>
<td></td>
</tr>
<tr>
<td>Mycifradin, 30</td>
<td></td>
</tr>
<tr>
<td>Mycalcine, 70</td>
<td></td>
</tr>
<tr>
<td>Mycogel, 1109</td>
<td></td>
</tr>
<tr>
<td>Myco-Gyne, 73</td>
<td></td>
</tr>
<tr>
<td>Mycobutan, 884</td>
<td></td>
</tr>
<tr>
<td>Mycolog II Topical, 1109</td>
<td></td>
</tr>
<tr>
<td>mycopherenolate, 674</td>
<td></td>
</tr>
<tr>
<td>Mycostatin, 70, 73, 721</td>
<td></td>
</tr>
<tr>
<td>Mydfrin, 1164</td>
<td></td>
</tr>
<tr>
<td>Mydriacyl, 1163</td>
<td></td>
</tr>
<tr>
<td>Mydriaffair, 1163</td>
<td></td>
</tr>
<tr>
<td>HYDROCLORIC, CYCLOGLYCIC, 1162, 1163</td>
<td></td>
</tr>
<tr>
<td>Myfedrine, 856</td>
<td></td>
</tr>
<tr>
<td>Mykrox, 636</td>
<td></td>
</tr>
<tr>
<td>Mylanta, 1109</td>
<td></td>
</tr>
<tr>
<td>Mylanta AR, 472</td>
<td></td>
</tr>
<tr>
<td>Mylanta Double Strength, 591</td>
<td></td>
</tr>
<tr>
<td>Mylanta Double Strength Liquid, 1109</td>
<td></td>
</tr>
<tr>
<td>Mylanta Gas, 923</td>
<td></td>
</tr>
<tr>
<td>Mylanta Gas Relief, 923</td>
<td></td>
</tr>
<tr>
<td>Mylanta Gelscaps, 1109</td>
<td></td>
</tr>
<tr>
<td>Mylanta Lozenges, 142</td>
<td></td>
</tr>
<tr>
<td>Mylanta Natural Fiber Supplement, 858</td>
<td></td>
</tr>
<tr>
<td>Myleran, 132</td>
<td></td>
</tr>
<tr>
<td>Myloncon Drops, 923</td>
<td></td>
</tr>
<tr>
<td>Mytnasone, 230</td>
<td></td>
</tr>
<tr>
<td>Myrosinoid, 308</td>
<td></td>
</tr>
<tr>
<td>Myrtusquein, 454</td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (*W*), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
N

nalbuphine, 682, 1120
nalbuphine, see DrugGuide.com
naldecon, 1173
Naldecon, 4109
Naldecon DX Adult Liquid, 1109
Naldecon DX Adult Liquid, 1109
Naldecon DX Children's Syrup, 1109
Naldecon DX Pediatric Drops, 1109
Naldecon EX Children's Syrup, 1109
Naldecon EX Pediatric Drops, 1110
Naldecon Pediatric Drops, 1110
Naldecon Pediatric Syrup, 1110
Naldecon Senior DX Liquid, 1110
Naldecon Senior EX, 454
Naldecon Syrup, 1109
Nalipen, 767
naloxone, 685, C17, P–27, P–28
NAXDA nursing diagnoses, 1188
nandrolone decanoate, 687, 1123, P–5, P–6
napazoline, 116i
Naphcon, 116i
Napoleon-A Ophthalmic Solution, 1110
Naprelan, P–98
Napron X, P–98
Naprosyn, P–98
Naprosyn-E, P–98
Naprosyn-SR, P–98
naproxen, P–81, P–82, P–98
naproxen sodium, P–98
Naqua, 1183
naratriptan, 688, C58, P–90
Narcan, 685
Nardil, 661
Naropin, 342
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Neothylline, 120
Neozol, 70
Nephro-Calci, 142
Nephro-Fer, 533
Nephron, 345
Neprazone, 152
Nercoaine, 577
Nestrex, 863
netilmicin, 30, P–37
Netromycin, 30
• nettle, 1095
Neumega, 730
Neupogen, 396
Neuroforte-R, 1047
neuromuscular blocking agents, ophthalmic, 1172
neuromuscular blocking agents, see Drug
Guide.com
Neurontin, 433
Neu, 926
Neutralca-S, 591
Neutra-Phos, 815
Neutra-Phos-K, 817
nevirapine, 695, C38, P–50
Nia-Bid, 697
Niac, 697
Niacin, 697, 1149, C55, C59, P–78, P–92
niacinamide, 697, C55, C59, P–78, P–92
Niacor, 697
Niaspan, 697
nicardipine, 699, C2, C25, P–11, P–35
Nico-400, 697
Nicobid, 697
Nicoderm CQ, 702
Nicolar, 697
Nicorette, 702
nicotinamide, 697
nicotinamide, 697
nicotine, 702
nicotine chewing gum, 702
nicotine inhaler, 702
nicotine nasal spray, 702
nicotine transdermal, 702
Nicotinex, 697
nicotinic acid, 697
Nictrol, 702
Nictrol Inhaler, 702
Nicotrol NS, 702
Nidagel, 641
nifedipine, 705, C2, C25, P–11, P–35
Niferex, 533
Niferex-150 Forte, 1110
Nilandron, 708
Nilstat, 70, 73, 721
nilutamide, 708, C30, P–39, P–41
nimodipine, 709
Nipent, 1179
Nipride, 1131
nisoldipine, 711, C25, P–35
NITRATES, C1, C2, P–11
Nitrek, 714
NITRITES, C2, P–11. See also sodium nitrite
Nitrobid, 714, 1130
Nitrobid IV, 714
Nitrocap T.D., 714
Nitrocide, 714
Nitrodisc, 714
Nitro-Dur, 714
Nitrofuracel, 712
nitrofurantoin, 712, C27, P–38
Nitrogard, 714
Nitrogard SR, 714
nitroglycerin, 714, 1130, C2, P–11
Nitroglycin, 714
Nitrol, 714, 1130
Nitrolin, 714
Nitroingles, 714
Nitroyl, 714
Nitropriester, 717, 1131
nitroprusside, 717, 1131, C25, P–35
Nitroquick, 714
Nitrosan, 714
Nitrostat, 714, 1130
Nitro-Time, 714
Nix, 781
nizatidine, 472, C45, P–58
Nizoral, 70, 548
Nolvadex, 954
Nolvadex-D, 954
nomograms, 1136
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, C38, P–50

*Entries for generic names appear in boldface type, trade names appear in regular type, classificatons appear in boldface small caps. Combination Drugs appear in italics. herbal products are preceded by a leaf icon (•), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nova Rectal, 776</td>
<td>Novo-Oxytetracycline, 235</td>
</tr>
<tr>
<td>Novo-Alprazolam, 23</td>
<td>Novo-Ampicillin, 51</td>
</tr>
<tr>
<td>Novo-Atenolol, 79</td>
<td>Novo-AZT, 1066</td>
</tr>
<tr>
<td>Novo-Allopurinol, 235</td>
<td>NovoBetasalicylate, 246</td>
</tr>
<tr>
<td>Novo-Butamate, 1182</td>
<td>Novo-Butazolidine, 244</td>
</tr>
<tr>
<td>Novo-Chlorhydrate, 184</td>
<td>Novo-Chlorpromazine, 191</td>
</tr>
<tr>
<td>Novocaine, 71</td>
<td>Novo-Flurazine, 1018</td>
</tr>
<tr>
<td>Novo-Flurprofen, 423</td>
<td>Novo-Flurprofen, 423</td>
</tr>
<tr>
<td>Novo-Flurprofen, 423</td>
<td>Novo-Flurprofen, 423</td>
</tr>
<tr>
<td>Novo-Furosemide, 492</td>
<td>Novo-Glimepiride, 533</td>
</tr>
<tr>
<td>Novo-Naprox, P–98</td>
<td>Novo-Naprox Sodium, P–98</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novo-Naprox Sodium DS, P±98</td>
<td></td>
</tr>
<tr>
<td>Novo-Niacin, 697</td>
<td></td>
</tr>
<tr>
<td>Novonidazol, 641</td>
<td></td>
</tr>
<tr>
<td>Novo-Nifedipin, 705</td>
<td></td>
</tr>
<tr>
<td>Novopentobarb, 776</td>
<td></td>
</tr>
<tr>
<td>Novo-Pen-Vk, 764</td>
<td></td>
</tr>
<tr>
<td>Novo-Peridol, 463</td>
<td></td>
</tr>
<tr>
<td>Novo-Pheniram, 190</td>
<td></td>
</tr>
<tr>
<td>Novo-Pindol, 799</td>
<td></td>
</tr>
<tr>
<td>Novo-Pirocam, 807</td>
<td></td>
</tr>
<tr>
<td>Novopoxide, 188</td>
<td></td>
</tr>
<tr>
<td>Novopramine, 509</td>
<td></td>
</tr>
<tr>
<td>Novopranol, 849</td>
<td></td>
</tr>
<tr>
<td>Novo-Profen, 499</td>
<td></td>
</tr>
<tr>
<td>Novo-Propanidide, 1172</td>
<td></td>
</tr>
<tr>
<td>Novoquinidin, 869</td>
<td></td>
</tr>
<tr>
<td>Novo-Ridazine, 978</td>
<td></td>
</tr>
<tr>
<td>Novo-rythro, 360</td>
<td></td>
</tr>
<tr>
<td>Novo-Salmol, 13</td>
<td></td>
</tr>
<tr>
<td>Novosemide, 308</td>
<td></td>
</tr>
<tr>
<td>Novosorbide, 539</td>
<td></td>
</tr>
<tr>
<td>Novospironot, 312</td>
<td></td>
</tr>
<tr>
<td>Novo-Sundac, 946</td>
<td></td>
</tr>
<tr>
<td>Novo-Tamoxifen, 954</td>
<td></td>
</tr>
<tr>
<td>Novotetra, 969</td>
<td></td>
</tr>
<tr>
<td>Novo-Timol, 986</td>
<td></td>
</tr>
<tr>
<td><strong>Novo-Tolmetin, 1003</strong></td>
<td></td>
</tr>
<tr>
<td>Novo-Trimel, 1025</td>
<td></td>
</tr>
<tr>
<td>Novo-Trimel DS, 1025</td>
<td></td>
</tr>
<tr>
<td>Novo-Trilamine, 1016</td>
<td></td>
</tr>
<tr>
<td>Novotrtylala, 39</td>
<td></td>
</tr>
<tr>
<td>Novo-Veramil, 1037</td>
<td></td>
</tr>
<tr>
<td>Novoxapamil, 735</td>
<td></td>
</tr>
<tr>
<td>NPH Iletin I, 520</td>
<td></td>
</tr>
<tr>
<td>NPH insulin, 520, C14, P–25</td>
<td></td>
</tr>
<tr>
<td>NPH-N, 520</td>
<td></td>
</tr>
<tr>
<td>NPH/regular insulin mixture, 520, C14, P–25</td>
<td></td>
</tr>
<tr>
<td>Nu-Alpraz, 23</td>
<td></td>
</tr>
<tr>
<td>Nu-Amoxi, 43</td>
<td></td>
</tr>
<tr>
<td>Nu-Ampl, 51</td>
<td></td>
</tr>
<tr>
<td>Nu-Abin, 682, 1120</td>
<td></td>
</tr>
<tr>
<td>Nu-Cal, 142</td>
<td></td>
</tr>
<tr>
<td>Nu-Cephalos, 167</td>
<td></td>
</tr>
<tr>
<td><strong>NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, C38, P–50</strong></td>
<td></td>
</tr>
<tr>
<td>Nu-Cloxi, 767</td>
<td></td>
</tr>
<tr>
<td>Nu-Cotrimox, 1025</td>
<td></td>
</tr>
<tr>
<td>Nuprin, 499</td>
<td></td>
</tr>
<tr>
<td>Nu-Tears, 1159</td>
<td></td>
</tr>
<tr>
<td>Nu-Tears II, 1159</td>
<td></td>
</tr>
<tr>
<td>Nu-Tret, 969</td>
<td></td>
</tr>
<tr>
<td>Nutracort, 245</td>
<td></td>
</tr>
<tr>
<td>Nutra Tear, 1159</td>
<td></td>
</tr>
<tr>
<td>Nu-Trizao, 1016</td>
<td></td>
</tr>
<tr>
<td>Nutropin, 451</td>
<td></td>
</tr>
<tr>
<td>Nutropin AQ, 451</td>
<td></td>
</tr>
<tr>
<td>Nu-Verap, 1037</td>
<td></td>
</tr>
<tr>
<td>Nyadem, 70</td>
<td></td>
</tr>
<tr>
<td>Nydrazi, 537</td>
<td></td>
</tr>
<tr>
<td><strong>Nyquil Hot Therapy, 1110</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Nyquil Nighttime Cold/Flu Medicine Liquid, 1110</strong></td>
<td></td>
</tr>
<tr>
<td><strong>nystatin topical, 70, C21, P–31</strong></td>
<td></td>
</tr>
<tr>
<td><strong>vaginal, 73, C21, P–31</strong></td>
<td></td>
</tr>
<tr>
<td>Nystex, 70, 721</td>
<td></td>
</tr>
<tr>
<td>Nytol Maximum Strength, 300</td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in **boldface type**, trade names appear in regular type, **CLASSIFICATIONS** appear in **BOLDFACE SMALL CAPS**, Combination Drugs appear in **italics**, herbal products are preceded by a leaf icon (†), and web references are underlined. A “C” and a **boldface** page number following a generic name identify the page in the “Classification” section on which that drug is listed.
| Ocu-Caine, 1156 | OPIOID ANALGESICS, 1123, 1176, P–83 FOR MILD TO MODERATE PAIN, 1122 oprelvekin, 730 |
| Ocu-Carpine, 1160 |  |
| Ocu-Chlor, 1157 |  |
| OcuClear, 1164 | Opioids, 1156 |
| Ocufen, 1164 | Opticrom, 1163 |
| Oculox, 1157 | Opticyl, 1165 |
| Ocu-Mycin, 1157 | Optigene, 3, 1164 |
| Ocu-Pentolate, 1162 | Optimine, 84 |
| Ocu-Phrin, 1164 | Optimist, 1181 |
| Ocupress, 1159 | Optipranolol, 1160 |
| Ocuseret Pilo, 1160 | Orabase-HCA, 245 |
| Ocu-Sul, 1158 | Oractil, 930 |
| Ocusalf, 1158 | Oralet, 1176 |
| Ocu-Tropic, 1163 | ORAL HYPOGLYCEMIC AGENTS, 1182 |
| Ocu-Tropic, 1162 | Oralmorph SR, 666 |
| Ocu-Zoline, 1164 | Oratop, 1179 |
| ofloxacin, 408, 1157, P–38 | Oraphen-PD, 3 |
| Ogen, 371 | Orasone, 236 |
| olanzapine, 725, C35, P–48 | Orazinc, 1069 |
| olopatadine, 1157 | Orbenin, 767 |
| olopatadine, see DrugGuide.com | Oretic, 315 |
| Omeprazole, 727, C45, P–56, P–57, P–58 | Organidin NR, 454 |
| Omnicef, 176 | Orgaran, 469 |
| Omnipen, 51 | Orinase, 1182 |
| OMS Concentrate, 666 | Orldam, 1177 |
| Oncazar, 754 | orlistat, 732 |
| Oncet, 485 | Ormax, 1110 |
| Oncost, 1043 | Ormax No Drowsiness, 1110 |
| ondansetron, 728, C19, P–30 | orphenadrine, 1178, P–86 |
| Opeco-A Ophthalmic Solution, 1110 | Orophengesic, 1110 |
| Ophthalmic, 1156 | Orophengesic forte, 1110 |
| Ophthalmgan, 1164 | Ortho-cept, 1110 |
| OPHTHALMIC MEDICATIONS, 1156 | Ortho-CEPT, 225, 1110 |
| ADMINISTRATION OF, 1138 | Orthoclone OKT3, 672 |
| ANTIVIRAL, 1183 | Ortho/CS, 75 |
| OPHTHALMIC NONSTEROIDAL ANTI-INFLAMMATORY | Ortho-cyclen, 1110 |
| DRUGS, P–82 | Ortho Dienestrol, 1174 |
| Ophthalmic, 1156 | Ortho-Est, 371 |
| Ophthochlor, 1157 | Ortho-Novum 10/11, 225 |
| Ophthalmic, see DrugGuide.com | Ortho-Novum 1/55, 225 |
| OMEPRAZOLE TABLETS, 1120 | Ortho-Novum 1/50, 225 |
| MIXED, FOR MILD TO MODERATE PAIN, 1122 | Ortho-Novum 7/7/7, 225 |
| OPIOID AGONIST/ANTAGONISTS, P–85 | PHASE I, 1110 |
| EQUIANALGESIC TABLES, 1120 | PHASE II, 1110 |
| OPIOID AGONISTS, P–85 | PHASE III, 1110 |
| EQUIANALGESIC TABLES, 1119 | Ortho-Prefest, 1167 |
| INFREQUENTLY USED, 1177 | Ortho-Tri-Cyclen, 225 |
| PARTIAL, EQUIANALGESIC TABLES, 1120 |  |

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (•), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
COMPREHENSIVE INDEX

Orudis, 550
Orudis-E, 550
Orudis KT, 550
Orudis SR, 550
Os-Cal, 142
Osmitrol, 597
OSMOTIC AGENTS

LAXATIVE, C54, P–76

OPHTHALMIC, 1164

Osteocalcin, P–93
Ostoforte, 1050
Otocort Otic Suspension, 1110
Occon 35, 225
Occon-50, 1110
Occon 50, 225
Orol, 923
Orol-40, 923
Oracl, 225
Ovren, 226
oxacillin, 767, C27, P–38
oxaprozin, 733, P–82
oxazepam, 735, 1124, P–13
oxcarbazepine, 736, C10, P–19, P–20
oxiconazole, 70, C21, P–31
Oxistat, 70
oxtriphylline, 120, C48, P–61
oxybutynin, 738
Oxycoct, P–101
Oxycodan, P–101
oxycodeone, 1119, 1122, 1123, P–85, P–101
oxycodeone/acetaminophen, P–101
oxycodeone/aspirin, P–101
Oxycontin, P–101
OxyFAST, P–101
OxyIR, P–101
oxymetazoline, 1164
oxymorphone, 1119, P–85
oxymorphone, see DrugGuide.com
oxytocics, P–2
oxytocin, 740, P–1, P–2
Oyso, 142
Oyst-Cal, 142
Oysterel, 142

P

Pacaps, 135

Pacerone, 35
paclitaxel, 743, C30, P–39, P–41
Pain-X Topical, 1111
Palafer, 533
Pamelor, 719
pamidronate, 745
Panprin-IB, 499
Pamprin Maximum Pain Relief, 1111
Pamprin Multi-Symptom, 1111
Panacet, 483
Panacet 5/500, 1111
Panadol, 3
Panosal, 485
Panosal 5/500, 1111
Panaxol-S, 236
Panax ginseng, 1082
Pancoate, 747
Pancrease, 747, 1111
Pancrease MT 10, 747
Pancrease MT 16, 747
Pancrease MT 20, 747
Pancrease MT 4, 747
Pancrebarb MS-8, 747
Pancrelipase, 747
pancuronium, 749
Pandel, 245
Panlor, 483
Panmycin, 969
Panretin, 19
pantoprazole, 751, C45, P–57, P–58
panthothenic acid, 1149
papaverine, 1179
paracetamol, 3
Paraflex, 195, 1172
Parafon Forte DSC, 195, 1172
Paralube, 1159
Paraplatin, 154
Paraplatin-Q, 154
Parepectolin, 1171
paricalcitol, 1050, C59, P–91
Parlodel, 116
Parnate, 661
paromomycin, 1179
paroxetine, 752, C12, P–22
Patanol, 1157
Pathocil, 767
Pavabid, 1179
Pavabid HP, 1179
*

Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics. herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pavacot</td>
<td>1179</td>
<td></td>
</tr>
<tr>
<td>Pavagen</td>
<td>1179</td>
<td></td>
</tr>
<tr>
<td>Pavarine</td>
<td>1179</td>
<td></td>
</tr>
<tr>
<td>Pavased</td>
<td>1179</td>
<td></td>
</tr>
<tr>
<td>Pavatine</td>
<td>1179</td>
<td></td>
</tr>
<tr>
<td>Pavatym</td>
<td>1179</td>
<td></td>
</tr>
<tr>
<td>Pavalen</td>
<td>221</td>
<td></td>
</tr>
<tr>
<td>Pavaran</td>
<td>1179</td>
<td></td>
</tr>
<tr>
<td>Pavulon</td>
<td>749</td>
<td></td>
</tr>
<tr>
<td>Paxil</td>
<td>752</td>
<td></td>
</tr>
<tr>
<td>PCE</td>
<td>360</td>
<td></td>
</tr>
<tr>
<td>Pectin. See kaolin/pectin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentacarinat</td>
<td>771</td>
<td></td>
</tr>
<tr>
<td>Pentam 300</td>
<td>771</td>
<td></td>
</tr>
<tr>
<td>Pentamidine</td>
<td>771, 126</td>
<td>P–37</td>
</tr>
<tr>
<td>Pentamycin</td>
<td>1157</td>
<td></td>
</tr>
<tr>
<td>Pentasa</td>
<td>164</td>
<td></td>
</tr>
<tr>
<td>Pentazide</td>
<td>839</td>
<td></td>
</tr>
<tr>
<td>Pentazocine</td>
<td>774, 1120, 1222, 1224, P–85</td>
<td></td>
</tr>
<tr>
<td>Pentobarbital</td>
<td>776, 1123, P–13</td>
<td></td>
</tr>
<tr>
<td>Pentothal</td>
<td>1182</td>
<td></td>
</tr>
<tr>
<td>Pentoxifylline</td>
<td>778</td>
<td></td>
</tr>
<tr>
<td>Pen-Vee</td>
<td>764</td>
<td></td>
</tr>
<tr>
<td>Pen-Vee K, 764</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pepcid</td>
<td>472</td>
<td></td>
</tr>
<tr>
<td>Pepcid AC, 472</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pepto MC Acid Controller</td>
<td>472</td>
<td></td>
</tr>
<tr>
<td>Pepto BD, 472, 1167</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pepto-Bismol</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Pepto Diarrhea Control</td>
<td>585</td>
<td></td>
</tr>
<tr>
<td>Peptol</td>
<td>472</td>
<td></td>
</tr>
<tr>
<td>Percoet</td>
<td>1119, P–101</td>
<td></td>
</tr>
<tr>
<td>Percoet 10/500, 1111</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percoet 2.5/325, 1111</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percoet 5.5/25, 1111</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percoet 7.5/500, 1111</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percodan</td>
<td>1119, 1119, P–101</td>
<td></td>
</tr>
<tr>
<td>Percodan-Demi</td>
<td>P–101</td>
<td></td>
</tr>
<tr>
<td>Percogesic</td>
<td>1111</td>
<td></td>
</tr>
<tr>
<td>Percolone</td>
<td>P–101</td>
<td></td>
</tr>
<tr>
<td>Perdiem</td>
<td>858</td>
<td></td>
</tr>
<tr>
<td>Perdim Granules</td>
<td>1111</td>
<td></td>
</tr>
<tr>
<td>pergolide</td>
<td>780, 132, P–43</td>
<td></td>
</tr>
<tr>
<td>Pergonal</td>
<td>1177</td>
<td></td>
</tr>
<tr>
<td>Pertactin</td>
<td>254</td>
<td></td>
</tr>
<tr>
<td>Perindopril</td>
<td>463</td>
<td></td>
</tr>
<tr>
<td>Peri-Colace</td>
<td>1111</td>
<td></td>
</tr>
<tr>
<td>Peri-Colace Syrup</td>
<td>1111</td>
<td></td>
</tr>
<tr>
<td>Permopril, C1, 24, P–35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permisulfone</td>
<td>780</td>
<td></td>
</tr>
<tr>
<td>Perpermethrin</td>
<td>781</td>
<td></td>
</tr>
<tr>
<td>Permiul</td>
<td>419</td>
<td></td>
</tr>
<tr>
<td>Persantine</td>
<td>504</td>
<td></td>
</tr>
<tr>
<td>Persantine IV, 304</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
Pertussin Cough Suppressant, 277
Pertussin CS, 277
Pertussin ES, 277
pethidine, 611
Pfizerpen, 764
Pfizerpen-AS, 764
Pharma-Cort, 245
Pharmagasic, 135
Phase I, 1110
Phase II, 1110, 1115, 1116
Phase III, 1110, 1115, 1116
Phazyme 125, 923
Phazyme Drops, 923
Phenazine, 839
Phenazo, 783
Phenazolide, 783
phenazopyridine, 783, P–81
Phencen-50, 839
prenzeline, 661, C12, P–22
Phenerbel-S, 1111
Phenergan, 839
Phenergan Fortis, 839
Phenergan Plain, 839
Phenergan VC Syrup, 1111
Phenergan VC w/Codeine Syrup, 1111
Phenergan w/Codeine Syrup, 1111
Phenerzine, 839
Phenteron, 190
phenobarbital, 784, 1124, C10, P–13, P–19, P–20
Phenoject, 839
PHENOTHIAZINES, C19, C35, P–30, P–47
phenoxybenzamine, 1179, P–35
Phentercost, 1179
pentermine, 1179, P–9
phentolamine, 786
Phentride, 1179
phenylalanine mustard, 609
phenylephrine, 1164
Phenytoin/Phenobarbital, 1111
phenylpropanolamine, 788, P–9
phenytoin/osphenytoin, 790, C10
Phenergan DM Syrup, 1111
Phenergesic, see DrugGuide.com
Phyllocontin, 120
piperacillin, 802, C4, P–61
piperacillin/tazobactam, 802, C48, P–61
pipercacillin, 802, C27, P–38
pipercacillin/tazobactam, 802, C27, P–38
piperazine estrone sulfate, 371
Piper methysticum, 1086
Pipracil, 802
Pirbuterol, 809, C48, P–61
Piroxicam, 807, P–62
potassium, 740
Prex, 70
Pleur, 226
Plecanal, 489
plasma protein fraction, see DrugGuide.com
plasminogen activators, 1183
Platelet aggregation inhibitors, 1168
Platelet reduction agents, 1170
Platindol, 199

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics. Herbs products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classifications” section on which that drug is listed.
<table>
<thead>
<tr>
<th>Page</th>
<th>COMPREHENSIVE INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>P±150</td>
<td>Platinol-AQ, 199</td>
</tr>
<tr>
<td>1168</td>
<td>Plavix, 215</td>
</tr>
<tr>
<td>107</td>
<td>Plendil, 384</td>
</tr>
<tr>
<td>198</td>
<td>Pletal, 198</td>
</tr>
<tr>
<td>809</td>
<td>Plavix, 215</td>
</tr>
<tr>
<td>C30</td>
<td>Poliovax, 1151</td>
</tr>
<tr>
<td>P±39</td>
<td>Polycarbophil, 811, C16, C54, P±26, P±76</td>
</tr>
<tr>
<td>P±41</td>
<td>Polyclin, 51</td>
</tr>
<tr>
<td>610</td>
<td>Polycitra Syrup, 1111</td>
</tr>
<tr>
<td>812</td>
<td>polyethylene glycol, 812</td>
</tr>
<tr>
<td>813</td>
<td>polyethylene glycol/electrolyte, 813, C54, P±76</td>
</tr>
<tr>
<td>814</td>
<td>Polysporin Ophthalmic Ointment, 1112</td>
</tr>
<tr>
<td>815</td>
<td>Polysporin Ophthalmic Solution, 1112</td>
</tr>
<tr>
<td>816</td>
<td>Potassium acetate, 819, P±79</td>
</tr>
<tr>
<td>817</td>
<td>potassium and sodium phosphates, 815, P±79</td>
</tr>
<tr>
<td>818</td>
<td>potassium bicarbonate, 819, P±79</td>
</tr>
<tr>
<td>819</td>
<td>potassium bicarbonate/potassium citrate, 819</td>
</tr>
<tr>
<td>820</td>
<td>potassium bicarbonate/potassium chloride, 819</td>
</tr>
<tr>
<td>821</td>
<td>potassium bicarbonate/potassium citrate, 819</td>
</tr>
<tr>
<td>822</td>
<td>potassium chloride, 819, P±79</td>
</tr>
<tr>
<td>823</td>
<td>potassium chloride/potassium bicarbonate/potassium citrate, 819</td>
</tr>
<tr>
<td>824</td>
<td>potassium citrate, P±79</td>
</tr>
<tr>
<td>825</td>
<td>potassium gluconate, 820, P±79</td>
</tr>
<tr>
<td>826</td>
<td>potassium gluconate/potassium chloride, 820</td>
</tr>
<tr>
<td>827</td>
<td>potassium gluconate/potassium citrate, 820</td>
</tr>
<tr>
<td>828</td>
<td>potassium iodide, saturated solution, 525, C39, P±52</td>
</tr>
<tr>
<td>829</td>
<td>Potassium phosphate, 817, P±79</td>
</tr>
<tr>
<td>830</td>
<td>Potassium-Rougier, 820</td>
</tr>
<tr>
<td>831</td>
<td>Potassium Sandoz, 819</td>
</tr>
<tr>
<td>832</td>
<td>POTASSIUM SUPPLEMENTS, 819, P±79</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (<W>), and web references are underlined. A "C" and a boldface page number following a generic name identify the page in the "Classification" section on which that drug is listed.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pro-Med, 839</td>
<td></td>
</tr>
<tr>
<td>Promet, 839</td>
<td></td>
</tr>
<tr>
<td>promethazine, 839, C19, C22, P–13, P–30, P–33</td>
<td></td>
</tr>
<tr>
<td>Prometrium, 857</td>
<td></td>
</tr>
<tr>
<td>Promine, 828</td>
<td></td>
</tr>
<tr>
<td>Prenestil, 828, 1131</td>
<td></td>
</tr>
<tr>
<td>Prenestil-SR, 828</td>
<td></td>
</tr>
<tr>
<td>Propacet, 100, 847, 1112</td>
<td></td>
</tr>
<tr>
<td>propanolone, 841, C4, P–13, P–15</td>
<td></td>
</tr>
<tr>
<td>Propagast, 788</td>
<td></td>
</tr>
<tr>
<td>propantheline, 845, C5, C6, P–15, P–16</td>
<td></td>
</tr>
<tr>
<td>proparacaine, 1156</td>
<td></td>
</tr>
<tr>
<td>Propecia, 399</td>
<td></td>
</tr>
<tr>
<td>Propine, 1165</td>
<td></td>
</tr>
<tr>
<td>propiomazine, see DrugGuide.com</td>
<td></td>
</tr>
<tr>
<td>propofol, 844, P–7, P–8</td>
<td></td>
</tr>
<tr>
<td>Propoxacet-N, 847</td>
<td></td>
</tr>
<tr>
<td>propoxyphene, 847, 1122, 1124, P–85</td>
<td></td>
</tr>
<tr>
<td>propoxyphene/acetaminophen, 847</td>
<td></td>
</tr>
<tr>
<td>propoxyphene/aspirin, 847</td>
<td></td>
</tr>
<tr>
<td>Propoxyphene with APAP, 847</td>
<td></td>
</tr>
<tr>
<td>Propyl-Thiouracil, 853, C39, P–52</td>
<td></td>
</tr>
<tr>
<td>Prorazin, 833</td>
<td></td>
</tr>
<tr>
<td>Proscar, 399</td>
<td></td>
</tr>
<tr>
<td>Pro-Sof, 322</td>
<td></td>
</tr>
<tr>
<td>Prostacyclin, 1175</td>
<td></td>
</tr>
<tr>
<td>Prostaglandin agonist, ophthalmic, 1165</td>
<td></td>
</tr>
<tr>
<td>PROSTAGLANDINS</td>
<td></td>
</tr>
<tr>
<td>infrequently used, 1168, 1172</td>
<td></td>
</tr>
<tr>
<td>vasodilator, 1175</td>
<td></td>
</tr>
<tr>
<td>Prostep, 702</td>
<td></td>
</tr>
<tr>
<td>Prostigmin, 693</td>
<td></td>
</tr>
<tr>
<td>Prostine E Vaginal Suppository, 297</td>
<td></td>
</tr>
<tr>
<td>protamine sulfate, 854, C17, P–27, P–28</td>
<td></td>
</tr>
<tr>
<td>Protease inhibitors, 1171, C38, P–51</td>
<td></td>
</tr>
<tr>
<td>PROTEASE INHIBITORS, 1171</td>
<td></td>
</tr>
<tr>
<td>Prothazine, 839</td>
<td></td>
</tr>
<tr>
<td>Protilase, 747</td>
<td></td>
</tr>
<tr>
<td>Protonix, 1180</td>
<td></td>
</tr>
<tr>
<td>Protozoa, 751</td>
<td></td>
</tr>
<tr>
<td>Protopen, 1180</td>
<td></td>
</tr>
<tr>
<td>Proteopin, 451</td>
<td></td>
</tr>
<tr>
<td>Provera, 605</td>
<td></td>
</tr>
<tr>
<td>Prozac, 417</td>
<td></td>
</tr>
<tr>
<td>Pseudo, 856</td>
<td></td>
</tr>
<tr>
<td>Pseudo-Chlor, 1112</td>
<td></td>
</tr>
<tr>
<td>pseudoephedrine, 856</td>
<td></td>
</tr>
<tr>
<td>pseudogest, 856</td>
<td></td>
</tr>
<tr>
<td>Pseudo-Gest Plus, 1112</td>
<td></td>
</tr>
<tr>
<td>Psorcon, 244</td>
<td></td>
</tr>
<tr>
<td>psyllium, 858, C54, P–76</td>
<td></td>
</tr>
<tr>
<td>PTU, 853</td>
<td></td>
</tr>
<tr>
<td>Pulmicort, 229</td>
<td></td>
</tr>
<tr>
<td>Pulmozyme, 1172</td>
<td></td>
</tr>
<tr>
<td>Purinethol, 1178</td>
<td></td>
</tr>
<tr>
<td>Purinol, 21</td>
<td></td>
</tr>
<tr>
<td>PVK, 764</td>
<td></td>
</tr>
<tr>
<td>P-V-Tussin, 1110</td>
<td></td>
</tr>
<tr>
<td>pyrazinamide, 859, C41, 1180, P–53</td>
<td></td>
</tr>
<tr>
<td>Pyri, 863</td>
<td></td>
</tr>
<tr>
<td>Pyridate, 783</td>
<td></td>
</tr>
<tr>
<td>Pyridium, 783</td>
<td></td>
</tr>
<tr>
<td>pyridostigmine, 860, C50, P–66</td>
<td></td>
</tr>
<tr>
<td>pyridoxine, 863, C59, P–92</td>
<td></td>
</tr>
<tr>
<td>pyrimethamine, 864</td>
<td></td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>Q-Profen, 499</td>
<td></td>
</tr>
<tr>
<td>Quadrial, 1112</td>
<td></td>
</tr>
<tr>
<td>quazepam, 1180</td>
<td></td>
</tr>
<tr>
<td>Quazepam, see DrugGuide.com</td>
<td></td>
</tr>
<tr>
<td>Quelidrine Cough Syrup, 1112</td>
<td></td>
</tr>
<tr>
<td>Quercus robur, 1095</td>
<td></td>
</tr>
<tr>
<td>Questran, 105</td>
<td></td>
</tr>
<tr>
<td>Questran Light, 105</td>
<td></td>
</tr>
<tr>
<td>quetiapine, 867, C35, P–48</td>
<td></td>
</tr>
<tr>
<td>Quinbron-300, 1112</td>
<td></td>
</tr>
<tr>
<td>Quinbron-T, 120</td>
<td></td>
</tr>
<tr>
<td>Quinaglate Dura-Tabs, 868</td>
<td></td>
</tr>
<tr>
<td>Quinalan, 868</td>
<td></td>
</tr>
<tr>
<td>quinaapril, 64, C1, C24, P–8, P–35</td>
<td></td>
</tr>
<tr>
<td>Quinate, 868</td>
<td></td>
</tr>
<tr>
<td>Quinex Extentabs, 869</td>
<td></td>
</tr>
<tr>
<td>quinidine, 868, C4, P–13, P–15</td>
<td></td>
</tr>
<tr>
<td>quinidine gluconate, 868</td>
<td></td>
</tr>
<tr>
<td>quinidine polygalacturonate, 869</td>
<td></td>
</tr>
<tr>
<td>quinidine sulfate, 869</td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italicics. Herbal products are preceded by a leaf icon (ناقٌ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
COMPREHENSIVE INDEX

quinine, P–37, P–103
Quinora, 869
Quinsana Plus, 70
quinupristin/dalfopristin, 871
Quar, 229

R
rabeprazole, 875, C45, P–57, P–58
RADOGRAPHIC, 1181
Radiostol, 1050
ralsoxifene, 870
ramipril, 64, C1, C24, P–8, P–35
R-Z-C Shampoo, 1112
ranitidine, 472, C45, P–58
ranitidine bismuth citrate, 472, P–56
Rapamune, 924
Razide, 1112
Rexar, 1167
RDAs. See Recommended Dietary Allowances
rDNA origin, C14
Rebetol, 882
Rebetron, 1112
Recombinant, 654
Recombivax, 1151
Recombivax HB, 1154
Recombivax HB dialysis formulation, 1154
Recommended Dietary Allowances (RDAs), 1149
Redtemp, 3
Refresh, 1159
Refresh PM, 1159
Regitine, 786
Reglan, 654
Regonol, 860
Regranex, 94
Regulate, 1112
Regular (Concentrated) Iletin II U-500, 520
Regular Iletin I, 520
regular insulin (insulin injection, crystalline zinc insulin), 520
regular insulin mixture. See NPH/regular insulin mixture
Regular Pork Iletin II, 520
Regular Purified Pork Insulin, 520
Regular-8S, 322
Regulax, 322
Reguloid Natural, 858
Relafen, 677
Relaxazone, 195, 1172
Relefact TH, 1180
Relenza, 1065
Remeron, 654
Remicade, 518
remifentanil, see DrugGuide.com
Remular, 195, 1172
Remular-S, 195
Renagel, 918
Reneldil, 384
Renese-R, 1112
Renova, 1185
ReoPro, 1168
repaglinide, 877, C15, P–25
Repan, 135
reporting forms, 1184
Rep-Pred, 236
Requip, 900
Rescriptor, 270, 1173
Resectisol, 597
Resp-GF, 454
Respibid, 1112
Respipaire-60, 1112
Respibid, 120
Restoral, 957
ResYL, 454
Retarase, 980
reteplase, 980, P–89
Retin-A, 1183
Retin-A Micro, 1183
RETINOSIDS
ANTICLACNE, 1183
ANTINEOPLASTIC, 1183
Retrovir, 1066
Rev-Eyes, 1156
Revimine, 326
Rezulin, 1167
R-Gel, 148
Rh(D) globulin IV, 879
Rh(D) globulin microdose IM, 879
Rh(D) immune globulin standard dose IM, 879, P–2
Rheabon, 1171
Rhesonativ, 879
Rheumatrex, 627
Rhinac, 253
Rhinedeecon, 788

*Entries for generic names appear in boldface type, trade names appear in regular type, classificatons appear in boldface small caps, Combination Drugs appear in italics. herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
RhinoCort, 233
RhinoCort Aqua, 233
Rhodis, 550
RhoGAM, 879
rhGM-CSF (recombinant human granulo-
cyte/macrophage colony-stimulating fac-
tor), 911
Rhinocort, 245
ribavirin, 882
riboflavin, 883, C59, P–92
Ridenol, 3
RID Shampoo, 1112
rifabutin, 884
Rifadin, 886
Rifaximate, 1112
rifampin, 886, C41, P–53
rifampicine, 888, C41, P–53
Rifater, 1112
Rilutek, 1181
riluzole, 1181
rimantadine, 1181, P–60
rimexolone, 1162, P–68
Ripan, 591
Ripan Extra Strength, 591
Ripan Plus Suspension, 1112
risperidone, 891, C35, P–48
Ritalin, 632
Ritalin-SR, 632
ritodrine, 1181, P–1, P–2
Ritonavir, 894, C38, P–101
Rivodril, 211
rizatriptan, 896, C58, P–90
RMS, 666
Robaxin, 626
Robaxiscal, 1112
Robidex, 277
Robidone, 483
Robidrine, 856
Robigescic, 3
Robinul, 444
Robinul-Forte, 444
Robinul SR, 969
Robitussin, 454
Robitussin A-C Syrup, 1112
Robitussin-CF Liquid, 1112
Robitussin Cold & Cough Liqui-Gels, 1112
Robitussin Cough Calmers, 277
Robitussin-DM Liquid, 1112
Robitussin Maximum Strength Cough and
Cold Liquid, 277, 1112
Robitussin Night Relief Liquid, 1112
Robitussin Pediatric, 277
Robitussin Pediatric Cough & Cold Liquid, 1113
Robitussin-PE Syrup, 1113
Robitussin Severe Congestion Liqui-Gels, 1113
Robitussin-PE Syrup, 1113
Robitussin DM Drops, 1113
Robitussin DM Suspension, 1113
Robitussin Severe Congestion Syrup, 1113
Robitussin-PE Syrup, 1113
Rogaine, 1178
Rogaine Extra Strength for Men, 1178
Rogaine for Men, 1178
Rogaine for Women, 1178
Rogaine, 1178
Rogitine, 786
Rolaid Calcium Rich, 142, 1113
Romaizeon, 406
Rondec, 1113
Rondec DM Drops, 1113
Rondec DM Suspension, 1113
Rondec Oral Drops, 1113
Ropenil, 899, C32, P–43
ropivacaine, 342, P–8
rosiglitazone, P–25, P–105
Rotasid, 1167
rotavirus vaccine, 1167
Roubac, 1025
Rourex, 5
Rowasa, 614
Roxanol, 666
Roxanol Resudrau, 666
Roxanol-T, 666
Roxicet, 1113, P–101
Roxicet 5/500, 1113
Roxicet 500, 1113
Roxicodon, 1119, P–101
Roxicodon SR, P–101
Roxicodon, P–101
Roxiprin, P–101
Roxchlor, 819

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
COMPREHENSIVE INDEX P–155

Rubesol-1000, 1047
Rubex, 332
Rubramin PC, 1047
Rufen, 499
Rulox, 591
Rulox No. 1, 591
Rulox No. 2, 591
Rum-K, 819
Ru-Tuss, 1113
Ru-Tuss DE, 1113
Ru-Tuss Expectorant Liquid, 1113
Ru-Tuss w/Hydrocodone Liquid, 1113
Ryna-C Liquid, 1113
Rynacrom, 598
Ryna Liquid, 1113
Rynatan, 1113
Rynatan Pediatric Suspension, 1113
Rynatuss, 1113
Rythmodan, 306
Rythmodan-Lh, 306
Rythmol, 841
Saizen, 451
Salagen, 797
Salazopyrin, 943
Salbutamol, 13
Salco, 499
Sallie, 903
Salgesic, 903
SALICYLATES, P–81
  choline, C36, P–81, P–82
  choline and magnesium, C36, P–49, P–81, P–82
Salivart, 1181
saliva substitutes, 1181
Salix, 1181
salmeterol, 907, C48, P–61
Salmol, P–93
Salofalk, 614
salsalate, 903, C36, P–49, P–81, P–82
Saltsalt, 903
Salutsen, 1113
Salutsen-Demi, 1113
Sandimmune, 252
Sandostatin, 723
Sandostatin LAR, 723
SangCya, 252
Sanzo-Acne, 360
saquinavir, 909, C38, P–51
sargramostim, 911
saw palmetto, 1096
Scabene, 581
scopolamine, 913, 1163, C5, C6, P±15, P±16, P±29
Scot-Tussin DM Liquid, 1113
Scot-tussin Expectorant, 454
Scot-Tussin Original 5-Action Liquid, 1113
Scot-Tussin Senior Clear Liquid, 1113
Sectral, 1
Sedapap, 135
Sedapap-10, 1113
sedatives, 1123
SEDATIVES/HYPNOTICS, 1180, P–11
Sedatuss, 277 See also defenox- in/atropine; diphenoxylate/atropine; ISOPTO ATROPINE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, C12, P–22
selegiline, see DrugGuide.com
Selostject, 236
Semprex-D, 1113
Sena-Gen, 915
Senexon, 915
senna, 915, C54, P–76
sennosides, 915, C54, P–76
Senokot, 915
Senokot-S, 1113
Senokot Syrup, 915
SenokotXTRA, 915
Senolax, 915
Sensocrine, 342
Septra, 1025, 1113
Septra DS, 1025, 1113
Septra IV For Injection, 1113
Septra Suspension, 1113
Ser-AP-Es, 1113
Serox, 735
Serenoa repens, 1096

*Entries for generic names appear in boldface type, trade names appear in regular type, CLASSIFICATIONS appear in BOLDFACE SMALL CAPS, Combination Drugs appear in italics, herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Comprehensive Index

Serevent, 907
Serquel, 867
Serostim, 451
Serotonin Agonists, C58, P±90
Serotonin Antagonists, C19, P-30
Sertraline, 916, C12, P-22
Serutan, 858
Serozone, 690
sevelamer, 918
Seroquel, 867
Sinutab Maximum Strength Sinus Allergy, 1114
Sinutab Maximum Strength Without Drowsiness, 1114
Sirolimus, 924, P-75
Skeletum, 300
Skelid, 994
Sleep-Eze 5, 300
Slo-Mag, 593
Slo-Niacin, 697
Slo-Phyllin, 120
Slo-Phyllin GG, 1114
Sloprin, 903
Sodium bicarbonate, 926, G45, P-58, P-79
Sodium calcium edetate, 1175
Silphen, 300
Silprussia SA, 454
Silvadene, 1181
Silver sulfadiazine, 1181, P-38
Silybum marianum, 1094
Simethicone, 923
Simron, 533
Simulene, 92
Simvastatin, 478, C55, P-78
Simulect, 92
Simulect CR, 574
Simulect CR 25-100, 1114
Simulect CR 50-200, 1114
Simulect Extra Strength No Drowsiness Formula Caplets, 1114
Simulect No Drowsiness, 1113
Simulect Sinus, 1113
Simulect IB, 1113
Simulect Maximum Strength, 1114
Sine-Aid IB, 1113
Sine-Aid Maximum Strength, 1114
Sine-Aid Maximum Strength No Drowsiness Formula Caplets, 1114
Sine-Aid Sinus Medicine, 1114
Singulair, 664
Sominex, 451
Soma, 157
Soma Compound, 1114
*Somatic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and reference comments are underlined. A "C" and a boldface number following a generic name identify the page in the "Classification" section on which the drug is listed.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
<th>Classifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somnol</td>
<td>422</td>
<td></td>
</tr>
<tr>
<td>Sonata</td>
<td>1064</td>
<td></td>
</tr>
<tr>
<td>Sorbitrate</td>
<td>539</td>
<td></td>
</tr>
<tr>
<td>Sotacor</td>
<td>935</td>
<td></td>
</tr>
<tr>
<td>sotalol, 935, C4, P–13, P–15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Span FF, 533</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sparfloxacin, 408, P–38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectzacole</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>spectinomycin, see DrugGuide.com</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spec-T Lozenge, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectro-Caine, 1156</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectro-Chlor, 1157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectro-Cyl, 1163</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectro-Genta, 1157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectro-Homatropine, 1162</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectro-Pentolate, 1162</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spectro-Sulf, 1158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spersacarpine, 1160</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spersadex, 1161</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spersaphrine, 1164</td>
<td></td>
<td></td>
</tr>
<tr>
<td>spironolactone, 312, C52, P–71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sporanox, 543</td>
<td></td>
<td></td>
</tr>
<tr>
<td>spruce, 1097</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPS, 933</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSKI, 525</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stadol, 137, 1120</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stadol NS, 137</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stagesic, 485</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staphcillin, 767</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statex, 666</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staticin, 360</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stauvudine, 937, C38, P–50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stelazine, 1018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stemetetic, 1022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stemetil, 833</td>
<td></td>
<td></td>
</tr>
<tr>
<td>steps for using, 1139</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sterapred, 236</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stieva-A, 1183</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimate, 272</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimulants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CENTRAL NERVOUS SYSTEM, P–63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAXATIVE, C54, P–76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STOOL SOFTENERS, C54, P–76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Storzolamide, 152</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptase, 980</td>
<td></td>
<td></td>
</tr>
<tr>
<td>streptokinase, 980, P–89</td>
<td></td>
<td></td>
</tr>
<tr>
<td>streptomycin, 50, P–37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>streptozocin, 1181, P–39, P–41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strifon Forte DCS, 1172</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strifon Forte DSC, 195</td>
<td></td>
<td></td>
</tr>
<tr>
<td>strong iodine solution, 525, C39, P–52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>strontium-89 chloride, 1181</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stulex, 322</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sublimaze, 391</td>
<td></td>
<td></td>
</tr>
<tr>
<td>succimer, 939, C17, P–27, P–28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>succinamide, P–20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>succralfate, 941, C45, P–58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sucrets Cough Control Formula, 277</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudafed, 856</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudafed 12 Hour, 856</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudafed Cold &amp; Cough Liquicaps, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudafed Plus, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudafed Severe Cold, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudafed Sinus Maximum Strength, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudal 120/600, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudal 60/500, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safedrin, 856</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sufentanil, see DrugGuide.com</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solar, 711</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulbactam. See also ampicillin/ sulbactam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulconazole, 70, C21, P–31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulcrate, 941</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulf, 1158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulfacetamide, 1158, P–38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfair, 1158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulfamethoxazole, 942, C27, P–38</td>
<td>See also trimethoprim/sulfamethoxazole</td>
<td></td>
</tr>
<tr>
<td>sulfamethoxazole, see DrugGuide.com</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfamide, 1158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulfasalazine, 943</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulflatrim, 1025</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfotrim DS, 1025</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfex, 1158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfolax, 322</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulfonamides, C27, P–38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulfonyleureas, C15, P–25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sulindac, 946, P–82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulien, 1158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulitrin Triple Sulfaglycine, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulitrin Triple Sulfa Vaginal Tablets, 1114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sumatriptan, 94, C58, P–90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sumycin, 969</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunlax, 75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supedol, 101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SuperChar Aqueous, 7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Supprelin, 1176
Suprax, 176
**suprofen, 1164, P–83**
Surfac, 322
Suvanta, 1172
Sus-Phrine, 345
Susivir, 539
Syllact, 858
Symadine, 1169
Symmetrel, 1169
SYMPATHOMIMETICS, OPHTHALMIC, 1165
Symphytum officinale, 1092
Symcort, 245
Symptak-BC, 1114
Synalar, 244
Synamol, 244
Synarel, 681
Syn-Clonazepam, 211
Syn-Diltiazem, 293
Synemol, 244
Synercid, 871
Synflex, P–98
Synflex DS, P–98
Syn-Nadolol, 678
Syn-Pindolol, 799
Synthroid, 985
Synoconio, 740
T
T, 985
T/T, 986
T, 985
tacrine, 951, C50, P–66
tacrolimus, 952
Tagamet, 472
Tagamet HB, 472
Talacen, 1114
Talwin, 774, 1120, 1122
Talwin Compound, 1114
Talwin XL, 774, 1114
Tambocor, 400
Tamiflex, 954
Tamone, 954
Tamopex, 954
tamoxifen, 954, C30, P–39, P–41
tamsulosin, 956
**Tanacetum parthenium, 1093**
Tapanol, 3
Tapazol, 624
Targretin, 1166
Tarka 182, 1114
Tarka 241, 1114
Tarka 242, 1114
Tarka 244, 1114
Tarsist-D, 1114
Tarsist Sinus, 1114
TAXOIDS, ANTI NEOPLASTIC, C28, C30, P–39, P–41
Taxol, 743
Taxotere, 319
Tazicef, 177
Tazidime, 177
tazobactam. See piperacillin/tazobactam
3TC, 559
T-CPionate, 966
T-Diet, 1179
Tear Drop, 1159
Teargard, 1159
Teargen, 1159
Tearsol, 1159
Tears Naturale, 1159
Tears Naturale Free, 1159
Tears Naturale II, 1159
Tears Plus, 1159
Tears Renewed, 1159
Tebamide, 1022
Tebrazid, 859, 1180
Tecnal, 135
Teoczem, 1114
Teen Midol. See Midol, Teen
Tegamide, 1022
Tegretol, 149
Tegretol XR, 149
Tegretol-XR, 149
Tegrin-LT Shampoo, 1114
Teladar, 244
Teldrin, 130
telmisartan, 61
temazepam, 957, 1124, P–13
Temodar, 959
Temovate, 244
temozolamide, 959, C30, P–39, P–41
temporalia, 52
Tempa, 3
Tenact, 135
Tencon, 135

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (◆), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
**COMPREHENSIVE INDEX**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenex</td>
<td>459</td>
</tr>
<tr>
<td>teniposide</td>
<td>1182, P–39, P–41</td>
</tr>
<tr>
<td>Ten-K</td>
<td>819</td>
</tr>
<tr>
<td>Tenoretic</td>
<td>100, 1114</td>
</tr>
<tr>
<td>Tenoretic 50</td>
<td>1114</td>
</tr>
<tr>
<td>tenormin</td>
<td>79</td>
</tr>
<tr>
<td>Tequin</td>
<td>408</td>
</tr>
<tr>
<td>Teramine</td>
<td>1179</td>
</tr>
<tr>
<td>Terazol</td>
<td>73</td>
</tr>
<tr>
<td>terazosin</td>
<td>960, C25, P–36</td>
</tr>
<tr>
<td>terbinafine</td>
<td>70, C21, P–31</td>
</tr>
<tr>
<td>terbutaline</td>
<td>964, C48, P–61</td>
</tr>
<tr>
<td>terconazole, vaginal</td>
<td>73, C21, P–31</td>
</tr>
<tr>
<td>Terfluzine</td>
<td>1018</td>
</tr>
<tr>
<td>Terra-Cortril Ophthalmic Suspension,</td>
<td>1114</td>
</tr>
<tr>
<td>Terramycin with Polymyxin B Sulfate Ophthalmic Ointment,</td>
<td>1114</td>
</tr>
<tr>
<td>Tessalon</td>
<td>95, 1171</td>
</tr>
<tr>
<td>Testa-C</td>
<td>966</td>
</tr>
<tr>
<td>Testamone</td>
<td>966</td>
</tr>
<tr>
<td>Testapra</td>
<td>966</td>
</tr>
<tr>
<td>Testaex</td>
<td>966</td>
</tr>
<tr>
<td>Testoject</td>
<td>966</td>
</tr>
<tr>
<td>Testoject-LA</td>
<td>966</td>
</tr>
<tr>
<td>Testosterone</td>
<td>966, P–6, P–39, P–41</td>
</tr>
<tr>
<td>testosterone base</td>
<td>966</td>
</tr>
<tr>
<td>testosterone cypionate</td>
<td>966</td>
</tr>
<tr>
<td>testosterone enanthate</td>
<td>966</td>
</tr>
<tr>
<td>testosterone propionate</td>
<td>966</td>
</tr>
<tr>
<td>testosterone transdermal</td>
<td>966</td>
</tr>
<tr>
<td>Testred</td>
<td>966</td>
</tr>
<tr>
<td>Testrip-Pa</td>
<td>966</td>
</tr>
<tr>
<td>tetanus-diphtheria vaccine</td>
<td>1154</td>
</tr>
<tr>
<td>tetanus toxoid</td>
<td>1151</td>
</tr>
<tr>
<td>tetracycline</td>
<td>1156</td>
</tr>
<tr>
<td>tetracyclines</td>
<td>969, C27, P–30</td>
</tr>
<tr>
<td>Tetracyn</td>
<td>960</td>
</tr>
<tr>
<td>tetrahydrozoline</td>
<td>1164</td>
</tr>
<tr>
<td>Tetrazine</td>
<td>1164</td>
</tr>
<tr>
<td>Texcort</td>
<td>245</td>
</tr>
<tr>
<td>T-Gen</td>
<td>1022</td>
</tr>
<tr>
<td>T-Gestic</td>
<td>483, 1114</td>
</tr>
<tr>
<td>thalidomide</td>
<td>972</td>
</tr>
<tr>
<td>Thallitone</td>
<td>315</td>
</tr>
<tr>
<td>Thalomid</td>
<td>972</td>
</tr>
<tr>
<td>Theo-24</td>
<td>120</td>
</tr>
<tr>
<td>Theochron</td>
<td>120</td>
</tr>
<tr>
<td>Theoclear</td>
<td>120</td>
</tr>
<tr>
<td>Theodrine</td>
<td>1115</td>
</tr>
<tr>
<td>Theo-Dur</td>
<td>120</td>
</tr>
<tr>
<td>Theolar</td>
<td>120</td>
</tr>
<tr>
<td>theophylline</td>
<td>120, C48, P–61</td>
</tr>
<tr>
<td>Theo-Time</td>
<td>120</td>
</tr>
<tr>
<td>Theovent</td>
<td>120</td>
</tr>
<tr>
<td>Theo-X</td>
<td>120</td>
</tr>
<tr>
<td>Thera-Cys</td>
<td>1171</td>
</tr>
<tr>
<td>Thera-Flu, Flu &amp; Cold Medicine Powder,</td>
<td>1115</td>
</tr>
<tr>
<td>Thera-Flu, Flu, Cold &amp; Cough Powder,</td>
<td>1115</td>
</tr>
<tr>
<td>Thera-Flu NightTime Powder,</td>
<td>1115</td>
</tr>
<tr>
<td>Thera-Flu Non-Drowsy Flu, Cold &amp; Cough Maximum Strength Powder,</td>
<td>1115</td>
</tr>
<tr>
<td>Thera-Flu Non-Drowsy Formula Maximum Strength Caplets,</td>
<td>1115</td>
</tr>
<tr>
<td>Theramix, 108</td>
<td></td>
</tr>
<tr>
<td>Theramycin Z</td>
<td>360</td>
</tr>
<tr>
<td>Therapy Bayer</td>
<td>903</td>
</tr>
<tr>
<td>Therexac SB</td>
<td>522</td>
</tr>
<tr>
<td>Thermazene</td>
<td>1181</td>
</tr>
<tr>
<td>thiamine</td>
<td>974, 1149, C59, P–92</td>
</tr>
<tr>
<td>thioridazine</td>
<td>976, C35, P–47</td>
</tr>
<tr>
<td>thioguanine</td>
<td>1182, P–39, P–41</td>
</tr>
<tr>
<td>thioridazine, vaginal</td>
<td>73, C21, P–31</td>
</tr>
<tr>
<td>thiophene</td>
<td>980, P–86</td>
</tr>
<tr>
<td>thyroid</td>
<td>986</td>
</tr>
<tr>
<td>thyroid Strong</td>
<td>986</td>
</tr>
<tr>
<td>Thyrolar</td>
<td>986</td>
</tr>
</tbody>
</table>

*Entries for generic names appear in **boldface** type, trade names appear in regular type, classifications appear in **boldface small caps**, combination drugs appear in *italics*, herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a **boldface** page number following a generic name identify the page in the “Classification” section on which that drug is listed.*
tiagabine, 989, C10, P–19, P–20
tiamate, 293
Tiazac, 293
ticarcillin, 990, C27, P–37
ticarcillin/clavulanate, 990, C27, P–37
Tizid, 993
ticlopidine, 993, P–45
ticon, 1022
Tigan, 1022
Tject-20, 1022
Tikosyn, 1022
tiludronate, 994
Timentin, 990
Timentin For Injection, 1115
Timodide 10–25, 1115
timolol, 996, 1160, C25, P–35
Timoptic-XE, 1160
Tinactin, 70
tioconazole, vaginal, 73, C21, P–31
Tipramine, 509
tirofibian, 998, P–45
tissue plasminogen activator, 980
Titralac, 142
Tobramycin, 30, 1158, P–37
Tobrex, 1158
tocaaine, 1002, C4, P–13, P–15
tocolytics, 1181, P–2
Tofranil, 509
Tofranil PM, 509
Tolazamide, 1182
tolazamide, see DrugGuide.com
tolbutamide, 1182
tolbutamide, see DrugGuide.com
Tolectin, 1093
Tolmetin, 1003, P–82
tolnaftate, 70, C21, P–31
Tol-Tab, 1182
tolterodine, 1005
Topocard, 1002
topamax, 1006
topicort, 244
topilene, 244
topiramate, 1006, C10, P–19, P–20
Topisone, 244
topotecan, 1008, C30, P–39, P–41
Toprol-XL, 638
topyn, 244
toradol, 552
Toracan, 976
toremifene, 1010, C30, P–39, P–41
torsemide, 308, C52, P–35, P–71
Totacillin, 51
Touro EX, 454
t-PA, 980
T-Phyl, 120
trimadol, 1011, P–81
Tranlate, 555
trandolapril, 64, C1, C24, P–8, P–35
tranexamic acid, 1183
Transderm-Nitro, 714
Transderm-Scp, 913
Transderm-V, 913
Tranxene, 216
Tranxene-SD, 216
translycromyne, 661, C12, P–22
trastuzumab, 1013, C30, P–39, P–41
Travelabs, 296
trazadone, 1015, C12, P–22
Trazon, 1015
Trendar, 499
Trenal, 778
tretinoin, oral, 1183, P–42
tretinoin, topical, 1183
Triacet-C Cough Syrup, 1115
Triad, 135
Triadacin, 350
Triaderm, 245
Triadoline, 1015
Triam-A, 246
triamcinolone, 229, 233, 236, 245,
P–68, P–69
Triam-Forte, 236
Triamcinic Allergy, 1115

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination Drugs appear in italics. herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Triaminic AM Cough & Decongestant Formula Liquid, 1115
Triaminic Cold, 1115
Triaminic-DM Syrup, 1115
Triaminic Expectorant DH Liquid, 1115
Triaminic Expectorant Liquid, 1115
Triaminic Expectorant w/Codeine Liquid, 1115
TriaminicinCold, Allergy, Sinus, 1115
Triaminic Nite Light Liquid, 1115
Triaminicin Multi-Symptom Cough and Cold, 1115
Triaminicin Multi-Symptom Relief Liquid, 1115
Triaminin Oral Infant Drops, 1115
Triaminin Sore Throat Formula Liquid, 1115
Triaminic Syrup, 1115
Triamolone, 236
Triamodone, 236
Triamterene, 312, C52, P–71
Triamidine, 245
Triaprin, 135
Triaril 2-10, 1115
Triaril 2-25, 1115
Triaril 4-10, 1115
Triaril 4-25, 1115
Triaril 4-50, 1115
Triazolam, 1016, 1124, P–13
Triban, 1022
Trienzanil, 1022
Tricalcium phosphate, 142, P–79
Trichloromethiazide, 1183, P–71
Tricor, 386
Tricosal, 903
TRICYCLIC ANTIDEPRESSANTS, 1174, C11, C12, 1174, P–21, P–22
Trideslalom, 244
Tridil, 714, 1130
trifluoperazine, 1018, C19, C35, P–30, P–17
trifluridine, 1158
Trihexane, 1021
Trihexy, 1021
Trihexyphenidyl, 1021, C32, P–43
Tri-Hydroserpine, 1115
Tri-K, 820
Trikacide, 641
trikates, 820, P–79
Tri-Kort, 236
Trileptal, 736
Tri-Levlen, 225
Phase I, 1115
Phase II, 1115
Phase III, 1115
Trilisate, 903
Trillog, 236
Trilone, 236
Trizamine, 1022
trimethobenzamide, 1022, C19, P–30
trimethoprim, 1024, C27, P–38
trimethoprim, 1024, C27, P–38
trimethoprim/sulfamethoxazole, 1025, C26, C27, P–38
Triminol Cough Syrup, 1116
Trimox, 43
TrimpeX, 1024
Trimadin Replactabs, 1116
Tri-Norinyl, 225
Triostat, 985
Tripedia, 1151
Tripbavil, 225
Phase I, 1116
Phase II, 1116
Phase III, 1116
Triple Antibiotic Ophthalmic Ointment, 1116
Triprolidine, see DrugGuide.com
Triprolidine/pseudoephedrine Syrup (generic), 1116
Triprolidine/pseudoephedrine Tablets (generic), 1116
Triprosed Tablets, 1116
Triptone Caplets, 296
Tristoject, 236
Tritec, 472
troglitazone, 1167
Tropicacid, 1163
tropicaclid, 1163
trovafloxacin, 408, P–38
Trovan (IV), 408
Trovan (oral), 408
Truphylne, 120
Trusopt, 1160
T-Stat, 360
Tuinal 100 mg, 1116

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps. Combination drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
P-162

COMPREHENSIVE INDEX

Tums, 142
Tums E-X, 142
Tussibron-DM Syrup, 1116
Tussibron, 454
Tusségom (U.S. antitussive formulations contain homatropine), 483
Tussin, 454
Tussinex Penkinetic Suspension, 1116
Tussi-Organiadin IM NR Liquid, 1116
Tussi-Organiadin NR Liquid, 1116
Tussstat, 300
Twilite, 300
Twin-8, 820
Two-Dyne, 135
Tylenol, 3
Tylenol Allergy Sinus, Maximum Strength Gelcaps, 1116
Tylenol Children’s Cold, 1116
Tylenol Children’s Cold Liquid, 1116
Tylenol Children’s Cold Multi-Symptom Plus Cough Liquid, 1116
Tylenol Children’s Cold Plus Cough Chewable, 1116
Tylenol Cold Multi-Symptom, 1116
Tylenol Cold No Drowsiness, 1116
Tylenol Flu Maximum Strength Gelcaps, 1116
Tylenol Flu NightTime Maximum Strength Gelcaps, 1116
Tylenol Flu NightTime Maximum Strength Powder, 1116
Tylenol Headache Plus, Extra Strength, 1116
Tylenol Multi-Symptom Cough Liquid, 1116
Tylenol Multi-Symptom Cough w/Decongestant Liquid, 1116
Tylenol Multi-Symptom Hot Medication, 1116
Tylenol PM, Extra Strength, 1116
Tylenol Severe Allergy, 1116
Tylenol Sinus Maximum Strength, 1116
Tylenol w/Codetine Elsir, 1117
Tylenol w/Codetine No. 2, 1117
Tylenol w/Codetine No. 3, 1117
Tylenol w/Codetine No. 4, 1117
Tylox, 1117, 1119, P-101
Tyrodone Liquid, 1117

U
Ugesic, 483
ultralente insulin. See insulin zinc suspension, extended
Ultralente U, 520
Ultram, 1041
Ultrase MT 12, 747
Ultrase MT 20, 747
Ultra Tears, 1359
Utravate, 244
Utrazine, 833
Utasyn, 54
Unayn For Injection 1.5 g, 1117
Unayn For Injection 3 g, 1117
Uni-Bent Cough, 300
Unicort, 245
Unipen, 767
Uniphyl, 120
Uniretic, 1117
Unison SleepGels Maximum Strength, 300
Unituss BC Syrup, 1117
Uni-tussin, 454

V
Vagifen, 365
Vaginal antifungals, C21
Vagistat, 73
Valacyclovir, 1029, C46, P-60

*Entries for generic names appear in boldface type, trade names appear in regular type, classifcations appear in boldface small caps. Combination Drugs appear in italics, herbal products are preceded by a leaf icon (禋), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Valerian, 1097

- Valeriana officinalis, 1097

- Valisone, 244

- Valium, 279

- Velbe, 1040

- Velosof, 167

- Velosulin Human, 520

- Venlafaxine, 1035, C12, P±22

- Ventodisk, 13

- Ventiolin, 13

- Verapamil, 1037, C2, C4, C25, P±11, P±13, P±15, P±35

- VePesid, 380

- Verelan, 1037

- Verelan PM, 1037

- Vesanoid, 1183

- Vesanox, 1162

- V-Gan, 839

- Vicox, 921

- Vi-Acro, 303

- Vical, 1047

- Vical LA, 1048

- Vibramycin, 969

- Vibra-Tabs, 969

- Vibutal, 135

- Vicks Children’s NyQuil Nighttime

- Cough/Cold Liquid, 1117

- Vicks Cough Silencers, 1117

- Vicks DayQuil Allergy Relief 12 Hour ER, 1117

- Vicks DayQuil Allergy Relief 12 Hour ER, 1117

- Vicks DayQuil Liquid, 1117

- Vicks DayQuil Sinus Pressure & Pain Relief, 1117

- Vicks 44M Cough & Head Congestion Liquid, 1117

- Vicks 44L Liquid, 1117

- Vicks 44M Cold, Flu & Cough Liquicaps, 1117

- Vicks 44 Non-Drowsy Cold & Cough Liquicaps, 1117

- Vicks Formula 44 Pediatric Formula, 277

- Vicks NyQuil Liquicaps, 1117

- Vicks NyQuil Multi-Symptom Cold Flu Relief Liquid, 1117

- Vicks Pediatric Formula 44e Liquid, 1117

- Valproates, 1030, C10, P±19, P±20

- Valproic acid, 1030, C10, P±20

- Valrelease, 279

- valproate sodium, 1030, C10, P±20

- Verapamil, 1037, C2, C4, C25, P±11, P±13, P±15, P±35

- Valtrex, 1029

- Valteric, 177

- Vasocon-A Ophthalmic Solution, 1117

- Vasoconstrictors, Ophthalmic, 1164

- Vasodilators, P±36

- Antihypertensive, C25

- Infrequently Used, 1175, 1179

- Vasopressin, 1183

- Vasopressors, 1177, 1178

- Vecrtin, 969

- Velebs, 764

- Velban, 1040

*Entries for generic names appear in **boldface type**, trade names appear in regular type, classifications appear in **boldface small caps**, combination drugs appear in *italics*, herbal products are preceded by a leaf icon (W), and web references are underlined. A “C” and a **boldface** page number following a generic name identify the page in the “Classification” section on which that drug is listed.
P-164

COMPREHENSIVE INDEX

Vicks Pediatric Formula 44e Multi-Symptom Cough & Gold Liquid, 1117
Vicodin, 483, 1117, 1119, 1122
Vicodin ES, 1117
Vicodin HP, 1117
Vicodin Tuss, 1117
Vicoprofen, 483, 1117
Vidarabine, 1158, 1183
Videx, 284
vinblastine, 1040, C30, P±39, P–41
vinca alkaloids, C28, C30, P–39, P–41
Vincasar PFS, 1043
vincristine, 1042, C30, P–39, P–41
vinorelbine, 1045, C30, P–39, P–41
Vloksar, 47
Vloxx, 898
Vira-A, 1158, 1183
Virelce, 691
Viramune, 695
Viraol, 882
Viridium, 783
Virilon IM, 966
Virotec, 1158
Visine, 1164
Visine LR, 1164
Vistear, 493
Vistatine-50, 493
Vistide, 190
Vitabees-12, 1047
Vitabee 6, 863
Vit-A-Drops, 1159
Vitalax, 858
vitamin A, see DrugGuide.com
vitamin A acid, 1183
vitamin B, 428, 697, 863, 883, 974, 1048
vitamin B1, C59, P–92
vitamin B2, C59, P–92
vitamin B3, C59, P–92
vitamin B12, 1149, C59, P–91, P–92
vitamin C, C59, P–91
vitamin D3, 1050
vitamin D2, 1050
vitamin D compounds, 1050, P–91
vitamin E, 1053, C59, P–91
vitamin K, 795, P–27, P–91
VITAMINS, C58, P–90
FAT-SOLUBLE, C59, P–91

W

warfarin, 1057, G6, G8, P–18
Warfarin, 1057
Webber Vitamin E, 1053
Wellbutrin, 129
Wellcovorin, 567
Westcort, 245
Westhroid, 986
Wigraine Supps, 1117
Winfred, 236
Wielho SDF, 879
Wielho SD, 879
Woodruff, 1098

W

woodruff, 1098
Wycillin, 764
Wygesic, 847
Wyctin, 43
Wytsensin, 455

X

Xalatan, 1165
Xanax, 23
XANTHINES, BRONchodilATOR, 120, C48, P–61
Xeloda, 146
Xenical, 752
Xopenex, 573
X-Prep Liquid, 915
Xylocaine, 577, 1129
Xylocaine Viscous, 577
Xylocard, 577

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, Combination Drugs appear in italics, herbal products are preceded by a leaf icon ( ), and web references are underlined. A “C” and a boldface page number following a generic name identify the page in the “Classification” section on which that drug is listed.
Y
Yutopar, 1181

Z
Zaditor, 1163
zafirlukast, 1060, C48, P–61
Zagam, 408
zalcitabine, 1061, C38, P–50
zaleplon, 1061, 1124, P–13
zaleplon, see DrugGuide.com
Zanaflex, 1000
zanamivir, 1065, C48, P–60
Zanosar, 1181
Zantac, 472
Zantac 75, 472
Zantac-C, 472
zanamivir, 1065, C48, P–60
Zoladex, 446
Zanamivir, 1175
Zarontin, 1175
Zaroxolyn, 636
Zeasorb-AF, 70
Zofran, 1181
Zofran, 728
Zoladex, 446
zofloxacin, 1067, C46, P–60
Zofran, 728
Zanosar, 1181
Zanamivir, 1065, C48, P–60
Zosyn, 802
Zorprin, 903
Zosyn, 802
Zopiclone, 483
Zopiclone, 1122
Zopiclone, 1122
Zyban, 129
Zestoretic 10/12.5, 1118
Zestoretic 20/12.5, 1118
Zestoretic 20/25, 1118
Ziac 2.5 mg, 1118
Ziac 5 mg, 1118
Ziac 10 mg, 1118

*Entries for generic names appear in boldface type, trade names appear in regular type, classifications appear in boldface small caps, combination drugs appear in italics, herbal products are preceded by a leaf icon (W), and web references are underlined. A "C" and a boldface page number following a generic name identify the page in the "Classification" section on which that drug is listed.